NZ552501A

NZ552501A - Novel cyclic aminobenzoic acid derivative

Info

Publication number: NZ552501A
Application number: NZ552501A
Authority: NZ
Inventors: Masahiro Nomura; Yasuo Takano; Kazuhiro Yumoto; Takehiro Shinozaki; Shigeki Isogai; Koji Murakami
Original assignee: Kyorin Seiyaku Kk
Priority date: 2004-08-11
Filing date: 2005-08-11
Publication date: 2010-03-26
Also published as: JPWO2006016637A1; AU2005272389B2; IL180314A0; WO2006016637A1; EP1780210A1; EP1780210A4; US20070249580A1; US7902367B2; AU2005272389A1; BRPI0515015A; CN101014595A; ZA200700064B; MX2007001634A; NO20070750L; RU2391340C2; CA2575039A1; RU2007108415A; KR20070050475A

Abstract

The disclosure relates to cyclic amino benzoic acid derivatives of formula (1) which are effective in therapy of lipid metabolism abnormality, diabetes and the like as a human peroxisome proliferators-activated receptor (PPAR) agonist, in particular, as an agonist against human PPAR-alpha isoform, and addition salts thereof, and pharmaceutical compositions containing these compounds, wherein the variables shown in formula (I) are as defined in the specification.

Description

<div class="application article clearfix" id="description"> New Zealand Paient Spedficaiion for Paient Number 552501 RECEIVED at IPONZ on 30 November 2009 552501 DESCRIPTION NOVEL CYCLIC AMINOBENZOIC ACID DERIVATIVE Technical field

[0001] The present invention relates to cyclic amino benzoic acid derivatives which are effective in therapy of lipid metabolism abnormality, diabetes and the like as a human peroxisome proliferators-activated receptor (PPAR) agonist, in particular, as an agonist against human PPARa isoform, and addition salts thereof, and pharmaceutical compositions containing these compounds. Background art

[0002] Peroxisome proliferators-activated receptor (PPAR) is a ligand-dependent transcription factor belonging to a nuclear receptor super-family likewise steroid receptors, retinoid receptors, thyroid receptors and the like. The receptor includes three isoforms (type a, type y and type 5 {or type (5) ), which have been identified in various animal species (Non-patent document 1) . Among these, PPARa distributes in liver, kidney or the like having high fatty acid catabolic ability (Non-patent document 2), and positively or negatively controls expression of genes involved in fatty acid metabolism or intracellular transport (for example, acyl CoA synthetase, fatty acid binding protein or lipoprotein lipase) and genes of apolipoproteins (AI, All, CIII) involved in metabolism of cholesterol and neutral lipid. PPARy is highly expressed in 1 552501 adipocyte, and involved in differentiation of adipocyte (Non-patent document 3) . PPAR5 is universally expressed in biological tissues, mainly in nerve cells. As to physiological significance of PPAR5, involvement in fatty 5 acid burning is recently reported (Non-patent documents 4 and 7), however, there still remain a lot of unclear points . In this manner, each isoform of PPAR plays a specific role in a specific organ or tissue. ^ [0003] 10 Furthermore, it is also reported that PPARa-knockout mouse exhibits hypertriglycemia with age, and gets obesity which is mainly associated with increase in white adipocyte (Non-patent document 5) . This strongly suggests the relation between activation of PPARa and blood lipid (cholesterol and neutral lipid) lowering activity. 15 [0004] On the other hand, as antihyperlipidernic drugs that are dominantly used at the present day, statin drugs and fibrate drugs are known. Statin drugs, however, are poor in free fatty acid and triglyceride lowering ability, and fibrate drugs are poor in 20 cholesterol lowering ability. As to fibrate drugs, various side effects that are attributable to exhibition of wide pharmacological property, such as gastrointestinal damages, eruption, headache, hepatic function disorder, renal function impairment, gallstone have been reported, and hence there is need for development of an 2 552501 antihyperlipidemic drug based on a specific mechanism that will not cause such side effects.

[0005] In consideration of the current cases of conventional antihyperlipidemic drugs and relationship between the role regarding lipid metabolism control function of transcription factor called PPARa, and clinical condition of hyperlipemia that has been revealed heretofore, creation of a compound that directly binds as a ligand to PPARa, in particular, to human PPARa and is able to potently activate human PPARa may provide a therapeutic agent exhibiting blood lipid (both cholesterol and neutral lipid) lowering activity according to an extremely specific mechanism.

[0006] As an endogenous ligand against PPARa, eicosanoid of hydroxyeicosatetraenoic acid (HETE) group generated through oxidation by cytochrome P-450, in particular 8-HETE, 8-HEPE and the like are reported as well as LTB4 which is a metabolite of arachidonic acid (Non-patent document 6). These endogenous unsaturated fatty acid derivatives are instable in both metabolic and chemical aspects, so that they cannot be provided as pharmaceuticals.

[0007] On the other hand, as a compound which is reported to have PPARa agonist activity, compounds of the formulas (A) to (J) listed in Table 1 are known, however, none of these include compounds having 552501 a benzoic acid structure substituted with alicyclic amino group, and hence they differ in structure from compounds of the present invention.

[0008] [Table 1] Patent Formula Patent Formula i H \ ff (A) 0 N^R5 Hs <F) 2 «-en£oi& (B) 7 y caH„ ^^-acooh (GO 3 HOOC^X,^ R« (C) 8 CH) 4 E /R' /R1 R» (D) 9 H°n>CCjx-'CH5R^-Y-^ A Ri «> 5 ^ k k «" <E) 10 ? ,VYYFf ho/m^o |0 x- (CH^-Y W^IV BP A R1 CJ)

[0009] Furthermore, as a compound having a similar structure to compounds of the present invention and reported for PPARy agonist activity, Patent document 11 discloses a compound represented by the general formula (K)

[0010] [Chemical formula 1] 4 552501 (K)

[0011] [wherein R1 represents the general formula (K-a)

[0012] [Chemical formula 2] O s^NH <K"a) 0

[0013] or general formula (K-b)

[0014] [Chemical formula 3] Rs (K-b) R6 (wherein R5 represents a hydroxyl group, or C1-C9 alkoxy group, and R6 represents a C1-C5 alkyl group or the like) ; R2 and R3 represent a hydrogen atom, alkyl group or the like; X represents -CH2-NR8CO-, -N (R8) -COCH2- or the like; R4 represents a phenyl group, benzyl group or the like; R8 represents a hydrogen atom or C1-C6 alkyl group] (explanation for substituents is partly extracted), however this 552501 compound is a biphenyl alkanoic acid derivative, and is different in structure from compounds in accordance with the present invention.

[0015] Furthermore, as a compound having a similar structure to compounds in accordance with the present invention, and reported to have PPAR agonist activity, Patent document 12 discloses a compound represented by the general formula (L)

[0016] [Chemical formula 4] [wherein L represents a single bond, or a Ci-C6 alkylene group which may have one or more substituents or the like; M represents a single bond, or a Ci-C6 alkylene group which may have one or more substituents or the like; T represents a single bond or the like; W represents carboxyl group; [Chemical formula 5] represents a single bond or a double bond; X represents a single bond, an oxygen atom or the like; Y represents a 5 to 14-membered aromatic group which may have one or more substituents and one or more hetero atoms, or a C3-C7 alicyclic hydrocarbon group; rings W (L)

[0017]

[0018] 552501 Z and U represent 5 to 14-membered aromatic groups which may be identical or different, and may have one to four substituents, and one or more hetero atoms, and may be saturated in a part of the ring] (explanation for substituents is partly extracted). As a compound that is reported as a PPAR receptor ligand, Patent document 13 discloses a compound represented by the general formula (M) [0019] [Chemical formula 6] [wherein ring Arl, ring Aril, and ring Arlll independently represent an aryl, heteroaryl or the like; A represents an oxygen atom, sulfur atom or the like; B represents an oxygen atom, sulfur atom, a single bond or the like; D represents an oxygen atom, sulfur atom, single bond or the like; E represents a single bond or ethylene group; a, b, c and e represent 0 to 4; d represents 0 to 5; f represents 0 to 6, R1, R3, R5, R7, R9 and R11 independently represent a hydrogen atom, halogen atom or the like; R2, R4, R6, R8, R10 and R12 independently represent -(CH2)q-X; q represents 0 to 3, X represents a hydrogen atom, halogen atom or the like; Z represents R2102C~, R21CO- and the like; R21 represents a hydrogen or the like] (explanation for substituents is partly extracted) . However, ring Z or ring Aril of these compounds (Patent documents 12 and 13) does not contain an alicyclic amino group which 7 552501 is characteristic of compounds in accordance with the present invention, and differs in structure from compounds in accordance with the present invention.

[0020] Furthermore, as a compound having a similar structure to compounds in accordance with the present invention and reported to have PPAR agonist activity, Patent document 14 discloses a compound represented by the general formula (N)

[0021] [Chemical formula 7] O

[0022] [wherein ring A represents a C3-C6 cycloalkyl which may contain an oxygen atom, or C3-C8 cycloalkenyl which may contain an oxygen atom; R1, R2, R4 and R5 represent a hydrogen atom, fluorine atom, chlorine atom, bromine atom, hydroxyl group, nitro group, trifluoromethyl group, trifluoromethoxy group, Ci-C6 alkyl group, or C1-C6 alkoxy group; R3 represents a hydrogen atom, or Ci-Cg alkyl group; and X, Y represent a Ci-Cg alkylene which may be substituted with an oxygen atom]. However, ring A does not contain an alicyclic amino group which is characteristic of compounds in accordance with the present invention, and ring A and the benzoic acid moiety are bound via 552501 Y, so that it is different in structure from compounds in accordance with the present invention. Furthermore, as a compound having a similar structure to compounds in accordance with the present invention and reported to have triglyceride and cholesterol lowering activity, Patent documents 15 to 19 disclose a compound represented by the general formula (0)

[0024] [Chemical formula 8] [wherein Z represents an oxygen atom or sulfur atom; X represents a hydrogen atom, halogen atom, lower alkyl group, carboxyl group, lower alkoxycarbonyl group or the like; Y represents a hydrogen atom, halogen atom, lower alkyl group when Z is a sulfur atom, and represents a hydrogen atom, halogen atom, lower alkyl group, lower alkoxy group or the like when Z is an oxygen atom] (explanation for substituents is partly extracted). However, this compound is a derivative of morpholinone which is different from an alicyclic amino group which is characteristic of compounds in accordance with

[0023] (O)

[0025] 552501 10 the present invention, and has a different structure from compounds in accordance with the present invention because only para-substituted benzoic acid derivative (X = COOR) is described in Examples of the patent documents. Furthermore, the patent documents include no report about PPARa agonist activity.

[0026] As a compound having a cyclic amino benzoic acid structure, Patent document 20 discloses as a compound having integrin antagonist activity, a compound represented by the general formula (P)

[0027] [Chemical formula 9] (P) W [0028] 15 [wherein R1 represents a hydrogen atom, hydroxyl group or the like; R2 represents a hydrogen atom or halogen atom, or R1 and R2 together represent a 4 to 7-membered ring which may contain up to two oxygen atoms, nitrogen atoms, or sulfur atoms, and up to two double bonds; R3 represents a hydrogen atom, Ci-Cm alkyl group or the like; R4 20 represents a hydrogen atom, halogen atom or the like; R5 represents a hydrogen atom, C1-C6 alkyl group or the like, or R3 and R5 together represent a 4 to 7-membered ring which may contain up to two oxygen 10 552501 10 15 20 atoms, nitrogen atoms, or sulfur atoms, or up to two double bonds; R6 represents a hydrogen atom, C1-C4 alkyl group or the like; R7 represents a hydrogen atom or C1-C4 alkyl group, or R3 and R7 bind to each other to represent a ring; X represents an oxygen atom or two hydrogen atoms] (explanation for substituents is partly extracted). However, for this compound, no report about PPARa agonist activity is found, and the compound is a benzoic acid derivative having a cyclic amino group at para position of carboxylic acid, and hence differs in structure from compounds in accordance with the present invention.

[0029] Furthermore, as a compound having a cyclic amino benzoic acid structure, Patent document 21 discloses a compound having serine protease inhibitory activity, a compound represented by the general formula (Q)

[0030] [Chemical formula 10] R5HN COOR8 V0T - R6N | R2 (Q) R7

[0031] [wherein ring B represents a phenyl group or pyridyl group, W represents a C2-C10 alkyl group and the like; Z1 represents a 5 to 11 552501 7-membered monocyclic or 8 to 11-membered bicyclic aryl group or the like; L represents - (R13R19) S-Y- (R18aR19a) t-; Y represents a carbonyl group or the like; R1 and R2 independently represent a hydrogen atom or the like, or R1 and R2 together represent a 5 to 7-membered saturated heterocycle which may be substituted with one or two R26; R5 and R6 independently represent a hydrogen atom or the like; R7 represents a hydrogen atom, halogen atom or the like; R8 represents a hydrogen atom, alkyl group or the like; R18, R18a, R19, and R19a represent a hydrogen atom, lower alkyl group or the like; R26 and R27 represent a hydrogen atom, alkyl group or the like; m represents 0, 1, or 2 when ring B is phenyl, or represents 0 or 1 when B is pyridyl; s, t independently represent 0, 1 or 2] (explanation for substituents is partly extracted). However, for this compound, no report about PPARa agonist activity is found. Furthermore, this compound is an amidine derivative, and differs in structure from compounds in accordance with the present invention in that the rings B and L to be substituted adjacently bind to the ring formed by R1 and R2.

[0032] As a compound having cyclic amino benzoic acid structure, Patent document 22 discloses as a compound having factor Xa inhibitory activity, a compound represented by the general formula (R)

[0033] [Chemical formula 11] ro—Q-X-Q'-W-U-V-G-M ( R ) 12 552501

[0034] [wherein R° represents aryl group or the like which may be substituted with R2; Q, Q' represent a bonding hand, carbonyl or the like; X represents a bonding hand, 3 to 7-membered heteroaryl group or the like; W represents a 5 to 14-membered aryl group which may be substituted with R1, 5 to 14-membered heteroaryl group which may be substituted with R1 or the like; U and G represent a bonding hand, - (CH2)m— r ~ (CH2) m-0- (CH2)m- or the like; V represents 3 to 7-membered cycle which may contain 1 to 4 oxygen atoms, nitrogen atom, and sulfur atom, and may be substituted with R14, bonding hand, or the like; M represents a 6 to 14-membered aryl group which may be substituted with R14, hydrogen atom or the like; R1 represents a halogen atom, nitro group or the like; R2 represents a halogen, nitro group or the like; R14 represents a halogen atom, OH, COOH or the like] (explanation for substituents is partly extracted) , and Patent document 23 discloses a compound represented by the general formula (S)

[0035] [Chemical formula 12] N x-R3 (S)

[0036] 13 552501 [wherein R1, R2 and R3 which are identical or different, represent a hydrogen atom, hydroxyl group or the like; and R represents the general formula (S-a)

[0037] 5 [Chemical formula 13] 15 N X ya y3 — R7 (S-a) (CH2)m — V1 ~^AJ- Y2 Y3 R7 ) (CH2)n—Y4 Y5 R8

[0038] (wherein R7 represents a hydrogen atom, lower alkyl group, or -C(=R9)R10; R8 represents hydrogen atom, lower alkyl group or the 10 like; Y1 represents an oxygen atom, -CONH- or the like; Y2 represents an oxygen atom, sulfur atom, or a single bond; Y3 represents a single bond,

[0039] ^ [Chemical formula 14] (pH^)s "A /N" N , (CHa),

[0040] , Y4 represents an oxygen atom, a single bond or the like, Y5represents -(CH2)P-, a single bond or the like; A represents

[0041] 20 [Chemical formula 15] 14 552501 N— or R<4 N—

[0042] ; m and n which are identical or different, each represents 0 or an integer from 1 to 3; s, t which are identical or different, each 5 represent an integer from 1 to 3; R9 represents an oxygen atom, sulfur R14 represents a carboxyl group or the like) and so on] (explanation for substituents is partly extracted) . However, as to the compound described in Patent document 22, no report about PPARa agonist 10 activity is found. Furthermore, all the benzoic acid derivatives substituted with a cyclic amino group that are described in examples in patent specification are compounds in which 4-position of benzoic acid is substituted with an alicyclic amino group and hence are different from compounds in accordance with the present invention. ^^5 Furthermore, as to the compound in Patent document 23, no report about PPARa agonist activity is found, and examples of the patent specification lack description on benzoic acid derivative substituted with an alicyclic amino group.

[0043] 20 As a compound having a similar structure to compounds in accordance with the present invention, compounds shown by formulas (T) to (AA) in Table 2 having histone deacetylation inhibitory activity [in general formulas (T) to (AA), R1 represents -CONR8R9 15 atom or the like; R10 represents a lower alkyl, lower alkoxy group; 552501 (wherein RB and R9 each independently represent a hydrogen atom, hydroxyl group, Ci-6 alkyl group or the like) , NHCOR10 (wherein R10 represents a hydrogen atom, Cx-6 alkyl group or the like) or the like, and in general formulas (T) to (Y) , R2 represents a hydrogen atom, halogen atom, hydroxyl group or the like] (explanation for substituents is partly extracted) are known. However, no reports about PPARa agonist activity are found for these compounds . In these compounds, the substituent R1 is a functional group such as amide or hydroxamic acid, and a carboxyl group and a lower alkoxycarbonyl group which provide structural feature of the present invention are not contained. Therefore, these compounds are different in structure from compounds in accordance with the present invention. Furthermore, in examples of patent specifications of Patent documents 24 to 29, benzoic acid derivatives substituted with a cyclic amino group are described as intermediates, however, these compounds are also different in structure from compounds in accordance with the present invention because the cyclic amino group being bound thereto is 1-piperadyl group, 4-aminopiperidino group or the like, and no report about PPARa agonist activity is found. Furthermore, examples in patent specifications of Patent documents 30 and 31 completely lack description about benzoic acid derivatives . [0044] [Table 2] 16 552501 Patent Document Formula Patent Document Formula 24 CT) 28 R'\a-x^ J-tcHj. jfc, y-N ' 2—U-CO-N—(A) (X) 25 T RSp-K 9 /-~A " PP (V) 29 CT) 26 (V) 30 Ri W H Z-(CMj)„ s-/ <Z) 27 FP "SP-* Awx * 00 31 H'^QX V~' (M)

[0045] Furthermore, as a compound having a similar structure to compounds in accordance with the present invention, compounds shown by formulas (AB) to (AD) listed in Table 3 are known as a compound having integrin auP3 antagonist activity. Inanyof these compounds, however, a carboxyl group binds to a benzene ring via a linker, and no report about PPARa agonist activity is found. Although benzoic acid derivatives substituted with an alicyclic amino group are described as intermediates in examples of the patent specifications, no report about PPARa agonist activity is found for these compounds.

[0046] 17 552501 [Table 3; Patent Document Formula 32 Rf> \f-vD—C02R (AB) 33 (R7) A— D—R9 R10 (AC) 34 (%,ch)d 3?" f r A_D—J-CH-CXJgR (CH2)q W (AD) 10

[0047] Furthermore, as a compound having a similar structure to compounds in accordance with the present invention, Patent document 35 discloses a compound represented by the general formula (AE) as an inhibitory agent of Na+/H+ alternate transport function:

[0048] [Chemical formula 16] R3V R4_ (AE) [wherein R1 and R2 each independently represent a hydrogen atom, Ci~C6 alkyl group, Ph, PhCO or the like; R3 and R4 each independently represent a hydrogen atom, Ci-Cg alkyl group or the like] 18 552501 (explanation for substituents is partly extracted). However, no report about PPARa agonist activity is found for these compounds. Furthermore, this compound is characterized by a benzoyl guanidine structure, and is different in structure fromcompounds in accordance 5 with the present invention in that the cyclic amino group that is to bind to a phenyl group is 4-aminopiperidino group. Furthermore, in examples of the patent specification, benzoic acid derivatives substituted with a cyclic amino group are describedas intermediates, ^ however, these compounds are also different in structure from 10 compounds in accordance with the present invention, and no report about PPARa agonist activity is found. Furthermore, as a compound having a similar structure to compounds in accordance with the present invention and reported to be a PPAR receptor ligand, Patent document 36 discloses compound represented by the general formula (AF) 15 [0049] [Chemical formula 17] ~ R1 R3 v R5 R7 AH) ( )a A-fByfArlAf-frrB-f-hj-E-Z (AF) R2 R4 R6 R8

[0050] [wherein ring Arl and ring Aril independently represent an aryl, 20 heteroaryl or the like, A represents an oxygen atom, sulfur atom, compound represented by the general formula (AF-a)

[0051] [Chemical formula 18] 19 552501 R14 R15 I —N (I )h O— (AF-a) R16

[0052] (wherein h represents 1 to 4; R14, R15 and R16 represent a hydrogen atom, alkyl group or the like, or R14 and R15 represent, together 5 with nitrogen atom, 5-membered or 6-membered hetero cycle or the like) or the like, B represents an oxygen atom, sulfur atom or the like, E represents a single bond or an ethylene group, a and d represent 0 to 6, b and c represent 0 to 4, R1, R3, R3 and R7 independently represent a hydrogen atom, halogen atom or the like, R2, R4, R6, 10 and R8 and R12 independently represent -(CH2)q-X, q represents 0 to 3, X represents a hydrogen atom, halogen atom or the like,. Z represents R2102C-, R21CO- or the like, and R21 represents a hydrogen or the like] (explanation for substituents is partly extracted). However, in this compound, the cyclic amino group represented by the general formula (AF-a) binds to ring Aril via a linker, so that it is different in structure from compounds in accordance with the present invention. Furthermore, examples in patent specification lack description on a compound having a cyclic amino group. Furthermore, as a compound having a similar structure to compound of the present invention 20 and reported to have PPARa agonist activity, Patent document 37 discloses a compound represented by the general formula (AG)

[0053] [Chemical formula 19] 20 552501 (CH2lm r (9H2>n ^ (AG)

[0054] [wherein Y and V represent methylene or carbonyl group; F and G represent a hydrogen atom, halogen atom or the like; X represents 5 Z or -B-C (R1!^2)-Z; B represents an oxygen atom, sulfur atom or the ^ like; Z represents -C(C>)0H, -C (0) 0-(Ci-C6) alkyl or the like; R1 represents a hydrogen atom, (Ci-Ce) alkyl group or the like; R represents a hydrogen atom, (C3-Cs) cycloalkyl group or the like; E represents a carbonyl group, sulfonyl group, methylene; W 10 represents a bonding hand, carbonyl group, -N(H)- or the like; and A represents a mono-N- or di-N, N- (C^-Cg) alkyl amino group, (C2-C6) alkanoyl amino group, partly or fully saturated or fully unsaturated 3 to 8-membered ring which may have 1 to 4 oxygen atom, sulfur atom, ^ or nitrogen atom] (explanation for substituents is partly extracted) . 15 However, this compound is featured in that the ring J binds at a position other than nitrogen atom of the alicyclic amino group containing Y and V, and excludes compounds having the feature of compounds in accordance with the present invention that benzoic acid binds to a nitrogen atom of the alicyclic amino group, and 20 hence is different in structure from compounds in accordance with the present invention. Furthermore, as a compound having a similar structure to compounds in accordance with the present invention 21 552501 and reported to have lipid lowering activity, Patent document 38 discloses a compound represented by the general formula (AH) [0055] [Chemical formula 20] [wherein Ar represents a naphthyl group, pyridyl group or the like; X represents -CO-, or -SO2-, Y represents [0057] [Chemical formula 21]

[0058] , Q represents -0- or a single bond; Z represents a 1 to 3 alkylene group or -CR5R6- (wherein R5 and R° represent an alkyl group); R4 represents a hydroxyl group or -NH(CH2)mCOOH (wherein m represents a number from 1 to 3)] (explanation for substituents is partly extracted) , and Patent document 39 discloses a compound represented by the general formula (AI)

[0059] [Chemical formula 22] (AH) Q_Z C0R4

[0056] Q-Z—COR4 22 552501

[0060] [wherein Ar represents a naphthyl group, pyridyl group or the like; Y represents

[0061] [Chemical formula 23] ^ pH -N N— —N . x . \ / > \ / * \ / "• v

[0062] , Q represents -0- or a single bond, Z represents a 1 to 3 alkylene group or -CR5R6- (wherein R5 and R6 represent an alkyl group), R4 10 represents a hydroxyl group or -NH(CH2) mCOOH (wherein m represents a number from 1 to 3)] (explanation for substituents is partly extracted) . In these compounds, however, substituent Ar-X or Ar-CO-binds to 4-position nitrogen atom of ring Y with respect to the phenyl group, and the substituted COR4 of these compounds binds to 15 phenyl group via -Q-Z-, so that they do not include a benzoic acid derivative and are different in structure from compounds in accordance with the present invention. Furthermore, for these compounds, no report about PPARa agonist activity is found. As a compound having a cyclic amino benzoic acid structure, 20 Patent document 40 discloses, as a compound having serine protease inhibitory activity, a compound represented by the general formula (AJ)

[0063] [Chemical formula 24] 23 552501 COOR3 (AJ)

[0064] [wherein ring B represents a phenyl group or pyridyl group; X2 represents N, CH or the like; W represents a C2-C10 alkyl group or ^^5 the like; Z represents a 5 to 7-membered monocyclic or 8 to 11-membered bicyclic aryl group and the like; L represents - (R18R19) s-Y- (R18aR19a) t~; R1 and R2 independently represent a hydrogen atom or the like; R1 and R2 together represent an aromatic ring, heteroaromatic ring or the like; R8 represents a hydrogen atom or 10 the like; R3 represents a hydrogen atom, alkyl group or the like; R18, R1Sa, R19 and R19a represent a hydrogen atom, lower alkyl group or the like; Y represents CO or the like; m represents 0, 1 or 2 when ring B is a phenyl, or represents 0 or 1 when ring B is a pyridyl; and s, t independently represent 0, 1 or 2] (explanation for 15 substituents is partly extracted). For this compound, however, no report about PPARa agonist activity is found. Furthermore, it is different in structure from compounds in accordance with the present invention in that substituent rings B and L bind adjacently to the ring formed by the R1 and R2. 20 Furthermore, as a compound having a similar structure to the present invention, Patent document 41 discloses as a compound having 24 552501 p38MAP kinase inhibitory activity, a compound represented by the general formula (AK)

[0065] [Chemical formula 25] [wherein A ring represents a C5-Cx0 monocyclic, bicyclic hydrocarbon ring or the like; R1 represents COOR11, Ci-C8 alkyl group, C2-C8 alkenyl group or the like; R2 represents a Ci-Ce alkyl group; G and J each independently represent a carbon atom, nitrogen atom or the like; E represents a Ci-C8 alkylene group, C2-C8 alkenylene group, -O- or the like; B ring represents a C5-Ci0 monocyclic, bicyclic hydrocarbon ring or the like; R3 represents a Ci-Cg alkyl group, C2 -Cg alkenyl group or the like; R11 represents a hydrogen atom, Ci to C8 alkyl group or the like; m represents 0 or integer from 1 to 5; n represents 0 or integer from 1 to 7; and 1 represents 0 or integer from 1 to (AK) 12

[0066] [Chemical formula 26]

[0067] 552501 represents a single bond or double bond] (explanation for substituents is partly extracted). However, this compound is a cyclic amide derivative which is different from the alicyclic amino group that is characteristic of compounds in accordance with the present invention, and all the benzoic acid derivatives that are described in examples of patent specification are para-substituted compounds and hence are different in structure from compounds in accordance with the present invention. Furthermore, no report about PPARa agonist activity is found. Furthermore, as a compound having a similar structure Lo the present invention, Patent document 42 discloses as a compound having (J3 adrenaline receptor agonist activity, a compound represented by the general formula (AL)

[0068] [Chemical formula 27]

[0069] [wherein ring A represents an aromatic ring or hetero ring; X represents -0CH2-, -SCH2-, or bonding hand; T1 represents (CH2)m; T2 represents (CH2)n; T represents a bonding hand, C1-C6 alkyl group and R3 each independently represent a hydrogen atom, Cl to 6 alkyl (al) which may be substituted with substituent R11 or the like; R1, R2 552501 group or the like; R4 represents a hydrogen atom, CI to 6 alkyl group or the like; R5 represents a COOR6, or a compound represented by the general formula (AL-a)

[0070] [Chemical formula 28] M, <AL-a> Y

[0071] (wherein Y, Z each independently represent NR7, 0 or S; R6 represents a hydrogen atom, C1-C6 alkyl group which may be substituted with R11, R12 and R13, or the like; and a broken line represents a single bond or a double bond) or the like; m represents 1 to 3; n represents 1 to 3; R6 represents a hydrogen atom, alkyl group having 1 to 6 carbon (s) and the like; R11, R12, R13 each independently represent a Ci-C6 alkyl group, halogen atom or the like] (explanation for substituents is partly extracted). However, this compound is featured by an amino ethanol structure, and the benzoic acid derivatives substituted with a cyclic amino group described in examples of patent specification are merely the compounds in which substitution with cyclic amino group occurs at para position of benzoic acid, and differ in structure from compounds in accordance with the present invention. Furthermore, no report about PPARa agonist activity is found. 27 552501 < As a compound having a similar structure to the present invention, Patent document 43 discloses as a compound having calcium receptor antagonist activity, a compound represented by the general formula (AM) [wherein m represents an integer from 0 to 2; n represents an integer 10 from 1 to 3; X represents a cyano group, nitro group or the like; Y represents a chlorine atom, fluorine atom or the like; Q and Z independently represent a hydrogen atom, Rif SO2R1' , C(0)0Ri" or the like; A represents a phenyl group or naphthyl group which may be substituted with a hydroxyl group, halogen atom or the like; Ri, ^^5 Ri' and Ri" independently represent a hydrogen atom, C1-C4 alkyl group or the like] (explanation for substituents is partly extracted). However, no report about PPARa agonist activity of this compound is found. In examples of the patent specification, no description is found about a benzoic acid derivative substituted with a cyclic 20 amino group. As a compound having a similar structure to the present invention, Patent document 44 discloses as a compound having integrin 5 [0072] [Chemical formula 29] (AM)

[0073] 28 552501 inhibitory activity, a compound represented by the general formula (AN)

[0074] [Chemical formula 30] U-V—A-(Alk)—(CO-NH)h-(Alk) — B (AN )

[0075] [wherein g, h and I each independently represent 0 or 1; Alk represents an alkylene; U represents an amidino group, guanidine group or -(G-Alk)k-C(Q)-N(R)Ri (wherein G represents a single bond, oxygen atom or the like, Q represents an oxygen atom, sulfur atom or the like, R represents a hydrogen atom, alkyl group or the like; RI represents an alkyl group, aryl group or the like; k represents 0 or 1), V represents general formula (AN-a)

[0076] [Chemical formula 31] (AN-a)

[0077] , general formula (AN-b)

[0078] [Chemical formula 32] 552501 10 15 W (AN-b) w, ,w5 3 w; 5

[0079] (wherein Wi represents an oxygen atom, sulfur atom or the like; W3, W4, W5 and W6 represent N or C-R4; W7 represents a nitrogen atom or the like; R4 represents a hydrogen atom, halogen atom or the like; Rg represents a hydrogen atom, halogen atom or the like) ; A represents general formula (AN-c)

[0080] [Chemical formula 33] R sr-s R '10 8.X1. (AN-c) Yi )m

[0081] , general formula (AN-d)

[0082] [Chemical formula 34] R, y 110 NY 1vL TRh (AN-d) 10 r/ JX 2 <r

[0083] (wherein Xi represents a nitrogen atom or C-H; X2 represents C-H; Yi represents -C(O)-, -C(S)- or the like; Z2 represents an oxygen 30 552501 atom, sulfur atom or the like; n, m each independently represent 0, 1 or 2, and n + m=l, 2, 3 or 4; r represents 1 or 2; Rs, Rg, Rio and Rn each independently represent a hydrogen atom, alkyl group or the like), B represents general formula (AN-e)

[0084] [Chemical formula 35] (wherein R15 represents a hydrogen atom, alkyl group or the like; Riv represents a hydrogen atom, alkyl group, aryl group or the like; R1S and Rig each independently represent a hydrogen atom, or alkyl group; E represents a carboxyl group, amide group or the like)] (explanation for substituents is partly extracted) . However, this compound is a cyclic amide derivative and the like which is different from an alicyclic amino group which is characteristic of compounds in accordance with the present invention, and substituent U is amidino group, guanidine group or the like functional group. Therefore, the above compound lacks a carboxyl group and a lower alkoxycarbonyl group which are structural features of the present invention, and hence differs in stricture from compounds in accordance with the present invention. Furthermore, no report about PPARa agonist activity is found. Furthermore, as a compound having a similar structure to compounds in accordance with the present invention, Patent document (AN-e)

[0085] 31 552501 10 45 discloses as a compound having integrin av(33 antagonist activity, a compound represented by the general formula (AO)

[0086] [Chemical formula 36] Jfr (AO) hrk J \R3 R6'° lG

[0087] [wherein Q represents general formula (AO-a)

[0088] [Chemical formula 37] T ' (x)t (AO-a)

[0089] ^ (wherein R7 represents a hydrogen atom, Ci_8 alkyl group or the like; R13 represents a hydrogen atom, Ci_8 alkyl group or the like; R19 represents a hydrogen atom, Ci_e alkyl group or the like; X represents 15 a halogen atom, cyano group or the like; p represents an integer from 0 to 4; t represents an integer from 0 to 5), E, G, L and M each independently represent a hydrogen atom, Ci_8 alkyl group or the like, J represents a hydrogen atom, Ci_8 alkyl group or the like, R1 represents a halogen atom, phenyl group which may be substituted 20 with (CH2) 0-4CO2R16 or the like; R2 represents a hydrogen atom, Ci-8 32 552501 alkyl group or the like; R3 and R6 each independently represent a hydrogen atom, Ci_8 alkyl group or the like; R15 represents a hydrogen atom, Cl-8 alkyl group or the like; m, n and p each independently represent an integer from 0 to 4; o represents an integer from 2 5 to 5] (explanation for substituents is partly extracted) . However, this compound is featured in that an aminoalkyl amino group binds to a cyclic amino group; and any cyclic amino group that binds to a benzoic acid derivative described in examples of the patent specification is 4-aminopiperidino group, and hence is different 10 in structure from compounds in accordance with the present invention. Furthermore, no report about PPARa agonist activity is found. As a compound having a similar structure to the present invention, Patent document 4 6 discloses as a compound having factor Xa inhibitory activity, a compound represented by the general formula (AP) 15 [0090] [Chemical formula 38] ft A-Y-D-E-G-J-Z-L (AP)

[0091] [wherein A represents a phenyl group, Ci~C6 alkyl group, or C3-C8 20 cycloalkyl group which may be substituted with 0 to 2 RI or the like; Y represents a bonding hand, -C (=0) - or the like; D represents a bonding hand, phenyl group substituted with 0 to 2 Rla or the like; E represents-N (R5)-C(=0)-, -C(=0)-N(R5) - or the like; G represents a bonding hand, -CR7R8- or the like; J represents general formula 25 (AP-a) 33 552501

[0092] [Chemical formula 39] R11a R11 ntlh N. '0-2 (AP-a) Rltb

[0093] (wherein Rn, Rlla and Rllb independently represent a hydrogen atom, hydroxyl group or the like) or the like, Z represents a phenyl substituted with 0 to 2 Rlb, naphthyl group substituted with 0 to 2 Rlb or the like; L represents a hydrogen atom, cyano group, C (=0) NR12R13, C (~NR12) NR12R13 or the like; R1 represents a halogen atom, Ci-4 alkyl group or the like; Rla represents a halogen atom, C1-4 alkyl group or the like; Rlb represents a halogen atom, -OCH2-COOR2b or the like; R2b represents a hydrogen atom, Ci_4 alkyl group or the like; R12 and R13 independently represent a hydrogen atom, C1-4 alkyl group or the like] (explanation for substituents is partly extracted) This compound dose not include benzoic acid derivatives which are substituted with a cyclic amino group, and differs in structure from compounds in accordance with the present invention. Furthermore, no report about PPARa agonist activity is found. [Patent document 1] W000/23407 pamphlet [Patent document 2] W000/75103 pamphlet [Patent document 3] W001/40207 pamphlet [Patent document 4] W002/38553 pamphlet [Patent document 5] W002/28821 pamphlet 34 552501 [Patent document 6] W002/064549 pamphlet [Patent document 7] W003/051821 pamphlet [Patent document 8] W003/059875 pamphlet [Patent document 9] W02004/010936 pamphlet 5 [Patent document 10] W02004/010992 pamphlet [Patent document 11] W003/055867 pamphlet [Patent document 12] W002/098840 pamphlet [Patent document 13] WO00/64876 pamphlet [Patent document 14] W003/020269 pamphlet 10 [Patent document 15] Japanese Patent Laid-Open Publication No. Sho 52-8367 6 [Patent document 16] Japanese Patent Laid-Open Publication No. Sho 51-149234 [Patent document 17] Japanese Patent Laid-Open Publication No. Sho 15 51-149235 [Patent document 18] Japanese Patent Laid-Open Publication No. Sho ^ 51-146478 [Patent document 19] Japanese Patent Laid-Open Publication No. Sho 51-146479 20 [Patent document 20] W003/030889 pamphlet [Patent document 21] W002/37937 pamphlet [Patent document 22] W002/051831 pamphlet [Patent document 23] Japanese Patent Laid-Open Publication No. 2000-136190 25 [Patent document 24] W003/075929 pamphlet 35 552501 [Patent document 25] W003/076395 pamphlet [Patent document 26] WO03/076400 pamphlet [Patent document 27] W003/07 6401 pamphlet [Patent document 28] W003/076421 pamphlet 5 [Patent document 29] W003/076422 pamphlet [Patent document 30] W003/07 6430 pamphlet [Patent document 31] W003/076438 pamphlet [Patent document 32] WOOl/54726 pamphlet [Patent document 33] W001/27090 pamphlet 10 [Patent document 34] W001/27082 pamphlet [Patent document 35] Japanese Patent Laid-Open Publication No. Hei 7-267926 [Patent document 36] WOOO/64888 pamphlet [Patent document 37] W02004/048334 pamphlet 15 [Patent document 38] W093/12086 pamphlet [Patent document 39] EP0607536 pamphlet ft [Patent document 40] W002/42273 pamphlet [Patent document 41] W003/043988 pamphlet [Patent document 42] W002/06232 pamphlet 20 [Patent document 43] W000/09132 pamphlet [Patent document 44] W001/44230 pamphlet [Patent document 45] W098/57638 pamphlet [Patent document 4 6] WOOO/71515 pamphlet [Non-patent document 1] Proc. Natl. Acad. Sci., 1992, 89, 4653 25 [Non-patent document 2] Endocrinology, 1995, 137, 354 36 RECEIVED at IPONZ on 30 November 2009 552501 [Non-patent document 3] J. Lipid. Res., 1996, 37, 907 [Non-patent document 4] Nat. Med.,1998, 4, 1046 [Non-patent document 5] J. Biol. Chem., 1998, 273, 29577 [Non-patent document 6] Proc. Natl. Acad. Sci., 1997, 94, 312 [Non-patent document 7] Cell, 2003, 113, 159 Disclosure of the invention Means to be solved by the invention

[0094] It is an object of the present invention to provide compounds which are different in chemical structure from known compounds described above, and has potent PPARa agonist activity while exhibiting potent effect in biological bodies, or to at least provide the public with a useful choice. Means for solving the problem

[0095] The inventors of the present invention made diligent efforts in light of a specific role of human PPARa to lipid metabolism for creating a structurally novel pharmaceutical having excellent efficacy, sustention and safety as an antihyperlipidemic drug, and found that novel cyclic amino benzoic acid derivatives of the present invention, namely, cyclic amino benzoic acids and cyclic amino benzoic acid esters and addition salts thereof have excellent human PPARa transcription activating activity, and exhibit excellent lipid lowering activity in a biological body.

[0096] That is, the present invention relates to (1) to (24) below. 37 552501

[0097] (1) The cyclic amino benzoic acid derivatives represented by the general formula (1)

[0098] [Chemical formula 40]

[0099] [wherein a ring Ar represents an aryl group which may have substituent , 5-membered or 6-membered aromatic heterocyclic group which may have substituent or condensed ring group thereof, Yrepresents a C1-C4alkylene, C2-C4alkenylene, C2-C4alkynylene or the general formula (2)

[0100] [Chemical formula 41] (wherein T represents a single bond, C1-C4alkylene, C2-C4 alkenylene or C2-C4 alkynylene, U represents a single bond, C1-C4 alkylene or C2-C4 alkenylene, A represents a carbonyl group, oxygen atom, sulfur atom, -NR1-(R1 represents a hydrogen atom, lower alkyl group which may be X (1) -T —A — U — (2)

[0101] 38 552501 RECEIVED at IPONZ on 30 November 2009 substituted with a halogen atom, aralkyl group which may have substituent, aryl group which may have substituent or 5-membered or 6-membered aromatic heterocyclic group which may have substituent or condensed ring group thereof), the general formula (3)

[0102] [Chemical formula 42] (3) R1

[0103] (wherein L1 represents a single bond or -NR1-, and R1 is as defined above) or the general formula (4)

[0104] [Chemical formula 43] (wherein L2 represents a single bond or oxygen atom, and R1 is as defined above)), 2 represents an oxygen atom, sulfur atom or -(CH2)n- (n represents 0,1 or 2), X represents a hydrogen atom, halogen atom, lower alkyl group which may be substituted with a halogen atom, lower alkoxy group which may be substituted with a halogen atom, hydroxyl group, nitro group, cyano group, optionally substituted amino group, aryl group 39 552501 which may have substituent, 5-membered or 6-membered aromatic heterocyclic group which may have substituent and condensed ring group thereof, aralkyl group which may have substituent, aryloxy group which may have substituent or aralkyloxy group which may have substituent, R represents a hydrogen atom or lower alkyl group, and -C00R is substituted at ortho position or metha position of binding position of ring W], or the pharmaceutically acceptable salt thereof,

[0105] (2) The cyclic amino benzoic acid derivative as described in the above (1) and the pharmaceutically acceptable salt thereof, wherein in the general formula (1) , Y is represented by the general formula (2a)

[0106] [Chemical formula 44] — T1 —A1— U1— (2a)

[0107] (wherein T1 represents a single bond, Ci-C4 alkylene or C2-C4 alkenylene, U1 represents a single bond or C1-C4 alkylene, and A1 represents an oxygen atom, sulfur atom, the general formula (3)

[0108] [Chemical formula 45] 40 RECEIVED at IPONZ on 30 November 2009 552501 A (3) R1

[0109] (wherein L1 represents a single bond or -NR1-, and R1 is as defined above) or the general formula (4)

[0110] [Chemical formula 46] <4> R1

[0111] (wherein L2 represents a single bond or oxygen atom, and R1 is as defined above)),

[0112] (3) The cyclic amino benzoic acid derivative as described in the above (1) or the pharmaceutically acceptable salt thereof, wherein in the general formula (1) , Y is represented by the general formula (2b)

[0113] [Chemical formula 47] — Ti —A2—LJ1— (2b)

[0114] 41 552501 (wherein T1 represents a single bond, C1-C4 alkylene or C2-C4 alkenylene, U1 represents a single bond or C1-C4 alkylene, A2 represents an oxygen atom, sulfur atom, the general formula (3a) 5 [0115] [Chemical formula 48] o (3a)

[0116] (wherein Rla represents a hydrogen, alkyl group which may be 10 substituted with halogen atom or aralkyl group which may have substituent), or represented by the general formula (4a)

[0117] [Chemical formula 49] o • (4a) R1a 15 [0118] (wherein Rla is as defined above) ) ,

[0119] (4) The cyclic amino benzoic acid derivative as described in the above (1) or the pharmaceutically acceptable salt thereof, wherein 20 in the general formula (1) , Y is represented by the general formula (2c) 42 552501

[0120] [Chemical formula 50] — T1—A3—U2— (2c)

[0121] 5 (wherein T1 represents a single bond, C1-C4 alkylene or C2-C4 alkenylene, U2 represents a single bond or methylene, A3 represents the general formula (3a)

[0122] 10 [Chemical formula 51] 0 [sl^ (3a) 1 R1a

[0123] (wherein Rla represents a hydrogen atom, alkyl group which may be ^ substituted with halogen atom or aralkyl group which may have 15 substituent) or the general formula (4a)

[0124] [Chemical formula 52] n|nj" ^ (4a) I R1a

[0125] 20 (wherein Rla is as defined above)), 43 552501

[0126] (5) The cyclic amino benzoic acid derivative as described in any one of the above (1) to (4) or thepharmaceutically acceptable salt thereof, wherein in the general formula (1) , Z represents an oxygen atom, sulfur atom or methylene,

[0127] (6) The cyclic amino benzoic acid derivative as described in any one of the above (1) to (5) or the pharmaceutically acceptable salt thereof, wherein in the general formula (1) , Z represents methylene,

[0128] (7) The cyclic amino benzoic acid derivative as described in any one of the above (1) to (6) or thepharmaceutically acceptable salt thereof, wherein in the general formula (1) , X represents a hydrogen atom, halogen atom, lower alkyl group which may be substituted with a halogen atom, lower alkoxy group which may be substituted with a halogen atom, hydroxyl group or optionally substituted amino group,

[0129] (8) The cyclic amino benzoic acid derivative as described in any one of the above (1) to (7) or thepharmaceutically acceptable salt thereof, wherein in the general formula (1), ring Ar represents 5-membered or 6-membered aromatic heterocyclic group which may have substituent,

[0130] (9) The cyclic amino benzoic acid derivative as described in any one of the above (1) to (8) or thepharmaceutically acceptable salt 552501 thereof, wherein in the general formula (1), ring Ar represents the general formula (5)

[0131] [Chemical formula 53] (wherein R2 represents a lower alkyl group which may be substituted with a halogen atom, cyclic alkyl group, lower alkoxy group which may be substituted with a halogen atom, optionally substituted amino group, 5-membered or 6-membered cyclic amino group, aryl group which may have substituent or 5-membered or 6-membered aromatic heterocyclic group which may have substituent, R3 represents a hydrogen atom, lower alkyl group which may be substituted with a halogen atom or cycloalkyl group, and G represents an oxygen atom or sulfur atom), (10) The cyclic amino benzoic acid derivative as described in the above (1) or thepharmaceutically acceptable salt thereof, wherein the compound represented by the general formula (1) is 2- [3-[ [2-(4-chlorophenyl)-4-methylthiazol-5-yl]methoxymet hyl]piperidin-l-yl] benzoic acid,

[0132]

[0133] 45 552501 3- [3- [ [2-(4-chlorophenyl)-4-methylthiazol-5-yl]methoxymet hyl]piperidin-l-yl] benzoic acid, 3- [3-[[2-(4-chlorophenyl)-4-methylthiazol-5-yl]methoxy]pi peridin-l-yl] benzoic acid, 2- [3- [ [2-(4-chlorophenyl)-4-methylthiazol-5-yl]carbonylam inomethyl]piperidin-l-yl] benzoic acid, 3- [3-[[2-(4-chlorophenyl)-4-methylthiazol-5-yl]carbonylam inomethyl]piperidin-l-yl] benzoic acid, 3-[3-[[2-(4-chlorophenyl)-4-methylthiazol-5-yl]carbonylam ino]piperidin-l-yl] benzoic acid, 2-[3-[N-[[2-(4-chlorophenyl)-4-methylthiazol-5-yl]methyl] carbamoyl]piperidin-l-yl] benzoic acid, (S)-2- [3-[[2-(4-chlorophenyl)-4-methylthiazol-5-yl]methox ymethyl]piperidine-l-yl] benzoic acid, (R)-2-[3-[[2-(4-chlorophenyl)-4-methylthiazol-5-yl]methox ymethyl]piperidin-l-yl] benzoic acid, (S)-3-[3-[[2-(4-chlorophenyl)-4-methylthiazol-5-yl]methox ymethyl]piperidin-l-yl] benzoic acid, (R)-3-[3-[[2-(4-chlorophenyl)-4-methylthiazol-5-yl]methox ymethyl]piperidin-l-yl] benzoic acid, (S)-3-[3-[[2-(4-chlorophenyl)-4-methylthiazol-5-y1]methox y]piperidin-l-yl] benzoic acid, (R)-3-[3-[[2-(4-chlorophenyl)-4-methylthiazol-5-yl]methox y]piperidin-l-yl] benzoic acid, 46 552501 (S)-2- [3-[[2-(4-chlorophenyl)-4-methylthiazol-5-yl]carbon ylaminomethyl]piperidin-l-yl] benzoic acid, (R)-2- [3-[ [2-(4-chlorophenyl)-4-methylthiazol-5-yl]carbon ylaminomethyl]piperidin-l-yl] benzoic acid, 5 (S)-3-[3-[ [2-(4-chlorophenyl)-4-methylthiazol-5-yl]carbon ylaminomethyl]piperidin-l-yl] benzoic acid, (R)-3-[3-[[2-(4-chlorophenyl)-4-methylthiazol-5-yl]carbon ^ ylaminomethyl]piperidin-l-yl] benzoic acid, (S)-3- [3-[[2-(4-chlorophenyl)-4-methylthiazol-5-yl]carbon 10 ylamino]piperidin-l-yl] benzoic acid, (R)-3- [3-f[2-(4-chlorophenyl)-4-methylthiazol-5-yl]carbon ylamino]piperidin-l-yl] benzoic acid, (S)-2-[3-[N-[[2-(4-chlorophenyl)-4-methylthiazol-5-yl]met hyl]carbamoyl]piperidin-l-yl] benzoic acid, or 15 (R) -2-[3-[N-[[2-(4-chlorophenyl)-4-methylthiazol-5-yl]met hyl]carbamoyl]piperidin-l-yl] benzoic acid, ^ [0134] (11) A pharmaceutical comprising at least one of the cyclic amino benzoic acid derivative or the pharmaceutically acceptable salt 20 thereof as described in any one of the above (1) to (10) as an active ingredient, (12) A PPARa agonist comprising at least one of the cyclic amino benzoic acid derivative or the pharmaceutically acceptable salt thereof as described in any one of the above (1) to (10) as an active 25 ingredient, 47 552501 (13) A PPAR a, y dual agonist comprising at least one of the cyclic amino benzoic acid derivative or the pharmaceutically acceptable salt thereof as described in any one of the above (1) to (10) as an active ingredient, 5 (14) A PPAR a, 5 dual agonist comprising at least one of the cyclic amino benzoic acid derivative or the pharmaceutically acceptable salt thereof as described in any one of the above (1) to (10) as an active ingredient, (15) A PPAR a, Y/ 5 triple agonist comprising at least one of the 10 cyclic amino benzoic acid derivative or the pharmaceutically acceptable salt thereof as described in any one of the above (1) to (10) as an active ingredient, (16) A PPAR modulator comprising at least one of the cyclic amino benzoic acid derivative or the pharmaceutically acceptable salt 15 thereof as described in any one of the above (1) to (10) as an active ingredient, ft (17) A lipid lowering agent comprising at least one of the cyclic amino benzoic acid derivative or the pharmaceutically acceptable salt thereof as described in any one of the above (1) to (10) as 20 an active ingredient, (18) A prophylactic or therapeutic agent for arteriosclerosis, comprising at least one of the cyclic amino benzoic acid derivative or the pharmaceutically acceptable salt thereof as described in any one of the above (1) to (10) as an active ingredient, 48 552501 RECEIVED at IPONZ on 30 November 2009 (19) A prophylactic or therapeutic agent for diabetes, comprising at least one of the cyclic amino benzoic acid derivative or the pharmaceutically acceptable salt thereof as described in any one of the above (1) to (10) as an active ingredient, and (20) A prophylactic or therapeutic agent for obesity, comprising at least one of the cyclic amino benzoic acid derivative or the pharmaceutically acceptable salt thereof as described in any one of the above (1) to (10) as an active ingredient. [0134a] (21) A use of at least one cyclic amino benzoic acid derivative or a pharmaceutically acceptable salt thereof according to any one of the above (1) to (10) in the manufacture of a medicament for treating abnormal lipid metabolism in a subject in need thereof. [0134b] (22) A use of at least one cyclic amino benzoic acid derivative or a pharmaceutically acceptable salt thereof according to any one of the above (1) to (10) in the manufacture of a medicament for treating or preventing arteriosclerosis. [0134c] (23) A use of at least one cyclic amino benzoic acid derivative or a pharmaceutically acceptable salt thereof according to any one of the above (1) to (10) in the manufacture of a medicament for treating or preventing diabetes. 49 (followed by page 49a) RECEIVED at IPONZ on 30 November 2009 552501 [0134d] (24) A use of at least one cyclic amino benzoic acid derivative or a pharmaceutically acceptable salt thereof according to any one of the above (1) to (10) in the manufacture of a medicament for treating or preventing obesity. Effect of the invention

[0135] The novel cyclic amino benzoic acid derivative or the addition salt thereof according to the present invention has excellent human PPARa transcription activating ability, andexhibits excellent lipid lowering activity in a living body.

[0136] These compounds of the present invention are effective as a lipid lowering agent, in particular, as a lipid lowering agent in liver and an inhibitor against development of arteriosclerosis. Best mode for carrying out the invention

[0137] For the compound represented by the general formula (1) of the present invention, definitions in the formula will be concretely explained below.

[0138] 4 9a (followed by page 50) 552501 The term "halogen atom" includes fluorine, chlorine, bromine, and iodine.

[0139] The term "lower alkyl group" includes straight chain or 5 branched chain group consisting of 1 to 6 carbons such as methyl, ethyl, n-propyl, i-propyl and the like.

[0140] The term "cycloalkyl group" includes the ring group consisting of 3 to 7 carbons such as cyclopropyl, cyclopentyl, cyclohexyl and 10 the like.

[0141] The term "lower alkoxy group" includes straight chain or branched chain group consisting of 1 to 5 carbons such as methoxy, ethoxy, n-propoxy, i-propoxy and the like. 15 [0142] The term "lower alkyl group which may be substituted with a ft halogen atom" includes the aforementioned lower alkyl group, and lower alkyl group substituted with a halogen atom such as chloromethyl group, trifluoromethyl group and the like. 20 [0143] The term "lower alkoxy group which may be substituted with a halogen atom" includes the aforementioned lower alkoxy group, and lower alkoxy group substituted with a halogen atom such as trifluoromethoxy group. 25 [0144] 50 552501 The term "aryl group" includes an aromatic hydrocarbon group such as phenyl group, naphthyl group and the like.

[0145] The term "aryloxy group" includes a phenoxy group, naphthoxy group and the like.

[0146] The term "aralkyl group" includes a benzyl group, diphenylmethyl group, triphenyl methyl group, phenethyl group, phenylpropyl group and the like.

[0147] The term "aralkyloxy group" includes a benzyloxy group, phenethyloxy group and the like.

[0148] The term "5-membered or 6-membered aromatic heterocyclic group" in "5-membered or 6-membered aromatic heterocyclic group and condensed ring group thereof" means 5-membered or 6-membered aromatic ring group which may contain 1 to 3 nitrogen, oxygen, sulfur atom, and examples thereof include furanyl group, thienyl group, pyrazolyl group, imidazolyl group, oxazolyl group, thiazolyl group, isoxazolyl group, isothiazolyl group, triazolyl group, oxadiazolyl group, thiadiazolyl group, pyridyl group, pyrimidyl group, pyridadyl group, and pyrazinyl group, and the term "condensed ring group thereof" means a benzene condensed ring group of the aforementioned "5-membered or 6-membered aromatic heterocyclic group" or condenced ring consisting of two rings arbitrarily selected from the 51 552501 aforementioned "5-membered or 6-membered aromatic heterocyclic group", and examples thereof include indolyl group, benzoxazolyl group, benzothiazolyl group, benzofuranyl group, benzothienyl group, benzimidazolyl group, quinolyl group, isoquinolyl group, quinazolyl group, quinoxalinyl group, imidazopyridyl group, pyrazolopyridyl group, imidazopyrimidyl group and the like. [0149] The term "optionally substituted amino group" includes unsubstituted amino group or amino group which is substituted with acyl group such as acetyl group, lower alkylsulfonyl group which may be substituted with a halogen atom such as methanesulfonyl group, and trifluoromethane sulofnyl group, aryl sulfonyl group which may have substituent such as phenylsulfonyl group, and tolylsulfonyl, lower alkyl group which may be substituted with a halogen atom, aryl group which may have substituent, or aralkyl group which may have substituent. The term "5-membered or 6-membered cyclic amino group" includes a pyrrolidinyl group, piperidinyl group, piperadinyl group, morpholinyl group, thiomorpholinyl group or the like. The term "substituent" used in the wordings "aryl group which may have substituent", "5-membered or 6-membered aromatic heterocyclic group which may have substituent or condensed ring group thereof", "aralkyl group which may have substituent", "aralkyloxy group which may have substituent", and "aryloxy group which may have substituent" means a halogen atom, hydroxyl group, 52 552501 lower alkyl group which may be substituted with a halogen atom, cycloalkyl group; lower alkoxy group which may be substituted with a halogen atom, lower alkylthio group, lower alkoxycarbonyl group, nitro group, optionally substituted amino group, 5-membered or 5 6-membered cyclic amino group, cyano group, carboxyl group, aldehyde group, aryl group which may have substituent, aralkyl group which may have substituent, aralkyloxy group which may have substituent, aryloxy group whichmay have substituent, or 5-membered or 6-membered aromatic heterocyclic group which may have substituent or condensed 10 ring thereof, and the term "lower alkylthio group" indicates straight-chained or branched-chained group consisting of 1 to 5 carbon(s) such as methylthio group, ethylthio group, propylthio group or the like, and the term "lower alkoxycarbonyl group" indicates the like straight-chained or branched-chained group having 1 to 15 6 carbon(s) such as methoxycarbonyl group, ethoxycarbonyl group or the like. The substituent used herein refers to the "substituent" ft as explained above.

[0150] The compound represented by general formula (1) of the present 20 invention may be in the form of a pharmaceutically acceptable salt as needed. Examples of the pharmaceutically acceptable salt include inorganic salts with "hydrochloric acid, hydrobromic acid, sulfuric acid" and the like, organic salts with "acetic acid, fumaric acid, maleicacid, oxalic acid, citric acid, methane sulfonic acid, tosylic 53 552501 acid" and the like, andsalts withbase such as "sodiumsalt, potassium salt, calcium salt" and the like.

[0151] Furthermore, the compound represented by the general formula (1) of the present invention and its pharmaceutically acceptable salt maybe in the formof its intramolecular salt thereof, anhydride, hydrate, or solvate thereof.

[0152] Furthermore, the compound represented by the general formula (1) of the present invention includes optical isomers based on asymmetric carbon, geometrical isomers, stereo isomers, tautomers and the like, and all of these isomers and mixture thereof are encompassed by the scope of the present invention.

[0153] The compound represented by the general formula (1) which is a compound of the present invention can be prepared by a method described in Production method 1 or by combination of known methods.

[0154] [Production method 1]

[0155] [Chemical formula 54] 54 552501 (3~yY^nh . .-A (6) (7) COOff ( Ar 4—Y 1-B e~\_l/ (8) CHO (*)~yV^n' iV (9) CHO ^Txrv (la) 1-D ©~YV ^ v—' I w (1b) COOFP COOH

[0156] [wherein E represents a leaving group, Ra represents a lower alkyl group, and ring Ar, W, X, Y, and Z are as defined above] 5 [0157] As the leaving group denoted by E, a halogen atom, sulf onyloxy ft group such as trifluoromethanesulfonyloxy group and p-tolylsulfonyloxy group, trialkylsutanyl group such as trimethylstanyl group, (HO)2B- and the like can be exemplified. 10 [0158] Conversion from the compounds represented by the general formula (6) and the general formula (7) to the compound represented by the general formula (la) (Step 1-A) can be performed, when the leaving group E in the compound represented by the general formula 15 (7) represents a halogen atom, or sulfonyloxy group, at room 55 552501 temperature to 120°C for 12 to 48 hours in an appropriate solvent, for example, toluene, 1,4-dioxane, t-butylalcohol, N, N-dimethylformamide, tetrahydrofuran, a mixture thereof or the like, in the presence of ligand such as 2,2'-bis (diphenylphosphino)-1,1'-binaphthyl, 1,1'-bis(diphenylphosphino)ferrocene or the like ligand, and base such as sodium carbonate, potassium carbonate, cesium carbonate, sodium tert-butoxide, potassium tert-butoxide, tripotassium phosphate, triethylamine, pyridine or the like base, by using palladium catalyst such as palladium (II) acetate, tris (dibenzylidene acetone) dipalladium (0), or [1,1' -bis (diphenylphosphino) ferrocene] dichloro palladium (II) , or nickel catalyst such as bis (1,5-cyclooctadiene) nickel (0). [0159] When the leaving group E is a halogen atom, the conversion can be performed at room temperature to 160°C for 1 to 70 hours in an appropriate solvent such as toluene, N,N-dimethylformamide, N,N-dimethylacetamide, dimethylsulfoxide, isopropanol, 1,2-dimethoxyethane, 1,4-dioxane or the like, in the presence of a base such as potassium carbonate, sodium carbonate, cesium carbonate, cesium acetate, tripotassium phosphate or the like, and, if need be, by using a cuprous salt such as copper iodide (I) , copper bromide (I) or the like, and, if need be, by using a ligand such as proline, N-methyl glycine, ethylene glycol, ethylene diamine, 56 552501 and, if need be, by using a phase transfer catalyst such as tetrabutyl ammonium iodide or the like.

[0160] When the leaving group E in the compound represented by the 5 general formula (7) represents a trialkylstanyl group, or (HO)2B-, the conversion can be performed at 0 to 60°C for 6 to 70 hours in an appropriate solvent, for example, dichloromethane, 1,4-dioxane, N-methylpyrrolidone, tetrahydrofuran, N,N-dimethylformamide, ^ N,N-dimethylacetamide or the like, in the presence of a base such 10 as triethylamine, pyridine, 2,6-lutidine, tetrabutyl ammonium fluoride or the like, in the presence of copper (II) acetate, and, if need be, by using molecular sieves , and, if need be, by using an appropriate reaction auxiliary agent such as pyridine N-oxide, 1,1,6,6-tetramethylpiperidinyloxy radical, myristic acid or the 15 like cooxidant .

[0161] ft Conversion from the compounds represented by the general formula (6) and the general formula (8) to the compound represented by the general formula (9) (Step 1-B) can be performed in a similar 20 manner as described in Step 1-A.

[0162] Conversion from the compound representedby the general formula (9) to the compound represented by the general formula (la) (Step 1-C) can be performed at 0 to 100 °C for 1 to 24 hours in a mixture 25 of an alcohol such as methanol, ethanol or the like and an appropriate 57 552501 solvent such as dichloromethane, tetrahydrofuran or the like, in the presence of acid such as acetic acid or the like if need be, by using manganese dioxide and cyanide salt such as potassium cyanide, sodium cyanide or the like . 5 [0163] Conversion from the compound represented by the general formula (la) to the compound represented by the general formula (lb) (Step 1-D) can be performed by hydrolysis using acid such as hydrochloric acid, sulfuric acid or nitric acid or the like or base such as lithium 10 hydroxide, sodiumhydroxide, potassiumhydroxide, sodium carbonate, potassium carbonate or the like at 0 to 100°C for 1 to 48 hours in the absence or in the presence of an appropriate solvent such as water, acetic acid, methanol, ethanol, tetrahydrofuran, 1,4-dioxane, a mixture thereof or the like. 15 [0164] Among compounds represented by the general formula (la), a ft compound represented by the general formula (1c) can also be prepared by a synthesis method described in Production method 2.

[0165] 20 [Production method 2]

[0166] [Chemical formula 55] 58 552501 10 15 ho-u n (10a) H-AS-U cooff n (10) coor? 2-c V_y (11) j-u n i fXYT Aa"H 2-A coofp 2-b N-y (13> (ArVT A*"U^ coorp (12) (1C)

[0167] [wherein Aa represents an oxygen atom, sulfur atom, or -NR1-, J represents a leaving group, and ring Ar, T, U, W, X, Z, R1, and Ra are as defined above]

[0168] As a leaving group denoted by J, a halogen atom, lower alkylsulfonyloxy group which may be substituted with halogen atom such as methanesulfonyloxy group and trifluoromethanesulfonyloxy group, arylsulfonyloxy group which may be substituted with lower alkyl group such as phenylsulfonyloxy group and p-tolylsulfonyloxy group can be exemplified.

[0169] Conversion from the compounds represented by the general formula (10) and the general formula (11) to the compound represented by the general formula (lc) (Step 2-A) can be performed at -15 to 120°C for 1 to 24 hours, in an appropriate solvent for example, 59 552501 toluene, hexane, tetrahydrofuran, diethyl ether, dichloromethane, N,N-dimethylformamide, dimethylsulfoxide, acetone, a mixture thereof or the like, in the presence of a base such as sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium 5 hydride, sodium methoxide, potassium t-butoxide, pyridine, triethylamine, N,N-dimethyl aniline or the like, with addition of an appropriate iodide salt, for example, sodium iodide, potassium iodide, tetrabutyl ammonium iodide and the like if need be. 10 Conversion from the compounds represented by the general formula (12) and the general formula (13) to the compound represented by the general formula (lc) (Step 2-B) can be performed in a similar manner as described in Step 2-A.

[0171] 15 Conversion from the compound represented by the general formula (10a) to the compound represented by the general formula (12) (Step ft 2-C) can be performedg by using a halogenating agent such as thionyl chloride, phosphorous oxychloride, thionyl bromideor the like at -20 to 80°C for 0.5 to 6 hours in the absence or in the presence 20 of an appropriate solvent for example, dichloromethane, chloroform, tetrahydrofuran, benzene, a mixture thereof or the like, in the presence of a base such as pyridine or the like if need be, , or by using an appropriate sulfonylating agent for example, methane sulfonyl chloride, trifluoromethane sulfonic anhydride or the like 25 at -20 to 60°C for 0.5 to 3 hours in an appropriate solvent, for 552501 example, dichloromethane, tetrahydrofuran, N,N-dimethylformamide, a mixture thereof or the like, in the presence of a base such as triethylamine, pyridine or the like.

[0172] 5 The conversion can also be performed at -20 to 60°C for 0.5 to 6 hours in the absence or in the presence of an appropriate solvent for example, dichloromethane, chloroform, tetrahydrofuran, benzene, a mixture thereof or the like, in the presence of imidazole if need ^ be, by using triphenylphosphine and carbon tetrabromide, carbon 10 tetrachloride or iodide.

[0173] Among compounds represented by the general formula (la), a compound represented by the general formula (Id) can also be prepared by a synthesis method described in Production method 3. 15 [0174] [Production method 3] W [0175] [Chemical formula 56] X ^ ^,X rTv0H <13a> - 0_u r ;N COORP ~ v y I w I COOFP 3-A iV (10a) (id) 20 [0176] [wherein ring Ar, U, W, X, Z, and Ra are as defined above] [0177] 61 552501 Conversion from the compounds represented by the general formula (10a) and the general formula (13a) to the compound represented by the general formula (Id) (Step 3-A) can be performed by using an electrophilic agent such as diethyl azodicarbonate, diisopropyl azodicarbonate, dipiperidine azodicarbonate or the likeat 0 to 60 °C for 3 to 24 hours, in an appropriate solvent, for example, toluene, hexane, tetrahydrofuran, a mixture thereof or the like, in the presence of organic phosphorous compound such as triphenylphosphine, tributylphosphine or the like, or by using a phosphorane compound such as cyanomethylene tributylphosphcran cyanomethylene trimethylphosphorane or the like at room to 120°C for 1 to 24 hours in an appropriate solvent, for example, toluene, benzene, hexane, tetrahydrofuran, a mixture thereof or the like.

[0178] Among compound represented by the general formula (la), a compound represented by the general formula (le) can also be prepared by a synthesis method described in Production method 4.

[0179] [Production method 4]

[0180] [Chemical formula 57] 62 552501 COORP 4-A (10b) COOFP (15) (1e)

[0181] [wherein Ta represents a single bond, C1-C3 alkylene, C2-C3 alkenylene, or C2-C3 alkynylene, Ua represents a single bond, C1-C3 alkylene, or C2-C3 alkenylene, and ring Ar, T, U, W, X, Z, R1, and Ra are as defined above] Conversion from the compounds represented by the general formula (10b) and the general formula (14) to the compound represented by the general formula (le) (Step 4-A) can be performed by using a reducing agent such as lithium borohydride, sodium borohydride, sodium cyanoborohydride, sodium triacetoxyborohydride or the like at 0 to 60 °C for 1 to 24 hours in an appropriate solvent, for example, methanol, ethanol, dichloromethane, chloroform, tetrahydrofuran a mixture thereof or the like, in the presence of acid such as hydrochloric acid, hydrobromic acid, acetic acid or the like or Lewis acid such as aluminum chloride, zinc chloride or the like if need be.

[0182]

[0183] 63 552501 Conversion from the compounds represented by the general formula (15) and the general formula (13b) to the compound represented by the general formula (le) (Step 4-B) can be performed in a similar manner as described in Step 4-A.

[0184] Among compounds represented by the general formula (la), compounds represented by the general formula (If) and the general formula (lg) can also be prepared by a synthesis method described in Production method 5.

[0185] [Production method 5]

[0186] [Chemical formula 58] hooc-u COOFF (16) (1fl ,X T-oc-Uv^nAo^ ■ coofp (1 g)

[0187] [wherein M represents a leaving group, and Ar, T, U, W, X, Z, R1, and Ra are as defined above]

[0188] 64 552501 Here, as a leaving group denoted by M, lithium atom, copper atom, -MgX1 (X1 represents halogen atom) and the like can be exemplified.

[0189] Conversion from the compounds represented by the general formula (16) and the general formula (13b) to the compound represented by the general formula (If) (Step 5-A) can be performed by using a condensing agent such as dicyclohexylcarbodiimide, 3-(3-dimethylaminopropyl)-1-ethylcarbodiimide hydrochloride, diethyl cyanophosphate, azide diphenylphosphate, carbonyldiimidazole or the likeat -15 to 120°C for 1 to 24 hours, in an appropriate solvent, for example, dichloromethane, chloroform, tetrahydrofuran, diethyl ether, N, N-dimethylformamide, a mixture thereof or the like, in the presence of a base such as pyridine, triethylamine, N-methylmorpholine, 4-(dimethylamino)pyridine or the like, in the presence of a reaction auxiliary agent such as N-hydroxybenzotriazole, N-hydroxy succinimide, 3,4-dihydro-3-hydroxy-4-oxo-l,2,3-benzotriazine or the like if need be.

[0190] Alternatively, the conversion can aloso be performed first by letting the compound represented by the general formula (16) reacts with thionyl chloride, thionyl bromide, acetic anhydride, ethyl chlorocarbonate or the like, in the presence of a base such as pyridine, triethylamine or the like if need be,at -15 to 50°C 65 552501 for 5 minutes to 3 hours, in the absence or in the presence of an appropriate solvent, for example, toluene, tetrahydrofuran, dichloromethane, N,N-dimethylformamide, a mixture thereof or the like if need be,so that a carboxyl group is made into a reactive 5 derivative group such as acid chloride, acid bromide, acid anhydride or the like, and then reaction with the compound represented by the general formula (13b) is conducted at -15 to 50°C for 30 minutes to 6 hours in an appropriate solvent, for example, toluene, tetrahydrofuran, dichloromethane, N,N-dimethylformamide, a 10 mixture thereof or the like, in the presence of a base such as pyridine, triethylamine, 4-(dimethylamino) pyridine or the like.

[0191] Conversion from the compounds represented by the general formula (16) and the general formula (17) to the compound represented 15 by the general formula (lg) (Step 5-B) can be performed first by letting the compound represented by the general formula (16) react ft with thionyl chloride, thionyl bromide, acetic anhydride, ethyl chlorocarbonate or the like at -15 to 50°C for 5 minutes to 3 hours in the absence or in the presence of an appropriate solvent, for 20 example, toluene, tetrahydrofuran, dichloromethane, a mixture thereof or the like, in the presence of a base such as pyridine, triethylamine or the like if need be, so that a carboxyl group is made into a reactive derivative group such as acid chloride, acid bromide or acid anhydride, and then reaction with the compound 25 represented by the general formula (17) is conducted at -78 to 50°C 66 552501 for 0.5 to 12 hours in an appropriate solvent, for example, toluene, tetrahydrofuran, diethyl ether, a mixture thereof or the like.

[0192] Among compounds represented by the general formula (la), a compound represented by the general formula (lh) can also be prepared by a synthesis method described in Production method 6.

[0193] [Production method 6]

[0194] [Chemical formula 59] [wherein ring Ar, T, U, W, X, Z, R1, and Ra are as defined above] [0196] Conversion from the compounds represented by the general formula (10b) and the general formula (18) to the compound represented by the general formula (lh) (Step 6-A) can be performed in a similar manner as described in Step 5-A. Among compounds represented by the general formula (la), a compound represented by the general formula (li) can also be prepared by a synthesis method described in Production method 7. (10b) (1h)

[0195]

[0197] 67 552501

[0198] [Production method 7]

[0199] [Chemical formula 60] (10c) 09

[0200] [wherein Ab represents an oxygen atom, or -NR1-, and ring Ar, T, U, W, X, Z, R1, and Ra are as defined above]

[0201] 10 Conversion from the compounds represented by the general formula (10c) and the general formula (19) to the compound represented ft by the general formula (li) (Step 7-A) can be performed at 0 to 100°C for 0.5 to 12 hours in an appropriate solvent, for example, toluene, tetrahydrofuran, dichloromethane,N,N-dimethylformamide, 15 a mixture thereof or the like, in the presence of a base such as pyridine or triethylamine if need be.

[0202] Conversion from the compounds represented by the general formula (10c) and the general formula (13b) to the compound 20 represented by the general formula (li) (Step 7-B) can be 68 552501 performedreacting at 0 to 60°C for 0.5 to 12 hours in an appropriate solvent, for example, toluene, tetrahydrofuran, dichloromethane, N, N-dimethylformamide, a mixture thereof or the like, in the presence of a base such as pyridine, triethylamine or the like if need be, 5 by using carbonyl diimidazole.

[0203] Among compounds represented by the general formula (la), a compound represented by the general formula (lj) can also be prepared ^ by a synthesis method described in Production method 8. 10 [0204] [Production method 8]

[0205] [Chemical formula 61] 'T-OH W (13c) ^Vt^n-Vn R< TwJ COOF? - pi twj COOFP p (10b) (10 15 [0206] [wherein ring Ar, T, U, W, X, Z, R1, and Ra are as defined above]

[0207] Conversion from the compounds represented by the general formula (10b) and the general formula (13c) to the compound 20 represented by the general formula (lj) (Step 8-A) can be performed in a similar manner as described in Step 7-B.

[0208] 69 552501 Among compounds represented by the general formula (la), compounds represented by the general formula (lk) and the general formula (11) can also be prepared by a synthesis method described in Production method 9.

[0209] [Production method 9]

[0210] [Chemical formula 62] Ja-CH2-(CH,)c N (12a) OHC-(CH,)q COOP N (^yfC^-CHO (20) (Ik) COOff (15a) (d-y-CH.-ja (21) COOFP X COOFP 10 [0211] [wherein Ja represents a halogen atom; p, q which are identical or different, represent 0, 1 or 2, and p + q represents 0, 1 or 2; k represents 2, 3 or 4, and ring Ar, W, X, Z, and Ra are as defined above] 15 [0212] Conversion from the compounds represented by the general formula (12a) and the general formula (20) to the compound represented 70 552501 by the general formula (lk) (Step 9-A) can be performed first by letting the compound represented by the general formula (12a) react with an organic phosphorous compound such as triphenylphosphine, triethyl phosphate or the like at -78 to 120°C for 1 hour to 12 5 hours in the absence or in.the presence of an appropriate solvent, for example, toluene, tetrahydrofuran, benzene, a mixture thereof or the like, and then letting the same react with the compound represented by the general formula (20) at -78 to 120°C for 1 to 12 hours in an appropriate solvent, for example, toluene, 10 tetrahydrofuran, diethyl ether, dimethylsulfoxide, a mixture thereof or thelike, in the presence of a base such as sodium hydride, n-butyl lithium, lithium diisopropyl amide, lithium bis(trimethylsilyl)amide, potassium t-butoxide, sodium hydroxide or the like. 15 [0213] Conversion from the compounds represented by the general ft formula (15a) and the general formula (21) to the compound represented by the general formula (lk) (Step 9-B) can be performed in a similar manner as described in Step 9-A. 20 [0214] Conversion from the compounds represented by the general formula (lk) to the general formula (11) (Step 9-C) can be performed at 0 to 80°C for 0 .5 to 12 hours in hydrogen atmosphere at atmospheric pressure to 0 . 5 MPa in an appropriate solvent, for example, methanol, 25 ethanol, ethyl acetate, tetrahydrofuran, N,N-dimethylformamide, 71 552501 a mixture thereof or the like, in the presence of metal catalyst such as palladium on activated carbon, palladium on activated carbon-ethylene diamine complex, platinum on activated carbon, platinum oxide, rhodium on aluminum or the like. 5 [0215] Among compounds represented by the general formula (la), a compound represented by the general formula (lm) can also be prepared by a synthesis method described in Production method 10. ^ [0216] 10 [Production method 10]

[0217] [Chemical formula 63] (C^)-C=CH Tw jn co°*—iz) Tw' COORP (12a) (1m) ) [0218] 15 [wherein ring Ar, W, X, Z, Ra, Ja, p, and q are as defined above] [0219] Conversion from the compounds represented by the general formula (12a) and the general formula (22) to the compound represented by the general formula (lm) (Step 10-A) can be performed at -78°C 20 to room temperature for 1 to 12 hours, in an appropriate solvent, for example, toluene, tetrahydrofuran, diethyl ether, dimethylsulfoxide, hexamethylphosphoric triamide, a mixture 72 552501 thereof or the like, in the presence of a base such as sodium hydride, n-butyl lithium, lithium amide, potassium carbonate or the like, with addition of appropriate iodide salt such as sodium iodide, copper (I) iodide, tetrabutyl ammonium iodide, or the like if need be. In Production method 1, among compounds represented by the general formula (6) , a compound represented by the general formula (6a) can be prepared by a synthesis method described in Production method 11.

[0221] [Production method 11]

[0222] [Chemical formula 64]

[0220] (23a) (23) 11-C -T-Aa-H J-U i-'PG1 11-B (13) xPG1 (24) (25) Jl1-D (6a) 73 552501

[0223] [wherein PG1 represents a protecting group, and ring Ar, T, U, W, Z, Aa, and J are as defined above]

[0224] As a protecting group shown by PG1, acyl group such as acetyl group or trifluoroacetyl group, lower alkoxycarbonyl group such as t-butoxycarbonyl group, aralkyloxy carbonyl group which may have substituent such as benzyloxycarbonyl group, or aralkyl group which may have substituent such as benzyl group or p-methoxybenzyl group can be exemplified.

[0225] Conversion from the compounds represented by the general formula (23) and the general formula (11) to the compound represented by the general formula (25) (Step 11-A) can be performed in a similar manner as described in Step 2-A.

[0226] Conversion from the compounds represented by the general formula (24) and the general formula (13) to the compound represented by the general formula (25) (Step 11-B) can be performed in a similar manner as described in Step 2-B.

[0227] Conversion f romthe compound represented by the general formula (23a) to the compound represented by the general formula (24) (Step 11-C) can be performed in a similar manner as described in Step 2-C. 74 552501

[0228] Conversion fromthe compoundrepresentedby the general formula (25) to the compound represented by the general formula (6a) (Step 11-D) can be performed by deprotection according to a known method, for example, those disclosed in "Protecting Groups in Organic Synthesis (published by John Wily and Sons(1999))".

[0229] As such amethod, methods using acids, bases,ultraviolet rays, hydrazine, tetrabutyl ammonium fluoride, trimethylsilyl iodide and the like, as well as a reducing method can be exemplified.

[0230] In Production method 11, among compounds represented by the general formula (25) , a compound represented by the general formula (25a) can also be prepared by a synthesis method shown by Production method 12.

[0231] [Production method 12]

[0232] [Chemical formula 65] (23a) (25a)

[0233] [wherein ring Ar, U, W, Z, and PG1 are as defined above] 75 552501

[0234] Conversion from the compounds represented by the general formula (23a) and the general formula (13a) to the compound represented by the general formula (25a) (Step 12-A) can be performed in a similar manner as described in Step 3-A.

[0235] In Production method 11, among compounds represented by the general formula (25) , a compound represented by the general formula (25b) can also be prepared by a synthesis method described in Production method 13.

[0236] [Production method 13]

[0237] [Chemical formula 66] (26) (25b)

[0238] [wherein ring Ar, T, Ta, U, Ua, W, Z, R1, and PG1 are as defined above]

[0239] 76 552501 Conversion from the compounds represented by the general formula (2 3b) and the general formula (14) to the compound represented by the general formula (25b) (Step 13-A) can be performed in a similar manner as described in Step 4-A. 5 [0240] Conversion from the compounds represented by the general formula (26) and the general formula (13b) to the compound represented by the general formula (25b) (Step 13-B) can be performed in a similar manner as described in Step 4-B. 10 [0241] In Production method 1, among compounds represented by the general formula (6), a compound represented by the general formula (6b) can be prepared by a synthesis method described in Production method 14. 15 [0242] [Production method 14] 9 [0243] [Chemical formula 67] /^VTf hooc-IK^^pg1 Vjy R1(13b) ^T-ru^PG1 w , 14-A (27) (28) 14-B ©"-r^jr (6b) 20 [0244] 77 552501 [wherein ring Ar, T, U, W, Z, R1, and PG1 are as defined above]

[0245] Conversion from the compounds represented by the general formula (27) and the general formula (13b) to the compound represented by the general formula (28) (Step 14-A) can be performed in a similar manner as described in Step 5-A.

[0246] Conversion from the compound represented by the general formula (28) to the compound represented by the general formula (6b) (Step 14-B) can be performed in a similar manner as described in Step 11-D,

[0247] In Production method 1, among compounds represented by the general formula (6) , a compound represented by the general formula (6c) can be prepared by a synthesis method described in Production method 15.

[0248] [Production method 15]

[0249] [Chemical formula 68] 78 552501 HN- i R (^VT-oocn :%CfPG' ^ m f^YT^r V»' 1 ^ ^ w R' Iwj PG1 (23b) (29) ©-"T"rVr — » i»j (60)

[0250] [wherein ring Ar, T, U, W, Z, R1, and PG1 are as defined above] ^ [0251] 5 Conversion from the compounds represented by the general formula (23b) and the general formula (18) to the compound represented by the general formula (29) (Step 15-A) can be performed in a similar manner as described in Step 5-A.

[0252] 10 Conversion from the compound represented by thegeneral formula (29) to the compound represented by the general formula (6c) (Step ^ 15-B) can be performed in a similar manner as described in Step 11-D.

[0253] 15 In Production method 1, among compounds represented by the general formula (6) , a compound represented by the general formula (6d) can be prepared by a synthesis method described in Production method 16.

[0254] 20 [Production method 16] 79 552501

[0255] [Chemical formula 69] (6d)

[0256] [wherein ring Ar, Ab, T, U, W, Z, R1, and PG1 are as defined above]

[0257] Conversion from the compounds represented by the general formula (23c) and the general formula (19) to the compound represented by the general formula (30) (Step 16-A) can be performedin a similar manner as described in Step 7-A.

[0258] Conversion from the compounds represented by the general formula (23c) and the general formula (13b) to the compound represented by the general formula (30) (Step 16-B) can be performed in a similar manner as described in Step 7-B.

[0259] Conversion from the compound represented by the general formula (30) to the compound represented by the general formula (6d) (Step 80 552501 16-C) can be performed in a similar manner as described in Step 11-D.

[0260] In Production method 1, among compounds represented by the 5 general formula (6), a compound represented by the general formula (6e) can be prepared by a synthesis method described in Production method 17.

[0261] ^ [Production method 17] 10 [0262] [Chemical formula 70] # <6e)

[0263] [wherein ring Ar, T, U, W, Z, R1, and PG1 are as defined above] 15 [0264] Conversion from the compounds represented by the general formula (23b) and the general formula (13c) to the compound represented by the general formula (31) (Step 17-A) can be performed in a similar manner as described in Step 7-B. 20 [0265] 81 552501 Conversion from the compound representedby the general formula (31) to the compound represented by the general formula (6e) (Step 17-B) can be performed in a similar manner as described in Step 11-D. [0266] In Production method lr among compounds represented by the general formula (6) , compounds represented by the general formulas (6f) and (6g) can be prepared by a synthesis method described in Production method 18.

[0267] [Production method 18]

[0268] [Chemical formula 71] (24a) (26a) /PG1 (32) <33) Ifl-C 18"E (6f) (6g)

[0269] 82 552501 [wherein ring Ar, W, Z, Ja, p, q, k, and PG1 are as defined above]

[0270] Conversion from the compounds represented by the general formula (24a) and the general formula (20) to the compound represented by the general formula (32) (Step 18-A)can be performed in a similar manner as described in Step 9-A.

[0271] Conversion from the compounds represented by the general formula (26a) and the general formula (21) to the compound represented by the general formula (32) (Step 18-B) can be performed in a similar manner as described in Step 9-B.

[0272] Conversion from the compound representedby the general formula (32) to the compound represented by the general formula (6f) (Step 18-C) can be performed in a similar manner as described in Step 11-D.

[0273] Conversion from the compound representedby the general formula (32) to the compound represented by the general formula (33) (Step 18-D) can be performed in a similar manner as described in Step 9-C.

[0274] Conversion from the compound representedby the general formula (33) to the compound represented by the general formula (6g) (Step 83 552501 18-E) can be performed in a similar manner as described in Step Conversion from the compound representedby the general formula (6f) to the compound represented by the general formula (6g) (Step 18-F) can be performed in a similar manner as described in Step In Production method 1, among compounds represented by the general formula (6) , a compound represented by the general formula (6h) can be prepared by a synthesis method described in Production method 19.

[0277] [Production method 19]

[0278] [Chemical formula 72] 11-D.

[0275] 9-C.

[0276] © (CH^CHCH J'-CCH*),, ^PG« (22) 0 ,(CHyp-CEc-(Chv 19-A (24a) (34) (6h)

[0279] [wherein ring Ar, W, Z, Ja, p, q, and PG1 are as defined above] 84 552501

[0280] Conversion from the compounds represented by the general formula (24a) and the general formula (22) to the compound represented by the general formula (34) (Step 19-A) can be performed in a similar 5 manner as described in Step 10-A.

[0281] Conversion f romthe compound representedby the general formula (34) to the compound represented by the general formula (6h) (Step 19-B) can be performed in a similar manner as described in Step 10 11-D.

[0282] In Production methods 2 to 10, compounds represented by the general formulas (10) , (15) and (16) can be prepared by a synthesis method described in Production method 20. 15 [0283] [Production method 20] 9 [0284] [Chemical formula 73] 85 552501 10 PG2-AC-U 20-B (7) COOFP PG2-Ac-Uv_^\n, (36) 20-D PG2—Ac-U COOff H-A«-U N COOFP OHC-U (10,16) 20-E N X COOFP (15)

[0285] [wherein PG2 represents a protecting group or hydrogen atom, Ac represents an oxygen atom, sulfur atom, -NR.1", or -00C-, and U, Ua, W, X, Z, R1, Ra, and E are as defined above]

[0286] As a protecting group shown by PG1, acyl group such as acetyl group or trifluoroacetyl group, lower alkoxycarbonyl group such as t-butoxycarbonyl group, aralkyloxy carbonyl group which may have substituent such as benzyloxycarbonyl group, aralkyl groups which have substituent such as benzyl group, p-methoxybenzyl group or triphenyl group, silyl group such as trimethylsilyl group or 86 552501 t-butyldimethylsilyl, phthaloyl group or the like can be exemplified.

[0287] Conversion from the compounds represented by the general formula (35) and the general formula (7) to the compound represented by the general formula (36) (Step 20-A) can be performed in a similar manner as described in Step 1-A.

[0288] Conversion from the compounds represented by the general formula (35) and the general formula (8) to the compound represented by the general formula (37) (Step 20-B) can be performedin a similar manner as described in Step 1-B.

[0289] Conversion from the compound representedby the general formula (37) to the compound represented by the general formula (36) (Step 20-C) can be performed in a similar manner as described in Step 1-C.

[0290] In the general formula (36), conversion from a compound in which PG2 represents a protecting group to the compound represented by the general formulas (10) , or (16) (Step 20-D) can be performed by deprotection according to a known method, for example, those disclosed in "Protecting Groups in Organic Synthesis (published by John Wily and Sons(1999))". 87 552501 As such a method, methods using acid, base, ultraviolet rays, hydrazine, tetrabutyl ammonium fluoride, trimethylsilyl iodide and the like, as well as a reducing method can be exemplified.

[0291] In the general formula (10), conversion from a compound in which Ac is an oxygen atom (excluding compound in which U represents a single bond) to the compound represented by the general formula (15) (Step 20-E) can be performe at -78 to 50°C for 15 minutes to 6 hours in an appropriate solvent, for example, dichloromethane, tetrahydrofuran, diethyl ether, a mixture thereof or the like, in the presence of a base such as triethylamine, pyridine, diisopropylethylamine or the like, and in the presence of dimethylsulfoxide, and, if need be, acid such as trifluoro acetic acid, by using an electrophilic agent such as oxalyl chloride, dicyclohexyl carbodiimide, sulfur trioxide pyridine complex, or acetic anhydride.

[0292] Alternatively, the compound representedby the general formula (15) can be prepared by reaction at 0 to 50°C for 30 minutes to 12 hours in an appropriate solvent, for example, dichloromethane, dichloromethane, acetonitrile or the like, using Dess-Martin periodinane (1,1,1-tris(acetoxy)-1,1-dihydro-l,2-benziodoxol-3- (1H)-one) . Furthermore, it can be prepared by reaction at 0 to 50°C for 10 minutes to 36 hours in an appropriate solvent, for example, 552501 chloroform, dichloromethane, acetonitrile or the like, using tetrapropyl ammonium perrutenate in the presence of 4-methylmorpholine N-oxide. Furthermore, it can be prepared by reaction at 0 to 50°C for 0.5 to 6 hours in an appropriate solvent, for example, chloroform, dichloromethane, benzene, toluene or the like, in the presence of a cooxidant such as sodium hypochlorite, a reaction auxiliary agent such as potassium bromide and a buffer such as sodium hydrogen carbonate aqueous solution, using 2,2,6,6-tetramethylpiperidine N-oxide.

[0293] In the general formula (10), the compound in which Ac represents an oxygen atom can be converted into a compound in which Ac represents NH, for example, by Gabriel reaction in accordance with a known method, for example, "Jikken Kagaku Koza (Experimental Chemistry Lecture) (published by Maruzen)."

[0294] Among compounds represented by the general formula (la), a compound represented by the general formula (lo) can alsobe prepared by a synthesis method described in Production method 21.

[0295] [Production method 21]

[0296] [Chemical formula 74] 89 552501 (10) (16)

[0297] [wherein Ad represents an oxygen atom, or -NR1-, and ring Ar, T, LJ, W, X, Z, R1, Ra are as defined above] Conversion from the compounds represented by the general formula (16) and the general formula (13c) to the compound represented by the general formula (lo) (Step 21-A) can be performed first by letting the compound represented by general formula (16) react at room temperature to 150°C for 3 to 12 hours in an appropriate solvent, for example, benzene, toluene, tetrahydrofuran, 1,4-dioxane, a mixture thereof or the like, in the presence of a base such as pyridine, triethylamine, N-methylmorpholine, 4-(dimethylamino)pyridine or the like, using phosphonic azide such as diphenylphosphonic azide or the like to convert a carboxyl group into an isocyanate group, and then conducting reaction with the compound represented by the general formula (13c) at 0 to 150 °C for 0 . 5 to 12 hours in an appropriate solvent, for example, benzene, toluene, tetrahydrofuran, 1,4-dioxane, a mixture thereof or the like, in the presence of a base such as pyridine, triethylamine, N-methylmorpholine, or 4-(dimethylamino)pyridine if need be.

[0298] 90 552501 The conversion may be performed by letting the compound represented by the general formula (16) react at -15 to 50 °C for 5 minutes to 3 hours in the absence or in the presence of an appropriate solvent, for example, benzene, toluene, tetrahydrofuran, 5 dichloromethane, a mixture thereof or the like, in the presence of a base such as pyridine or triethylamine if need be, using thionyl chloride, thionyl bromide, acetic anhydride or ethyl chlorocarbonate, thereby making a carboxyl group into a reactive derivative group such as acid chloride, acid bromide or acid anhydride, and then 10 conducting reacting at 0 to 50°C for 0. 5 to 6 hours in an appropriate solvent, for example, water, acetone, 1,4-dioxane, tetrahydrofuran, benzene, toluene, dichloromethane, a mixture thereof or the like, in the presence of an auxiliary agent such as 18-crown~6 if need be, using salt azide such sodium azide or silyl azide such as 15 trimethylsilyl azide, and then conducting reaction at room temperature to 150°C for 3 to 12 hours in an appropriate solvent, ^ for example, benzene, toluene, tetrahydrofuran, 1,4-dioxane, a mixture thereof or thelike, thereby making a carboxyl group into an isocyanate group, and then conducting reaction with the compound 20 represented by the general formula (13c) at 0 to 150°C for 0. 5 to 12 hours in an appropriate solvent, for example, benzene, toluene, tetrahydrofuran, 1,4-dioxane, a mixture thereof or the like, in the presence of a base such as pyridine, triethylamine, N-methylmorpholine, 4-(dimethylamino)pyridine or the like if need 25 be. 91 552501 Among compounds represented by the general formula (la), a compound represented by the general formula (lg) can alos be prepared by a synthesis method described in Production method 22.

[0299] [Production method 22]

[0300] [Chemical formula 75] Ar •T-CHO (38) R6 I Re-Si-CN R4 (39) J- Vn I W I OHC- (12) N (41) 22-A COOR3 COOP CN RS (ZY^O-f-PP (40) I R4 22-B R5 I R6—Si—CN I R4 (39) 22-C 0r0C~UNr^p rs CN I J- Rfi-Si-0 R4 0g) 22-D COOFP c=r w (11) N COOFP (42)

[0301] [wherein R4, R5 and R6 which are identical or different, represent a lower alkyl group or aryl group, and ring Ar, T, U, W, X, Z, Ra, and J are as defined above]

[0302] 92 552501 Conversion from the compounds represented by the general formula (38) and the general formula (39) to the compound represented by the general formula (40) (Step 22-A) can be performed at 0 to 60°Cfor3to24 hours in the absence or in the presence of an appropriate 5 solvent, for example, dichloromethane, chloroform, tetrahydrofuran, diethyl ether, N,N-dimethylformamide, 1,4-dioxane, acetonitrile, a mixture thereof or the like, in the presence of Lewis acid such as zinc iodide if need be. ® [0303] 10 Conversion from the compounds represented by the general formula (12) and the general formula (40) to the compound represented by the general formula (lg) (Step 22-B) can be performed first by letting the compound represented by the general formula (40) react with the compound represented by the general formula (12) at -7 8 15 to 60°C for 1 to 12 hours in an appropriate solvent, for example, benzene, toluene, tetrahydrofuran, diethyl ether, 1,4-dioxane, ^ N, N-dimethylformamide, dimethylsulfoxide, a mixture thereof or the like, in the presence of a base such as sodium hydride, lithium diisopropyl amide, lithium bis (trimethylsilyl)amide, potassium 20 t-butoxide or the like, and then conducting reaction at 0 to 100°C for 1 to 48 hours in the absence or in the presence of an appropriate solvent, for example, water, acetic acid, methanol, ethanol, ethyleneglycol, tetrahydrofuran, 1,4-dioxane, a mixture thereof or the like, using acid such as hydrochloric acid, sulfuric acid, 25 nitric acid or the like. 93 552501

[0304] Conversion from the compounds represented by the general formula (41) and the general formula (39) to the compound represented by the general formula (42) (Step 22-C) can be performed in a similar manner as described in Step 22-A. Conversion from the compounds represented by the general formula (42) and the general formula (11) to the compound represented by the general formula (lg) (Step 22-D) can be performed in a similar manner as described in Step 22-B. Compounds represented by the general formula (lb) can also be prepared by a synthesis method described in Production method 23.

[0307] [Production method 23]

[0308] [Chemical formula 76]

[0305]

[0306] X X (1b)

[0309] [wherein ring Ar, Y, W, X, and Z are as defined above]

[0310] 94 552501 Conversion from the compound representedby the general formula (9) to the compound represented by the general formula (lb) (Step 23-A) can be performed at room temperature to 50 °C for 1 to 12 hours in water or in mixture of water and appropriate organic solvent 5 such as t-butyl alcohol, 2-propanol, acetonitrile or the like, by using isobutylene, chlorite such as sodium chlorite or the like, and sodium dihydrogenphosphate.

[0311] ^ Alternatively, the conversion can also be performed at room 10 temperature to refluxing temperatures for 1 to 6 hours in water or in mixture of water and appropriate organic solvent such as tetrahydrofuran, 1,4-dioxane or the like, by using silver (I) oxide and a base such as sodium hydroxide, potassium hydroxide, barium hydroxide, potassium carbonate or the like. 15 [0312] Furthermore, it can also be performed at room temperature to ^ refluxing temperatures for 1 to 6 hours in water or in mixture of water and appropriate organic solvent such as t-butyl alcohol, dichloromethane or the like, by using permanganate such as potassium 20 permanganate or the like.

[0313] Among compounds represented by the general formula (lb), a compound represented by the general formula (lq) can also be prepared by a synthesis method described in Production method 24. 25 [0314] 95 552501 [Production method 24] [0315] [Chemical formula 77] x 24-a 0/,C^,„CH-CH(C4)^a>Jco(w — x cooh Z dp) (iq) 5 [0316] [wherein p, q, k, ring Ar, W, X, and Z are as defined above] Conversion from the compound representedby the general formula (lp) to the compound represented by the general formula (lq) (Step 24-A) can be performed in a similar manner as described in Step 10 9-C. In Production method 1, among compounds represented by the general formula (6), a compound represented by the general formula (6i) can be prepared by a synthesis method described in Production method 25. ^ [0317] 15 [Production method 25]

[0318] [Chemical formula 78] r^VT"Aa-H HOOC-LK^^PG1 <13c) <^yT-Ad-CONH-lK^N/PG1 i w | 26-a znw j (6i) Z (27)

[0319] 96 552501 [wherein ring Ar, T, U, W, X, Z, R1, Ad, and PG1 are as defined above] Conversion from the compounds represented by the general formula (27) and the general formula (13c) to the compound represented by the general formula (6i) (Step 25-A) can be performed in a similar manner as described in Step 21-A. In Production method 1, among compounds represented by the general formula (6), a compound represented by the general formula (6j) can be prepared by a synthesis method described in Production method 26.

[0320] [Production method 26]

[0321] [Chemical formula 7 9] R5 I R6 -Si-CN (60 97 552501

[0322] [wherein ring Ar, T, U, W, Z, J, R4, R5, R6, and PG1 are as defined above] Conversion from the compounds represented by the general formula (24) and the general formula (40) to the compound represented by the general formula (43) (Step 26-A) can be performed in a similar manner as described in Step 22-B. Conversion from the compounds represented by the general formula (44) and the general formula (39) to the compound represented by the general formula (45) (Step 26-B) can be performed in a similar manner as described in Step 22-C. Conversion from the compounds represented by the general formula (45) and the general formula (11) to the compound represented by the general formula (43) (Step 26-C) can be performed in a similar manner as described in Step 22-D. Conversion from the compound representedby the general formula (43) to the compound represented by the general formula (6j) (Step 26-D) can be performed in a similar manner as described in Step 11—D. In Production method 22, among compounds represented by the general formula (41) can be prepared by a synthesis method described in Production method 27.

[0323] [Production method 27]

[0324] 98 552501 [Chemical formula 80] PG2—OCH,- Vi/ (7) COOFP PGz-°cH?LK^n I W I I W I 27-A Z 27-B 2. (46) E^,/ (8) CHO / 27-C HOCK^- (47) 27-D N PG2—OCHr X?' " "CHO Z (48) (49) 27-E OHC- U N (41) COOP COOP COOP

[0325] [wherein U, W, X, Z, Ra, and PG2 are as defined above] Conversion from the compounds represented by the general formula (4 6) and the general formula (7) to the compound represented by the general formula (47) (Step 27-A) can be performed in a similar manner as described in Step 1-A. Conversion from the compounds represented by the general formula (46) and the general formula (8) to the compound represented by the general formula (48) (Step 27-B) can be performed in a similar manner as described in Step 1-B. 99 552501 Conversion from the compound representedby the general formula (48) to the compound represented by the general formula (47) (Step 27-C) can be performed in a similar manner as described in Step 1-C. Conversion from the compound representedby the general formula (47) to the compound represented by the general formula (4 9) (Step 27-D) can be performed in a similar manner as described in Step 20-D. In the general formula (49), conversion from a compound in which PG2 represents a protecting group to the compound represented by the general formula (41) (Step 27-E) can be performed in a similar manner as described in Step 20-E.

[0326] In Production methods 1 to 27, compounds having a ring Ar representedby the general formulas (11), (13), (14), and (17) to (23) can be prepared according to known methods, for example, "Heterocyclic Chemistry (published by Chapman and Hall (1995))", "Synthetic Communication, 20(16), 2537-2547(1990)", "Heterocycles, 47(2), 857-864(1998)", "Journal of Organic Chemistry, 61(19), 6496-6497(1996)", "Journal of American Chemical Society, 71, 2328(1949)", "Synthesis Communication, 19(16), 2921-2924(1989)" and the like.

[0327] Substituents X and R1 in compounds shown in Production methods 1 to 27 can be converted according to a known method, such as " Jikken 100 552501 Kagaku Kouza (published by Maruzen)." For example, a compound in which the substituent X represents nitro group can be converted into a compound in which the substituent X represents amino group, by a reduction process using metal such as iron powder or zinc powder, or by a reduction process using palladium on activated carbon or the like, while a compound in which substituent R1 represents a hydrogen atommaybe converted into a compound in which the substituent R1 represents an alkyl group by alkylation using a halogenated alkyl such as methyl iodide, or reductive amination using aldehyde such as acetaldehyde and a reducing agent such as sodium borohydride.

[0328] Optical isomers of compounds representedby the general formula (1) can be prepared by using optically active material compounds according to the aforementioned Production methods 1 to 27.

[0329] Racemic compounds represented by the general formula (1) may be prepared by functional crystallization using optically active acid or base, or by separating diastereomeric ester derivative or oxazolidinone derivative obtained by reacting with optically active alcohol derivative or optically active oxazolidinone derivative through either technique of functional crystallization or chromatography, and followed by hydrolysis.

[0330] Furthermore, they can alsobe prepared by a chromatographic technique using a chiral support. 101 RECEIVED at IPONZ on 30 November 2009 552501 [0330a] The term "comprising" as used in this specification means "consisting at least in part of". When interpreting each statement in this specification that includes the term "comprising", features other than that or those prefaced by the term may also be present. Related terms such as "comprise" and "comprises" are to be interpreted in the same manner.

[0331] Examples The present invention will now be described in further detail with reference to examples, which are not intended to limit the scope of the invention in any way.

[0332] <Reference Example 1> 1-benzyl-2-oxoperhydroazepine

[0333] [Chemical formula 81] s-Caprolactum (3.00 g, 26.5 mmol) was dissolved in tetrahydrofuran (30 mL) . To this solution, potassium hydride (3.34 g, 29.2mmol) was added and the mixture was stirredat room temperature for 10 min. Benzyl chloride (3.36 mL, 29.2 mmol) and sodium iodide

[0334] 102 (followed by page 102a) RECEIVED at IPONZ on 30 November 2009 552501 (100 mg) were added and the reaction mixture was further stirred at room temperature for 3 hours. Subsequently, water was added and the mixture was extracted with ethyl acetate. The extract was washed with brine, dried over magnesium sulfate and concentrated. Purification of the residue by silica gel column chromatography (hexane : ethyl acetate = 10:1 -> 2:1) gave 3.04 g (57%) of the desired compound as a colorless oil. 102a (followed by page 103) 552501

[0335] XH NMR (400 MHz, CDC13) 5 1.46-1.51 (2H, m) , 1.66-1.74 (4H, m) , 2.60-2.62 (2H, m) , 3.28-3.30 (2H, m) , 4.59 (2H, s) , 7.25-7.33 (5H, m) . FAB+(m/z): 204 (M+H).

[0336] <Reference Example 2> Methyl l-benzyl-2-oxoperhydroazepine-3-carboxylate

[0337] [Chemical formula 82] Diisopropylamine (2.95mL, 21.0mmol) andn-butyllithium (11.3 mL, 18.0 mmol) were dissolved in diethyl ether (50 mL) at -78°C and the mixture was stirred for 10 min. 1-benzylperhydroazepine (3.04 g, 15.0 mmol) in diethyl ether (3 mL) was then added and the mixture was further stirred at room temperature for 10 min. The mixture was then stirred for another 10 min while bubbled with carbon dioxide. Subsequently, the reaction mixture was added to ice water and the aqueous layer was collected. 2 mol/L hydrochloric acid was added to make the mixture acidic. The mixture was then extracted with ethyl acetate and the extract washed with brine and dried over magnesium sulfate, followed by evaporation of the solvent. The

[0338] 103 552501 resulting colorless oil (2.97 g) was dissolved in a 10% hydrogen chloride/methanol solution and the mixture was stirred at room temperature for 2 hours . The mixture was then concentrated. Water was added to the residue and the mixture was extracted with ethyl 5 acetate. The extract was then washed with brine and was dried over magnesium sulfate, followed by evaporation of the solvent. Purification of the residue by silica gel column chromatography (hexane : ethyl acetate = 10:1 -> 2:1) gave 2.39 g (61%) of the ^ desired compound as a colorless oil. 10 [0339] *H NMR (400 MHz, CDC13) 5 1.24-1.33 (1H, m), 1.49-1.66 (2H, m) , 1.82-1.94 (2H, m) , 2.04-2.12 (1H, m) , 3.19-3.25 (1H, m) , 3.32-3.41 (1H, m), 3.70 (1H, dd, J = 2.4, 11.0 Hz), 3.79 (3H, s), 4.55 (1H, d, J = 14.7 Hz), 4.65 (1H, d, J = 14.7 Hz), 7 .23-7.37 (5H, m) . 15 FAB+(m/z): 262 (M+H).

[0340] ^ <Reference Example 3> 1-Benzyl perhydroazepin-3-yl methanol

[0341] 20 [Chemical formula 83]

[0342] Methyll-benzyl-2-oxoperhydroazepine-3-carboxylate (2 . 39 g, 9.15mmol) was dissolved in tetrahydrofuran (50mL) . To this solution, 104 552501 lithium aluminum hydride (8 68 mg, 18. 3 mmol) was added and the mixture was stirred for 2 hours while being refluxed. Subsequently, ice water and a 10% aqueous sodium hydroxide solution were added and the mixture was stirred at room temperature for 1 hour. The reaction mixture was then filtered through Ce lite . The filtrate was extracted with ethyl acetate and the extract was washed with brine, followed by drying over magnesium sulfate and evaporation of the solvent. Purification of the residue by silica gel column chromatography (Chromatorex NH-DM2035 (Fuji Sylysia Chemical Co., Ltd.) hexane : ethyl acetate = 20 :1 -> 3 : 1) gave 1. 30 g (65%) of the desired compound as a colorless oil. XH NMR (4.00 MHz, CDCI3) 5 1.49-1.65 (3H, m) , 1.70-1. 86 (4H, m) , 2.22-2.29 (1H, m), 2.70-2.80 (3H, m), 3.45 (1H, dd, J= 10.4, 4.3 Hz), 3.57-3.60 (3H, m), 7.23-7.29 (1H, m), 7.30-7.38 (4H, m). FAB+(m/z): 22 0 (M+H).

[0344] <Reference Example 4> 1-(tert-Butoxycarbonyl)perhydroazepin-3-yl methanol

[0345] [Chemical formula 84]

[0343]

[0346] 105 552501 1-Benzyl perhydroazepin-3-yl methanol (1.30 g, 5. 93 mmol) was dissolved in a 4.4% formic acid/methanol solution (30 mL) . To this solution, 10% palladium on activated carbon (1.30 g) was added and themixture was stirred at room temperature for 2 hours. Subsequently, 5 water was added and the mixture was filtered through Celite. The filtrate was concentrated. The resulting residue was dissolved in acetonitrile (15mL). While the solution was ice-chilled and stirred, triethylamine (1.81 mL, 13.0 mmol) and t-butyl dicarbonate (1.42 g, 6.52 mmol) were added. The reaction mixture was then stirred 10 at room temperature for 4 hours. Subsequently, the mixture was concentrated and ethyl acetate was added. The mixture was sequentially washed with a 5% aqueous citric acid solution, a saturated aqueous sodium bicarbonate solution and brine, followed by drying over magnesium sulfate. Evaporation of the solvent gave 15 1.13g (83%) of the desired compound as a colorless oil.

[0347] £ XH NMR (4 00 MHz, CDC13) 5 1.36-1. 4 3 (1H, m) , 1.4 7 (9H, s) , 1. 60-1. 69 (3H, m), 1.93-1.99 (1H, m), 2.96-3.03 (1H, m), 3.11-3.16 (1H, m), 3.39-3.54 (4H, m), 3.68-3.74 (1H, m), 3.77-3.85 (2H, m). 20 FAB+ (m/z) : 230 (M+H) .

[0348] <Reference Example 5> N-[[1-(tert-Butoxycarbonyl)perhydroazepin-3-yl]methyl]phthalim ide 25 [0349] 106 552501 [Chemical formula 85]

[0350] 1- (tert-Butoxycarbonyl) perhydroazepin-3-yl methanol (1.13 g, 5 4 . 93mmol) was dissolved in tetrahydrofuran (lOmL) . To this solution, triphenylphosphine (1.60 g, 5.92 mmol) and phthalimide (871 mg, 5 . 92 mmol) were added and the mixture was stirred at room temperature for 5 min. A 40% toluene solution of diethyl azodicarboxylate (3.23 mL, 7.40 mmol) was then added and the mixture was stirred at room 10 temperature for 4 hours. Subsequently, water was added and the mixture was extracted with ethyl acetate. The extract was washed with brine and was dried over magnesium sulfate, followed by evaporation of the solvent. Purification of the residue by silica gel column chromatography (hexane : ethyl acetate = 10:1 -> 2:1) ^5 gave 1.27 g (72%) of the desired compound as a colorless powder.

[0351] ^ NMR (400 MHz, CDC13) 5 1.14-1.44 (11H, m) , 1.52-1.94 (4H, m) , 2.13-2.35 (1H, m) , 2.79-3.05(1H, m), 3.11-3.27 (1H, m) , 3.41-3.71 (4H, m) , 7.69-7.74 (2H, m) , 7.82-7.86 (2H, rti) . 20 EI+(m/z): 358 (M+).

[0352] <Reference Example 6> 1-(tert-Butoxycarbonyl)perhydroazepin-3-yl methylamine 107 552501

[0353] [Chemical formula 86]

[0354] N- [ [ (1-tert-Butoxycarbonyl)perhydroazepin-3-yl]methyl]pht halimide (1.27 g, 3.54 mmol) was dissolved in methanol (30 mL). To this solution, hydrazine monohydrate (0.343 mL, 7.08 mol) was added and the mixture was stirred for 3 hours while being refluxed. The mixture was then allowed to cool and the precipitates were removed by filtration. The filtrate was concentrated and ethyl acetate was added to the residue. The mixture was then washed sequentially with a lmol/L aqueous potassium hydroxide solution and brine and was dried over magnesium sulfate. The solvent was evaporated to give 712 mg (88%) of the desired compound as a colorless oil.

[0355] XH NMR (400 MHz, CDC13) 5 1.16-1.62 (14H, m), 1.67-1.85 (4H, m) , 2.51-2.70 (2H, m), 2.91-3.14 (1H, m) , 3.27-3.60 (3H, m) . EI+(M/Z) : 228 (M+) .

[0356] <Reference Example 7> 3-(tert-Butyldimethylsilyloxymethyl)piperidine

[0357] Step Al) 1-(Benzyloxycarbonyl)piperidin-3-yl methanol 108 552501

[0358] [Chemical formula 87]

[0359] An aqueous solution (20 mL) of sodium carbonate (6.90 g, 65.1 mmol) was added to 3-piperidinylmethanol (5.00 g, 43.4 mmol) in tetrahydrofuran (20 mL) . While the mixture was chilled in an ice bath, benzyloxycarbonyl chloride (9.36 g, 52.1 mmol) was added and the mixture was stirred for 1 hour and subsequently 7 hours at room temperature. The solvent was then evaporated and ethyl acetate was added to the residue. The mixture was then washed sequentially with water, 0.1 mol/L hydrochloric acid and brinef followed by drying over magnesium sulfate and evaporation of the solvent. Purification of the residue by silica gel column chromatography (hexane : ethyl acetate = 5:1 -> 1:1) gave 9.15 g (85%) of the desired compound as a colorless powder.

[0360] *H NMR (400 MHz, DMSO-d6) 5 1.09 (1H, qd, J = 12.2, 3.1 Hz), 1.33 (1H, qt, J = 11.6, 3.7 Hz), 1.45-1.55 (1H, m), 1.59-1.64 (1H, m), 1.64-1.69 (1H, m) , 2.42-2.65 (1H, m) , 2.70-2.86 (1H, m) , 3.16-3.22 (1H, m), 3.27-3.31 (1H, m), 3.86-3.93 (1H, m), 4.04 (1H, dd, J= 12.8, 2.4 Hz) , 4.55 (1H, t, J = 5.5 Hz) , 5.03-5.10 (2H, m) , 7.2 9-7.39 (5H, m) . 109 552501

[0361] Step A2) 1-(Benzyloxycarbonyl)-3-(tert-butyldimethylsilyloxymethyl)pipe ridine

[0362] [Chemical formula 88] >[S/Ko-^QjiAo"^Q

[0363] Imidazole (3.00 g, 44.0 mmol) and tert-butyldimethylsilyl chloride (6.63 g, 44.0 mmol) were added to 1-(benzyloxycarbonyl) piperidin-3-yl methanol (9.15 g, 36.7 minol) in N,N-dimethylformamide (40 mL) . The solution was stirred at room temperature for 6 hours. Subsequently, water was added and the mixture was extracted with ethyl acetate. The extract was washed with brine and was dried over magnesium sulfate, followed by evaporation of the solvent. Purification of the residue by silica gel column chromatography (hexane : ethyl acetate = 20:1 -> 5:1) gave 13.2 g (99%) of the desired compound as a colorless oil.

[0364] NMR (400 MHz, CDC13) 5 0.02 (6H, s) , 0.88 (9H, s) , 1.11-1.25 (1H, m) , 1.40-1.53 (1H, m) , 1.61-1.71 (2H, m) , 1.72-1.80 (1H, m) , 2.54-2.66 (1H, m) , 2.7 9 (1H, td, J = 11.6, 3.1 Hz) , 3.34-3.51 (2H, m) , 3.99-4.09 (1H, m), 4.12-4.19 (1H, m), 5.12 (2H, s), 7.29-7.39 (5H, m). 110 552501 5 IP •s

[0365] Step A3) 3-(tert-Butyldimethylsilyloxymethyl)piperidine

[0366] [Chemical formula 89]

[0367] 10% palladium on activated carbon (1.32 g) was added to 1-(benzyloxycarbonyl)-3-(tert-butyldimethylsilyloxymethyl)pipe ridine (13.2 g, 36.3 mmol) in methanol (130 mL) . The mixture was stirred at room temperature for 1 hour in a hydrogen atmosphere. Subsequently, the mixture was filtered through Celite, followed by evaporation of the solvent to give 7.96g (96%) of the desired compound as a colorless oil.

[0368] XH NMR (400 MHz, CDC13) 5 0.03 (6H, s), 0.89 (9H, s) , 1.07 (1H, qd, J = 12.2, 3.7 Hz), 1.4 4 (1H, qt, J = 12.2, 3.7 Hz) , 1.59-1.69 (2H, m) , 1.73-1.78 (2H, m), 2.30 (1H, dd, J = 12.2, 10.4 Hz), 2.53 (1H, td, J = 12.2, 3.1 Hz), 3.00 (1H, dt, J = 12.2, 3.1 Hz), 3.11-3.15 (1H, m), 3.39 (1H, dd, J = 9.8, 7.3 Hz), 3.44 (1H, dd, J = 9.8, 5.5 Hz).

[0369] <Reference Example 8> 1-(tert-Butoxycarbonyl)nipecotic acid 111 Si 552501

[0370] [Chemical formula 90]

[0371] 5 A dichloromethane solution (5 mL) of ditert-butyl dicarbonate (10.9 g, 50.0 mmol) was added to nipecotic acid (6.46 g, 50.0 mmol) in a saturated sodium bicarbonate solution (20 mL). The mixture was stirred at room temperature for 18 hours. Subsequently, the reaction mixture was poured into ice water. This mixture was made 10 acidic by additionof diluted hydrochloric acidand was then extracted with ethyl acetate. The organic layer was washed with brine and dried over sodium sulfate, followed by evaporation of the solvent. The resulting residue was washed with hexane and was dried to give 5.30 g (46%) of the desired compound as a colorless solid. ^5 [0372] *H NMR (4 00 MHz, DMSO-d6) 5 1.2 5- 1.35 (1H, m), 1.39 (9H, s), 1.45-1.55 (1H, m), 1.55-1.65 (1H, m) , 1.87-1.93 (1H, m) , 2.27-2.32 (1H, m), 2.82 (1H, dt, J -13.4, 3.0Hz), 2.90-3.15 (1H, m), 3.60-3.75 (1H, m), 3.77-4.10 (1H, m), 12.37 (1H, brs). 20 FAB+(m/z): 230 (M+H).

[0373] <Reference Example 9> Benzyl nipecotate 112 552501

[0374] Step Bl) Benzyl 1-(tert-butoxycarbonyl)nipecotate

[0375] [Chemical formula 91] cx°o

[0376] » Benzyl bromide (4.34 g, 25.4 mmol) and potassium carbonate (4.80 g, 34.7 mmol) were added to 1-(tert-butoxycarbonyl) nipecotic acid (5.30 g, 23.1 mmol) in N,N-dimethylformamide (20 mL). The 10 mixture was stirred at room temperature for 6 hours. Subsequently, water was added and the mixture was extracted with ethyl acetate. The organic layer was washed sequentially with water and brine and was dried over sodium sulfate. The solvent was then evaporated to give 7.11 g (96%) of the desired compound as a pale yellow oil. ^5 [0377] 1H NMR (400 MHz, DMSO-d6) 5 1.30- 1.50 (2H, m) , 1.38 (9H, s) , 1.53-1.64 (2H, m), 1.90-1.93 (1H, m), 2.80-2.90 (2H, m), 3.55-3.70 (1H, m), 3.75-3.90 (1H, m), 5.10 (2H, s), 7.31-7.39 (5H, m).

[0378] 20 Step B2) Benzyl nipecotate

[0379] [Chemical formula 92] 113 552501 crA?"

[0380] Trifluoroacetic acid (43 mL, 558 mmol) was added to benzyl 1-(tert-butoxycarbonyl)nipecotate (7.11 g, 22.3 mmol) in dichloromethane (20 mL). The mixture was stirred for 3 hours. Subsequently, the reaction mixture was concentrated and water was added to the residue, followed by addition of lmol/L aqueous sodium hydroxide solution to make the mixture basic. The mixture was then extracted with ethyl acetate. The organic layer was washed with brine and was dried over sodium sulfate. The solvent was evaporated to give 5.97 g (quant.) of the desired compound as a yellow oil.

[0381] XH NMR (400 MHz, DMSO-d6) 5 1.45- 1.70 (3H, m) , 1.92-1.96 (1H, m) , 2.59-2.69 (2H, m), 2.81 (1H, t, J = 9.8 Hz), 2.94-3.02 (1H, m), 3.21 (1H, dd, J = 12.6, 3.3 Hz) , 5.10 (2H, d, J = 3.1 Hz) , 7.27-7.38 (5H, m). EI+ (m/z): 219 (M+).

[0382] <Reference Example 10> 1-Trifluoroacetyl-3-hydroxypiperidine

[0383] [Chemical formula 93] 114 552501 hov^n^cf3

[0384] Ethyl trifluoroacetate {1.31mL, 11.0 mmol) and triethylamine (1.68 mL, 12.0 mmol) were added to 3-hydroxypiperidine (1.01 g, 10.0 mmol) in ethanol (10 mL). The mixture was stirred at room temperature for 8 hours. Subsequently, the reaction mixture was concentrated and water was added. The mixture was then extracted with ethyl acetate and the extract was washed with brine and dried over magnesium sulfate. Purification of the residue by silica gel column chromatography (hexane : ethyl acetate = 10:1 ->2:1) gave 1.68 g (85%) of the desired compound as a colorless oil.

[0385] NMR (400 MHz, CDC13) 5 1.53-1.72 (2H, m) , 1.82-2.04 (3H, m) , 3.25-3.37 (1H, m) , 3.40-3.48 (1H, m) , 3.57-3.62 (1H, m) , 3.78-3.92 (2H, m) . FAB+(m/z): 198 (M+H).

[0386] <Reference Example 11> 1-Trifluoroacetylpiperidin-3-yl methanol

[0387] [Chemical formula 94] 115 552501 HO

[0388] Using 3-piperidinemethanol (1.15 g, 10.0 mmol), the same procedure was followed as in Reference Example 10 to give 1.91 g (90%) of the desired compound as a colorless oil. FAB+(m/z): 212 (M+H).

[0389] <Reference Example 12> 1-(tert-Butoxycarbonyl)-3-(iodomethyl)piperidine

[0390] [Chemical formula 95] Imidazole (1.58 g, 23.2 mmol), triphenylphosphine (6.09 g, 23.2 mmol) and.iodine (4.72 g, 18.6 mmol) were added to 1-(tert-butoxycarbonyl) piperidin-3-yl methanol (2.00 g, 9. 29 mmol) in benzene (50 mL). The mixture was stirred at room temperature for3hours. Subsequently, the reaction mixture was filtered through Celite and the solvent was evaporated. Water was added to the residue and the mixture was extracted with ethyl acetate. The extract was washed with brine and was dried over magnesium sulfate, followed

[0391] 116 552501 10 by evaporation of the solvent. Purification of the residue by silica gel column chromatography (hexane : ethyl acetate = 20:1 -> 5:1) gave 2.91 g (96%) of the desired compound as a pale yellow oil.

[0392] 1H NMR (400 MHz, CDC13) 5 1.19-1.28 (1H, m), 1.40-1.52 (10H, m) , 1.61-1.68 (2H, m) , 1.91-1.95 (1H, m) , 2.54-2.69 (1H, m) , 2.79-2.84 (1H, m) , 3.08 (2H, d, J = 6.7 Hz) , 3.84 (1H, td, J = 13.4, 3.7 Hz) , 3.97-4.13 (1H, m). FAB+(m/z): 326 (M+H).

[0393] <Reference Example 13> l-Benzyloxycarbonyl-3-formyl piperidine

[0394] [Chemical formula 96] An aqueous solution (2 mL) of potassium bromide (983 mg, 8.26 mmol) was added to l-benzyloxycarbonyl-3-piperidinyl methanol (2.00 g, 8.02 mmol) and 2, 2, 6, 6-tetramethyl piperidine-N-oxyl (12.5 mg, 0.0802 mmol) in dichloromethane (20 mL) . The mixture was stirred for 5 min while chilled in an ice bath. A 0.35 mol/L aqueous sodium hypochlorite solution (25.2 mL, 8.82 mmol) and sodium bicarbonate (1.96 g, 23.3 mmol) were added and the mixture was stirred for 10

[0395] 117 552501 min. Subsequently, the reaction mixture was extracted with ethyl acetate and the extract was washed with brine, followed by drying over magnesium sulfate and evaporation of the solvent. Purification of the residue by silica gel column chromatography (hexane : ethyl acetate = 10:1 -> 2:1) gave 1.78 g (90%) of the desired compound as a colorless oil.

[0396] XH NMR (400MHz, DMSO-d6) 5 1.36-1.47 (1H, m), 1.52-1.65 (2H, m), 1.86-1.95 (1H, m) , 3.10-3.16 (1H, m) , 3.27-3.33 (2H, m) , 3.51-3.62 (1H, m), 3.83 (1H, dd, J= 13.4, 3.7 Hz), 5.07 (2H, m)> 7.30-7.40 (5H, m) , 9 . 59 (1H, s) . FAB+ (M/Z) : 248 (M+H).

[0397] <Reference Example 14> 4-(tert-Butoxycarbonyl)morpholin-2-yl methanol

[0398] [Chemical formula 97] Ammonium formate (3.04 g, 48.2 mmol) and 10% palladium on activated carbon (500 mg) were added to (4-benzylmorpholin-2-yl)methanol (1.00 g, 4.82 mmol) in methanol (50 mL) . The mixture was stirred at room temperature for 4 hours.

[0399] 118 552501 Subsequently, the reaction mixture was filtered through Celite and the solvent was evaporated. The resulting residue was dissolved in acetonitrile (20 mL) . While this solution was chilled in an ice bath, ditert-butyl dicarbonate (1.58 g, 7. 23 mmol) and triethylamine 5 (1.35 mL, 9. 64 mmol) were added and the mixture was stirred at room temperature for 3 hours. The solvent was evaporated and water was added to the residue. The mixture was then extracted with ethyl acetate and the extract was washed with brine, followed by drying over magnesium sulfate and evaporation of the solvent. Purification 10 of the residue by silica gel column chromatography (hexane : ethyl acetate = 5:1 -> 1:1) gave 907 mg (87%) of the desired compound as a colorless oil.

[0400] 1H NMR (4 00 MHz, DMS0-d6) 5 1.4 0 (9H, s) , 2.47-2.66 (1H, m) , 2.73-2. 92 15 (1H, m),3.25-3.45 (4H, m), 3.70 (1H, d, J = 13.4 Hz), 3.79 (1H, dd, J = 11.6, 2.4 Hz), 3.85 (1H, d, J = 12.8 Hz), 4.77 (1H, t, J = 5.5 Hz).

[0401] <Reference Example 15> 20 4-(tert-Butoxycarbonyl)morpholin-2-yl methylamine

[0402] Step CI) N-[[4 - (tert-Butoxycarbonyl)morpholin-2-yl]methyl]phthalimide

[0403] 25 [Chemical formula 98] 119 552501

[0404] Triphenylphosphine (506 mg, 1.87 mmol) and phthalimide (275 mg, 1.87 mmol) were added to 4-(tert-butoxycarbonyl)morpholin-2-yl 5 methanol (340 mg, 1.56 mmol) in tetrahydrofuran (3mL). The mixture was stirred at room temperature for 5 min, followed by addition of a 40% diethyl azodicarboxylate/toluene solution (1.06 mL, 2.34 mmol) and stirring at room temperature for 4 hours. Subsequently, ethyl acetate was added and the mixture was washed sequentially 10 with tap water and brine. The mixture was then dried over magnesium sulfate and the solvent was evaporated. Purification of the residue by silica gel column chromatography (hexane : ethyl acetate =10:1 -> 3:1) gave 524 mg (97%) of the desired compound as a colorless powder. 05 [0405] lH NMR (40 0 MHz, CDC13) 5 1.46 (9H, s), 2.70-2.84 (1H, m), 2. 93-3.05 (1H, m), 3.4 5 (1H, td, J = 11.6, 3.1 Hz), 3.67 (1H, dd, J = 13.4, 4.9 Hz), 3. 72-3.79 (2H, m) , 3. 86-4.04 (3H, m) , 7. 72-7.74 (2H, m), 7.86-7.88 (2H, m). 20 [0406] Step C2) 4-(tert-Butoxycarbonyl)morpholin-2-yl methylamine [0407] [Chemical formula 99] 120 552501 0 HgN^Y^N 0 O

[0408] Hydrazine monohydrate (0.146 mL, 3.02 mmol) was added to N-[[4-(tert-butoxycarbonyl)morpholin-2-yl]methyl]phthalimide (524 mg, 1.51 mmol) suspended in methanol (15 mL) . The mixture was refluxed and stirred for 4 hours. Subsequently, the reactionmixture was allowed to cool and the crystallized product was removed by filtration. The solvent was evaporated and a lmol/L aqueous potassium hydroxide solution was added to the residue. The mixture was then extracted with dichloro methane and the extract was dried over sodium sulfate, followed by evaporation of the solvent. The residue was air-dried to give 272 mg (83%) of the desired compound as a colorless oil.

[0409] 1H NMR (400 MHz, CDC13) 5 1.47 (9H, s) , 2.10 (2H, brs), 2.64 (1H, m), 2.71-2.81(2H, m), 2.93 (1H, m), 3.35-3.41 (1H, m), 3.53 (1H, td, J - 11.6, J = 2.4 Hz), 3.75-4.00 (3H, m) .

[0410] <Reference Example 16> 4- (tert-Butoxycarbonyl)morpholine-2-carboxylic acid

[0411] Step Dl) Methyl 4-benzylmorpholine-2-carboxylate

[0412] 121 -V 552501 [Chemical formula 100] MeOOC xro

[0413] 4-Benzylmorpholine-2-carboxylic acid hydrochloride (1.00 g, 3.88 mmol) in a 10(w/w)% hydrochloric acid/methanol solution (20 mL) was stirred at room temperature for 2 hours. The solvent was evaporated and a saturated aqueous sodium bicarbonate solution was added to the residue to make the mixture basic. The mixture was then extracted with ethyl acetate and the extract was washed with brine and was dried over magnesium sulfate. Evaporation of the solvent gave 730 mg (80%) of the desired compound as a colorless oil. 1R NMR (400 MHz, DMS0-d6) 5 2.24 (2H, m) , 2.47-2.54 (1H, m) , 2.68 (1H, dd, J= 11.6, 2.4 Hz), 3.45-3.53 (2H, m), 3.53-3.59 (1H, m), 3.63 (3H, s), 3.85-3.90 (1H, m), 4.22 (1H, dd, J = 7.3, 3.1 Hz), 7.24-7.35 (5H, m). Step D2) Methyl 4-(tert-butoxycarbonyl)morpholine-2-carboxylate [0416] [Chemical formula 101]

[0414]

[0415] 122 552501

[0417] Ammonium formate (381 mg, 6.04 mmol) and 10% palladium on activated carbon (180 mg) were added to methyl 4-benzylmorpholine-2-carboxylate (355 mg, 1.51 mmol) in methanol (10 mL) . The mixture was stirred at room temperature for 1 hour. Subsequently, the reaction mixture was filtered through Celite. The solvent was evaporated and the resulting residue was suspended in acetonitrile (10 mL) . This suspension was chilled in an ice bath and di t-butyl dicarbonate (395 mg, 1.81 mmol) and triethylamine (0.253 mL, 1.81 mmol) were added. This mixture was stirred at room temperature for 2 hours. Subsequently, water was added and the mixture was extracted with ethyl acetate. The extract was washed sequentially with a 5% aqueous citric acid and brine and was dried over magnesium sulfate. The solvent was then evaporated. Purification of the residue by silica gel column chromatography (hexane : ethyl acetate = 10:1 -> 2:1) gave 251 mg (68%) of the desired compound as a colorless oil.

[0418] XH NMR (400 MHz, DMSO-d6) 51.40 (9H, s) , 3.06-3.13 (1H, m) , 3.29-3.38 (1H, m), 3.46-3.55 (2H, m), 3.68 (3H, s) , 3.74-3.86 (2H, m), 4.19 (1H, dd, J = 8. 6, 3.7 Hz) .

[0419] Step 3 D3) 4-(tert-Butoxycarbonyl)morpholine-2-carboxylic acid [Chemical formula 101] 123 552501 hooc.^n

[0420] A lmol/L aqueous potassium hydroxide solution (3mL) was added to methyl 4- (tert-butoxycarbonyl)morpholine-2-carboxylate (251 mg, 5 1.02 mmol) in methanol (15 mL). The mixture was stirred at room temperature for 8 hours . Subsequently, waterwas added to themixture, ^ followed by addition of a 5% aqueous citric acid solution to make themixture acidic. Themixture was then extractedwith ethyl acetate. The extract was washed with brine and was dried over magnesium sulfate. 10 Evaporation of the solvent gave 219 mg (93%) of the desired compound as a colorless powder.

[0421] 2H NMR (400 MHz, DMS0-d6) 5 1.40 (9H, s), 2.70 (1H, dd, J = 41.6, 15.3 Hz), 3.03-3.09 (1H, m) , 3.43-3.54 (2H, m) , 3.78 (1H, m) , 3.85 ^5 (1H, dt, J = 11.6, 3.7 Hz), 4.04 (1H, dd, J = 8.6, 3.7 Hz), 12.73 (1H, brs).

[0422] <Example 1> Methyl 20 2- [3- [ [2- (4-Chlorophenyl)-4-methylthiazol-5-yl]carbonylaminome thyl]piperidin-l-yl]benzoate

[0423] 124 552501 Step la) N-[(l-tert-Butoxycarbonyl)piperidin-3-yl methyl]-2-(4-chlorophenyl)-4-methylthiazole-5-carboxamide

[0424] [Chemical formula 102] 5

[0425] 2-{4-Chlorophenyl)-4-methylthiazole-5-carboxylic acid (507 mg, 2.00 mmol), 1-(tert-butoxycarbonyl) piperidin-3-yl methylamine (429 mg, 2.00 mmol) and 1-hydroxybenzotriazole monohydrate (368 10 mg, 2.40 mmol) were dissolved in N,N-dimethylformamide (10 mL) . The mixture was chilled in an ice bath and 3- (3-dimethylaminopropyl) -1-ethylcarbodiimide hydrochloride (460 mg, 2.40 mmol) and N-methylmorpholine (0.528 mL, 4.80 mmol) were added. The mixture was then stirred at room temperature for 4 hours ^^5 and a 5% aqueous citric acid was added. This mixture was extracted with ethyl acetate and the extract was washed sequentially with a saturated aqueous sodium bicarbonate solution and brine, followed by drying over magnesium sulfate and evaporation of the solvent. Purification of the resulting residue by silica gel column 20 chromatography (hexane : ethyl acetate = 10:1 -> 2:1) gave 851 mg (95%) of the desired compound as a colorless amorphous product.

[0426] 125 552501 ^ NMR (400 MHz, CDC13)5 1.42-1.51 (11H, m), 1.60-1.72 (1H, m) , 1.78-1.96 (2H, m) , 2.75 (3H, s) , 3.05-3.86 (6H, m) , 6.59 (1H, brs) , 7.42 (2H, d, J = 8.6 Hz), 7.87 (2H, d, J = 8.6 Hz).

[0427] 5 Step lb) N-(Piperidin-3-yl methyl)-2-(4-chlorophenyl)-4-methylthiazole-5-carboxamide

[0428] [Chemical formula 103] 10 [0429] N-[ [ (1-tert-Butoxycarbonyl)piperidin-3-yl]methyl]-2-(4-ch lorophenyl)-4-methylthiazole-5-carboxamide (2.78 g, 6.18 mmol) was dissolved in methanol (30 mL) . While this mixture was ice-chilled and stirred, 5.7mol/L hydrogen chloride/methanol solution (50 mL) 4^5 was added. The mixture was continuously chilled and stirred for 10 min. The mixture was then allowed to warm to room temperature and was stirred for the subsequent 3 hours. Subsequently, the reaction mixture was concentrated. To the resulting residue, water was added and the mixture was neutralized with a lmol/L aqueous 20 sodium hydroxide solution. Sodium chloride was then added to saturation and the mixture was extracted with ethyl acetate. The extract was washed with brine and was dried over magnesium sulfate. 126 552501 Evaporation of the solvent gave 2 . 09 mg (97%) of the desired compound as a colorless powder.

[0430] 1ti NMR (400 MHz, DMSO-d6) 6 1.00-1.10 (1H, m), 1.26-1.37 (1H, m) , 5 1.53-1.74 (3H, m), 2.18 (1H, dd, J = 9.8, 11.6 Hz), 2.40 (1H, dt, J = 2.4, 11.6 Hz), 2.59 (3H, s), 2.77-2.83 (1H, m), 2.91 (1H, dd, J = 2.4, 11.6 Hz), 3.68 (2H, t, J = 6.1 Hz), 7.42 (2H, d, J = 8.6 Hz), 7.87 (2H, d, J = 8.6 Hz), 8.30 (1H, t, J = 5.5 Hz). ^ [0431] 10 Step 1c) Methyl 2- [3- [ [2- (4-chlorophenyl)-4-methylthiazol-5-yl]carbonylaminome thyl]piperidin-l-yl]benzoate

[0432] [Chemical formula 104] H COOMe

[0433] N-(Piperidin-3-yl methyl)-2-(4-chlorophenyl)-4-methylthiazole-5-carboxamide (105 mg, 0.300 mmol) and methyl 2-fluorobenzoate (0.0382 mL, 0.300 mmol) 20 were added to dimethylsulfoxide (5 mL) . To this mixture, potassium carbonate (82.9 mg, 0.600 mmol) was added and the mixture was stirred for 6 hours at 130°C. Subsequently, water was added and the mixture was extracted with ethyl acetate . The extract was washed with brine, 127 552501 followed by drying over magnesium sulfate and evaporation of the solvent. Purification of the residue by silica gel column chromatography (hexane : ethyl acetate = 10:1 -> 2:1) gave 29.5 mg (20%) of the desired compound as a colorless oil. 5 [0434] XH NMR (400 MHz, CDC13) 5 1.23-1. 90 (3H, m) , 2.08-2.19 (1H, m) , 2.28-2.38 (1H, m) , 2.73-2.79 (4H, m) , 2.83-2.88 (1H, m) , 3.09-3.24 (2H, m) , 3.42-3.54 (2H, m), 3.85 (3H, s) , 6.37-6.44 (1H, m), 7.02 ^ (1H, t, J = 8.6 Hz), 7.11 (1H, d, J = 7.9 Hz), 7.38-7.44 (3H, m) , 10 7.72 (1H, dd, J = 1.8, 7.9 Hz), 7.86 (2H, d, J =8.6 Hz).

[0435] <Example 2> Methyl 3~[3-[[2- (4-Chlorophenyl)-4-methylthiazol-5-yl]carbonylaminome 15 thyl]piperidin-l-yl]benzoate

[0436] ^ [Chemical formula 105]

[0437] 20 N-(Piperidin-3-yl methyl)-2-(4-chlorophenyl)-4-methylthiazole-5-carboxamide (172 mg, 0.492 mmol), 3-(methoxycarbonyl) phenylboric acid (177 mg, 0.934 mmol) and molecular sieves 4A (400 mg) were suspended in 128 552501 dichloromethane (10 mL) . To this suspension, copper (II) acetate (188 mg, 0. 984 mmol) and triethylamine (0.344 mL, 2.46 mmol) were added and the mixture was stirred at room temperature for 8 hours. Subsequently, the reaction mixture was filtered through Celite, 5 followed by addition of a saturated aqueous sodium bicarbonate solution. The mixture was then extracted with ethyl acetate and the extract was washed with brine, followed by drying over magnesium sulfate and evaporation of the solvent. Purification of the residue ^ by silica gel column chromatography (hexane : ethyl acetate =20:1 10 -> 2:1) gave 88.2 mg (37%) of the desired compound as a colorless powder.

[0438] 1H NMR (400 MHz, DMS0-d6) 5 1.14-1.23 (1H, m) , 1.52-1.61 (1H, m), 1.75-1.82 (2H, m) , 1.85-1.94 (1H, m) , 2.53-2.58 (1H, m) , 2.62 (3H, 15 s) , 2.7 2-2.79 (1H, m) , 3.19-3.27 (1H, m) , 3.30-3.38 (1H, m) , 3.60-3.69 (2H, m), 3.81 (3H, s), 7.19-7.24 (1H, m), 7.33-7.35 (2H, m), 7.46 ^ (1H, m), 7.59 (2H, d, J = 8.6 Hz), 7.97 (2H, d, J =8.6 Hz), 8.45 (1H, t, J = 5.5 Hz).

[0439] 20 <Example 3> Methyl 2- [3-[N- [ [2 - (4-Chlorophenyl)-4-methylthiazol-5-yl]methyl]carba moyl]piperidin-l-yl]benzoate

[0440] ' 129 552501 Step 3a) 1-(tert-Butoxycarbonyl)-N-[[2-(4-chlorophenyl)-4-methylthiazol -5-yl]methyl]piperidine-3-carboxamide

[0441] [Chemical formula 106] 2- (4-Chlorophenyl) -4-methylthiazol-5-yl methylamine (477 mg, 2 . 00 mmol) , 1-tert-butoxycarbonyl nipecotic acid (459 mg, 2 . 00 mmol) and 1-hydroxybenzotriazole monohydrate (368 mg, 2.40 mmol) were dissolved in N,N-dimethylformamide (10 mL). While this mixture was chilled in an ice bath, 3- (3-dimethylaminopropyl) -1-ethylcarbodiimide hydrochloride (460 mg, 2.40 mmol) and N-methylmorpholine (0.484 mL, 4.40 mmol) were added. The mixture was then stirred at room temperature for 6 hours . Subsequently, 5% aqueous citric acid was added and the mixture was extracted with ethyl acetate. The extract was washed sequentially with a saturated aqueous sodium bicarbonate solution and brine, followed by drying over magnesium sulfate and evaporation of the solvent. Purification of the residue by silica gel column chromatography (hexane : ethyl acetate = 5:1 -> 1:1) gave 916 mg (100%) of the desired compound as a colorless powder.

[0442]

[0443] 130 552501 NMR (400 MHz, CDC13) 5 1.36-1.51 (10H, m) , 1.56-1.62 (1H, m) , 1.67-1.85 (1H, m) , 2.28-2.40 (1H, m) , 2.45 (3H, s) , 2.93-3.95 (5H, m), 4.56-4.60 (2H, m) , 7.38(2H, d, J = 8.6 Hz), 7.81 (2H, d, J = 8.6 Hz).

[0444] Step 3b) N- [ [2-(4-Chlorophenyl)-4-methylthiazol-5-yl]methyl]piperidine-3-carboxamide hydrochloride

[0445] [Chemical formula 107] O HCI

[0446] 1-tert-Butoxycarbonyl-N-[[2-(4-chlorophenyl)-4-methylthia zol-5-yl]methyl]piperidine-3-carboxamide (916 mg, 2.04 mmol) was dissolved in a 10% hydrogen chloride/methanol solution (20 mL) and the mixture was stirred at room temperature for 1 hour. Subsequently, the reaction mixture was concentrated and the residue was air-dried to give 769 mg (98%) of the desired compound as a colorless amorphous product.

[0447] XH NMR (400 MHz, DMSO-d6) 5 1.49-1.59 (1H, m) , 1.64-1. 80 (2H, m) , 1.88-1. 93 (1H, m) , 2.39 (3H, s) , 2.68-2.75 (1H, m) , 2.78-2.86 (1H, m) , 2.8 8-2.97 <1H, m) , 4.35-4.47 (2H, m) , 7.54 (2H, d, J = 8.6 Hz) , 131 552501 7 . 87 (2H, d, J = 8 . 6 Hz) , 8 . 93 (1H, t, J = 5.5 Hz), 8. 96-9. 0 9 (1H, m) , 9.15-9.35 (1H, m) .

[0448] Step 3c) Methyl 2- [3-[N- [ [2-(4-chlorophenyl)-4-methylthiazol-5-yl]methyl]carba moyl]piperidin-l-yl]benzoate

[0449] [Chemical formula 108] N-[[2-(4-Chlorophenyl)-4-methylthiazol-5-yl]methyl]piperi dine-3-carboxamide hydrochloride (198 mg, 0.513 mmol) and methyl 2-fluorobenzoate (0.0653 mL, 0.513 mmol) were dissolved in dimethylsulfoxide (5 mL) . To this solution, potassium carbonate (142 mg, 1.03 mmol) was added and the mixture was stirred for 6 hours at 160 °C. Subsequently, the mixture was allowed to cool and water was added. The mixture was then extracted with ethyl acetate and the extract was washed with brine, followed by drying over magnesium sulfate and evaporation of the solvent. Purification of the residue by silica gel column chromatography (hexane : ethyl acetate = 5:1 -> 1:1) gave 9.80 mg (4%) of the desired compound as a colorless oil.

[0450]

[0451] 132 552501 XH NMR (400 MHz, CDC13) 5 1.63-1.69 (1H, m), 1.93-2.17 (2H, m) , 2.29-2.36 (1H, m) , 2.44-2.45 (3H, m) , 2.55-2.65 (1H, m) , 2.73-2.80 (1H, m), 3.09-3.12 (2H, m), 3.34-3.37 (1H, m), 3.84 (3H, s), 4.59 (2H, d, J = 5.5 Hz), 7.08-7.12 (2H, ra), 7.34 (2H, d, J = 8.6 Hz), 7.46-7.50 (1H, m), 7.75-7.82 (4H, m).

[0452] <Example 4> Methyl 3- [3- [N- [ [2- (4-Chlorophenyl)-4-methylthiazol-5-yl]methyl]carba moyl]piperidin-l-yl]benzoate

[0453] [Chemical formula 109]

[0454] N-[[2-(4-chlorophenyl)-4-methylthiazol-5-yl]methyl]piperi dine-3-carboxamidehydrochloride (123mg, 0.318mmol) was suspended in diethyl ether. The suspension was washed sequentially with a O.lmol/L aqueous sodium hydroxide solution and brine and was dried over magnesium sulfate. The solvent was then evaporated and the resulting residue was dissolved in dichloromethane (lOmL). To this solution, 3-(methoxycarbonyl)phenylboricacid(114mg, 0.636mmol), molecular sieves 4A (300 mg), copper (II) acetate (122 mg, 0.636 mmol) and triethylamine (0.222 mL, 1.59 mmol) were added and the 133 552501 mixture was stirred at room temperature for 16 hours. Subsequently, the reaction mixture was filtered through Celite and a saturated aqueous sodium bicarbonate solution was added to the filtrate. The mixture was extracted with ethyl acetate. The extract was washed 5 with brine, followed by drying over magnesium sulfate and evaporation of the solvent. Purification of the resulting residue by silica gel column chromatography (hexane : ethyl acetate = 2:1 -> 0:1} gave 20.1 mg (13%) of the desired compound as a colorless powder. ® [0455] 10 XH NMR (400 MHz, CDCI3) 5 1.68-1. 97 (4H, m) , 2.43 (3H, s) , 2.59-2.65 (1H, m) , 3.14-3.24 (2H, m) , 3.32-3.41 (2H, m) , 3.88 (3H, s) , 4.55-4.65 (2H, m), 6.96-6.99 (1H, m), 7.13 (1H, dd, J = 2.4, 8.6 Hz), 7.31 (1H, t, J = 7.9 Hz), 7.38 (2H, d, J = 8.6 Hz), 7.57 (1H, d, J = 7.3 Hz), 7.63-7.64 (1H, m), 7.80 (2H, d, J = 8.6 Hz). 15 [0456] <Example 5> ^ Methyl 2-[3-[[2-(4-Chlorophenyl)-4-methylthiazol-5-yl]methoxymethyl]p iperidin-l-yl]benzoate 20 [0457] Step 5a) 1-(tert-Butoxycarbonyl)-3-[[2-(4-chlorophenyl)-4-methylthiazol -5-y1]methoxymethyl]piperidine

[0458] 25 [Chemical formula 110] 134 552501

[0459] 1- (tert-Butoxycarbonyl)piperidin-3-ylmethanol (215mg, 1.00 mmol) was dissolved in tetrahydrofuran (5 mL) . While this solution was chilled in an ice bath, 60% sodium hydride in oil (44.0 mg, 1.10 mmol) was added and the mixture was stirred for 20 min. Subsequently, 5-chloromethyl-2-(4-chlorophenyl)-4-methylthiazole (258 mg, 1.00 mmol) in tetrahydrofuran (5 mL) and sodium iodide (15.0 mg, 0.100 mmol) were added. The mixture was stirred for 2 hours while chilled in an ice bath and was further stirred for 6 hours at room temperature . Subsequently, ethyl acetate was added and the mixture was washed sequentially with 5% aqueous citric acid and brine, followed by drying over magnesium sulfate and evaporation of the solvent. Purification of the resulting residue by silica gel column chromatography (hexane : ethyl acetate = 20:1 -> 5:1) gave 258 mg (59%) of the desired compound as a colorless oil.

[0460] 1R NMR (400 MHz, CDC13) 6 1.17-1.29 (1H, m) , 1.40-1.49 (10H, m), 1.60- 1.67 (1H, m) , 1.74-1.86 (2H, m) , 2.44 (3H, s) , 2.64 (1H, m) , 2.77-2.84 (1H, m) , 3.32-3.39 (2H, m), 3.87-3.90 (1H, m), 4.01 (1H, m) , 4.62 (2H, s), 7.39 (2H, d, J = 8.6 Hz), 7.84 (2H, d, J = 8.6 Hz) . 135 552501

[0461] Step 5b) 3-[[2-(4-Chlorophenyl)-4-methylthiazol-5-yl]methoxymethyl]pipe ridine 5 [0462] [Chemical formula 111]

[0463] Using 10 1-(tert-butoxycarbonyl)-3-[[2-(4-chlorophenyl)-4-methylthiazol -5-yl]methoxymethyl]piperidine(258 mg, 0.590 mmol), the same procedure was followed as in Step lb of Example 1 to give 169 mg (85%) of the desired compound as a colorless oil.

[0464] XH NMR (400 MHz, CDC13) 5 1.08-1.18 (1H, m) , 1.40-1.51 (1H, m) , 1.62-1.69 (1H, m) , 1.75-1.86 (2H, m) , 2.35 (1H, dd, J= 9.8, 12.2 Hz), 2.44 (3H, s) , 2.55 (1H, dt, J = 3.1, J = 11.6 Hz), 2.97-3.02 (1H, m), 3.12-3.16 (1H, m), 3.30-3.36 (2H, m), 4.62 (2H, s) , 7.39 (2H, d, J = 8.6 Hz), 7.84 (2H, d, J = 8.6 Hz). 20 [0465] Step 5c) 2- [3-[ [2-(4-Chlorophenyl)-4-methylthiazol-5-yl]methoxymethyl]p iperidin-l-yl]benzaldehyde 136 552501

[0466] [Chemical formula 112] ci^q-^x"°"x3i cho

[0467] 5 Using 3-[[2-(4-chlorophenyl)-4-methylthiazol-5-yl]methoxymethyl]pipe ^ ridine (106 mg, 0.315 mmol) and 2-fluorobenzaldehyde (0.0329 mL, 0.315 mmol) , the same procedure was followed as in Step lc of Example 1 to give 45.2 mg (32%) of the desired compound as a colorless oil. 10 [0468] XHNMR (40 0MHz,CDC13) 51.19-1.28(1H, m), 1.73-1.87(3H, m), 2.11-2.21 (1H, m) , 2.43 (3H, s) , 2 . 68-2 . 73 (1H, m) , 2.82-2.8 9 (1H, m) , 3.19-3.21 (1H, m) , 3.33-3.37 (1H, m) , 3.41-3.48 (2H, m) , 4.63 (2H, m) , 7.06-7.11 (2H, m), 7.38 (2H, d, J = 8.6 Hz), 7.47-7.51 (1H, m) , 7.77-7.84 ^ (3H, m), 10.29 (1H, s).

[0469] Step 5d) Methyl 2-[3-[[2-(4-chlorophenyl)-4-methylthiazol-5-yl]methoxymethyl]p iperidin-l-yl]benzoate 20 [0470] [Chemical formula 113] 137 552501

[0471] 2-[3-[[2-(4-Chlorophenyl)-4-methylthiazol-5-yl]methoxymet hyl]piperidin-l-yl]benzaldehyde (45.2mg, 0.102mmol) was dissolved inmethanol (5mL). To this solution, sodium cyanide (25.8mg, 0.510 mmol) and manganese dioxide (88.7 mg, 1.02 mmol) were added and themixture was stirredat room temperature for 3 hours . Subsequently, a saturated aqueous sodium bicarbonate solution was added and the mixture was filtered through Celite. The filtrate was extracted with ethyl acetate and the extract was washed with brine, followed by drying over magnesium sulfate and evaporation of the solvent. Purification of the resulting residue by silica gel column chromatography (Chromatorex NH-DM2035, Fuji Silysia Chemical Co., Ltd.) (hexane : ethyl acetate = 50:1 -> 10:1) gave 27.9 mg (58%) of the desired compound as a colorless oil.

[0472] NMR (400 MHz, CDCl3) 5 1.13-1.23 (1H, m), 1. 69-1.82 (3H, m) , 2.08-2.19 (1H, m), 2.4 3 (3H, s), 2.55 (1H, dd, J = 9.8, 11.6 Hz), 2.70-2.76 (1H, m), 3.22-3.25 (1H, m), 3.37-3.47 (3H, m), 3.85 (3H, s), 4.59-4.66 (2H, m), 6.94 (1H, t, J = 7.3 Hz), 7.01 (1H, d, J = 7.9 Hz), 7.35-7.40 (3H, m), 7.67 (1H, dd, J = 1.8, 7.9 Hz), 7.82 (2H, d J = 8.6 Hz).

[0473] 138 552501 <Example 6> Methyl 2- [3- [ [2- (4-chlorophenyl)-4-methylthiazol-5-yl]methoxymethyl] p iperldln-l-yl]benzoate

[0474] Step 6a) 1-(tert-Butoxycarbonyl)-3-[[2-(4-chlorophenyl)-4-methylthiazol -5-yl]methoxy]piperidine

[0475] [Chemical formula 114] Using 1-(tert-butoxycarbonyl)-3-hydroxypiperidine (201 mg, 1. 00 mmol) and 5-chloromethyl-2-(4-chlorophenyl)-4-methylthiazole (258 mg, 1.00 mmol), the same procedure was followed as in Step 5a of Example 5 to give 187 mg (44%) of the desired compound as a colorless oil. 1H NMR (400 MHz, CDC13) 5 1.41-1.62 (11H, m) , 1.71-1.82 (1H, m) , 1.88-1.97 (1H, m), 2.44 (3H, s), 3.12-3.22 (2H, m), 3.46 (1H, m), 3.53-3.56 (1H, m), 3.79 (1H, m), 4.64-4.81 (2H, m), 7.38 (2H, d, J = 8.6 Hz), 7.83 (2H, d, J = 8.6 Hz).

[0476]

[0477]

[0478] 139 552501 Step 6b) 3- [ [2- (4-Chlorophenyl) -4-methylthia'zol-5-yl]methoxy] piperidine [0479] [Chemical formula 115] Using 1- (tert-butoxycarbonyl)-3-[[2-(4-chlorophenyl)-4-methylthiazol -5-yl]methoxy]piperidine (187 mg, 0.442 mmol), the same procedure was followed as in Step lb of Example 1 to give 119 mg (83%) of the desired compound as a colorless oil.

[0481] *H NMR (400 MHz, CDCI3) 5 1.39-1.49 (1H, m) , 1.53-1.61 (1H, m), 1. 72-1.80 (1H, m) , 1.91-2.00 (1H, m) , 2.44 (3H, s) , 2.64-2.70 (2H, m) , 2.81-2.86 (1H, m) , 3. 10 (1H, dd, J = 2 . 4, J = 12.2 Hz) , 3.41-3.4 6 (1H, m), 4.65-4.72 (2H, m), 7.39 (2H, d, J = 8.6 Hz), 7.83 (2H, d, J = 8.6 Hz).

[0482] Step 6c) 2-[3-[[2 - (4-Chlorophenyl)-4-methylthiazol-5-yl]methoxy]piperid in-l-yl]benzaldehyde

[0483] [Chemical formula 116]

[0480] 140 552501 3-[ [2- (4-Chlorophenyl)-4-methylthiazol-5-yl]methoxy]piper idine (59.1 mg, 0.183 mmol) and 2-fluorobenzaldehyde (0.0984 mL, 0.915 mmol) were dissolved in dimethylsulfoxide (2 mL). To this solution, cesium carbonate (119 mg, 0.366 mmol) was added and the mixture was stirred at 130°C for 3 hours. Subsequently, water was added and the mixture was extracted with ethyl acetate and the extracted was washed with brine, followed by drying over magnesium sulfate and evaporation of the solvent. Purification of the resulting residue by silica gel column chromatography (hexane : ethyl acetate = 20 : 1-> 5 :1) gave 47. 8 mg (61%) of the desired compound as a colorless oil.

[0484] NMR (400 MHz, CDCI3) 5 1.47-1.54 (1H, m) , 1.71-1.82 (1H, m) , 1.89-1.97 (1H, m) , 2.11-2.15 (1H, m) , 2.44 (3H, s) , 2.84-2.92 (2H, m) , 3.14-3.18 (1H, m) , 3.43-3. 47 (1H, m) , 3.73-3.79 (1H, m) , 4.69-4.77 (2H, m) , 7.10-7.12 (2H, m), 7.39 (2H, d, J = 8.6 Hz), 7.51 (1H, dt, J = 1.8, 7.9 Hz), 7.79-7.85 (3H, m), 10.32 (1H, s).

[0485] Step 6d) Methyl 2-[3-[[2-(4-chlorophenyl)-4-methylthiazol-5-yl]methoxy]piperid in-l-yl]benzoate

[0486] 141 552501 [Chemical formula 117]

[0487] Using 5 2- [3-[ [2- (4-Chlorophenyl)-4-methylthiazol-5-yl]methoxy]piperid in-l-yl]benzaldehyde (47.8 mg, 0.112 mmol), the same procedure was followed as in Step 5d of Example 5 to give 19.7 mg (38%) of the desired compound as a colorless oil.

[0488] 10 NMR (400 MHz, CDC13) 5 1. 34-1. 43 (1H, m) , 1.68-1.87 (2H, m) , 2.15-2.19 (1H, m), 2.44 (3H, s), 2.63 (1H, dd, J = 9.8, 11.6 Hz), 2.70 (1H, dt, J = 3.1, 11.6 Hz), 3.21-3.24 (1H, m), 3.54-3.58 (1H, m), 3.70-3.77 (1H, m), 3.87 (3H, s), 4.69-4.76 (2H, m) , 6.97-7.01 (1H, m), 7.04-7.06 (1H, m), 7.37-7.43 (3H, m), 7.73 (1H, dd, J= ^ 1.8, 7.9 Hz), 7.83 (2H, d, J = 8.6 Hz).

[0489] <Example 7> Methyl 3-[3-[[2-(4-Chlorophenyl)-4-methylthiazol-5-yl]methoxymethyl]p 20 iperidin-l-yl]benzoate

[0490] [Chemical formula 118] 142 552501 i_Oh_,cxro"X3i COOMe CI

[0491] Using 3- [ [2- (4-chlorophenyl) -4-methylthiazol-5--yl]methoxymethyl]pipe ridine (62.2 mg, 0.185 mmol) and 3-(methoxycarbonyl)phenylboric acid (66.6 mg, 0.370 mmol), the same procedure was followed as in Example 2 to obtain 69. 2 mg (79%) of the desired compound as a colorless oil.

[0492] 1R NMR (400 MHz, CDC13) 5 1.17-1.26 (1H, m) , 1.63-1.83 (3H, m) , 1.99-2.10 (1H, m), 2.45 (3H, s), 2.64 (1H, dd, J = 9.8, 11.6 Hz), 2 .78-2.84 (1H, m) , 3.41-3.48 (2H, m) , 3.56-3.59 (1H, m) , 3.68-3.72 (1H, m) , 3.89 (3H, s), 4.62-4.69 (2H, m), 7.12 (1H, dd, J = 1.8, 7. 9 Hz) , 7.2 6-7.31 (1H, m) , 7 .39 (2H, d, J = 8 . 6 Hz) , 7 .4 6-7 . 50 (1H, m) , 7.60-7.6K1H, m) , 7.84(2H, d J = 8.6 Hz).

[0493] <Example 8> Methyl 3-[3-[[2-(4-chlorophenyl)-4-methylthiazol-5-yl]methoxy]piperid in-l-yl]benzoate

[0494] [Chemical formula 119] 552501 cK3-CCo^yCX COOMe

[0495] Using 3-[ [2-(4-chlorophenyl)-4-methylthiazol-5-yl]methoxy]piperidine 5 (60.2mg, 0.186mmol) and 3-(methoxycarbonyl) phenylboric acid (66.9 mg, 0.372 mmol), the same procedure was followed as in Example 2 to give 61.0 mg (72%) of the desired compound as a colorless oil.

[0496] NMR (400 MHz, CDC13) 5 1.48-1.72 (2H, m) , 1.88-1.96 (1H, m) , 10 2.05-2.14 (1H, m), 2.46 (3H, s), 2.85-2.93 (2H, m), 3.47 (1H, td, J = 4.3, 12.2 Hz), 3.62-3.72 (2H, m), 3.90 (3H, s) , 4.72-4.7 9 (2H, m) , 7.10-7.12 (1H, m), 7.30 (1H, t, J = 7.9 Hz), 7.39 (2H, d, J = 8.6 Hz), 7.49-7.51 (1H, m), 7.61 (1H, m), 7.84 <2H, d, J = 8.6 Hz) .

[0497] <Example 9> Methyl 2-[3-[[2-(4-Chlorophenyl)-4-methylthiazol~5-yl]carbonylaminome thyl]pyrrolidin-l-yl]benzoate 20 [0498] Step 9a) N-[[(1-tert-Butoxycarbonyl)pyrrolidin-3-yl]methyl]-2-(4-chloro phenyl)-4-methylthiazole-5-carboxamide 144 552501

[0499] [Chemical formula 120] CI

[0500] 5 10 * Using 2-(4-chlorophenyl)-4-methylthiazolyl-5-carboxylic acid (804 mg, 3.17 mmol) and 1-(tert-butoxycarbonyl)pyrrolidine-3-yl methylamine (635 mg, 3.17 mmol), the same procedure was followed as in Step la of Example 1 to give 1.22 g (88%) of the desired compound as a colorless powder.

[0501] NMR (400 MHz, CDC13) 5 1.4 6 (9H, s) , 1.61-1.7 6 (1H, m) , 2.01-2.07 (1H, m) , 2.4 8-2. 57 (1H, m), 2.7 3 (3H, s) , 3.01-3.18 (1H, m) , 3.34-3.56 (5H, m), 5.90 (1H, m), 7.43 (2H, d, J = 8.6 Hz), 7.87 (2H, d, J = 8.6 Hz) . FAB+ (m/z) : 436 (M+H).

[0502] Step 9b) N-(Pyrrolidin-3-yl methyl)-2-(4-chlorophenyl)-4-methylthiazole-5-carboxamide

[0503] [Chemical formula 121] O 145 552501

[0504] Using N-[[ (1-tert-butoxycarbonyl)pyrrolidin-3-yl]methyl]-2-(4-chloro phenyl)-4-methylthiazole-5-carboxamide (1.22 g, 2.80 mmol), the same procedure was followed as in Step lb of Example 1 to give 598 mg (64%) of the desired compound as a colorless powder.

[0505] XH NMR (400 MHz, DMS0-d6) 5 1.37-1.46 (1H, m) , 1.76-1.85 (1H, m) , 2.28-2.35 (1H, m) , 2.57-2.61 (4H, m) , 2.75-2.81 (1H, m) , 2.86-2.93 (2H, m) , 3.18-3.22 (3H, m) , 7.57 (2H, d, J = 8.6 Hz), 7.94 (2H, d, J = 8.6 Hz), 8.41 <1H, t, J = 5.5 Hz). FAB+ (m/z) : 336 (M+H).

[0506] Step 9c) Methyl 2-[3-[[2-(4-chlorophenyl)-4-methylthiazol-5-yl]carbonylaminome thyl]pyrrolidin-l-yl]benzoate

[0507] [Chemical formula 122] N-(Pyrrolidin-3-yl methyl)-2-(4-chlorophenyl)-4-methylthiazole-5-carboxamide (168 mg, 0.500 mmol) and methyl 2-fluorobenzoate (0.127 mL, 1.00 mmol) 0

[0508] 146 552501 were dissolved in dimethylsulfoxide (4 mL). To this solution, potassium carbonate (138 mg, 1.00 mmol) and tetrabutylammonium iodide (18.5 mg, 0.0500 mmol) were added and the mixture was stirred at 14 0 °C for 6 hours . Subsequently, the reaction mixture was allowed 5 to cool and water was added. The mixture was then extracted with ethyl acetate and the extract was washed with brine, followed by drying over magnesium sulfate and evaporation of the solvent. Purification of the resulting residue by silica gel column ^ chromatography (hexane : ethyl acetate = 4:1 -> 2:1) gave 136 mg 10 (58%) of the desired compound as a colorless amorphous product.

[0509] 1H NMR (400 MHz, CDC13) 5 1.77-1. 86 (1H, m) , 2.11-2.19 (1H, m), 2.60-2.67 (1H, m), 2.71 (3H, s), 3.21-3.38 (4H, m), 3.54 (2H, t, J = 6.1 Hz), 3.87 (3H, s), 6.26 (1H, t, J = 6.1 Hz) , 6.78 (1H, t, 15 J = 7.9 Hz) , 6.82 (1H, d, J = 8.6 Hz) , 7.32-7.36 (1H, m) , 7.41 (2H, d, J = 8.6 Hz), 7.63 (1H, dd, J = 1.8, 7.3 Hz), 7.85 (2H, d, J = ^ 8.6 Hz). FAB+ (m/z) : 4 70 (M+H).

[0510] 20 <Example 10> Methyl 3-[3-[[2-(4-chlorophenyl)-4-methylthiazol-5-ylj carbonylaminome thyl]pyrrolidin-l-yl]benzoate

[0511] 25 [Chemical formula 123] 147 552501 o ^ ' IN N / COOMe

[0512] Using N-(pyrrolidin-3-yl methyl) -2- (4-chlorophenyl) -4-methylthiazole-5-carboxamide (168 5 mg, 0.500 mmol) and 3-(methoxycarbonyl)phenylboric acid (180 mg, 1.00 mmol) , the same procedure was followed as in Example 2 to give 73.7 mg (31%) of the desired compound as a colorless powder. XH NMR (400 MHz, CDC13) 5 1.84-1. 93 (1H, m), 2.21-2.29 (1H, m) , 10 2.70-2.77 (4H, m), 3.20 (1H, dd, J = 6.1, 9.2 Hz), 3.33-3.40 (1H, m) , 3.4 9-3.63 (4H, m) , 3.90 (3H, s) , 6.04 (1H, t, J = 6.1 Hz) , 6.7 8 (1H, dd, J = 1.2, 8.6 Hz), 7.26-7.31 (2H, m) , 7. 37-7.43 (3H, m), 7.86 (2H, d, J = 8.6 Hz). Methyl 2-[3-[[2-(4-chlorophenyl)-4-methylthiazol-5-yljcarbonylaminome thyl]perhydroazepin-l-yl]benzoate

[0515] 20 Step 11a) N- [ [ (l-tert-Butoxycarbonyl)perhydroazepin-3-yl]methyl]-2-(4-ch lorophenyl)-4-methylthiazole-5-carboxamide

[0516]

[0513]

[0514] <Example 11> 148 552501 [Chemical formula 124] 9 H "KKXVQ °

[0517] Using 2-(4-chlorophenyl)-4-methylthiazolyl-5-carboxylic acid (792 mg, 3.12 mmol) and 1-(tert-butoxycarbonyl)perhydroazepin-3-yl methylamine (712 mg 3.12 mmol) , the same procedure was followed as in Step la of ExampL 1 to give 1.26 g {81%) of the desired compound as a colorless amorphou product.

[0518] XH NMR (400 MHz, CDC13) 5 1.41-1.49 (10H, m), 2.03-2.12 (1H, m) 2.77 (3H, s), 2.99-3.09 (2H, m), 3.13 (1H, dd, J = 3.7, 14.7 Hz) 3.58-3.64 (1H, m), 3.65-3.72(1H, m), 3.78 (1H, dd, J = 4.3, 14. Hz), 7.41 (2H, d, J = 8.6 Hz), 7.64 (1H, t, J = 5.5 Hz) , 7.87 (2H d, J = 8.6 Hz) . FAB+ (m/z) : 464 (M+H).

[0519] Step lib) N- (Perhydroazepin-3-yl methyl)-2-(4-chlorophenyl)-4-methylthiazole-5-carboxamide

[0520] [Chemical formula 125] 149 552501 •KKcVtJ

[0521] Using N-[[(1-tert-butoxycarbonyl)perhydroazepin-3-yl]methyl]-2-(4-ch 5 lorophenyl)-4-methylthiazole-5-carboxamide (1.26 g, 2.72 mmol), the same procedure was followed as in Step lb of Example 1 to give ^ 896 mg (90%) of the desired compound as a colorless powder.

[0522] NMR (400 MHz, CDC13) 5 1.43-1.59 (3H, m) , 1.76-1.84 (2H, m), 10 1.90-2.01 (2H, m), 2.62-2.68 (1H, m), 2.75 (3H, s) , 2.97 (2H, d, J = 4.3 Hz), 3.06 (1H, td, J =4.3, 12.8 Hz), 3.33 (1H, td, J = 3.7, 12.8 Hz), 3.53 (1H, td, J - 5.2, 12.8 Hz), 7.41 (2H, d, J = 8.6 Hz), 7.74 (1H, m), 7.87 (2H, d, J = 8.6 Hz). FAB+{m/z): 364 (M+H).

[0523] Step 11c) Methyl 2- [3- [ [2- (4-chlorophenyl)-4-methylthiazol-5-yl]carbonylaminome thyl]perhydroazepin-l-yl]benzoate

[0524] 20 [Chemical formula 126] 150 552501

[0525] Using N-(perhydroazepin-3-yl methyl)-2-(4-chlorophenyl)-4-methylthiazole-5-carboxamide (200 5 mg, 0.550 mmol) and methyl 2-fluorobenzoate (0.140 mL, 1.10 mmol), ^ the same procedure was followed as in Step 9c of Example 9 to give 52.7 mg (19%) of the desired compound as a colorless oil.

[0526] 1R NMR (400 MHz, CDC13) 5 1.52-1.58 (1H, m) , 1.66-1.79 (5H, m), 10 2.28-2.38 (1H, m) , 2.56 (3H, s), 3 .10-3.16(1H, m), 3.21-3.30 (2H, m) , 3.36-3.42 (1H, m), 3.46 (1H, dd, J = 2.4, 13.4 Hz), 3.54-3.60 (1H, m), 3.88 (3H, s), 6.51 (1H, t, J = 5.5 Hz), 6.90 (1H, t, J = 7.3 Hz), 7.06 (1H, d, J = 7.9 Hz), 7.34 (1H, dt, J = 1.2, 7.3 ) Hz) , 7.4 0 (2H, d, J - 8.6 Hz), 7.54 (1H, dd, J = 1.2, 7.3 Hz) , 7.78 15 (2H, d, J = 8.6 Hz). FAB+(m/z): 498 (M+H).

[0527] <Example 12> Methyl 2 0 3-[3-[ [2- (4-chlorophenyl)-4-methylthiazol-5-yl]carbonylaminome thyl]perhydroazepin-l-yl]benzoate

[0528] 151 552501 [Chemical formula 127]

[0529] Using N-(perhydroazepin-3-yl methyl)-2- (4-chlorophenyl)-4-methylthiazole-5-carboxamide (200 mg, 0.550 mmol) and 3-(methoxycarbonyl)phenylboric acid (198 mg, 1.10 mmol) , the same procedure was followed as in Example 2 to give 126 mg (46%) of the desired compound as a colorless powder.

[0530] XH NMR (400 MHz, CDC13) 5 1.30-1.46 (2H, m) , 1.66-1.84 (3H, m), 1.97-2.06 (1H, m), 2.16-2.26 (1H, m), 2.75 (3H, s), 3.10 (1H, dd, J = 10.4, 15.3 Hz), 3.30-3.37 (1H, m) , 3.38-3. 46 (2H, m), 3.63-3.70 (1H, m), 3.81 (1H, dd, J = 4.3, 14.7 Hz),3.86 (3H, s), 5.96 (1H, t, J = 5.5 Hz), 6.87 (1H, dd, J = 1.8, 7.9 Hz), 7.24 (1H, t, J = 7.9 Hz), 7.29 (1H, d, J = 7.9 Hz), 7.35-7.36 (1H, m) , 7.42 (2H, d, J = 8.6 Hz), 7.88 (2H, d, J = 8.6 Hz). FAB+ (m/z) : 498 (M+H).

[0531] <Example 13> Methyl 3-[3-[2-[2-(4-chlorophenyl)-4-methylthiazol-5-yl]acetylamino]p iperidin-l-yl]benzoate

[0532] 152 552501 Step 13a) N-[1-(tert-Butoxycarbonyl)piperidin-3-yl]-2-[2-(4-chlorophenyl )-4-methylthiazol-5-yl]acetamide

[0533] 5 [Chemical formula 128] Using 2- [2-(4-chlorophenyl)-4-methylthiazol-5-yl]acetic acid (1.50 g, 5.99 mmol) and 10 1-(tert-butoxycarbonyl)-3-aminopiperidine (1.20 g, 5. 99 mmol), the same procedure was followed as in Step la of Example 1 to give 1.59 g (59%) of the desired compound as a colorless powder.

[0535] 1ti NMR (4 00 MHz, CDC13) 5 1.41 (9H, s), 1.4 9-1.57 (2H, m), 1.59-1. 68 £ (1H, m), 1.73-1.81 (1H, m), 2.42 (3H, s), 3.19-3.54 (4H, m), 3.69 (2H, s) , 3.98 (1H, m) , 5.70 (1H, m) , 7.3 9 (2H, d, J = 8.6 Hz) , 7.83 (2H, d, J = 8.6 Hz). FAB+(m/z): 450 (M+H).

[0536] 20 Step 13b] N-(Piperidin-3-yl)-2-[2-(4-chlorophenyl)-4-methylthiazol-5-yl] acetamide

[0537]

[0534] 153 552501 [Chemical formula 129] "-o-floVr

[0538] Using 5 N-[1-(tert-butoxycarbonyl)piperidin-3-yl]-2-[2-(4-chlorophenyl )-4-methylthiazol-5-yl]acetamide (1.59 g, 3.53 mmol), the same ^ procedure was followed as in Step lb of Example 1 to give 1.06 g (86%) of the desired compound as a colorless powder.

[0539] 10 XE NMR (400 MHz, CDC13) 5 1. 46-1.53 (1H, m) , 1.56-1.64 (1H, m) , 1.66-1.80 (2H, m) , 2.43 (3H, s), 2.60-2.64 (1H, m) , 2.70-2.79 (2H, m), 2.96 (1H, dd, J =3.1, 11.6 Hz), 3.70 (2H, s), 3.94-4.03 (1H, m) , 6.18 (1H, m), 7.39 (2H, d, J = 8.6 Hz), 7.84 (2H, d, J = 8.6 Hz) . )B FAB+ (m/z) : 350 (M+H) .

[0540] Step 13c) Methyl 3-[3-[2-[2-(4-chlorophenyl)-4-methylthiazol-5-yl]acetylamino]p iperidin-l-yl]benzoate 20 [0541] [Chemical formula 130] 154 552501 ^chnXTo xy COOMe CI

[0542] 5 10 Using N-(piperidin-3-yl)-2-[2-(4-chlorophenyl)-4-methylthiazol-5-yl] acetamide (200 mg, 0.572 mmol) and 3-(methoxycarbonyl)phenylboric acid (205 mg, 1.14 mmol), the same procedure was followed as in Example 2 to give 162 mg (59%) of the desired compound as a colorless powder.

[0543] 1H NMR (4 00 MHz, CDC13) 5 1.65-1.7 6 (4H, m) , 2.41 (3H, s) , 3.01-3.0 6 (1H, m) , 3.12 (1H, dd, J = 5.5, 12.2 Hz), 3.22-3.29 (2H, m), 3.72 (2H, s) , 3.8 9 (3H, s) , 4.19-4.2 6 (1H, m) , 6.02 (1H, d, J - 7.9 Hz), 7.03-7.06(1H, m), 7.25 (1H, t, J = 7.9 Hz), 7.38 (2H, d, J = 8.6 Hz), 7.49-7.52 (1H, m) , 7.53-7.54 (1H, m) , 7.78 (2H, d, J = 8.6 Hz) . FAB+ (m/z) : 484 (M+H).

[0544] <Example 14> Methyl 2-[3-[[2-(4-chlorophenyl)-4-methylthiazol-5-yl]carbonylamlno]p iperidin-l-yl]benzoate

[0545] 155 552501 Step 14a) N-[(1-tert-Butoxycarbonyl)piperidin-3-yl]-2-(4-chlorophenyl)-4-methylthiazole-5-carboxamide

[0546] [Chemical formula 131]

[0547] Using 2-(4-chlorophenyl)-4-methylthiazole-5-carboxylic acid (1.52 g, 5.99 mmol) and 1-(tert-butoxycarbonyl)-3-aminopiperidine (1.20g, 5.99 mmol), the same procedure was followed as in Step la of Example 1 to give 2.30 g (88%) of the desired compound as a colorless powder.

[0548] *H NMR (4 00 MHz, CDC13) 5 1.4 7 (9H, s) , 1.56-1.74 (2H, m) , 1.78-2.03 (2H, m) , 2.73 (3H, s) , 3.12-3.24 (1H, m) , 3.34-3.50 (1H, m) , 3.68-3.71 (2H, m) , 4.13-4.19 (1H, m) , 6.04 (1H, m) , 7.42 (2H, d, J = 8.6 Hz) , 7.86 (2H, d, J = 8.6 Hz). FAB+(m/z): 436 (M+H).

[0549] Step 14b) N-(Piperidin-3-yl)-2-(4-chlorophenyl)-4-methylthiazole-5-carbo xamide

[0550] [Chemical formula 132] 156 552501 CI-O^Y N ^ W S-\n^n NH

[0551] 5 10 m Using N-[(1-tert-butoxycarbonyl)piperidin-3-yl]-2-(4-chlorophenyl)-4 -methylthiazole-5-carboxamide(2.30 g, 5.28 mmol), the same procedure was followed as in Step lb of Example 1 to give 1.7 5 g (99%) of the desired compound as a colorless powder.

[0552] 1H NMR (400 MHz, DMS0-d6) 5 1.33-1.49 (2H, m), 1.57-1.61 (1H, m) , 1.80-1.84 (1H, m), 2.37-2.42 (2H, m), 2.57 (3H, s), 2.72-2.77 (1H, m), 2.93 (1H, dd, J = 3.1, 11.6 Hz), 3.70-3.79 (1H, m), 7.57 (2H, d, J = 8 . 6 Hz) , 7 . 94 (2H, d, J = 8. 6 Hz) , 8 . 05 (1H, d, J = 7.9 Hz).

[0553] Step 14c) 2-[3-[[2-(4-Chlorophenyl)-4-methylthiazol-5-yl]carbonylamlno]p iperidin-l-yl]benzaldehyde

[0554] [Chemical formula 133]

[0555] Using 157 552501 N-(piperidin-3-yl)-2-(4-chlorophenyl)-4-methylthiazole-5-carbo xamide (67.2 mg, 0.200 mmol) and 2-fluorobenzaldehyde (0.211 mL, 2.00 mmol) , the same procedure was followed as in Step 6c of Example 6 to give 14.9 mg (17%) of the desired compound as a colorless powder.

[0556] XH NMR (400 MHz, CDCl3) 5 1.68-1.81 (2H, m) , 2.01-2.11 (2H, m) , 2.76 (3H, s) , 2.92-2.99 (1H, m) , 3.13 (1H, dd, J = 2.4, 12.2 Hz) , 3.2 4-3.30 (2H, m) , 4.36-4.43 (1H, m), 7.15 (1H, d, J = 8.6 Hz), 7.20 (1H, t, J = 7.3 Hz) , 7.4 0-7.4 6 (3H, m), 7.56 (1H, dt, J = 1.8, 7.3 Hz) , 7.79 (1H, dd, J = 1.8, 7.9 Hz), 7.88 (2H, d, J = 8.6 Hz), 10.14 (1H, s) .

[0557] Step 14d) Methyl 2 - [3- [ [2-(4-chlorophenyl)-4-methylthiazol-5-yl]carbonylamino] p iperidin-l-yl]benzoate

[0558] [Chemical formula 134]

[0559] Using 2-[3-[[2-(4-chlorophenyl)-4-methylthiazol-5-yl]carbonylamino]p iperidin-l-yl]benzaldehyde (14.9 mg, 0.0339 mmol), the same procedure was followed as in Step 5d of Example 5 to give 2.60 mg 158 552501 (16%) of the desired compound as a colorless oil.

[0560] 1E NMR (400 MHz, CDC13) 5 1. 58-1.64 (1H, m) , 1. 68-1.73 (1H, m) , 1.97-2.09 (1H, m), 2.14-2.17 (1H, m), 2.79 (3H, s), 2.86 (1H, dt, J = 2.4, 11.6 Hz), 2.98 (1H, dd, J = 2.4, 12.2 Hz) , 3.20-3.2 9 (2H, m) , 3.84 (3H, s) , 4.34-4.39 (1H, m), 7.07 (1H, dt, J =1.2, 7.3 Hz) , 7.13 (1H, dd, J = 1.2, 7.9 Hz) , 7.41 (2H, d, J = 8.6 Hz) , 7.48 (1H, dt, J = 1.8, 7.3 Hz), 7.77 (1H, d, J = 6.7 Hz), 7.83 (1H, dd, J = 1.8, 7.9 Hz), 7.88 (2H, d, J = 8.6 Hz).

[0561] <Example 15> Methyl 3-[3-[[2-(4-Chlorophenyl)-4-methylthiazol-5-yl]carbonylamino]p iperidin-l-yl]benzoate

[0562] Step 15a) Methyl 3-[3-(tert-butoxycarbonylamino)piperidin-l-yl]benzoate

[0563] [Chemical formula 135]

[0564] 3-(tert-Butoxycarbonylamino)piperidine (200 mg, 1.00 mmol), 3-(methoxycarbonyl)phenylboric acid (360 mg, 2.00 mmol) and 159 552501 molecular sieves 4A (100 mg) were suspended in dichloromethane (10 mL) . To this suspension, copper (II) acetate (182 mg, 1.00 mmol) and triethylamine (0.280 mL, 2.00 mmol) were added and the mixture was stirred at room temperature for 15 hours- Subsequently, the 5 reaction mixture was filtered through Celite and a saturated aqueous sodium bicarbonate solution was added to the filtrate . This mixture was extracted with ethyl acetate and the extract was washed with brine, followed by drying over magnesium sulfate and evaporation ^ of the solvent. The resulting residue was purified by silica gel 10 column chromatography (hexane : ethyl acetate - 10:1 -> 5:1, to give a colorless oil. This product was further purified by silica gel column chromatography (Chromatorex NH-DM2035 (Fuji Sylysia Chemical Co., Ltd.) hexane : ethyl acetate = 10:1) to give 154 mg (46%) of the desired compound as a colorless powder. 15 [0565] lH NMR (40 0 MHz, CDC13) 5 1.46 (9H, s), 1.55-1.59 (1H, m), 1.68-1.76 £ (1H, m) , 1.78-1.8 9 (2H, m) , 3.01-3.05 (1H, m) , 3.16 (2H, m) , 3.37-3.40 (1H, m), 3.82-3.90 (4H, m), 4.87 (1H, m), 7.12-7.14 (1H, m), 7.31 (1H, t, J = 7.9 Hz), 7.52 (1H, d, J = 7.3 Hz), 7.59 (1H, m). 20 EI+ (m/z) : 334 (M+) .

[0566] Step 15b) Methyl 3-[3-[[2-(4-chlorophenyl)-4-methylthiazol-5-yl]carbonylamino]p ■ iperidin-l-yl]benzoate 25 [0567] 160 552501 [Chemical formula 136] C1

[0568] Methyl 3-[3-(tert-butoxycarbonylamino)piperidin-l-yl]benzoate (154 mg, 0.461 mmol) was dissolved in a 10% hydrogen chloride/methanol solution (10 mL) and the solution was stirred at room temperature for 1 hour. Concentration of the reaction mixture resulted in 135 mg of a brown amorphous product. This product (118 mg) , along with 2-(4-chlorophenyl)-4-methylthiazole-5-carboxylic acid (111 mg, 0.436 mmol) and 1-hydroxybenzotriazole monohydrate (80.1 mg, 0.523 mmol) , was dissolved in N, N-dimethylformamide (5 mL) . While this solution was chilled in an ice bath, 3- (3-dimethylaminopropyl) -1-ethylcarbodiimide hydrochloride (100 mg, 0.523 mmol) and N-methylmorpholine (0.115 mL, 1.05 mmol) were added. The mixture was stirred at room temperature for 6 hours and 5% aqueous citricacidwas added. The resultingmixture was extracted with ethyl acetate and the extract was washed sequentially with a saturated aqueous sodium bicarbonate solution and brine. The washed product was dried over magnesium sulfate and the solvent was evaporated. Purification of the resulting residue by silica gel column chromatography (hexane : ethyl acetate = 5:1 -> 1:1) gave 112 mg of the desired compound as a pale yellow powder. 161 552501

[0569] XH NMR (400 MHz, CDCI3) 5 1.78-1.95 (4H, m) , 2.72 (3H, s) , 3. 04-3.10 (1H, m), 3.29-3.41 (3H, m), 3.91 (3H, s), 4.41 (1H, m), 6.31 (1H, d, J = 7.9 Hz), 7.17 (1H, dd, J = 2.4 , 8.6 Hz), 7.34 (1H, t, J 5 = 7.9 Hz), 7.41 (2H, d, J = 8.6 Hz), 7.56-7.58 (1H, m), 7.64 (1H, m), 7.87 (2H, d, J = 8.6 Hz). FAB+ (m/z): 470 (M+H).

[0570] <Example 16> 10 Methyl (R)-3- [3- [ [2-(4-chlorophenyl)-4-methylthiazol-5-yl]carbonylami no]piperidin-l-yl]benzoate

[0571] Step 15 16a)(R)-N-[(1-tert-Butoxycarbonyl)piperidin-3-yl]-2-(4-chlorop henyl) -4-rnethylthiazole-5-carboxamide 0 [0572] [Chemical formula 137] 20 [0573] Using 2-(4-chlorophenyl)-4-methylthiazole-5-carboxylic acid (12.4 g, 48.9 mmol) and (R)-1-(tert-butoxycarbonyl)-3-aminopiperidine(9.79 g, 48.9mmol), 162 552501 the same procedure was followed as in Step la of Example 1 to give 18.3 g (86%) of the desired compound as a colorless powder. XH NMR (4 00 MHz, CDC13) 5 1.47 (9H, s) , 1.58-1.74 (2H, m) , 1.78-2.01 (2H, m) , 2.73 (3H, s) , 3.11-3.26 (1H, m) , 3.34-3.50 (1H, m) , 3.57-3.82 (2H, m) , 4.13-4.19 (1H, m) , 6.01 (1H, m) , 7.42 <2H, d, J = 8.6 Hz) , 7.86 (2H, d, J = 8.6 Hz). FAB+ (m/z) : 436 (M+H).

[0574] Step 16b) (R)-N-(Piperidin-3-yl)-2-(4-chlorophenyl)-4-methylthiazole-5-c arboxamide

[0575] [Chemical formula 138] (R)-N- [ (1-tert-butoxycarbonyl)piperidin-3-yl]-2-(4-chloropheny 1)-4-methylthiazole-5-carboxamide (18.2 g, 41.7 mmol), the same procedure was followed as in Step lb of Example 1 to give 14.9 g (quant.) of the desired compound as a colorless powder. 1H NMR (400 MHz, DMSO-d6) 5 1.35-1.52 (2H, m) , 1.59-1.63 (1H, m) , 1.82-1.86 (1H, m) , 2.39-2. 44 (2H, m) , 2.59 (3H, s) , 2.75-2.78 (1H, m) , 2. 95 (1H, dd, J = 3 .1 Hz, J = 11. 6 Hz) , 3.72-3.80 (1H, m), 7 . 58 - (2H, d, J = 8.6 Hz), 7 .95 (2H, d, J = 8.6 Hz) , 8 .07 (1H, d, J = 7. 9 Hz) . Using 163 552501 FAB+(ra/z): 336 (M+H).

[0576] Step 16c) Methyl (R)-3- [3- [ [2-(4-chlorophenyl)-4-methylthiazol-5-yl]carbonylami no]piperidin-l-yl]benzoate

[0577] [Chemical formula 139] (R)-N-(piperidin-3-yl)-2-(4-chlorophenyl)-4-methylthiazole-5-c arboxamide (336 mg, 1.00 mmol) and 3-(methoxycarbonyl)phenylboric acid (360 mg, 2.00 mmol), the same procedure was followed as in Example 2 to give 142 mg (30%) of the desired compound as a pale yellow powder. XH NMR (400 MHz, CDC13) 5 1. 78-1.93 (4H, m) , 2.72 (3H, s) , 3.04-3.10 (1H, m), 3.29-3.41 (3H, m), 3.91 (3H, s), 4.39-4.44 (1H, m), 6.31 (1H, d, J = 7.9 Hz), 7.17 (1H, m), 7.34 (1H, t, J = 7.9 Hz), 7.41 (2H, d, J = 8.6 Hz), 7.56-7.58 (1H, m), 7.63-7.64 (1H, m), 7.87 (2H, d, J = 8.6 Hz). FAB+(m/z): 470 (M+H). [a] 27'4°d -110° (C = 1.2, CHCI3)

[0578] Using 164 552501 HPLC (CHIRALCEL OJ (Daicel Chemical Industries, Co,. Ltd.) <|> 0.46 x 25 cm, mobile phase: hexane/ethanol = 80/20, flow rate: 1 mL/min, Temp.: 40°C): Rt 39.1 min (98% ee)

[0579] <Example 17> Methyl(S)-3-[3-[[2-(4-chlorophenyl)-4-methylthiazol-5-yl]carbo nylamino]piperidin-l-yl]benzoate

[0580] Step 17a)(S)-N- [ (1-tert-Butoxycarbonyl)piperidin-3-yl]-2-(4-chlorop henyl)-4-methylthiazole-5-carboxamide

[0581] [Chemical formula 140]

[0582] Using 2-(4-chlorophenyl)-4-methylthiazole-5-carboxylic acid (1.27 g, 4.99 mmol) and (S) -1-(tert-butoxycarbonyl)-3-aminopiperidine (1.00 g, 4. 99 mmol), the same procedure was followed as in Step la of Example 1 to give 1.84 g (85%) of the desired compound as a colorless powder. XH NMR (4 00 MHz, CDCI3) 5 1.4 7 (9H, s) , 1.57-1.7 4 (2H, m) , 1.7 8-2.01 (2H, m) , 2.73 (3H, s) , 3.13-3.24 (1H, m) , 3.35-3.49 (1H, m) , 3. o4-3.7S (2H, m) , 4.13-4.19 (1H, m) , 6.04 (1H, m) , 7.42 (2H, d, J = 8.6 Hz) , 165 552501 7.86 (2H, d, J = 8.6 Hz). FAB+(m/z): 436 (M+H).

[0583] Step 17b) 5 (S)-N-(Piperidin-3-yl)-2-(4-chlorophenyl)-4-methylthiazol-5-yl carboxamide

[0584] [Chemical formula 141] 10 [0585] Using (S)-N-[(1-tert-butoxycarbonyl)piperidin-3-yl]-2-(4-chloropheny 1)-4-methylthiazole-5-carboxamide (1.74 g, 3.99 mmol), the same procedure was followed as in Step lb of Example 1 to give 1.23 g ^5 (92%) of the desired compound as a colorless powder. XH NMR (400 MHz, DMSO-d6) 5 1.35-1.51 (2H, m), 1.60-1.63 (1H, m) , 1.82-1.85 (1H, m) , 2.38-2.44 (2H, m) , 2.59 (3H, s), 2.75-2.78 (1H, m) , 2.93-2.9 6 (1H, m) , 3.7 0-3.82 (1H, m) , 7.58 (2H, d, J = 8.6 Hz) , 7.95 (2H, d, J = 8.6 Hz), 8.05 (1H, d, J = 7.3 Hz). 20 FAB+(m/z): 336 (M+H).

[0586] 166 552501 Step 17c) Methyl (S)-3- [3-[[2-(4-chlorophenyl)-4-methylthiazol-5-yl]carbonylami no]piperidin-l-yl]benzoate [0587] [Chemical formula 142] (S)-N-(piperidin-3-yl)-2-(4-chlorophenyl)-4-methylthiazol-5-ca rboxamide (336 mg, 1.00 mmol) and 3-(methoxycarbonyl)phenylboric acid (360 mg, 2.00 mmol), the same procedure was followed as in Example 2 to give 233 mg (50%) of the desired compound as a colorless powder. XH NMR (4 00 MHz, CDC13) 5 1.78-1.93 (4H, m) , 2.72 (3H, s) , 3.04-3.10 (1H, m), 3.29-3.41 (3H, m), 3.91 (3H, s), 4.38-4.44 (1H, m), 6.31 (1H, d, J = 7.9 Hz), 7.16-7.18 (1H, m), 7.34 (1H, t, J = 7.9 Hz), 7.41 (2H, d, J = 8.6 Hz), 7.55-7.58 (1H, m) , 7 . 63-7.64 (1H, m) , 7.86 (2H, d, J = 8.6 Hz). FAB+(m/z): 470 (M+H) [oc] 27,6°d +113° (C = 1.0, CHC13) . HPLC (CHIRALCEL OJ (Daicel Chemical Industries, Co, . Ltd.) (j) 0.46 x 25 cm, mobile phase: hexane/ethanol = 80/20, flow rate: 1 mL/min, Temp.: 40°C): Rt 24.4 min (98% ee)

[0588] Using 167 552501

[0589] <Example 18> 2- [3- [ [2- (4-Chlorophenyl)-4-methylthiazol-5-yl]carbonylaminome thyl]piperidin-l-yl]benzoic acid 5 [0590] [Chemical formula 143]

[0591] Methyl 10 2-[3- [ [2- (4-chlorophenyl)-4-methylthiazol-5-yl]carbonylaminome thyl]piperidin-l-yl]benzoate (29.5 mg, 0.0609 mmol) was dissolved in methanol (3 mL) . To this solution, a lmol/L aqueous potassium hydroxide solution {0.183 mL, 0.183 mmol) was added and the mixture was stirred for 2 hours while being refluxed. Subsequently, the ^5 reaction mixture was concentrated and water was added to the residue, followed by 2mol/L hydrochloric acid to make the mixture acidic. The crystallized powdery product was collected by filtration and was washed with water to give 23.2 mg (81%) of the desired product as a colorless powder. 20 [0592] :H NMR (400 MHz, DMSO-d6) 5 1.11-1.34 (2H, m) , 1.59-1.72 (1H, m) , 1.85-1.95 (2H, m), 1.97-2.10 (1H, m), 2.58 (3H, s), 2.85 (1H, t, J = 11.0 Hz), 2.99-3.12 (3H, m), 3.15-3.22 (1H, m), 7.44 (1H, t, 168 552501 J = 7.3 Hz), 7.58 (2H, d, J = 8.6 Hz), 7.66-7 . 74 (2H, m) , 7.95 (2H, d, J = 8.6 Hz), 8.04 (1H, dd, J = 1.8, 7.9 Hz), 8.37 (1H, t, J = 5.5 Hz), 17.91 (1H, brs). HR-FAB+ (m/z) : 470.1291 (-1.4 mmu) . 5 Elemental analysis calcd (%) for C24H24ClN303S-2/5H20: C 60.41, H5.24, N 8.81; found: C 60.25, H 5.09, N 8.62.

[0593] <Examples 19 through 32> ^ The compounds obtained in Examples 2 through 17 were reacted 10 in the manner described in Example 18 to obtain compounds given in Table 4 below.

[0594] 15 20 25 169 552501 [Table 4] J-COOH ci Y. -2 N ^ T N 1 2 3 Example Y Z Binding position of carboxylic acid Example 19 Racemic mixture conhch2 ch2 Position 3 Example 20 Racemic mixture ch2imhco ch2 Position 2 Example 21 Racemic mixture ch2nhco ch2 Position 3 Example 22 Racemic mixture ch2och2 ch2 Position 2 Example 23 Racemic mixture chgo ch2 Position 2 Example 24 Racemic mixtire ch2och2 ch2 Position 3 Example 25 Racemic mixture ch2o ch2 Posilion 3 Example 26 Racetric mixture conhch 2 - Position 2 Example 27 Racemic mixture conhch 2 _ Position 3 Example Example 28 29 Racemic nrixtitre Racemic mixture conhch 2 conhch 2 ch2ch2 ch2ch2 Position 2 Position 3 Example 30 Racemic mixture ch2conh ch2 Position 3 Example 31 Racemic mixture conh ch2 Position 2 Example 32 Racemic mixture conh ch2 Position 3 Example Example 33 34 R S conh conh ch2 ch„ Position 3 Position 3

[0595] <Compound of Example 19> Colorless powder 1H NMR (400 MHz, DMS0-d6) 5 1.13-1.23 (1H, m) , 1.52-1.62 (1H, m), 1.75-1.95 (3H, m) , 2.50-2.57 (1H, m) , 2.62 (3H, s), 2.71-2.77 (1H, m) , 3.17-3.35 (2H, m) , 3.5 9-3.62 (1H, m) , 3.66-3.67 (1H, m) , 7.17-7.2 0 (1H, m) , 7.29-7.35 (2H, m), 7.47-7.48 (1H, m), 7.59 (2H, d, J = 8.6 Hz), 7.97 (2H, d, J =8.6 Hz), 8.45 (1H, t, J = 5.5 Hz), 12.30 (1H, brs). 170 552501 HR-FAB+ (m/z): 470.1303 (-0.2 mmu). Elemental analysis calcd (%) for C24H24CIN3O3S • 1/10H20: C 61.10, H 5.17, N 8.91/ found: C 60.95, H 5.08, N 8.84.

[0596] 5 <Compound of Example 2 0> Colorless powder 1H NMR (400 MHz, DMS0-d6) 5 1.24 (1H, m) , 1.60-1.68 (2H, m) , 1.87-1.96 (2H, m) ,2.37 (3H, s) , 2.96-3.0 4 (2H, m) , 3.08-3.15 (2H, m) , 4.39-4.41 ^ (2H, m) , 7.41 (IH, t, J = 7.3 Hz), 7.51 (2H, d, J= 8.6 Hz), 7.65 10 (IH, t, J = 7.3 Hz), 7.72 (IH, d, J = 7.3 Hz), 7.85 (2H, d, J = 8.6 Hz) , 8.01 (IH, d, J = 7.3 Hz), 8.70 (IH, t, J = 5.5 Hz), 17.3 9 (IH, brs) . HR-FAB+ (m/z): 470.1291 (-1.4 mmu).

[0597] 15 CCompound of Example 21> Colorless powder ^ 1H NMR (400 MHz, DMSO-dg) 5 1.50-1.62 (2H, m), 1 . 70-1.79 (IH, m) , 1.81-1.89 (IH, m) , 2.39 (3H, s) , 2.45-2.55 (IH, m) , 2.69-2.74 (IH, m), 2.84 (IH, t, J = 2.0 Hz), 3.62-3.65 (IH, m), 3.71-3.73 (IH, 20 m), 4.37-4.48 (2H, m), 7.17-7.20 (IH, m), 7.28-7.35 (2H, m), 7.46 (IH, m), 7.53 (2H, d, J = 8.6 Hz), 7.87 (2H, d, J =8.6 Hz), 8.62 (IH, t, J = 5.5 Hz) . HR-FAB+ (m/z): 470.1343 (+3.8 mmu).

[0598] 25 <Compound of Example 22> 171 552501 Colorless powder 2H NMR (4 00 MHz, DMSO-d6) 5 1.24 - 1.32 (IH, m) , 1. 62 - 1.71 (IH, m) , 1.80 - 1.90(2H, m), 1.99 - 2.10(1H, m), 2.36(3H, s), 2.85(1H, t, J = 11.6 Hz), 2.96 - 3.11(3H, m), 3.42 -3.48(2H, m), 4.66<2H, s), 5 7.43(IH, t, J = 7.3 Hz), 7.53(2H, d, J = 8.6 Hz), 7.64 - 7.71(2H, m) , 7.89(2H, d, J = 8.6 Hz) , 8.03(1H, d J = 7.9 Hz) , 17.86(1H, brs) . HR-FAB+ (ra/z) 457.1321 (-3.2 mmu).

[0599] ^ <Compound of Example 23> 10 Colorless powder XH NMR (400 MHz, DMSO-d6) 5 1.60-1.78 (2H, m) , 1.83-1.99 (2H, m) , 2.37 (3H, s), 2.91-3.10 (3H, m) , 3.25-3.41 (IH, m), 3.78-3.82 (IH, m), 4.70-4.81 (2H, m), 7.42 (IH, t, J = 7.9 Hz), 7.54 (2H, d, J = 8.6 Hz) , 7.65-7.73 (2H, m) , 7.90 (2H, d, J = 8.6 Hz) , 8.03-8.05 15 (IH, m) , 17.22 (IH, brs). HR-FAB+ (m/z): 443.1183 (-1.4 mmu). £ [0600] <Compound of Example 24> Colorless powder 20 1H NMR (400 MHz, DMSO-dg) 5 1.13-1.23 (IH, m) , 1.50-1.62 (IH, m) , 1.67-1.79 (2H, m), 1.86-1.98 (IH, m), 2.39 (3H, s), 2.58 (IH, dd, J= 9.8, 12.2 Hz), 2.70-2.77 (IH, m), 3.40-3.46 (2H, m), 3.56-3.59 (IH, m), 3.64-3.68 (IH, m), 4.66-4.73 (2H, m), 7.15-7.17 (IH, m), 7.28-7.34 (2H, m), 7.45 (IH, m), 7.54 (2H, d, J = 8.6 Hz), 7.91 25 (2H, d, J = 8.6 Hz), 12.81 (IH, brs). 172 552501 HR-FAB+ (m/z) : 457.1361 (+0.8 mmu).

[0601] <Compound of Example 25> Colorless powder 5 XH NMR (400 MHz, DMS0-de) 5 1.41-1.59 (2H, m) , 1.79-1.82 (IH, m) , 1.98-2.03 (IH, m) , 2.38 (3H, s), 2.83-2.92 (2H, m) , 3.41-3.44 (IH, m), 3.58-3. 64 (IH, m), 3.69-3.72 (IH, m), 4.79 (2H, s) , 7.20-7.22 (IH, m) , 7.2 8-7.34 (2H, m) , 7.4 6 (IH, m) , 7.54 (2H, d, J = 8.6 Hz) , ^ 7.90 (2H, d, J = 8.6 Hz), 12.82 (IH, brs). 10 HR-FAB4 (m/z) : 443.1196 (+0.0 mmu).

[0602] <Compound of Example 2 6> Colorless powder XH NMR (400 MHz, DMS0-d6) 5 1.68-1.77 (IH, m) , 2.01-2.09 (IH, m) , 15 2.53-2.56 (IH, m) , 2.59 (3H, s), 3.05 (IH, dd, J= 6.7, 9.8 Hz), 3.24-3.27 (5H, m), 6.76 (IH, t, J = 7.3 Hz), 6.90 (IH, d, J = 7.9 ^ Hz), 7.33 (IH, dt, J = 1.2, 7.9 Hz), 7.53 (IH, dd, J = 1.2, 7.9 Hz), 7.57(2H, d, J = 8.6 Hz), 7.94 (2H, d, J = 8.6 Hz), 8.4 5 (IH, t, J = 5.5 Hz), 13.24 (IH, brs). 20 HR-FAB+ (m/z): 456.1129 (-1.9 mmu).

[0603] CCompound of Example 27> Colorless powder XH NMR (400 MHz, DMSO-dg) 5 1.75-1.84 (IH, m) , 2.06-2.14 (IH, m) , 25 2.56-2.64 (4H, m), 3.0 9 (IH, dd, J = 6.1, 9.8 Hz), 3.23-3.4 3 (5H, 173 552501 m), 6.74 (IH, dd, J = 1.8, 8.6 Hz), 7.06 (IH, m), 7.16 (IH, d, J = 7.9 Hz), 7.2 6 (IH, t, J = 7.9 Hz) , 7.57 (2H, d, J = 8.6 Hz) , 7.95 (2H, d, J = 8.6 Hz), 8.48 (IH, t, J = 6.1 Hz), 12.68 (IH, brs). HR-FAB+ (m/z) : 456. 1149 (+0. 0 mmu). 5 Elemental analysis calcd (%) for C23H22C1N303S,1/10H20: C 60.35, H 4.89, N 9.18; found: C 60.17, H 4.78, N 8.94.

[0604] CCompound of Example 28> ^ Colorless powder 10 rH NMR (400 MHz, DMS0-d6) 5 1.38-1.46 (IH, m), 1.56-1.62 (IH, m), 1.77-1.89 (4H, m), 2.16-2.25 (IH, m), 2.51 (3H, s) , 3.08-3.27 (6H, m), 7.33-7.37 (IH, m) , 7.58 (2H, d, J = 8.6 Hz), 7.61-7.66 (2H, m) , 7.93 (2H, d, J = 8.6 Hz) , 7.96 (IH, dd, J = 1.2, 7.9 Hz) , 8.39 (IH, t, J = 5.5 Hz), 17.74 (IH, brs). 15 HR-FAB+ (m/z) : 484 . 1469 ( + 0.7 mmu). Elemental analysis calcd (%) for C25H26CIN3O3S" I/IOH2O: C 61.81, H £ 5.44, N 8.65; found: C 61.57, H 5.36, N 8.39.

[0605] CCompound of Example 2 9> 20 Colorless powder XH NMR (400 MHz, DMS0-d6) 5 1.20-1.33(2H, m), 1.54-1.67 (2H, m), 1.68-1.78 (IH, m) , 1.86-1.98 (IH, m) , 2.06-2.19 (IH, m) , 2.63 (3H, s), 3.02 (IH, dd, J = 10.4, 15.3 Hz), 3.15-3.30 (3H, m), 3.65 (IH, td, J = 5.5, 14.7 Hz), 3.7 8 (IH, dd, J =3.7, 14. 7 Hz), 6.92 (IH, 25 dd, J = 1.8, 7.9 Hz) , 7.13 (IH, d, J = 7.3 Hz) , 7.20-7.24 (2H, m) , 174 552501 7.59 (2H, d, J = 8.6 Hz), 7.97 (2H, d, J = 8.6 Hz), 8.47 (IH, t, J = 5.5 Hz) , 12.70 (IH, brs) . HR-FAB+ (m/z) : 484.1461 (-0.1 mmu). Elemental analysis calcd (%) for C25H26CIN3O3S• 1/10H20: C 61.81, H 5 5.44, N 8.65; found: C 61.61, H 5.31, N 8.37.

[0606] <Compound of Example 30> Colorless powder ^ 1R NMR (400 MHz, DMS0-d6) 5 1.40-1.50 (IH, m), 1.55-1.66 (IH, m), 10 1.78-1.86 (2H, m) , 2.35 (3H, s) , 2.71-2.76 (IH, m) , 2.86-2.92 (IH, m) , 3.4 6-3.4 9 (IH, m), 3.58 (IH, dd, J = 3.1, 12.2 Hz), 3.71 (2H, s), 3.75-3.84 (IH, m), 7.16-7.19 (IH, m), 7.28-7.35 (2H, m), 7.44 (IH, m), 7.52 (2H, d, J = 8.6 Hz), 7.88 (2H, d, J = 8.6 Hz), 8.28 (IH, d, J = 7.3 Hz), 12.82 (IH, brs). 15 HR-FAB+ (m/z): 470.1303 (-0.2 mmu). Elemental analysis calcd (% ) for C24H24ClN303S* 1/5H20: C 60.87, H5.19, ^ N 8.87; found: C 60.78, H 5.18, N 8.67.

[0607] <Compound of Example 31> 20 Colorless powder XH NMR (400 MHz, DMSO-d6) 5 1.64-1.77 (2H, m), 1.90-2.00 (2H, m), 2.60 (3H, s), 2.97-3.07 (4H, m), 4.02-4.12 (IH, m), 7.37 (IH, t, J = 7.3 Hz), 7.58-7.60 (3H, m), 7.65 (IH, dt, J = 1.8 Hz, J = 7.9 Hz), 7.94-7.99 (3H, m), 8.32 (IH, d, J = 6.7 Hz), 16.46 (IH, bra;. 25 HR-FAB+ (m/z): 456.1165 (+1.6 mmu). 175 552501

[0608] <Compound of Example 32> Colorless powder 1H NMR (400 MHz, DMSO-d6) 5 1.53-1. 68 (2H, m), 1.81-1.85 (IH, m) , 5 1.92-1.95 (IH, m) , 2.61 (3H, s) , 2.77-2.83 (2H, m) , 3.59-3.62 (IH, m) , 3.7 3 (IH, dd, J = 3.6, 12.2 Hz) , 3.94- 4.00 (IH, m) , 7.2 3 (IH, td, J = 2.4, 7.3 Hz), 7.31-7.36 (2H, m), 7.47 (IH, m), 7.59 (2H, d, J = 8.6 Hz), 7.96 (2H, d, J - 8.6 Hz), 8.27 (IH, d, J = 7.3 Hz), ^ 12.84 (IH, brs). 10 HR-FAB+(m/z) : 456.1153 ( + 0.5 mmu). Elemental analysis calcd (%) for C23H22CIN3O3S: C 60.59, H 4.86, N 9.22; found: C 60.41, H 4.94, N 9.01.

[0609] <Compound of Example 33> 15 Colorless powder XH NMR (400 MHz, DMSO-d6) 5 1.53-1.68 (2H, m) , 1.81-1.85 (IH, m) , ^ 1.92-1.95 (IH, m) , 2.60 (3H, s) , 2.77-2.83 (2H, m) , 3.59-3.62 (IH, m), 3.73 (IH, dd, J = 3.6, 11.6 Hz), 3.91-4.01 (IH, m), 7.22 (IH, td, J = 2.4, 7.3 Hz), 7.31-7.36 (2H, m),7.47 (IH, m), 7.59 (2H, 20 d, J = 8.6 Hz), 7.96 (2H, d, J = 8.6Hz), 8.27 (2H, d, J=7.3Hz), 12.83 (IH, brs). HR-FAB+ (m/z) : 456.1147 (-0.2 mmu). Elemental analysis calcd (%) for C23H22CIN3O3S: C 60.59, H 4.86, N 9.22; found: C 60.41, H 4.79, N 8.93. 25 [a] 27'7°d -130° (C = 1.0, DMF) 176 552501 HPLC (CHIRALCEL OJ (Daicel Chemical Industries, Co,. Ltd.) (|> 0.46 x 25 cm, mobile phase: hexane/ethanol = 60/40 (0.1% TFA) , flow rate: 1 mL/min, Temp.: 40°C): Rt 26.6 min (99% ee)

[0610] 5 <Compound of Example 34> XH NMR (400 MHz, DMSO-d6) 5 1.53-1.68 (2H, m) , 1.81-1.85 (IH, m)r 1.92-1.95 (IH, m) , 2.60 (3H, s) , 2.77-2.83 (2H, m) , 3.59-3.62 (IH, m), 3.73 (IH, dd, J = 3.6, 11. 6 Hz) , 3.92-4.02 (IH, m), 7.22 (IH, ^ td, J = 2.4, 7.3 Hz), 7.31-7.36 (2H, m),7.47 (IH, m), 7.59 (2H, 10 d, J = 8.6 Hz), 7.96 (2H, d, J = 8.6 Hz), 8.27 (2H, d, J = 7.3 Hz) , 12.84 (IH, brs). HR-FAB+(m/z) : 456. 1180 ( + 3.1 mmu). Elemental analysis calcd (%) for C23H22CIN3O3S: C 60.59, H 4.86, N 9.22; found: C 60.48, H 4.77, N 8.93. 15 [a] 27,8'd +128° (C = 1.0, DMF) HPLC (CHIRALCEL OJ (Daicel Chemical Industries, Co,. Ltd.) <j) 0.46 ^ x 25 cm, mobile phase: hexane/ethanol = 60/40 (0.1% TFA), flow rate: 1 mL/min, Temp.: 40°C): Rt 17.2 min (99% ee)

[0611] 20 <Example 35> Methyl 2-[3-[(4'-chlorobiphenyl-4-yl)carbonylamino]piperidin-l-yl]ben zoate

[0612] 177 552501 Step 35a) Methyl 2-[3-(tert-butoxycarbonylamino)piperidin-l-yl]benzoate [Chemical formula 144] 5 3-(tert-Butoxycarbonylamino)piperidine (7.07 g, 35.3 mmol) was dissolved in N, N-dimethylformamide (120 mL). To this solution, potassium carbonate (9.80 g, 70. 9 mmol) and methyl 2-f luorobenzoate (5.0 mL, 39.2 mmol) were added and the mixture was stirred at 130 C for 8 hours. Subsequently, the mixture was allowed to cool, diluted 10 with ethyl acetate, and washed sequentially with water and brine. The washed product was dried over sodium sulfate and the solvent was evaporated. Purification of the resulting residue by silica gel column chromatography (hexane : ethyl acetate = 10:1 -> 5:1) gave 2.34 g (20%) of the desired compound as a yellow oil. ^ *H NMR (400 MHz, CDC13) 5 1.46 (9H, s) , 1.55-1.66 (2H, m) , 1.74-1.85 (IH, m), 1.86-1.98 (IH, m), 2.84 (IH, t, J = 9.8 Hz), 2.98 (IH, dd, J = 11.6, 5.0 Hz), 3.01-3.10 (2H, m), 3.86-3.92 (IH, m), 3.94 (3H, s), 5.62 (IH, brs), 7.01-7.07 (2H, m), 7.41 (IH, t, J =8.6 Hz) , 7 . 69 (IH, d, J = 6.1 Hz) . 20 [0613] Step 35b) Methyl 2-[3-[(4'-chlorobiphenyl-4-yl)carbonylamino]piperidin-l-yl]ben zoate 178 552501

[0614] [Chemical formula 145] CI C02Me

[0615] Methyl 2-[3-(tert-butoxycarbonylamino)piperidin-l-yl]benzoate (2.34 g, 7.00mmol) was dissolved in anhydrous dichloromethane (50mL) . While this solution was ice-chilled and stirred, trifluoroacetic acid. (5.2 mL, 6.82 mmol) was added and the mixture was stirred for 3 hours. Subsequently, the reaction mixture was concentrated and a 10% hydrochloric acid/methanol mixture (50 mL) was added to the residue. The mixture was stirred at room temperature for 1 hour and was concentrated. The same process was repeated 3 times and the resulting solid were washed with ethyl acetate. This gave 1. 33 g of a colorless powder. This product (113 mg) was dissolved in N,N-dimethylformamide (4 mL). While the solution was chilled to 0°C and stirred, 4'-chlorobiphenyl-4-carboxylic acid (103 mg, 0.443 mmol), 1-hydroxybenzotriazole monohydrate (63.8 mg, 0.417 mmol), N-methylmorpholine (160 pL, 1.46 mmol) and 3-(3-dimethylaminopropyl)-1-ethylcarbodiimide hydrochloride (78.0 mg, 0.407 mmol) were added. The mixture was stirred at 0°C for 20 min and at room temperature for the following 6 hours. 179 552501 Subsequently, the reaction mixture was diluted with ethyl acetate. The organic layer was washed sequentially with 5% aqueous citric acid, a saturated aqueous sodium bicarbonate solution, water and brine. The washed product was dried over anhydrous sodium sulfate 5 and the solvent was concentrated. Purification of the resulting residue by silica gel column chromatography (hexane : ethyl acetate = 3:1) gave 142 mg of the desired compound as colorless crystals. [0616] ^ NMR(400 MHz , CDC13) 5 1.54-1. 72 (2H, m), 1. 95-2.08 (IH, m) , 10 2.18-2.27 (IH, m), 2.89 (IH, dd, J =11.6, 2.4 Hz), 3.00 (IH, dd, J = 11.6, 2.4 Hz) , 3.2 3 (IH, d, J = 11.6 Hz), 3.30 (IH, d, J = 11. 6 Hz), 3.87 (3H, s), 4.36-4.42 (IH, m), 7.08 (IH, t, J - 8.6 Hz), 7.15 (IH, d, J = 8.6 Hz), 7.42 (2H, d, J = 8.6 Hz), 7.47 (IH, td, J = 7.3, 1.8 Hz), 7.56 (2H, t, J = 8.6 Hz), 7.62 (2H, d, J = 8.6 15 Hz), 7.81 (IH, dd, J=7.3, 1.8 Hz), 8.14-8.23 (3H, m). FAB+ (m/z) : 449 (M+H). ^ [0617] <Example 36 through Example 57> The processes were performed as in Example 15 or Example 35 20 to obtain compounds given in Table 6 below.

[0618] 25 180 552501 [Table 6-1] ©"Yy?rC00Me Absolute configuration Af Y Binding position of carboxylic acid Example 36 Racemic mixture FTX^ CONH Position 2 Example 37 Racemic mixture CONH Position 2 Example 38 S av CONH Position 3 Example 39 S ci^CK~^ CONH Position 3 Example 40 s «-<CKX CONH Position 3 Example 41 s <»-<XX CONH Position 3 Example 42 s «<rtC CONH Position 3 Example 43 s «<xc CONH Position 3 Example 44 s «<HC CONH Position 3 Example 45 s «-CHC CONH Position 3 Example 46 s CONH Position 3 Example 47 s CONH Position 3 Example 48 s s=\ N^^e CONH Position 3 Example 49 s CONH Position 3 Example 50 s F>=\ N^Me CHX. F CONH Position 3

[0619] 181 552501 [Table 6-2] Absolute Configration Ar Binding posion Y ofCOOMe Example 51 S F - Cl- < £ r^. CONH Position 3 Example 52 S I O XJ CONH Position 3 Example 53 s CI" ~c CONH Position 3 Example 54 Racemic mixture CI < > -it We - N H Position 2 Example 55 Racemic mixture CI < > -it We ^X - N H Pcsitjon3 Example 56 Racemic mixture CI f || s* vie ch2ch2conh Posifon2 Example 57 Racemic mixture Ci ~V S " We ch2ch2conh Portion 3

[0620] CCompound of Example 3 6> Colorless amorphous NMR (400 MHz, CDC13) 5 1.54-1.73 (2H, rn) , 1.90-2.09 (IH, m) , 2.18-2.26 (IH, m) , 2.90 (IH, dd, J = 11.6, 2.4 Hz), 3.01 (IH, dd J = 11.6, 2.4 Hz) , 3.24 (IH, d, J = 11.6 Hz) , 3.2 9 (IH, d, J - 11. Hz), 3.88 (3H, s), 4.34-4.41 (IH, m) , 6.97-7.13 (7H, m) , 7.17 (IH d, J = 7.9 Hz), 7.50 (IH, t, J = 7.9 Hz), 7.82 (IH, dd, J = 7.9 1.8 Hz), 8.07-8.15 (3H, m). FAB+ (m/z) : 449 (M+H).

[0621] 182 552501 <Compound of Example 37> Yellow amorphous XH NMR(400 MHz, CDC13) 5 1.65-1.82 (2H, m) , 1.95-2.06 (2H, m) , 2.93 (IH, t, J =9.8 Hz) , 3.14-3.21 (IH, m) , 3.22-3.2 8 (2H, m) , 4.02 (3H, 5 s), 4.40-4.47 (IH, m), 7.05-7.12 (2H, m), 7.42-7.47 (IH, m), 7.48 (IH, dd, J = 7.9, 1.2 Hz), 7.54 (IH, td, J = 7.9, 1.2 Hz), 7.78 (IH, dd, J = 7.9, 1.8 Hz), 7.98 (IH, d, J = 6.1 Hz),8.07 (IH, d, J = 7.9 Hz), 8.39-8.42 (IH, m) . ® FAB+(m/z): 396 (M+H). 10 [0622] CCompound of Example 38> Yellow oil 1H NMR (4 00 MHz, CDCI3) 6 1.76-1.86 (2H, m) , 1.93-2.02 (2H, m) , 3.19 (IH, dd, J = 12.2, 6.7 Hz), 3.23-3.31 (2H, m), 3.57 (IH, dd, J = 15 12.2, 3.0 Hz), 3.91 (3H, s), 4.36-4.44 (IH, m), 7.21 (IH, dd, J = 7.9, 1.2 Hz) , 7.34 (IH, t, J = 7.9 Hz) , 7 . 46-7.52 (IH, m) , 7.53-7.58 £ (2H, m), 7.64-7.67 (IH, m), 7.73 (IH, d, J = 7.9 Hz), 7.98 (IH, d, J = 7.9 Hz), 8.07 (IH, d, J = 7.9 Hz). FAB+ (m/z) : 396 (M+H). 20 [0623] CCompound of Example 3 9> Colorless powder lti NMR(4 00 MHz, CDC13) 5 1.7 5-1.97 (4H, m) , 3.10-3.20 (IH, m) , 3.2 9 (IH, dd, J = 12.2, 5.5 Hz), 3.30-3.39 (IH, m), 3.44 (IH, dd, J = 25 12.2, 3.1 Hz), 3.90 (3H, s) , 4.40-4.50 (IH, m), 6.56 (IH, d, J = 183 552501 7.9 Hz), 7.18 (IH, d, J = 7.9 Hz), 7.33 (IH, t, J = 7.9 Hz), 7.42 (2H, d, J = 8.6 Hz), 7.47-7.58 (4H, m) , 7.64 {IH, s) , 7.65-7.72 (2H, m), 7.97 (IH, s) . FAB+ (m/z): 449 (M+H). 5 [0624] CCompound of Example 4 0> Colorless powder *H NMR (400 MHz, CDC13). 5 1.73-1.8 6 (2H, m) , 1.87-1.98 (2H, m) , 3.17 ^ (IH, dd, J = 12.2, 6.7 Hz), 3.20-3.29 (2H, m), 3.50 (IH, dd, J = 10 12.2, 3.1Hz) , 3.91 (3H, s) , 4.35-4.4 4 (IH, m) , 6.97 (IH, s) , 7.14-7.2 0 (2H, m), 7.33 (IH, t, J = 7.9 Hz),7.47 (2H, d, J = 8.6 Hz), 7.55 (IH, d, J = 7.9 Hz), 7.61-7.65 (IH, m), 7.73 (2H, d, J = 8.6 Hz). FAB+ (m/z) : 440 (M+H). [a] 28'8°D+39 . 9° (C = 0.2, DMF) 15 [0625] CCompound of Example 41> ^ Pale yellow powder XH NMR (4 00 MHz, CDCI3) 5 1.7 5-1.96 (4H, m) , 3.10-3.18 (IH, m) , 3.2 6 (IH, dd, J = 12.2, 5.5 Hz), 3.30-3.39 (IH, m), 3.42 (IH, dd, J = 20 12.2, 2.4 Hz), 3.91 (3H, s), 4.37-4.45 (IH, m), 6.39 (IH, d, J = 7.9 Hz) , 7.18 (IH, dd, J = 7.9, 2.4 Hz) , 7.34 (IH, t, J = 7.9 Hz) , 7.44 (2H, d, J =8.6 Hz), 7.57 (IH, d, J =7.9 Hz), 7.62-7.66 (IH, m), 7.89 (2H, d, J = 8.6 Hz), 8.14 (IH, s). FAB+(m/z): 456 (M+H). 25 [0626] 184 552501 <Compound of Example 42> Colorless powder NMR (4 00 MHz, CDCI3) 5 1.75-1.95 (4H, m) , 2.51 (3H, s) , 3.05-3. 14 (IH, m), 3.30 (IH, dd, J = 12.2, 5.5 Hz), 3.33-3.42 (2H, m), 3.91 5 (3H, s), 4.35-4.45 (IH, m), 6.25-6.35 (IH, m), 7.07 (IH, s), 7.18 (IH, d, J = 7.9 Hz), 7.28-7.37 (3H, m),7.51 (2H, d, J = 8.6 Hz), 7.56 (IH, d, J = 7.9 Hz), 7.64 (IH, s). FAB+ (m/z) : 469 (M+H). ^ [0627] 10 CCompound of Example 43> Pale yellow powder XH NMR (400 MHz, CDC13) 5 1.69-1.1.86 (2H, m), 1.88-2.02 (2H, m) , 2.89 (3H, s), 3.08-3.24 (2H, m), 3.28-3.36 (IH, m), 3.60 (IH, dd, J = 11.2, 3.1 Hz), 3.90 (3H, s), 4.27-4.37 (IH, m), 7.16-7.24 (IH, 15 m), 7.31 (IH, t, J = 8.0 Hz) , 7.3 9 (2H, dd, J = 6.7, 1.8 Hz), 7.52 (IH, d, J = 7.3 Hz), 7.64-7.66 (IH, m) , 7.7 6 (2H, dd, J = 6.7, 1.8 B Hz) . FAB+ (m/z): 470 (M+H).

[0628] 20 CCompound of Example 44> Reddish brown solid XH NMR (400 MHz, CDCI3) 5 1.75-1.85 (2H, m) , 1.90-1.95 (2H, m) , 2.58 (3H, s), 3.20-3.25 (2H, m), 3.25-3.35 (IH, m), 3.49 (IH, dd, J= 12.2, 3.1 Hz), 3.92 (3H, s), 4.38 (IH, s), 6.57 (IH, d, J = 8.0 25 Hz) , 7.18 (IH, dd, J = 8.4, 2.4 Hz) , 7.33 (IH, t, J = 7.9 Hz) , 7.4 3 185 552501 (2H, d, J = 8.3 Hz), 7.55 (IH, d, J = 7.4 Hz), 7.65 (IH, s), 7.94 (2H, d, J = 8.6 Hz) . FAB+ (m/z) : 454 (M+H).

[0629] 5 <Compound of Example 4 5> Pale yellow powder 1R NMR (400 MHz, CDCl3) 5 1. 66-1. 8 4 (2H, m) , 1.8 6-2 .01 (2H, m) , 2.74 (3H, s) , 3.10 (IH, dd, J= 12. 9, 7. 6 Hz) , 3.16-3.22 (IH, m) , 3.28-3.36 ^ (IH, m) , 3.90 (3H, s) , 4.31 (IH, s) , 7.20 (IH, d, J = 8.0 Hz) , 7.32 10 (IH, t, J = 8.0 Hz), 7.4 3 (2H, dd, J = 6.7, 1.8 Hz), 7.53 (IH, d, J = 7.9 Hz), 7.63-7.65 (IH, m), 7.93 (2H, dd, J = 6.8, 2.4 Hz) FAB+ (m/z) : 453 (M+H).

[0630] CCompound of Example 4 6> 15 Colorless powder 1R NMR (400 MHz, CDCI3) 5 1.7 5-1.94 (4H, m) , 2.7 4 (3H, s) , 3.04-3.14 ft (IH, m) , 3.27-3. 4 3 (3H, m) , 3. 91 (3H, s) , 4.37-4. 4 6 (IH, m) , 6.25-6.36 (IH, m) , 7.15-7.21 (IH, m), 7.34 (IH, t, J = 8.0 Hz), 7.43-7.47 (3H, m), 7.57 (IH, d, J = 7.3 Hz), 7.64 (IH, s), 7.91-7.95 (2H, 20 m) . FAB+(m/z): 436 (M+H).

[0631] CCompound of Example 47> Colorless powder 18 6 552501 XH NMR (400 MHz, CDC13) 5 1.78-1. 86 (4H, m) , 2.40 (3H, s) , 2.73 (3H, s), 3.07-3.12 (IH, m), 3.26-3.42 (3H, m), 3.91 (3H, s), 4.37-4.43 (IH, m), 6.27 (IH, d, J =8.0 Hz), 7.17 (IH, d, J = 7.9 Hz), 7.24 (2H, d, J = 8.0 Hz), 7.33 (IH, t, J = 8.0 Hz), 7.56 (IH, d, J = 5 7.3 Hz), 7.64 (IH, s), 7.82 (2H, dd, J = 6.1, 1.8 Hz) . FAB+ (m/z) : 4 50 (M+H).

[0632] CCompound of Example 48> ^ Colorless powder 10 NMR (400 MHz, CDC13) 5 1.80-1.88 (4H, m) , 2.71 (3H, s) , 3.05-3.13 (IH, m), 3.28-3.42 (3H, m), 3.86 (3H, s), 3.91 (3H, s) , 4.36-4.44 (IH, m), 6.95 (2H, dd, J = 7.3, 1.8 Hz), 7.15-7.20 (IH, m) , 7.34 (IH, t, J = 8.0 Hz), 7.56 (IH, d, J = 7.9 Hz), 7.64 (IH, s), 7.87 (2H, dd, J = 6.7, 1.8 Hz) . 15 FAB+ (m/z) : 466 (M+H) .

[0633] ft CCompound of Example 4 9> Yellow powder XH NMR (4 00 MHz, CDC13) 5 1.78-1. 97 (4H, m) , 2.7 4 (3H, s) , 3.34 (2H, 20 d, J = 3.6 Hz), 3.38-3.45 (IH, m) , 3.91 (3H, s), 4.43-4.46 (IH, m) , 6.35 (IH, d, J = 7.9 Hz), 7.17 (IH, dd, J = 8.5, 1.8 Hz), 7.34 (IH, t, J = 8.0 Hz), 7.56 (IH, d, J = 7.9 Hz), 7.63-7.67 (IH, m) , 7.69 (2H, d, J = 8.6 Hz), 8.04 (2H, d, J = 8.0 Hz). FAB+(m/z): 504 (M+H) 25 [0634] 187 552501 <Compound of Example 50> Yellow powder NMR (400 MHz, CDC13) 5 1.7 7-1.97 (4H, m) , 2.72 (3H, s) , 3.03-3.10 (IH, m), 3.34 (2H, d, J = 4.3 Hz), 3.38-3.44 (IH, m), 3.91 (3H, 5 s), 4.38-4.46 (IH, m), 6.34 (IH, d, J = 7.9 Hz), 6.89 (IH, tt, J = 8.6, 2.4 Hz), 7.17 (IH, dd, J = 8.0, 1.8 Hz), 7.34 (IH, t, J = 8.0 Hz), 7.44-7.48 (2H, m), 7.57 (IH, d, J = 7.9 Hz), 7.62-7.65 (IH, m) . FAB+ (m/z) : 472 (M+H). 10 [0635] CCompound of Example 51> Colorless powder XH NMR (400 MHz, CDCI3) 5 1.74-1.96 (4H, m), 3.05 (IH, t, J = 8.5 Hz), 3.32-3.38 (3H, m) , 3.91 (3H, s), 4.41-4.46 (IH, m) , 6.75 (IH, 15 d, J = 8.0 Hz) , 7.15 (IH, dd, J = 7.9, 1.8 Hz) , 7 .28-7.34 (2H, m) , 7.41 (IH, d, J = 1.8 Hz), 7.55 (IH, d, J= 7.4 Hz), 7.60-7.63 (IH, 9 m), 7.66 (IH, d, J = 8.6 Hz). FAB+ (m/z) : 407 (M+H).

[0636] 20 CCompound of Example 52> Colorless powder XH NMR (400 MHz, CDCl3) 5 1.75-1. 95 (4H, m) , 3.06-3.16 (IH, m) , 3.24-3.28 (IH, m) , 3.31-3.44 (2H, m) , 3.90 (3H, s) , 4.38-4.46 (IH, m) , 6.46 (IH, d, J=8.6Hz), 6.96 (2H, dd, J=6.7, 2.4Hz), 6.98-7.09 188 552501 (4H, m) , 7.15-7.19 (IH, m), 7.33 (IH, t, J = 8.0 Hz), 7.54 (IH, d, J = 8.0 Hz), 7.62-7.64 (IH, m), 7.73 (2H, d, J = 9.2 Hz). FAB+(m/z): 449 (M+H).

[0637] 5 <Compound of Example 53> Colorless powder XH NMR (400 MHz, CDC13) 5 1.78-1.98 (4H, m) ; 3.08-3.17 (IH, m) , 3.23-3.43 (3H, m), 3.90 (3H, s), 4.44-4.50 (IH, m), 6.57 (IH, d, ^ J = 8.0 Hz) , 7.17-7.21 (IH, m) , 7.33 (IH, t, J = 8.6 Hz), 7.43 (2H, 10 dd, J = 6.7, 1.8 Hz), 7.50-7.65 (3H, m), 7.61 (2H, dd, J = 8.6, 1.8 Hz), 7.63-7.66 (IH, m), 7.83 (2H, d, J = 8.4 Hz). FAB+ (m/z) : 449 (M+H).

[0638] CCompound of Example 54> 15 Pale yellow powder 1ti NMR (400 MHz, CDCI3) 5 1.52-1.60 (IH, m) , 1.64-1.69 (IH, m), ft 1.93-2.03 (IH, m), 2.09-2.13 (IH, m), 2.57 (3H, s), 2.85-2.91 (IH, m), 2.93-2.97 (IH, m), 3.08-3.15 (IH, m), 3.19-3.22 (IH, m), 3.94 (3H, s), 4.23-4.29 (IH, m) , 6.37 (IH, d, J= 15.3 Hz), 7.09 (IH, 20 t, J = 7.3 Hz) , 7.13 (IH, d, J = 8.6 Hz), 7.41 (2H, d, J = 8.6 Hz), 7.47 (IH, td, J = 7.3, 1.2 Hz), 7.70 (IH, d, J = 6.7 Hz), 7.77 (IH, dd, J = 7.3, 1.2 Hz), 7.79 (IH, d, J = 15.3 Hz), 7.86 (2H, d, J = 8.6 Hz). FAB+(m/z): 496 (M+H). 25 [0639] 189 552501 <Compound of Example 55> Pale yellow powder 1H NMR (400 MHz, CDCI3) 5 1.76-1.92 (4H, m) , 2.57 (3H, s) , 3.07-3.12 (IH, m), 3.21 (IH, dd, J = 11.6, 5.5 Hz), 3.30-3.38 (2H, m), 3.91 5 (3H, s), 4.33-4.41 (IH, m) , 6.00 (IH, d, J = 7.9 Hz), 6.12 (IH,. d, J = 15.3 Hz), 7.17 (IH, dd, J = 7.9, 1.8 Hz), 7.33 (IH, t, J = 7 . 9 Hz) , 7.41 (2H, d, J = 8. 6 Hz) , 7 . 55 (IH, d, J = 7. 3 Hz) , 7 . 62-7 . 63 (IH, m), 7.80 (IH, d, J = 15.3 Hz), 7.85 (2H, d, J = 8.6 Hz). ^ FAB+(m/z): 496 (M+H). 10 [0640] CCompound of Example 5 6> Colorless oil 1ti NMR (400 MHz, CDC13) 5 1.42-1.52 (IH, m) , 1.53-1.57 (IH, m) , 1.73-1.84 (IH, m), 1.96-2.00 (IH, m), 2.43 (3H, s), 2.62 (2H, t, 15 J = 7.3 Hz), 2.79 (IH, td, J =11.6, 2.4 Hz), 2.85-2.89 (IH, m), 3.03-3.06 (IH, m), 3.09-3.12 (IH, m), 3.15-3.23 (2H, m), 3.85 (3H, £ s), 4.10-4.15 (IH, m), 7.03-7.08 (2H, m), 7.35 (2H, d, J=8.6Hz), 7.42 (IH, td, J = 7.3, 1.2 Hz), 7.48 (IH, d, J = 6.7 Hz), 7.74 (IH, dd, J = 7.9, 1.8 Hz), 7.77 (2H, d, J = 8.6 Hz). 20 FAB+ (m/z) : 498 (M+H).

[0641] CCompound of Example 57> Colorless powder XH NMR (4 00 MHz, CDCI3) 5 1.62-1.72 (4H, m) , 2.41 (3H, s) , 2.4 6-2.5 5 25 (2H, m) , 2.98-3.04 (IH, m) , 3.07 (IH, dd, J = 11.6, 5.5 Hz) , 3.13-3.17 190 552501 (2H, m), 3.22-3.26 (2H, m)r 3.90 (3H, s) , 4.19-4.25 (IH, m), 5.81 (IH, d, J = 7.9 Hz) , 7.07 (IH, dd, J = 7.9, 2.4 Hz) , 7.2 4-7.28 (IH, m), 7.35 (2H, d, J = 8.6 Hz), 7.52 (IH, d, J = 7.9 Hz), 7.57 (IH, brs), 7.77 (2H, d, J = 8.6. Hz). FAB+(m/z): 4 98 (M+H).

[0642] <Example 58> Methyl 2-[3-[2-[2-(4-chlorophenyl)-4-methylthiazol-5-yl]acetylamino]p iperidin-l-yl]benzoate

[0643] [Chemical formula 146] In an argon atmosphere, tri(dibenzylideneacetone)dipalladium (4.85 mg, 0.00530 mmol), 1, 1'-bis(diphenylphosphino)ferrocene (9.09 mg, 0.0159 mmol) and cesium carbonate (48.2 mg, 0.148 mmol) were added to a toluene solution (1 mL) containing N-(piperidin-3-yl)-2-[2-(4-chlorophenyl)-4-methylthiazol-5-yl] acetamide (37.2 mg, 0.106 mmol) and methyl 2-iodobenzoate (27.8 mg, 0.106 mmol). This reaction mixture was stirred at 100°C for 8 hours. Subsequently, the mixture was allowed to cool and was filtered through Celite. The filtrate was purified by silica gel

[0644] 191 552501 column chromatography (hexane : ethyl acetate = 2:1 -> 1:1) to give 23.0 mg (45%) of the desired compound as a colorless oil.

[0645] lH NMR (400 MHz, CDC13) 5 1.50 (IH, tt, J = 13.5, 4.3 Hz) , 1.60-1.65 (IH, m), 1.91 (IH, qt, J = 13.5, 4.3 Hz), 2.02-2.05 (IH, m), 2.47 (3H, s), 2.84 (IH, td, J= 11.6, 3.1 Hz), 2.90 (IH, dd, J = 11.6, 2.4 Hz), 3.09-3.16 (2H, m), 3.79 (2H, s) , 3.85 (3H, s) , 4.13-4.18 (IH, m), 7.05 (IH, td, J = 7.3, 1.2 Hz), 7.09 (IH, dd, J = 7.3, 1.2 Hz) , 7.37 (2H, d, J = 8.6 Hz) , 7.4 4 (IH, td, J = 7.3, 1.8 Hz) , 7.74 (IH, brs), 7.77 (IH, dd, J = 7.9, 1.8 Hz), 7.81 (2H, d, J = 8.6 Hz). FAB+ (m/z) : 484 (M+H).

[0646] <Example 5 9> Methyl 3-[3-[[2-(4-chlorophenyl)-4-methylthiazol-5-yl]methylamino]pip eridin-l-yl]benzoate

[0647] Step 59a) Methyl 3-(3-aminopiperidin-l-yl)benzoate

[0648] [Chemical formula 147] Trifluoroacetic acid (2 mL) was added to methyl 192 552501 3-[3-(tert-butoxycarbonylamino)piperidin-l-yl]benzoate (451 mg, 1.35 mmol) in dichloromethane (2 mL). The reaction mixture was stirred at room temperature for 1 hour. Subsequently, the mixture was concentrated and a saturated aqueous sodium bicarbonate solution was added to the residue to make it basic. The mixture was extracted with ethyl acetate and the organic layer was washed with brine and dried over magnesium sulfate. Evaporation of the solvent gave 158 mg (50%) of the desired compound as a pale yellow oil. 1H NMR (400 MHz, DMSO-d6) 5 1.32-1.41 (IH, m) , 1.53-1.63 (IH, m) , 1.75-1.83 (IH, m), 1.86-1.92 (IH, m), 2.73 (IH, dd, J = 12.2, 9.1 Hz), 2.78-2.84 (IH, m), 3.01-3.08 (IH, m), 3.47 (IH, td, J = 12.2, 4.3 Hz), 3.62 (IH, dd, J = 12.2, 3.1 Hz), 3.84 (3H, s), 7.20-7.25 (IH, m) , 7.34-7.38 (2H, m), 7.46-7.47 (IH, m) .

[0650] Step 59b) Methyl 3-[3-[[2-(4-chlorophenyl)-4-methylthiazol-5-yl]methylamino]pip eridin-l-yl]benzoate

[0651] [Chemical formula 148]

[0652] Acetic acid (0.0251 mL, 0.438 mmol) and sodium 193 552501 triacetoxyborohydride (97.7 mg, 0.438 mmol) were added to methyl 3-(3-aminopiperidin-l-yl)benzoate (79.0 mg, 0.337 mmol) and 2- (4-chlorophenyl)-4-methylthiazole-5-carboaldehyde (80.1 mg, 0.337 mmol) in tetrahydrofuran (5 mL) . The reaction mixture was 5 stirred at room temperature for 16 hours . Subsequently, a saturated aqueous sodium bicarbonate solution was added to make the mixture basic. The mixture was then extracted with ethyl acetate and the extract was washed with brine, followed by drying over magnesium ^ sulfate and evaporation of the solvent. Purification of the 10 resulting residue by silica gel column chromatography (Chromatorex NH-DM2035 (Fuji Sylysia Chemical Co., Ltd.) hexane : ethyl acetate = 5:1 ->2:1) gave 59.4 mg (39%) of the desired compound as a colorless oil.

[0653] 15 1E NMR (400 MHz, CDC13) 5 1. 37-1.46 (IH, m) , 1. 65-1.75 (IH, m) , 1.82-1.90 (IH, m), 1.94-2.01 (IH, m), 2.43 (3H, s), 2.79 (IH, dd, ^ J = 11.6, 7.9 Hz), 2.8 6-2.96 (2H, m), 3.4 3 (IH, td, J = 12.2, 4.3 Hz), 3.60-3.64 (IH, m), 3.90 (3H, s), 4.01 (IH, d, J = 14.7 Hz), 4.04 (IH, d, J = 14.7 Hz) , 7.11 (IH, dd, J = 8.6, 1.8 Hz) ,7.30 (IH, 20 t, J = 7.9 Hz), 7.38 (2H, d, J = 8.6 Hz), 7.50 (IH, td, J = 7.9, 1.2 Hz), 7.60-7.61 (IH, m), 7.83 (2H, d, J = 8.6 Hz). FAB+ (m/z) : 456 (M+H).

[0654] <Example 60> 194 552501 Methyl 2- [3- [ [2- (4-chlorophenyl) -4-methylthiazol-5-yl]itiethylamino] pip eridin-l-yl]benzoate

[0655] 5 Step 60a) Methyl 2-(3-aminopiperidin-l-yl)benzoate

[0656] [Chemical formula 149]

[0657] 10 Using methyl 2-[3-(tert-butoxycarbonylamino)piperidin-l-yl]benzoate (246 mg, 0.736 mmol) , the same procedure was followed as in Step 59a of Example 59 to give 91.6 mg (53%) of the desired compound as a brown oil. 1H NMR (400 MHz, DMS0-d6) 5 1.22-1.32 (IH, m) , 1.52-1.62 (IH, m) , ^ 1.72-1.79 (IH, m), 1.85-1.91 (IH, m), 2.56 (IH, dd, J = 11.0, 9.1 Hz), 2.69 (IH, td, J= 11.6, 2.4 Hz), 2.96-3.02 (lHr m), 3.07 (IH, td, J = 11.6, 4.3 Hz), 3.21 (IH, dd, J =11.0, 3.7 Hz), 3.82 (3H, s), 7.01 (IH, td, J = 7.3, 1.2 Hz), 7.09 (IH, d, J = 7.9 Hz), 7.45 (IH, td, J = 7.3, 1.8 Hz), 7.58 (IH, dd, J = 7.9, 1.8 Hz). 20 [0658] Step 60b) Methyl 2-[3-[[2-(4-chlorophenyl)-4-methylthiazol-5-yl]methylamino]pip eridin-l-yl]benzoate 195 552501

[0659] [Chemical formula 150]

[0660] Using methyl 2-(3-aminopiperidin-l-yl)benzoate (45.8 mg, 0 .195 mmol) , the same procedure was followed as in Step 59b of Example 59 to give 22.2 mg (25%) of the desired compound as a colorless oil.

[0661] 1H NMR (400 MHz, CDC13) 5 1.42-1.50 (IH, m) , 1.56-1.76 (2H, m) , 1.82-1.92 (IH, m), 2.40 (3H, s), 2.71-2.78 (IH, m), 2.82-2.88 (IH, m), 2.91-2.99 (IH, m) , 3.06-3.11 (IH, m), 3.30-3.34 (IH, m), 3.86 (3H, s), 3.98 (2H, brs), 6.99 (IH, t, J = 7.3 Hz), 7.04 (IH, d, J = 8.6 Hz) , 7.37 (2H, d, J = 8.6 Hz) , 7.40-7.42 (IH, m) , 7.71 (IH, dd, J = 7,3, 1.2 Hz), 7.82 (2H, d, J = 8.6 Hz). FAB+(m/z): 456 (M+H).

[0662] <Example 61> Methyl 2-[3- [ (4'-chlorobiphenyl-4-yl)carbonylaminomethyl]piperidin-l-yl] benzoate

[0663] Step 61a) 2-[3-(Hydroxymethyl)piperidin-l-yl]benzaldehyde 196 552501

[0664] [Chemical formula 151]

[0665] 2-Fluorobenzaldehyde (3.26 mL, 30.0 mmol), potassium carbonate (5.64 g, 40.0 mmol) and tetrabutylammonium iodide (739 mg, 2.00 mmol) were added to 3-piperidylmethanol (2.30 g, 20.0mmol) in N, N-dimethylformamide (20 mL) . The reaction mixture was stirred at 130°C for 8 hours. Subsequently, water was added and the mixture was extracted with ethyl acetate . The extract was washed with brine, followed by drying over magnesium sulfate and evaporation of the solvent. Purification of the resulting residue by silica gel column chromatography (hexane : ethyl acetate = 5:1 -> 1:1) gave 1.56 g (36%) of the desired compound as a yellow oil.

[0666] *H NMR (400 MHz, CDC13) 5 1.17-1.27 (IH, m) , 1.42 (IH, brs) , 1.74-1.90 (3H, m) , 1.9 9-2.09 (lHrm), 2.72 (IH, dd, J = 11.6, 9.8 Hz) , 2.84-2.90 (IH, m), 3.19-3.24 (IH, m), 3.36-3.40 (IH, m), 3.56-3.67 (2H, m), 7.09 (IH, t, J = 7.3 Hz), 7.12 (IH, d, J = 8.6 Hz), 7.48-7.53 (IH, m), 7.80 (IH, dd, J = 7.3, 1.8 Hz), 10.29 (IH, s).

[0667] Step 61b) Methyl 2-[3-(hydroxymethyl)piperidin-l-yl]benzoate

[0668] 197 552501 [Chemical formula 152] HO COOMe

[0669] 2-[3-(Hydroxymethyl)piperidin-l-yl]benzaldehyde (1.56 g, 7.11 mmol) was reacted as in Step 5d of Example 5 to obtain 1.29 g (73%) of the desired compound as a pale yellow oil. NMR (400 MHz, CDC13) 5 1.31-1.40 (IH, m) , 1.66-1.80 (2H, m) , 1.8 6-2.01 (2H, m) , 2.27 (IH, brs) , 2.81 (IH, dd, J = 11.6, 7.3 Hz), 2.84-2.90 (IH, m), 3.05-3.10 (IH, m), 3.26 (IH, dd, J = 11.6, 3.7 Hz), 3.64-3.73 (2H, m), 3.90 (3H, s), 6.99 (IH, td, J = 7.9, 1.2 Hz), 7.06 (IH, d, J = 7.9 Hz), 7.40 (IH, td, J = 7.3, 1.8 Hz), 7.71 (IH, dd, J = 7.3, 1.8 Hz) .

[0670] Step 61c) N-[[1-[2-(Methoxycarbonyl)phenyl]piperidin-3-yl]methyl]phthali mide

[0671] [Chemical formula 153]

[0672] Triphenylphosphine (1.68 g, 6.20 mmol) and phthalimide (799 198 552501 mg, 5.43 mmol) were added to methyl 2-[3-(hydroxymethyl)piperidin-l-yl]benzoate (1.29 g, 5.17 mmol) in tetrahydrofuran (10 mL) . The reaction mixture was stirred at room temperature for 10 min and a 40% diethyl 5 azodicarboxylate/toluene solution (3.52 mL, 7.76 mmol) was added. The mixture was then stirred at room temperature for 8 hours. Subsequently, water was added and the mixture was extracted with ethyl acetate . The extract was washed with brine, followed by drying ^ over magnesium sulf ate and evaporation of the solvent. Purification 10 of the resulting residue by silica gel column chromatography (hexane : ethyl acetate = 20:1 -> 5:1) gave 1.85 g (95%) of the desired compound as a pale yellow oil.

[0673] XH NMR (400 MHz, CDCl3) 5 1.14-1.24 (IH, m) , 1.67-1.78 (IH, m) , 15 1.80-1.88 (2H, m), 2.21-2.32 (IH, m), 2.59 (IH, dd, J= 11.6, 9.8 Hz), 2.72 (IH, td, J= 11.6, 2.4 Hz), 3.19-3.26 (2H, m) , 3.58 (IH, ) dd, J = 14.1, 7.9 Hz), 3.71 (IH, dd, J = 13.4, 6.7 Hz), 3.80 (3H, s) , 6.95 (IH, td, J = 7.3, 1.2 Hz) , 7.01 (IH, d, J = 8.6 Hz) , 7.37 (IH, td, J = 7.3, 1.8 Hz) , 7.64 (IH, dd, J = 7.3, 1.8 Hz) , 7.69-7.7 4 20 (2H, m), 7.83-7.87 (2H, m) .

[0674] Step 61d) Methyl 2-[3-(aminomethyl)piperidin-l-yl]benzoate

[0675] [Chemical formula 154] 199 552501 H/ry> C02Me

[0676] N- [ [ 1-[2-(Methoxycarbonyl)phenyl]piperidin-3-yl]methyl]ph thalimide (495 mg, 1.31 mmol) was dissolved in methanol (10 mL). 5 To this solution, hydrazine monohydrate (190 pL) was added and the mixture was refluxed for 3 hours. Subsequently, the reaction mixture ^ was diluted with water and extracted with ethyl acetate . The organic layer was washed with brine and dried over anhydrous sodium sulfate. Evaporation of the solvent gave 253 mg (78%) of the desired compound 10 as an orange oil.

[0677] 1H NMR (400 MHz, CDCl3) 5 1. 04-1.15 (IH, m) , 1.66-1. 90 (4H, m) , 2.47 (IH, dd, J = 11.6, 9.2 Hz), 2.65 (2H, d, J = 5.5 Hz), 2.66-2.75 (IH, m), 3.24 (IH, d, J = 11.6 Hz), 3.37 (IH, dt, J = 11.6, 1.8 £ Hz), 3.89 (3H, s), 6.96 (IH, td, J = 7.3, 1.8 Hz), 7.04 (IH, d, J = 7.3 Hz) , 7.38 (IH, td, J = 7.3, 1.8 Hz) , 7.69 (IH, dd, J = 7.3, 1.8 Hz).

[0678] Step 61e) Methyl 20 2-[3-[ (4'-chlorobiphenyl-4-yl)carbonylaminomethyl]piperidin-l-yl] benzoate

[0679] [Chemical formula 155] 200 552501 CO,Me

[0680] Methyl 2-[3-(aminomethyl)piperidin-l-yl]benzoate (78.2 mg, 0.315 mmol) was dissolved in N,N-dimethylformamide (3 mL) and the 5 solution was chilled to 0°C. While this solution was stirred, ^ 4'-chlorobiphenyl-4-carboxylic acid (81.1 mg, 0.349 mmol), 1-hydroxybenzotriazole monohydrate (54.1 mg, 0.353 mmol), N-methylmorpholine (90 |iL, 0.819 mmol) and 3-(3-dimethylaminopropyl)-1-ethylcarbodiimide hydrochloride 10 (64.6 mg, 0.337 mmol) were added and the mixture was stirred for 20 min. The reaction mixture was then stirred at room temperature for 12 hours. Subsequently, the mixture was extracted with ethyl acetate and the organic layer was washed sequentially with 5% aqueous ^ citric acid, a saturated aqueous sodium bicarbonate solution, water 15 andbrine. The washedproduct was dried over anhydrous sodium sulfate and the solvent was concentrated. Purification of the resulting residue by silica gel column chromatography (hexane : ethyl acetate = 2:1) gave 111 mg (76%) of the desired compound as a colorless powder. 20 [0681] XH NMR (400 MHz, CDCI3) 5 1.34-1.45 (IH, m) , 1.67-1.90 (3H, m), 2.08-2.23 (IH, m) , 2.75 (IH, t, J = 8.6 Hz), 2.86 (IH, t, J = 10.4 201 552501 Hz), 3.12-3.20 (IH, m), 3.24 (IH, d, J = 10.4 Hz), 3.48-3.60 (2H, m) , 3.84 (3H, s) , 6. 66-6.8 0 (ih, m) , 7. 01 (IH, t, J = 7. 9 Hz) , 7.10 (IH, d, J = 7.9 Hz), 7.38-7.45 (3H, m), 7.53 (2H, d, J = 8.6 Hz), 7.60 (2H, d, J = 8.6 Hz), 7.71 (IH, d, J = 6.1 Hz), 7.88 (2H, d, J = 8.6 Hz). FAB+ (m/z) : 463 (M+H).

[0682] <Example 62> Methyl 3-[3-[(4'-chlorobiphenyl-4-yl)carbonylaminomethyl]piperidin-l-yl ]benzoate

[0683] Step 62a) Methyl 3-[3-(hydroxymethyl)piperidin-l-yl]benzoate

[0684] [Chemical formula 156] Copper (II) acetate (5.85g, 30.6mmol) and triethylamine (4.28 mL, 30.6 mmol) were added to 3-(tert-butyldimethylsilyloxymethyl)piperidine (3.50 g, 15.3 mmol) and 3-(methoxycarbonyl) phenylboric acid (5.51 g, 30.6 mmol) in dichloromethane (150 mL) . The reaction mixture was stirred at room temperature for 48 hours. Subsequently, ethyl acetate and a

[0685] 202 552501 saturated aqueous sodium bicarbonate solution were added and the mixture was stirred for 30 min and was filtered through Celite. The organic layer was collected and washed with brine. The washed product was then dried over magnesium sulfate and the solvent was 5 evaporated. Purification of the resulting residue by silica gel column chromatography (hexane : ethyl acetate = 50:1 -> 10:1) gave 4.81 g of a pale yellow oil. This oil product (4.81 g) was dissolved in a 1:1:1 mixture of acetic acid, tetrahydrofuran and water (50 ^ mL) and the solution was stirred for 6 hours while refluxed. The 10 mixture was then allowed to cool and the solvent was evaporated. Water was added to the residue and the mixture was extracted with ethyl acetate . The extract was washed with brine, followed by drying over magnesium sulfate and evaporation of the solvent. Purification of the resulting residue by silica gel column chromatography (hexane : 15 ethyl acetate = 10:1 -> 1:1) gave 1.33 g (40%) of the desired compound as a colorless oil. 9 [0686] 1H NMR (4 00 MHz, CDC13) 5 1.16-1.25 (IH, m) , 1.47 (IH, brs) , 1.66-1.76 (IH, m), 1.80-1.86 (2H, m) , 1.88-1.98 (IH, m), 2.62 (IH, dd, J = 20 11.6, 10.4 Hz), 2.80 (IH, td, J = 11.6, 2.4 Hz), 3.57-3.67 (3H, m) , 3.72-3.76 (IH, m), 3.90 (3H, s), 7.14 (IH, dd, J = 7.9, 2.4 Hz), 7.30 (IH, t, J = 7.9 Hz), 7.48 (IH, d, J= 7.3 Hz), 7.61-7.62 (IH, m).

[0687] 203 552501 Step 62b) n-[[1-[3-(Methoxycarbonyl)phenyl]piperidin-3-yl]methyl]phthali mide [0688] [Chemical formula 157] Using methyl 3-[3-(hydroxymethyl)piperidin-l-yl]benzoate (1.33 g, 5.33 mmol), the same procedure was followed as in Step 61c of Example 61 to give 1.91 g (95%) of the desired compound as a colorless powder. NMR (400 MHz, CDC13) 5 1.20-1.30 (IH, m) , 1.61-1.72 (IH, m) , 1.80-1.89 (2H, m), 2.16-2.27 (IH, m), 2.67 (IH, dd, J = 12.2, 9.8 Hz), 2.81 (IH, td, J= 11.6, 2.4 Hz), 3.51-3.58 (2H, m) , 3.67 (IH, dd, J = 14.1, 7.3 Hz), 3.71 (IH, dd, J = 14.1, 7.3 Hz), 3.89 (3H, s) , 7.09 (IH, dd, J = 7.9, 1.8 Hz), 7.29 (IH, t, j = 8.6 Hz), 7.48 (IH, d, J = 7.9 Hz) , 7.58-7 . 59 (IH, m) , 7.72-7.74 (2H, m) , 7.86-7.88 (2H, m). Step 62c) Methyl 3-[3-(aminomethyl)piperidin-l-yl]benzoate [0692] [Chemical formula 158]

[0689]

[0690]

[0691] 204 552501

[0693] Using N-[ [1- [3-(methoxycarbonyl)phenyl]piperidin-3-yl]methyl]phthali mide (533 mg, 1.41 mmol), the same procedure was followed as in Step 61d of Example 61 to give 237 mg (68%) of the desired compound as a colorless oil. lH NMR (4 00 MHz, CDC13) 5 1.05-1.17 (IH, m) , 1.63-1.93 (4H, m) , 2.49 (IH, dd, J = 12.2, 10.4 Hz), 2.68 (2H, d, J = 6.7 Hz), 2.75 (IH, td, J = 11.6, 3.1 Hz), 3.64 (IH, d, J = 12.2 Hz), 3.72 (IH, dd, J = 11.6, 1.8 Hz), 3.90 (3H, s), 7.14 (IH, dd, J =7.9, 1.8 Hz), 7.29 (IH, t, J = 7.9 Hz) , 7.47 (IH, dd, J = 6.1, 1.8 Hz), 7.58-7.63 (IH, m) . FAB+ (m/z) : 249 (M+H).

[0694] Step 62d) Methyl 3-[3-[(4'-chlorobiphenyl-4-yl)carbonylaminomethyl]piperidin-l-yl ]benzoate

[0695] [Chemical formula 159] 205 552501 n N^N-^C02Me

[0696] Using methyl 3-[3-(aminomethyl)piperidin-l-yl]benzoate (76.2mg, 0.307 mmol) and 4' -chlorobiphenyl-4-carboxylic acid (77.2 5 mg, 0.332 mmol), the same procedure was followed as in Step 61e ^ of Example 61 to give 117 mg (82%) of the desired compound as a pale yellow powder. XH NMR (400 MHz, CDC13) 5 1.24-1.35 (IH, m), 1.66-1.78 (IH, m), 1.82-1.97 (2H, m), 2.00-2.13 (IH, m), 2.69(1H, t, J = 12.2 Hz), 10 2.85 (IH, t, J = 12.2 Hz), 3.50(2H, t, J = 6.1 Hz), 3.58 (IH, d, J = 12.2 Hz), 3.65 (IH, d, J = 12.2 Hz), 3.89 (3H, s), 6.25-6.40 (IH, m), 7.12 (IH, d, J = 8.6 Hz), 7.30 (IH, t, J = 8.6 Hz),7.43 (2H, d, J = 8.6 Hz), 7.51 (IH, d, J = 6.1 Hz), 7.54 (2H, d, J = ^ 8.6 Hz), 7.61 (IH, s), 7.63 (2H, d, J = 8.6 Hz), 7.86 (2H, d, J 15 = 8.6 Hz). FAB+ (m/z) : 463 (M+H).

[0697] <Examples 63 through 66> The procedures were performed in the same manner as in Example 20 61 or Example 62 to make compounds given in Table 7 below.

[0698] 206 552501 [Table 7] ■pCOOMe Ar Binding position ofCOOMe F Example 63 Position 2 O Example 64 Example 65 F 0 Positkm3 Position 2 Example 66 Position 3

[0699] <Compound of Example 63> Colorless solid XH NMR (400 MHz, CDC13) 5 1.30-1.45 (IH, m) , 1.70-1.95 (3H, m), 2.05-2.19 (IH, m) , 2.68-2.76 (IH, m) , 2.80-2.88 (IH, m) , 3.12-3.25 (2H, m) , 3.38-3.56 (2H, m) , 3.84 (3H, s) , 6.62 (IH, brs), 6.95 (2H, d, J = 8.6 Hz), 6.97-7.12 (6H, m), 7.41 (IH, t, J = 7.3 Hz), 7.69 (IH, d, J = 7.3 Hz), 7.78 (2H, d, J = 8.6 Hz). FAB+(m/z): 4 63 (M+H).

[0700] CCompound of Example 64> Yellow amorphous 1H NMR (400 MHz, CDC13) 5 1.26-1.37 (IH, m), 1.74-1.94 (3H, m) , 2.13-2.25 (IH, m), 2.67 (IH, t, J = 8.6 Hz), 2.81 (IH, t, J = 8.6 207 552501 Hz), 3.18-3.25 (IH, m), 3.30 (IH, d, J = 10.4 Hz), 3.52 (2H, t, J = 6.8 Hz), 4.11 (3H, s), 6.97 (IH, t, J = 7.9 Hz), 7.06 (IH, d, J = 8,6 Hz), 7.40 (IH, td, J = 7.9, 1.2 Hz), 7.49 (IH, td, J = 7.9, 1.2 Hz) , 7.55 (IH, td, J = 7. 9, 1.2 Hz), 7. 67 (IH, brs) , 7.73 (IH, dd, J = 7.9, 1.2 Hz), 7.97 (IH, d, J = 7.9 Hz), 8.04 (IH, d, J = 7.9 Hz). FAB+ (m/z) : 410 (M+H).

[0701] CCompound of Example 65> Colorless amorphous XH NMR (400 MHz, CDC13) 5 1.26-1.30 (IH, m) , 1.65-1.78 (IH, m) , 1.80-1.95 (2H, m), 2.00-2.10 (IH, m), 2.67 (IH, t, J = 9.8 Hz), 2.8 4 (IH, t, J = 11.6 Hz), 3.64 (2H, t, J = 6.7 Hz), 3.54-3.67 (2H, m) , 3.8 9 (3H, s) , 6.15-6.25 (IH, m) , 6.98 (2H, d, J =8. 6 Hz) , 6.95-7.15 (5H, m) , 7.29 (IH, t, J = 7.9 Hz), 7.49 (IH, d, J = 7.9 Hz), 7.60 (IH, s), 7.75 (2H, d, J = 8.6 Hz). FAB+ (m/z) : 463 (M+H).

[0702] CCompound of Example 66> Colorless amorphous 1H NMR (400 MHz, CDCl3) 5 1.27-1. 37 (IH, m) , 1.67-1.78 (IH, m) , 1.83-1.92 (IH, m), 1.93-2.00 (IH, m), 2.05-2.18 (IH, m), 2.69 (IH, t, J = 11.0 Hz), 2.83 (IH, t, J = 11.0 Hz) , 3.4 5-3.63 (2H, m) , 3.5 9 (IH, d, J = 12.2 Hz), 3.68 (IH, d, J = 12.2 Hz), 3.88 (3H, s), 7.13 208 552501 (IH, d, J = 6.1 Hz), 7.30 (IH, t, J = 7.3 Hz), 7.46-7.64 (5H, m) , 7.99 (IH, d, J = 7.3 Hz), 8.08 (IH, d, J = 7.3 Hz). FAB+ (m/z) : 410 (M+H).

[0703] <Example 67> Methyl 2-[3-[N-[(4' -chlorobiphenyl-4-yl)methyl]carbamoyl]piperidin-l-yl] benzoate

[0704] Step 67a) Benzyl 1-[2-(methoxycarbonyl)phenyl]nipecotate

[0705] [Chemical formula 160] Using benzyl nipecotate (5.90 g, 26.9 mmol) and methyl 2-fluorobenzoate (3.70 mL, 29.0 mmol), the same procedure was followed as in Step lc of Example 1 to give 1.64 g (17%) of the desired compound as a colorless oil. XH NMR(400 MHz, CDC13) 5 1.54-1.65 (IH, m), 1.67-1.87 (2H, m) , 2.07-2.16 (IH, m) , 2.73 (IH, td, J = 11.6, 3.1 Hz) , 2.8 0-2 . 94 (2H, m) , 3.25 (IH, d, J= 11.6 Hz), 3.52 (IH, d, J = 11.6 Hz), 3.84 (3H, s), 5.12 (2H, s), 6.98 (IH, t, J = 7.3 Hz), 7.04 (IH, d, J = 7.3 Hz), 7.29-7.42 (5H, m), 7.70 (IH, dd, J = 7.3, 1.8 Hz).

[0706] 209 552501

[0707] Step 67b) 1-[2-(Methoxycarbonyl)phenyl]nipecotic acid

[0708] [Chemical formula 161]

[0709] 1-[2-(Methoxycarbonyl)phenyl] benzylnipecotate (1.64g, 4.64 mmol) was dissolved in methanol (40 mL). To this solution, 10% palladium on activated carbon (169 mg) and 1, 4-cyclohexadiene (0.65 mL, 6.98 mmol) were added in an argon atmosphere and the mixture was stirred at room temperature for 8 hours. Subsequently, the mixture was filtered and the solvent evaporated. Purification of the resulting residue by silica gel column chromatography (hexane : ethyl acetate = 5 : 1 -> 1:2) gave 510 mg (42%) of the desired compound as a yellow oil. NMR (400 MHz, DMSO-d6) 5 1.40-1.63 (2H, m) , 1.70-1.74 (IH, m) , 1.90-2.00 (IH, m) , 2.48-2.60 (2H, m> , 2.65-2.73 (IH, m) , 2.77 (IH, t, J = 11.6 Hz) , 3.11 (IH, d, J = 11.6 Hz), 3.79 (3H, s), 7.00 (IH, t, J = 7.3 Hz), 7.10 (IH, d, J = 7.3 Hz), 7.43 (IH, td, J = 7.3, 1.8 Hz), 7.55 (IH, dd, J = 7.3, 1.8 Hz), 12.27 (IH, brs).

[0710] 210 552501 Step 67c) Methyl 2-[3-[N-[(4'-chlorobiphenyl-4-yl)methyl]carbamoyl]piperidin-l- yl] benzoate

[0711] [Chemical formula 162] H CO,Me

[0712] Using 1- [2- (methoxycarbonyl) phenyl] nipecotic acid (77.5 mg, 0.294 mmol) and (4' -chlorobiphenyl-4-yl) methylamine hydrochloride 10 (72.2 mg, 0.284 mmol), the same procedure was followed as in Step 3a of Example 3 to give 114 mg (87%) of the desired compound as a colorless amorphous product. 1H NMR (4 00 MHz, CDC13) 5 1.57-1.7 7 (2H, m) , 1.8 5-2.13 (2H, m) , 2. 67 ) (IH, t, J = 11.6 Hz), 2.75-2.81 (IH, m), 3.08-3.20 (2H, m), 3.36 15 (IH, d, J = 11.6 Hz), 3.74 (3H, s), 4.48 (IH, dd, J = 15.3, 5.5 Hz), 4.5 6 (IH, dd, J = 15.3, 5.5 Hz) , 7.05-7.15 (2H, m) , 7.30-7.50 (9H, m) , 7.79 (IH, dd, J = 7.9, 1.8 Hz), 8.71 (IH, brs). FAB+ (m/z) : 463 (M+H).

[0713] 2 0 <Example 68> Methyl 3-[3-[N-[(47-chlorobiphenyl-4-yl)methyl]carbamoyl]piperidin-l-yl] benzoate 211 552501

[0714] Step 68a) 1—[3—(Methoxycarbonyl)phenyl]benzyl nipecotate

[0715] [Chemical formula 163] Crv-Q O XX C02Me 5

[0716] Using benzyl nipecotate (4.39 g, 20.0 mmol) and 3-methoxycarbonylphenylboric acid (7.20 g, 40.0 mmol), the same procedure was followed as in Example 2 to give 2.34 g (33%) of the 10 desired compound as a colorless oil. 1H NMR (400 MHz, CDC13) 5 1.55-1.79 (2H, m), 1.80-1.87 (IH, m), 2.00-2.10 (IH, m) , 2.71-2.77 (IH, m) , 2,86-2.94 (IH, m) , 3.14 (IH, t, J = 11.0 Hz) , 3.48-3.52 (IH, m), 3.74 (IH, dd, J = 12.3, 3.7 Hz), 3.90 (3H, s), 5.16 (2H, s), 7.11 (IH, dd, J = 7.3, 1.8 Hz), ^ 7.26-7.37 (6Hf m) , 7.50 (IH, d, J = 7.3 Hz), 7.58-7.62 (IH, m) .

[0717] Step 68b) 1-[3-(Methoxycarbonyl)phenyl]nipecotic acid

[0718] [Chemical formula 164] 20

[0719] 212 552501 In an argon atmosphere, 10% palladium on activated carbon (234 mg) and ammonium formate (1.66 g, 26.4 mmol) were added to 1-[3-(methoxycarbonyl) phenyl] benzyl nipecotate (2.34 g, 6. 60 mmol) in methanol (50 mL) . The reaction mixture was stirred at room 5 temperature for 4 hours. Subsequently, the mixture was filtered through Celite and the filtrate was concentrated. 5% aqueous citric acid was added to the residue and the mixture was extracted with ethyl acetate. The organic layer was then washed with brine and ^ was dried over sodium sulfate. The solvent was evaporated to give 10 1.57 g (90%) of the desired compound as a pale reddish brown powder.

[0720] NMR (400 MHz, DMSO-d6) 5 1.54-1.62 (2H, m), 1.69-1.75 (IH, m), 1.86-1.96 (IH, m) , 2.51-2.60 (IH, m), 2.81-2.90 (IH, m), 3.01 (IH, dd, J = 12.2, 9.2 Hz), 3.47 (IH, d, J = 11.7 Hz), 3.66 (IH, dd, 15 J = 12.8, 3.7 Hz), 3.84 (3H, s) 7.21-7.25 (IH, m), 7.34-7.38 (2H, m) , 7.45-7.47 (IH, m) , 12.39 (IH, brs). EI+(m/z) : 2 63 (M+) .

[0721] Step 68c) Methyl 20 3-[3-[N-[(4'-chlorobiphenyl-4-yl)methyl]carbamoyl]piperidin-l-yl] benzoate

[0722] [Chemical formula 165] 213 552501 C02Me

[0723] Using 1-[3-(methoxycarbonyl)phenyl]nipecotic acid (108 mg, 0.410 mmol) and (4'-chlorobiphenyl-4-yl)methylamnine 5 hydrochloride (95.0mg, 0.37 4 mmol), the same procedure was followed ^ as in Step 3a of Example 3 to give 120 mg (69%) of the desired compound as colorless crystals. XH NMR (400 MHz, CDC13) 5 1.68-1.78 (IH, m) , 1.82-1.96 (3H, m) , 2.59-2.65 (IH, m) , 3.08-3.15 (IH, m) , 3.26-3.35 (2H, m) , 3.48 (IH, 10 dd, J = 12.2, 3.6 Hz), 3.89 (3H, s) , 4 . 48-4.55 (2H, m), 6.73-6.81 (IH, m), 7.12 (IH, dd, J = 7.9, 2.4 Hz), 7.30 (IH, t, J - 7.9 Hz), 7.34 (2H, d, J = 7.9 Hz), 7.40 (2H, d, J = 8.6 Hz), 7.47-7.54 (4H, m), 7.55 (IH, d, J = 7.3 Hz), 7.62 (IH, s). ^ FAB+ (m/z) : 463 (M+H). 15 [0724] <Example 69> Step 69a) 1- (tert-Butoxycarbonyl)-N-[2-(4-chlorophenyl)-4-methylthiazol-5-yl]piperidine-3-carboxamide 20 [0725] [Chemical formula 166] 214 552501 CI

[0726] 5 10 m Using 5-amino-2-(4-chlorophenyl)-4-methylthiazole (197 mg, 0.877 mmol) and 1- (tert-butoxycarbonyl) nipecotic acid (205mg, 0 . 877 mmol), the same procedure was followed as in Step 3a of Example 3 to give 115 mg (30%) of the desired compound as a yellow powder. XH NMR (400 MHz, CDC13) 5 1.45 (9H, s) , 1.53-1.61 (2H, m) , 1.66-1.76 (IH, m) , 1.84-1. 92 (IH, m) , 2.21-2.33 (IH, m) , 2.50 (3H, s) , 2.6 6-2.71 (IH, m) , 3.35-3.44 (IH, m) , 3.45-3.55 (IH, m), 3.60-3.63 (IH, m), 3.83-3.97 (IH, m), 7.37 (2H, d, J = 8.6 Hz), 7.82 (2H, d, J = 8.6 Hz) . FAB+ (m/z) : 436 (M+H).

[0727] Step 69b) N-[2-(4-Chlorophenyl)-4-methylthiazol-5-yl]piperidine-3-carbox amide [Chemical formula 167]

[0728] Using 1- (tert-butoxycarbonyl)-N-[2-(4-chlorophenyl)-4-methylthiazol- 215 552501 5-yl]piperidine-3-carboxamide (115 mg, 0.264 mmol), the same procedure was followed as in Step lb of Example 1 to give 72.3 mg (81%) of the desired compound as a yellow powder. 1H NMR (400 MHz, DMSO-d6) 5 1.36-1.46 (IH, m) , 1.56-1.66 (2H, m) , 1.83-1.90 (IH, m) , 2.40 (3H, s) , 2.53-2.59 (IH, m) , 2.64-2.74 (2H, m) , 2.84 (IH, td, J = 12.2, 3.1 Hz), 3.00 {IH, d, J = 11.0 Hz), 7.50 (2H, d, J = 8.6 Hz) , 7.84 (2H, d, J = 8.6 Hz) , 10.92 (IH, brs) .

[0729] Step 69c) Methyl 3-[3-[N-[2-(4-chlorophenyl)-4-methylthiazol-5-yl]carbamoyl]pip eridin-l-yl]benzoate

[0730] [Chemical formula 168] N- [2 - (4-chlorophenyl)-4-methylthiazole-5-yl]piperidine-3-carbo xamide (36.0 mg, 0.107 mmol) and 3-methoxycarbonylphenylboric acid (38.5 mg, 0.214 mmol), the same procedure was followed as in Example 4 to give 21.3 mg (42%) of the desired compound as a pale yellow powder. ^ NMR (400 MHz, CDC13) 5 1.80-1.91 (2H, m) , 1.93-2.01 (2H, m) , 2.16-2.21 (IH, m), 2.23 (3H, s), 2.92-2.98 (2H, m), 3.15 (IH, dd, Using

[0731] 216 552501 10 J = 12.2, 3.1 Hz), 3.64 (IH, td, J = 11.0, 3.7 Hz), 3.77-3.81 (IH, m) , 3.93 (3H, s), 7.33 (IH, dd, J = 7.9, 1.8 Hz), 7.37 (2H, d, J = 8. 6 Hz) , 7.44 (IH, t, J=7.9Hz), 7.73 (IH, d, J=7.3Hz), 7.79-7.80 (IH, xn) , 7.82 (2H, d, J = 8.6 Hz), 10.24 (IH, brs). FAB+ (m/z) : 470 (M+H) .

[0732] <Example 7 0 through 75> The processes were performed as in Example 67, Example 68 or Example 69 to obtain compounds given in Table 8 below.

[0733] [Table 8] Ar ) 4 -COOMe 1 2 3 Ar y %gm Binding position Example 70 Example 71 Example 74 Example 75 Q?> Example 72 CI ~\ / ^ w g. Example 73 CHgNHCO Position 2 CH NHCO Position 2 NHCO NHCO Position 2 CH2NHCO Posion 3 CH 2NHCO Position 3 Position 3 217 552501

[0734] CCompound of Example 70> Colorless oil XH NMR (4 00 MHz, CDCI3) 6 1.55-1.7 5 (2H, m) , 1.94-2.10 (2H, m) , 2.67 5 (IH, t, J = 11.6 Hz), 2.73-2.78 (IH, m) , 3.06-3.18 (2H, m), 3.33 (IH, d, J = 11.6 Hz), 3.77 (3H, s), 4.40 (IH, dd, J = 14.7, 5.5 Hz), 4.49 (IH, dd, J = 14.7, 5.5 Hz), 6.83 (2H, d, J = 8.6 Hz), 6.88-6.95 (2H, m) , 6.96-7.03 (2H, m) , 7.06-7.14 (2H, m) , 7.22 (2H, ^ d, J = 6.7 Hz), 7.47 (IH, td, J = 7.9, 1.8 Hz), 7.79 (IH, dd, J 10 = 7.9, 1.8 Hz), 8.63 (IH, brs). FAB+(m/z): 463 (M+H).

[0735] CCompound of Example 71> Colorless oil 15 1R NMR (400 MHz, CDC13) 5 1.63-1.7 8 (2H, m) , 2.08-2.22 (2H, m) , 2.66 (IH, t, J = 11.0 Hz), 2.83-2.88 (IH, m), 3.10 -3.22 (2H, m), 3.44 ^ (IH, d, J = 11.0 Hz), 3.71 (3H, s), 4.90 (IH, dd, J = 16.5, 6.1 Hz), 4.95 (IH, dd, J = 16.5, 6.1 Hz),7.10 (IH, t, J = 7.9 Hz), 7.15 (IH, d, J = 7.9 Hz), 7.32 (IH, td, J - 7.9, 1.2 Hz),7.42 (IH, td, 20 J = 7.9, 1.2 Hz), 7.49 (IH, td, J = 7.9, 1.2 Hz), 7.75-7.80 (2H, m) , 7.92 (IH, d, J = 7.9 Hz), 9.42 (IH, brs). FAB+ (m/z) : 410 (M+H).

[0736] CCompound of Example 72> 25 Yellow oil 218 552501 XH NMR (400 MHz, CDCI3) 5 1.67-1.74 (IH, m) , 1.78-1.83 (IH, m) , 1.99-2.06 (IH, m) , 2.09 (3H, s) , 2.21-2.27 (IH, m) , 2.66-2.72 (IH, m) , 2.97-3.00 (IH, m), 3.21-3.28 (2H, m), 3.56-3.59 (IH, m), 3.79 (3H, s), 7.14-7.18 (2H, m) , 7.35 (2H, d, J = 8.6 Hz), 7.54 (IH, 5 dd, J = 7.9, 1.2 Hz), 7.81 (2H, d, J = 8.6 Hz), 7.93 (IH, dd, J = 7.9, 1.2 Hz), 10.37 (IH, brs). FAB+(m/z): 470 (M+H).

[0737] <Compound of Example 73> 10 Colorless oil ^ NMR (400 MHz, CDCI3) 5 1.68-1.78 (IH, m) , 1.81-1.94 (3H, m) , 2.56-2.64 (IH, m) , 3.06-3.14 (IH, m) , 3.26-3.34 (2H, m) , 3.47 (IH, dd, J = 12.2, 3.1 Hz), 3.90 (3H, s) , 4.38-4.50 (2H, m), 6.66-6.72 (IH, m), 6.89-6. 98 (4H, m) , 6.99-7.05 (2H, m), 7.09-7.14 (IH, m), 15 7.23 (2H, d, J = 8.6 Hz), 7.31 (IH, t, J = 7.9 Hz), 7.56 (IH, d, J = 7.9 Hz), 7.60-7.62 (IH, m). ) FAB+ (m/z) : 4 63 (M+H).

[0738] <Compound of Example 7 4> 20 Colorless powder 1R NMR (400 MHz, CDCI3) 5 1.70-1.84 (IH, m), 1.85-2.03 (3H, m) , 2.66-2.78 (IH, m), 3.17-3.30 (2H, m>, 3.38-3.48 (2H, m), 3.89 (3H, s), 4.91 (2H, d, J = 5.5 Hz), 7.20-7.27 (2H, m) , 7.29-7.35 (IH, m) , 7.38 (IH, td, J = 7.9, 1.2 Hz) , 7.47 (IH, tdf J = 7.9, 1.2 Hz) , 219 552501 7.50-7.62 (2H, m), 7.68 (IH, s), 7.86 (IH, d, J = 7.9 Hz), 7.93 (IH, d, J = 7.9 Hz). FAB+ (m/z) : 410 (M+H).

[0739] 5 CCompound of Example 75> Colorless amorphous 1H NMR (CDCl3-d, 400 MHz) 5 1.77-2.02 (3H, m) , 2.04-2.13 (IH, m) , 2. 73-2.80 (IH, m) , 3.12-3.20 (IH, m) , 3.30-3.43 (2H, m) , 3.56 (IH, ^ d, J = 12.8, 5.5 Hz), 3.92 (3H, s), 6.90-6.96 (4H, m), 6.97-7.02 10 (2H, m) , 7.24-7.27 (2H, m), 7.39 (IH, t, J = 7.9 Hz), 7.47 (IH, d, J = 8.6 Hz), 7.65 (IH, d, J = 7.9 Hz) , 7.7 3 (IH, s), 8.90 (IH, s) . FAB+(m/z): 449 (M+H).

[0740] 15 CExample 7 6> Methyl ^ 3~ [3- [ (benzothiazol-2-yl)oxymethyl]piperidin-l-yl]benzoate

[0741] Step 7 6a) 20 1- (tert-Butoxycarbonyl)-3-[(benzothiazol-2-yl)oxymethyl]piperi dine

[0742] [Chemical formula 169] 220 552501 Qt i 1

[0743] 1-(tert-Butoxycarbonyl) piperidin-3-ylmethanol (300mg, 1.39 mmol) was dissolved in N,N-dimethylformamide (5 mL) . While this solution was chilled in an ice bath, 60% sodium hydride in oil (83.6 mg, 2.09 mmol) was added. The reaction mixture was stirred for 10 min while ice-chilled and for another 10 min at room temperature. 2-chlorobenzothiazole (0.344 mL, 2.78 mmol) and sodium iodide (208 mg, 1.39 mmol) were then added and the mixture was stirred at room temperature for 5 hours. Subsequently, water was added and the mixture was extracted with ethyl acetate. The extract was washed with brine . The washed product was then dried over magnesium sulfate and the solvent was evaporated. Purification of the resulting residue by silica gel column chromatography (hexane : ethyl acetate = 20 :1 -> 5 :1) gave 460 mg (95%) of the desired compound as a colorless powder.

[0744] 1H NMR (400 MHz, DMSO-d6) 5 1.25-1.45 (11H, m) , 1.56-1.67 (IH, m) , 1.75-1.85 (IH, m) , 1.93-2.06 (IH, m) , 2.59-3.11 (2H, m) , 3.53-4.07 (2H, m)f 4.38-4.48 (2H, m) , 7.28 (IH, td, J = 7.9, 1.2 Hz), 7.40 (IH, td, J = 7.9, 1.2 Hz), 7.66 (IH, d, J = 7.3 Hz), 7.88 (IH, dd, J = 7.9, 1.2 Hz).

[0745] 221 552501 Step 76b) 3-[(Benzothiazol-2-yl)oxymethyl]piperidine

[0746] [Chemical formula 17 0] NH 5 [0747] Trifluoroacetic acid (2 mL) was added to l-tert-butoxycarbonyl-3-[(benzothiazol-2-yl)oxymethyl]piperidi ne (460 mg, 1.32 mmol) in dichloromethane (2 mL) . The mixture was stirred at room temperature for 3 hours. Subsequently, the solvent 10 was evaporated and water was added to the residue, followed by a Imol/L aqueous sodium hydroxide solution to make the mixture basic. The mixture was then extracted with ethyl acetate and the extract was washed with brine. The washed product was dried over magnesium sulfate and the solvent was evaporated to give 297 mg (91%) of the desired compound as a colorless oil. 1H NMR (400 MHz, DMSO-ds) 5 1.20-1.30 (IH, m), 1.38-1.49 (IH, m), 1.61-1.66 (IH, m) , 1.77-1.82 (IH, m) , 1.99-2.09 (IH, m) , 2.45 (IH, dd, J = 11.6, 10.4 Hz) , 2.54 (IH, dd, J = 11.6, 3.1 Hz) , 2.90-2.95 (IH, m), 3.07 (IH, dd, J = 11.6, 2.4 Hz), 4.4 0 (IH, dd, J = 10.4, 20 7.3 Hz) , 4.4 4 (IH, dd, J = 10.4, 5.5 Hz) , 7.2 7 (IH, t, J = 7.3 Hz) , 7.40 (IH, t, J = 7.3 Hz), 7.66 (IH, d, J - 7.9 Hz), 7.88 (IH, d, J = 7.9 Hz) .

[0748] 222 552501 Methyl 3-[3-[(benzothiazol-2-yl)oxymethyl]piperidin-l-yl]benzoate [0749] [Chemical formula 171] Using 3-[(benzothiazol-2-yl)oxymethyl]piperidine (58.0 mg, 0.234 mmol) and 3-(methoxycarbonyl) phenylboric acid (84.2mg, 0.468 mmol) , the same procedure was followed as in Example 2 to give 17.6 mg (20%) of the desired compound as a colorless oil. lH NMR (400 MHz, CDCl3) 5 1.32-1.42 (IH, m), 1.71-1.80 (IH, m) , 1.85-1.96 (2H, m) , 2.29-2.40 (IH, m) , 2.75-2.80 (IH, m) , 2.83-2.90 (IH, m), 3.58-3.63 (IH, m), 3.75-3.79 (IH, m), 3.90 (3H, s), 4.50 (IH, dd, J = 10.4, 7.9 Hz) , 4.57 (IH, dd, J = 10.4, 5.5Hz), 7.14-7.16 (IH, m) , 7.23 (IH, td, J = 7.9, 1.2 Hz), 7.31 (IH, t, J = 7.9 Hz), 7.37 (IH, td, J = 8.6, 1.2 Hz) , 7.50 (IH, d, J = 6.7 Hz) , 7.62 (IH, brs), 7.65 (IH, d, J = 7.9 Hz), 7.68 (IH, d, J = 8.6 Hz). FAB+(m/z): 383 (M+H).

[0751] <Example 77> Methyl 3-[3-[(4'-chlorobiphenyl-4-yl)methoxy]piperidin-l-yl]benzoate

[0750]

[0752] 223 552501 Step 77a) 1-(tert-Butoxycarbonyl)-3-[(4'-chlorobiphenyl-4-yl)methoxy]pip eridine

[0753] [Chemical formula 172] Using 1-(tert-butoxycarbonyl)-3-hydroxypiperidine (403 mg, 2.00 mmol) and 4'-chloro-4-chloromethylbiphenyl (474 mg, 2.0 0 mmol), the same procedure was followed as in Step 6a of Example 6 to give 672 mg (84%) of the desired compound as a colorless powder. XH NMR (400 MHz, CDCI3) 5 1.41-1.50 (10H, m) , 1.54-1.63 (IH, m) , 1.73-1.84 (IH, m) , 1.93-2.02 (IH, m) , 3.04-3.26 (2H, m) , 3.40-3.49 (IH, m) , 3.59 (IH, td, J=13.4, 4.9Hz), 3.68-4.01 (IH, m) , 4.55-4.58 (IH, m), 4.66-4.69 (IH, m), 7.39-7.43 (4H, m), 7.49-7.53 {4H, m). FAB+(m/z): 402 (M+H).

[0755] Step 77b) 3-[(4'-Chlorobiphenyl-4-yl)methoxy]piperidine

[0756] [Chemical formula 173]

[0754] 224 552501 CI NH

[0757] Using 1- (tert-butoxycarbonyl)-3-[ (4'-chlorobiphenyl-4-yl)methoxy]pip eridine (672 mg, 1.67 mmol), the same procedure was followed as in Step 76b of Example 76 to give 441 mg (87%) of the desired compound as a colorless powder. 1H NMR (400 MHz, DMSO-d6) 5 1.23-1.38 (2H, m) , 1.57-1.66 (IH, m) , 1.93-2.02 (IH, m) , 2.34-2.42 (2H, m), 2.71 (IH, td, J = 11.6, 3.1 Hz) , 3.05 (IH, dd, J = 11. 6, 2.4 Hz) , 3.2 7-3.33 (IH, m) , 4.55 (2H, s), 7.41 (2H, d, J = 8.6 Hz), 7.51 (2H, d, J = 8.6 Hz), 7.64 (2H, d, J = 8.6 Hz), 7.69 (2H, d, J = 8.6 Hz).

[0758] Step 77c) Methyl 3-[3-[(4'-chlorobiphenyl-4-yl)methoxy]piperidin-l-yl]benzoate

[0759] [Chemical formula 17 4]

[0760] 225 552501 Using 3- [ (4'-chlorobiphenyl-4-yl)methoxy]piperidine (220 mg, 0.729 mmol) and 3-(methoxycarbonyl) phenylboric acid (263 mg, 1.46 mmol), the same procedure was followed as in Example 2 to give 107 mg (34%) of the desired compound as a colorless oil. 5 XH NMR (400 MHz, CDC13) 5 1.48-1. 58 (IH, m) , 1. 62-1.74 (IH, m) , 1.88-1.95 (IH, m) , 2.09-2.17 (IH, m) , 2.84-2.92 (2H, m) , 3.50 (IH, td, J = 11.6, 3.6 Hz), 3.61-3.69 (IH, m), 3.72-3.7 6 (IH, m), 3.90 (3H, s) , 4.65 (IH, d, J = 12.2 Hz) , 4.69 (IH, d, J = 12.2 Hz) , 7.11 ^ (IH, brs), 7.30 (IH, t, J = 7.9 Hz), 7.40 (2H, d, J = 8.6 Hz), 7.44 10 (2H, d, J = 8.6 Hz), 7.48-7.52 (3H, m), 7.54 (2H, d, J = 8.6 Hz), 7 . 61 (IH, brs). FAB+ (m/z) : 436 (M+H).

[0761] <Example 78> 15 Methyl 3-[3-[(4'-chlorobiphenyl-4-yl)methoxymethyl]piperidin-l-yl]ben

[0762] Step 78a) 20 1-(tert-Butoxycarbonyl)-3-[(4'-chlorobiphenyl-4-yl)methoxymeth yl]piperidine

[0763] [Chemical formula 175] 226 552501 CI 5 15 Using 1-(tert-butoxycarbonyl)-piperidin-3-yl methanol (431 mg, 2.00 mmol) and 4'-chloro-4-chloromethylbiphenyl (474 mg, 2.00 mmol), the same procedure was followed as in Step 5a of Example 5 to give 711 mg (86%) of the desired compound as a colorless oil. 2H NMR (400 MHz, CDC13) 5 1.20-1.30 (IH, m) , 1.42-1.50 (10H, m), 1.62-1.67 (IH, m) , 1.78-1.90 (2H, m) , 2.60-2.73 (IH, m) , 2.78-2.85 (IH, m) , 3.33-3.4 0 (2H, m) , 3.8 9 (IH, td, J = 13.5, 3.7 Hz) , 3.97-4.0 8 (IH, m), 4.53 (2H, s), 7.39-7.42 (4Hr m), 7.49-7.54 (4H, m). FAB+ (m/z) : 416 (M+H).

[0764] Step 78b) 3-[(4'-Chlorobiphenyl-4-yl)methoxymethyl]piperidine

[0765] [Chemical formula 176] 1- (tert-butoxycarbonyl)-3-[(4'-chlorobiphenyl-4-yl)methoxymeth yl]piperidine (711 mg, 1.71 mmol), the same procedure was followed as in Step 76b of Example 76 to give 474 mg (88%) of the desired

[0766] Using 227 552501 15 compound as a colorless oil. 1H NMR (400 MHz, DMSO-dg) 5 1.01-1.11 (IH, m), 1.27-1.38 (IH, m), 1.49-1.55 (IH, m), 1.64-1.74 (2H, m), 2.20 (IH, dd, J = 11.6, 9.8 Hz), 2.38 (IH, td, J = 11.6, 3.1 Hz), 2.81 (IH, td, J= 12.2, 3.7 Hz), 2.94-2.99 (IH, m), 3.27 (2H, d, J = 6.7 Hz), 4.48 (2H, s), 7.40 (2H, d, J = 8.6 Hz), 7.51 (2H, d, J = 8,6 Hz), 7.65 (2H, d, J = 8.6 Hz), 7.70 (2H, d, J = 8.6 Hz).

[0767] Step 78c) Methyl 3-[3-[(4'-chlorobiphenyl-4-yl)methoxymethyl]piperidin-l-yl]ben zoate

[0768] [Chemical formula 177] Using 3-[(4'-chlorobiphenyl-4-yl)methoxymethyl]piperidine (237 mg, 0.750 mmol) and 3-(methoxycarbonyl)phenylboric acid (270 mg, 1.50 mmol), the same procedure was followed as in Example 2 to give 168 mg (50%) of the desired compound as a colorless oil. 2H NMR (400 MHz, CDC13) 5 1.18-1.28 (IH, m) , 1.64-1.75 (IH, m) , 1.77-1.87 (2H, m), 2.03-2.14 (IH, m), 2.65 (IH, dd, J= 12.2, 9.8 Hz) , 2.77-2.8 4 (IH, m) , 3.41-3.48 (2Hr m) , 3.59 (IH, td, J = 11.6, 3.7 Hz), 3.74 (IH, dd, J = 12.2, 3.7 Hz), 3.89 (3H, s), 4.55 (IH, 228 552501 d, J =12.2 Hz), 4.57 (IH, d, J = 12.2 Hz), 7.13 (IH, dd, J = 7.9, 2.4 Hz), 7.29 (IH, t, J = 7.9 Hz), 7.39-7.43 (4H, m) , 7.47 (IH, d, J =7.9 Hz) , 7.51 (2H, d, J = 8.6 Hz) , 7.54 (2H, d, J = 8.6 Hz) , 7.61 (IH, brs). FAB+(m/z): 450 (M+H).

[0770] <Example 7 9> Methyl 3- [3-[(4'-Chlorobiphenyl-4-yl)oxymethyl]piperidin-l-yl]benzoat e 1-(tert-Butoxycarbonyl)-3-[(4' -chlorobiphenyl-4-yl)oxymethyl]p iperidine [Chemical formula 178] 1-(tert-Butoxycarbonyl)piperidin-3-ylmethanol (323mg, 1.50 mmol) and 4'-chloro-4-hydroxybiphenyl (307 mg, 1.50 mmol) were suspended in tetrahydrofuran (15 mL) . To this suspension, triphenylphosphine (608 mg, 2.25 mmol) was added and the mixture was stirred at room temperature for 10 min. A 40% diethylazodicarboxylate/toluene solution (1.36 mL, 3.00 mmol) was then added and the mixture was stirred at room temperature for 16 hours. Subsequently, water was added and the mixture was extracted 229 552501 5 with ethyl acetate. The extract was washed with brine, followed by drying over magnesium sulfate and evaporation of the solvent. Purification of the resulting residue by silica gel column chromatography (hexane : ethyl acetate = 50:1 -> 10:1) gave 401 mg (67%) of the desired compound as a colorless powder. XH NMR (400 MHz, CDCI3) 5 1.34-1.53 (11H, m), 1.67-1.74 (IH, m) , 1.86-1.95 (IH, m) , 1.98-2.08 (IH, m) , 2.62-3.02 (2H, m) , 3.80-4.25 (4H, m) , 6. 95 (2H, d, J = 8 . 6 Hz) , 7 .37 (2H, d, J = 8. 6 Hz) , 7 . 44-7.48 (4H, m). FAB+ (m/z) : 401 (M+H).

[0771] 3- [ (4'-Chlorobiphenyl-4-yl)oxymethyl]piperidine

[0772] [Chemical formula 17 9] 1-(tert-butoxycarbonyl)-3-[(4'-chlorobiphenyl-4-yl)oxymethyl]p iperidine (401 mg, 0.998 mmol), the same procedure was followed as in Step 76b of Example 76 to give 250 mg (83%) of the desired compound as a colorless powder. 15

[0773] Using 230 552501 10 XH NMR (400 MHz, DMSO-d6) 5 1.14-1.24 (IH, m) , 1.31-1.42 (IH, m) , 1.55-1.60 (IH, m), 1.78-1.89 (2H, m), 2.32 (IH, dd, J = 11.6, 9.2 Hz), 2.44 (IH, td, J = 11.6, 3.1 Hz), 2.83 (IH, td, J = 12.2, 3.1 Hz), 3.02 (IH, dd, J = 11.6, 3.1 Hz), 3.85 (2H, d, J = 6.7 Hz), 7.01 (2H, d, J = 8.6 Hz)r 7.47 (2H, d, J = 8.6 Hz), 7.59 (2H, d, J = 8.6 Hz), 7.64 (2H, d, J = 8.6 Hz).

[0774] Methyl 3- [3- [ (4'-chlorobiphenyl-4-yl)oxymethyl]piperidin-l-yl]benzoat e

[0775] [Chemical formula 180] " jl jl O^-COOMe ) [0776] 15 Using 3-[(4'-chlorobiphenyl-4-yl)oxymethyl]piperidine (125 mg, 0.414 mmol) and 3-(methoxycarbonyl)phenylboric acid (149 mg, 0.828 mmol), the same procedure was followed as in Example 2 to give 105 mg (58%) of the desired compound as a colorless powder. 1R NMR (400 MHz, CDC13) 5 1.32-1. 42 (IH, m) , 1.71-1.81 (IH, m) , 20 1.84-1.96 (2H, m) , 2.23-2.33 (IH, m) , 2.74-2.80 (IH, m) , 2.84-2.90 (IH, m), 3.62 (IH, td, J = 12.2, 3.7 Hz), 3.8 0 (IH, dd, J = 12.2, 3.7 Hz) , 3.91 (3H, s) , 3.92-4 . 00 (2H, m) , 6.99 (2H, d, J = 8.6 Hz) , 231 552501 7.15 (IH, d, J = 7.9 Hz), 7.31 (IH, t, J = 7.9 Hz), 7.38 (2H, d, J = 8.6 Hz), 7.46-7.50 (5H, m), 7.63 (IH, brs). FAB+(m/z): 436 (M+H).

[0777] <Example 80> Methyl 3-[3-[(4-phenylthiazol-2-yl)thiomethyl]piperidin-l-yl]benzoate

[0778] Step 80a) 1-(tert-Butoxycarbonyl)-3-[(4-phenylthiazol-2-yl)thiomethyl]pi peridine

[0779] [Chemical formula 181] 2-Mercapto-4-phenylthiazole (304 mg, 1.54 mmol) andpotassium carbonate (261 mg, 1.85 mmol) were added to 1-(tert-butoxycarbonyl)-3-iodomethylpiperidine (500 mg, 1.54 mmol) in N, N-dimethylformamide (5 mL) . The mixture was stirred at room temperature for 30 min. Subsequently, water was added and the mixture was extracted with ethyl acetate . The extract was then washed with brine, followed by drying over magnesium sulfate and evaporation of the solvent. Purification of the resulting residue by silica

[0780] 232 552501 gel column chromatography (hexane : ethyl acetate = 40:1 ->10:1) gave 598 mg (99%) of the desired compound as a colorless oil. XH NMR (400 MHz, CDCl3) 5 1.31-1.38 (IH, m) , 1.41-1.49 (10H, m) , 1.65-1.72 (IHr m) , 1.92-2.01 (2H, m) , 2.67-3.00 (2H, m) , 3.19-3.28 (2H, m), 3.77-3.85 (IH, m), 3.91-4.08 (IH, m) , 7.30-7.35 (2H, m), 7.39-7.43 (2H, m), 7.87-7.89 (2H, m). FAB+(m/z): 391 (M+H).

[0781] Step 80b) 3-[(4-Phenylthiazol-2-yl)thiomethyl]piperidine

[0782] [Chemical formula 182] 1-(tert-butoxycarbonyl)-3-[(4-phenylthiazol-2-yl)thiomethyl]pi peridine (598 mg, 1.53 mmol), the same procedure was followed as in Step 7 6b of Example 7 6 to give 420 mg (92%) of the desired compound as a pale yellow oil. XH NMR (400MHz, DMSO-d6) 5 1.15-1.24 (IH, m), 1.28-1.38 (10H, m), 1.54-1.61 (IH, m) , 1.73-1.83 (IH, m), 1.84-1.91 (IH, m), 2.30 (IH, dd, J = 11.6, 9.8 Hz), 2.42 (IH, td, J = 11.6, 3.1 Hz), 2.81 (IH, td, J = 12.2, 3.7 Hz), 3.00-3.03 (IH, m), 3.17 (IH, dd, J = 13.4,

[0783] Using 233 552501 6.7 Hz), 3.21 (IH, dd, J = 13.4, 6.7 Hz), 7.35 (IH, td, J = 7.3, 1.2 Hz), 7.43-7.46 (2H, m), 7.91-7.94 (2H, m), 8.02 (IH, m) .

[0784] Step 80c) Methyl 3-[3-[(4-phenylthiazol-2-yl)thiomethyl]piperidin-l-yl]benzoate

[0785] [Chemical formula 183] Using 3-[(2-phenylthiazol-4-yl)thiomethyl]piperidine (210 mg, 0.707 mmol) and 3-(methoxycarbonyl)phenylboric acid (254 mg, 1.41 mmol) , the same procedure was followed as in Example 2 to give 159 mg (53%) of the desired compound as a colorless oil. XH NMR (400 MHz, CDCI3) 5 1.29-1.39 (IH, m) f 1.65-1.76 (IH, m), 1.80-1.88 (IH, m), 2.00-2.06 (IH, m) , 2.14-2.25 (IH, m), 2.73 (IH, dd, J = 12.2, 9.8 Hz), 2.85 (IH, td, J = 11.6, 3.7 Hz), 3.30 (IH, dd, J = 13.4, 7.3 Hz), 3.34 (IH, dd, J = 13.4, 6.1 Hz), 3.57 (IH, td, J= 12.2, 3.7 Hz), 3.75-3.79 (IH, m), 3.89 (3H, s), 7.12 (IH, dd, J = 7.3, 1.8Hz), 7.2 5-7.2 9 (IH, m) , 7.31-7.35 (2H, m) , 7.39-7.43 (2H, m), 7.47-7.49 (IH, m), 7.59-7.60 (IH, m), 7.86-7.89 (2H, m) . FAB+(m/z): 425 (M+H).

[0787] <Example 81>

[0786] 234 552501 Methyl 3-[3-[[4-(4-fluorophenoxy)phenyl]methoxy]piperidin-l-yl]benzoa te

[0788] 5 Step 81a) 1-Trifluoroacetyl-3- [ [4-(4-fluorophenoxy)phenyl]methoxy]piperi dine

[0789] [Chemical formula 184] Using 1-trifluoroacetyl-3-hydroxypiperidine (394 mg, 2.00 mmol) and 4-(4-fluorophenoxy)benzylchloride (473 mg, 2.00 mmol), the same procedure was followed as in Step 6a of Example 6 to give 4^5 434 mg (55%) of the desired compound as a colorless oil. *H NMR (400 MHz, CDC13) 5 1.47-1.61 (IH, m) , 1.64-1.79 (IH, m) , 1.84-2.06 (2H, m) , 3.22-3.31 (IH, m) , 3.43-3.50 (IH, m) , 3.52-3.62 (2H, m) , 3.82-3.95 (IH, m), 4.46-4.63 (2H, m), 6.92-7.05 (5H, m), 7.26-7.29 (3H, m) . 20 FAB+ (m/z) : 397 (M+H).

[0791] Step 81b) 3-[[4-(4-Fluorophenoxy)phenyl]methoxy]piperidine

[0792] 10

[0790] 235 552501 [Chemical formula 185] Xf ll ,0 NH

[0793] A lmol/L aqueous potassium hydroxide solution (2 mL) was added 5 to l-trifluoroacetyl-3-[4-(4-fluorophenoxy)benzyloxy]piperidine (434 mg, 1.09 mmol) in methanol (4 mL). The mixture was refluxed ^ for 2 hours and was allowed to cool. Water was then added and the mixture was extracted with ethyl acetate. The organic layer was washed with brine and the washed product was dried over magnesium 10 sulfate. The solvent was evaporated to give 314 mg (95%) of the desired compound as a colorless oil. 1H NMR (400MHz, DMSO-d6) 5 1.23-1.36 (2H, m), 1.56-1.64 (IH, m), 1.92-1.99 (IH, m) , 2.32-2.42 (2H, m) , 2.69-2.73 (IH, m) , 3.01-3.04 (IH, m) , 3.24-3.31 (IH, m) , 4.47 (2H, s) , 6.95 (2H, d, J = 8.6 Hz) , ^5 7.05 (2H, dd, J = 9.2, 4.3 Hz), 7.22 (2H, t, J = 8.6 Hz), 7.32 (2H, d, J = 8.6 Hz).

[0794] Step 81c) Methyl 3- [3-[ [4-(4-fluorophenoxy)phenyl]methoxy]piperidin-l-yl]benzoa 20 te

[0795] [Chemical formula 186] 236 552501 COOMe Using 3-[4-(4-fluorophenoxy)benzyloxy]piperidine (157 mg, 0.521 mmol) and 3-(methoxycarbonyl)phenylboric acid (187 mg, 1.04 mmol) , the same procedure was followed as in Example 2 to give 94.8 5 mg (42%) of the desired compound as a colorless oil. 1H NMR (400 MHz, CDCI3) 5 1.46-1.55 (IH, m) , 1.59-1.75 (IH, m), ^ 1.87-1.94 (IH, m) , 2.07-2.15 (IH, m) , 2.81-2.90 (2H, m) , 3.50 (IH, td, J = 12.2, 4.3 Hz), 3.57-3.66 (IH, m), 3.70-3.74 (IH, m), 3.90 (3H, s), 4.57 (IH, d, J=11.6Hz), 4.61 (IH, d, J = 11.6Hz), 6.93-7.05 10 (6H, m), 7.09-7.11 (IH, m) , 7.28-7.34 (3H, m), 7.49 (IH, d, J = 7.3 Hz), 7.60 (IH, brs). FAB+(m/z): 436 (M+H).

[0796] <Example 82> ^5 Methyl 3-[3-[[4-(4-fluorophenoxy)phenyl]methoxymethyl]piperidin-l-yl] benzoate

[0797] Step 82a) 20 1-Trifluoroacetyl-3-[[4-(4-fluorophenoxy)phenyl]methoxymethyl] piperidine

[0798] [Chemical formula 187] 237 552501 [07 99] Using 1-trifluoroacetylpiperidin-3-yl methanol (422 rag, 2.00 mmol) and 4-(4-fluorophenoxy)benzylchloride (473 mg, 2.00 mmol), 5 the same procedure was followed as in Step 5a of Example 5 to give 110 mg (13%) of the desired compound as a colorless oil. XH NMR (400 MHz, DMSO-ds) 5 1.28-1.37 (IH, m) , 1. 38-1.50 (IH, m) , 1.69-1.78 (2H, m) , 1.80-1. 89 (IH, m) , 2. 77-3.40 (4H, m) , 3.72-3.93 (IH, m), 4.11-4.25 (IH, m), 4.42 (IH, d, J = 12.2 Hz), 4.43 (IH, 0 d, J = 12.2 Hz), 6.97 (2H, d, J = 8.6 Hz), 7.05-7.08 (2H, m) , 7.23 (2H, t, J = 8.6 Hz), 7.32 (2H, d, J = 8.6 Hz). FAB+(m/z): 411 (M+H).

[0800] Step 82b) 3-[[4-(4-Fluorophenoxy)phenyl]methoxymethyl]piperidine 5 [0801] [Chemical formula 188]

[0802] Using 0 1-trifluoroacetyl-3-[4-(4-fluorophenoxy)benzyloxymethyl]piperi dine (110 mg, 0.267 mmol), the same procedure was followed as in Step 81b of Example 81 to give 71.4 mg (85%) of the desired compound 238 552501 10 *5 as a colorless oil. 1H NMR (400 MHz, DMSO-d6) 5 1.01-1.11 (IH, m) , 1.29-1.40 (IH, m) , 1.51-1.58 (IH, m), 1.65-1.7 3 (2H, m), 2.23 (IH, dd, J = 11.6, 9.8 Hz), 2.42 (IH, td, J = 11.6, 3.1 Hz), 2.85 (IH, td, J = 11.6, 3.1 Hz), 2.96-2.99 (IH, m) , 3.24-3.26 (2H, m), 4.39 (IH, d, J = 12.2 Hz), 4.41 (IH, d, J = 12.2 Hz), 6.96 (2H, d, J = 8.6 Hz), 7.06 (2H, dd, J = 9.2, 4.9 Hz), 7.23 (2H, t, J = 8.6 Hz), 7.31 (2H, d, J = 8.6 Hz).

[0803] Step 82c) Methyl 3- [3- [ [4-(4-fluorophenoxy)phenyl]methoxymethyl]piperidin-l-yl] benzoate

[0804] [Chemical formula 18 9] (35.7 mg, 0.113 mmol) and 3-(methoxycarbonyl) phenylboric acid (40.7 mg, 0.226 mmol), the same procedure was followed as in Example 2 to give 29.1 mg (57%) of the desired compound as a colorless oil. XH NMR (400 MHz, CDC13) 5 1.16-1.25 (IH, m) , 1.45-1.93 (3H, m) , 2.02-2.12 (IH, m) , 2.60-2.65 (IH, m) , 2.76-2.83 (IH, m) , 3.38-3.45 (2H, m), 3.56-3.61 (IH, m) , 3.70-3.74 (IH, m), 3.89 (3H, s), 4.47

[0805] Using 3-[4-(4-fluorophenoxy)benzyloxymethyl]piperidine 239 552501 (IH, d, J= 11.6 Hz), 4.49 (IH, d, J = 11.6 Hz), 6.93-7.05 (6H, m), 7.11 (IH, dd, J = 8.6, 1.2 Hz), 7.29-7.31 (3H, m), 7.47 (IH, d, J = 7.3 Hz), 7.60 (IH, brs). FAB+(m/z): 450 (M+H).

[0806] <Example 83> Methyl 3-[3-[[2-(4-chlorophenyl)-4-methylthiazol-5-yl]methoxycarbonyl amino]piperidin-l-yl]benzoate

[0807] [Chemical formula 190] 1-[3-(Methoxycarbonyl)phenyl]nipecotic acid (105 mg, 0.400 mmol) was suspended in benzene (8 mL) . To this suspension, diphenylphosphoryl azide (0.0948 mL, 0.440 mmol) and triethylamine (0.0615 mL, 0.440 mmol) were added and the mixture was stirred for 2 hours while being refluxed. Subsequently, 2-(4-chlorophenyl)-4-methylthiazol-5-yl methanol (105 mg, 0.440 mmol) and triethylamine (0.0615 mL, 0.44 0 mmol) were added and the mixture was further stirred for 6 hours while refluxed. Water was then added and the mixture was extracted with ethyl acetate. The extract was washed sequentially with a saturated aqueous sodium CI COOMe

[0808] 240 552501 bicarbonate solution and brine. This was followed by drying over magnesium sulfate and evaporation of the solvent. Purification of the resulting residue by silica gel column chromatography (hexane : ethyl acetate = 10 :1 -> 2 :1) gave 103 mg (52%) of the desired compound as a colorless powder. XH NMR (4 00 MHz, CDC13) 5 1.52-1. 95 (4H, m) , 2.50 (3H, s) , 3.0 6-3.13 (2H, m) , 3.16-3.24 {IH, m) , 3.35-3.38 (IH, m) , 3.90 (3H, s) , 3.93-4.00 (IH, m), 5.16 (IH, d, J = 6.7 Hz), 5.24 (2H, s), 7.11 (IH, d, J = 7.3 Hz), 7.29 (IH, t, J = 7.9 Hz), 7.38 (2H, d, J = 8.6 Hz), 7.52 (IH, d, J = 7.9 Hz), 7.58 (IH, brs), 7.8 3 (2H, d, J = 8.6 Hz). FAB+(m/z): 500 (M+H).

[0809] <Example 84> Methyl 2 - [3-[[2-(4-chlorophenyl)-4-methylthiazol-5-yl]methoxycarbonyl amino]piperidin-l-yl]benzoate

[0810] [Chemical formula 191] Using 1 — [ 2 — (methoxycarbonyl) phenyl ] nipecotic acid (79.0mg, 0.300 mmol) and 2-(4-chlorophenyl)-4-methylthiazol-5-yl methanol (71.9 mg, 0.300 mmol), the same procedure was followed as in Example

[0811] 241 552501 83 to give 43.7 mg (29%) of the desired compound as a pale yellow oil.

[0812] XH NMR (4 00 MHz, CDCl3) 5 1.54-1.65 (2H, m) , 1.83-1.97 (2H, m) , 2.50 (3H, s), 2.83 (IH, td, J = 11.0, 1.8 Hz), 2.99-3.10 (3H, m), 3.89 (3H, s), 3. 90-3. 96 (IH, m) , 5.22 (IH, d, J = 13.4 Hz), 5.27 (IH, d, J = 13.4 Hz) , 6.16 (IH, d, J = 7.3 Hz) , 7.02-7.0 6 (2H, m) , 7.37-7.43 (3H, m), 7.71 (IH, dd, J = 7.3, 1.8 Hz), 7.83 (2H, d, J = 8.6 Hz). FAB+(m/z): 500 (M+H).

[0813] <Example 8 5> Methyl 3-[3-[3-[2-(4-chlorophenyl)-4-methylthiazol-5-yl]ureido]piperi din-l-yl]benzoate

[0814] [Chemical formula 192] 1-[3-(Methoxycarbonyl}phenyl]nipecotic acid (54.0 mg, 0.205 mmol) was suspended in benzene (4 mL) . To this suspension, diphenylphosphoryl azide (0.0487 mL, 0.226 mmol) and triethylamine (0.0316 mL, 0.226 mmol) were added and the mixture was stirred for 2 hours while being refluxed. Subsequently,

[0815] 242 552501 5-amino-2-(4-chlorophenyl)-4-methylthiazole (46.0 nig, 0.205 mmol) and triethylamine (0.0316 mL, 0.226 mmol) were added and the mixture was further stirred for 6 hours while refluxed. Water was then added and the mixture was extracted with ethyl acetate. The extract was 5 washed sequentially with O.lmol/L hydrochloric acid, a saturated aqueous sodium bicarbonate solution and brine. The washed product was dried over magnesium sulfate and the solvent was evaporated. Purification of the resulting residue by silica gel column ^ chromatography (hexane : ethyl acetate = 4:1 -> 1:4) gave 43.5 mg 10 (44%) of the desired compound as a yellow powder.

[0816] 2H NMR (4 00 MHz, CDC13) 5 1.68-1.8 0 (4Hr m) , 2.33 (3H, s) , 3.0 0-3.05 (IH, m) , 3.16 (IH, dd, J = 11.6, 5.5 Hz), 3.20-3.25 (IH, m), 3.28 (IH, dd, J = 11.6, 3.1 Hz), 3.87 (3H, s), 4.12-4.18 (IH, m), 5.49 15 (IH, d, J = 7.9 Hz), 6.72 (IH, brs), 7.07 (IH, dd, J = 7.9, 1.8 Hz), 7.25-7.29 (IH, m), 7.36 (2H, d, J = 8.6 Hz), 7.49 (IH, d, J ) =7.3 Hz), 7.53-7.54 (IH, m), 7.76 (2H, d, J = 8.6 Hz). FAB+ (m/z) : 485 (M+H).

[0817] 20 <Example 8 6> Methyl 2—[3— [3—[2—(4-chlorophenyl)-4-methylthiazol-5-yl]ureido]piperi din-l-yl]benzoate

[0818] 25 [Chemical formula 193] 243 552501 H H f^| cinynY~""n''t^ » M 0 ^ C0' Me COOMe

[0819] Using 1-(2-methoxycarbonylphenyl)nipecotic acid (7 9.0 mg, 0.300 mmol) and 5-amino-2-(4-chlorophenyl) -4-methylthiazole (67.4 mg, 0.300 mmol), the same procedure was followed as in Example 85 togive29.0mg (20%) of the desired compound as a pale yellow amorphous product. 2H NMR (4 00 MHz, CDC13) 5 1. 47-1.7 4 (2H, m) , 1.97-2.03 <2H, m) , 2.4 0 (3H, s), 2.84-2.90 (IH, m) , 2.95-2.98 (IH, m), 3.05-3.08 (IH, m), 3.13-3.16 (IH, m) , 3.85 (3H, s) , 4.10-4.13 (IH, m) , 6.83 (IH, brs), 6.92 (IH, brs) , 7.07 (IH, t, J = 7.3 Hz) , 7.11 (IH, d, J = 7.9 Hz), 7.35 (2H, d, J = 8.6 Hz), 7.4 6 (IH, td, J = 7.3, 1.2 Hz) , 7.7 5 (IH, dd, J = 7.3, 1.2 Hz), 7.79 (2H, d, J = 8.6 Hz). FAB+ (m/z) : 485 (M+H).

[0820] <Example 87> Methyl 3-[3-[2-[2-(4-chlorophenyl)-4-methylthiazol-5-yl]-2-oxoethyl]p iperidin-l-yl]benzoate

[0821] Step 87a) 2-[2-(4-Chlorophenyl)-4-methylthiazol-5-yl]-2-(trimethylsilylo xy)acetonitrile 244 552501

[0822] [Chemical formula 194] IWMe ci- ^ 3-> CN

[0823] 5 2-(4-Chlorophenyl)-4-methylthiazole-5-carboaldehyde (475 mg, 2.00 mmol) was suspended in acetonitrile (4 mL) . To this ^ suspension, trimethylsilyl cyanide (0.529 mL, 4.00 mmol) and zinc iodide (12.8 mg, 0.0400 mmol) were added and the mixture was stirred at room temperature for 2 hours. Subsequently, water was added and 10 the mixture was extracted with ethyl acetate. The extract was washed with brine, followedby drying over magnesium sulfate and evaporation of the solvent. The residue was air-dried to give 669 mg (quant.) of the desired compound as a pale yellow powder. XH NMR (4 00 MHz, CDCI3) 5 0.2 5 (9H, s) , 2.4 9 (3H, s) , 5. 69 (IH, s) , |[5 7.41 (2H, d, J = 8.6 Hz), 7.85 (2H, d, J = 8.6 Hz). FAB+ (m/z) : 337 (M+H).

[0824] Step 87b) 1-(tert-Butoxycarbonyl)-3-[2-[2-(4-chlorophenyl)-4-methylthiaz 20 ol-5-yl]-2-oxoethyl]piperidine

[0825] [Chemical formula 195] 245 552501 N Me In an argon atmosphere, a solution of 1.8mol/L lithium diisopropylamide in heptane/tetrahydrofuran/ethylbenzene (1.22 mL, 2.19 mmol), chilled to -78°C, was added to 5 2-[2-(4-chlorophenyl)-4-methylthiazol-5-yl]-2-(trimethylsilylo xy) acetonitrile (669 mg, 1.99 mmol) in tetrahydrofuran (2 mL) . The mixture was stirred for 20 min, followed by addition of 1-(tert-butoxycarbonyl)-3-iodomethylpiperidine (647 mg, 1.99 mmol) in tetrahydrofuran (2 mL) . The mixture was further stirred 10 for 1 hour as it warmed from -78°C to room temperature. 0.5mol/L ice-chilled hydrochloric acid was then added and the mixture was further stirred for 10 min. Subsequently, the mixture was extracted with ethyl acetate and washed sequentially with a saturated aqueous sodium bicarbonate solution and brine. The washed product was dried Is over magnesium sulfate and the solvent was evaporated. Purification of the resulting residue by silica gel column chromatography (hexane : ethyl acetate = 20:1 -> 5:1) gave 429 mg (50%) of the desired compound as a yellow oil. XH NMR (400 MHz, CDC13) 5 1.22-1.52 (12H, m), 1.61-1.68 (IH, m) , 20 1.86-1.93 (IH, m), 2.18-2.28 (IH, m), 2.67 (IH, dd, J= 7.3, 15.9 Hz), 2.78 (3H, s), 2.82 (IH, dd, J = 15.9, 6.1 Hz), 2.87-3.10 (IH, m) , 3.67-3.97 (2H, m), 7.44 (2H, d, J = 8.6 Hz), 7.92 (2H, d, J = 8.6 Hz). 246 552501 FAB+ (m/z) : 434 (M+H).

[0826] Step 87c) 3-[2-[2-(4-Chlorophenyl)-4-methylthiazol-5-yl]-2-oxoethyl]pipe ridine

[0827] [Chemical formula 196] Using 1- (tert-butoxycarbonyl)-3-[2-[2-(4-chlorophenyl)-4-methylthiaz ol-5-yl]-2-oxoethyl]piperidine (429 mg, 0.986 mmol), the same procedure was followed as in Step 7 6b of Example 76 to give 281 mg (85%) of the desired compound as a yellow oil. XH NMR (400 MHz, DMSO-d6) 5 1.08-1.18 (IH, m), 1.31-1.42 (IH, m) , 1.51-1.58 (IH, m), 1.72-1.78 (IH, m), 1.94-2.04 (IH, m), 2.25 (IH, dd, J = 11.6, 9.8 Hz), 2.43 (IH, td, J = 11.6, 2.4 Hz), 2.71 (3H, s), 2.75-2.85 (3H, m), 2.90 (IH, dd, J =11.6, 2.4 Hz), 7.60 (2H, d, J = 8.6 Hz), 8.03 (2H, d, J = 8.6 Hz).

[0829] Step 87d) Methyl 3-[3-[2-[2-(4-chlorophenyl)-4~methylthiazol-5-yl]-2-oxoethyl]p iperidin-l-yl]benzoate Me

[0828] 247 552501

[0830] [Chemical formula 197] Cl s-^Y^^N'>i%5^C00Me

[0831] 5 Using 3-[2- [2-(4-chlorophenyl)-4-methylthiazol-5-yl]-2-oxoethyl]pipe ^ ridine (140 mg, 0.418 mmol) and 3-(methoxycarbonyl) phenylboric acid (150 mg, 0.836 mmol) , the same procedure was followed as in Example 2 to give 88.7 mg (45%) of the desired compound as a yellow oil. 10 1R NMR (4 00 MHz, CDC13) 5 1.24-1.95 (4H, m) , 2.40-2.50 (IH, m) , 2.70 (IH, dd, J = 11.6, 9.8 Hz), 2.77-2.82 (4H, m), 2.87-2.93 (2H, m), 3.57 (IH, td, J = 12.2, 4.3 Hz), 3.65 (IH, dd, J = 12.2, 3.7 Hz) , 3.90 (3H, s), 7.13 (IH, dd, J = 7. 9, 1. 8 Hz), 7.29 (IH, t, J = 7 . 9 Hz), 7.44 (2H, d, J= 8.6 Hz), 7.47 (IH, d, J =7.9 Hz), 7.59 (IH, ^5 brs), 8.03 (2H, d, J = 8.6 Hz). FAB+(m/z): 468 (M+H).

[0832] <Example 8 8> Methyl 20 3-[3-[2-[2-(4-chlorophenyl)-4-methylthiazol-5-yl]ethenyl]piper idin-l-yl]benzoate

[0833] 248 552501 Step 88a) [2-(4-Chlorophenyl)-4-methylthiazol-5-yl]methyltriphenylphosph onium iodide

[0834] 5 [Chemical formula 198] Triphenylphosphine (1.15 g, 4.26 mmol) and sodium iodide (580 mg, 3.87 mmol) were added to 10 5-chloromethyl-2-(4-chlorophenyl)-4-methylthiazole (1.00 g, 3.87 mmol) in tetrahydrofuran (20 mL) . The react ion mixture was stirred for 5 hours while being stirred. Subsequently, the crystallized powdery product was collected by filtration and washed with hexane to give 2.43 g (quant.) of the desired compound as a colorless powder. NMR (400 MHz, DMSO-d6) 5 1.80 (3H, d, J = 3.1 Hz), 5.45 (2H, d, J = 14.1) , 7.52 (2H, d, J = 8.6 Hz) , 7.74-7.82 (14H, m) , 7.93-7.98 (3H, m).

[0836] Step 88b) 20 l-Benzyloxycarbonyl-3-[2-[2-(4-chlorophenyl)-4-methylthiazol-5 -yl]ethenyl]piperidine

[0837] [Chemical formula 199] Me

[0835] 249 552501 N Me ci-~0^0-^nAO In an argon atmosphere, a solution of 1. 59 mol/L n-butyl lithium in hexane (2.03 mL, 3.23 mmol), chilled to -78°C, was added to a suspension of [2-(4-chlorophenyl)-4-methylthiazol-5-yl]methyltriphenylphosph onium iodide (1.80 g, 2.94 mmol) in tetrahydrofuran (20 mL) . The reaction mixture was stirred for 1 hour as it warmed from -78°C to room temperature. Subsequently, the mixture was chilled again to -78°C and l-benzyloxycarbonyl-3-formylpiperidine (727 mg, 2.94 mmol) in tetrahydrofuran (5 mL) was added. The mixture was stirred at -7 8°C for 1 hour and at room temperature for the subsequent 6 hours. Subsequently, water was added and the mixture was extracted with ethyl acetate and washed with brine. The washed product was dried over magnesium sulfate and the solvent was evaporated. Purification of the resulting residue by silica gel column chromatography (hexane : ethyl acetate = 20:1 -> 5:1) gave 1.16 g (87%) of the desired compound as a yellow oil. FAB+ (m/z) : 453 (M+H).

[0838] Step 88c) 3-[2-[2-(4-Chlorophenyl)-4-methylthiazol-5-yl]ethenyl]piperidi ne [Chemical formula 200] 250. 552501 Me CI NH

[0839] l-Benzyloxycarbonyl-3- [2- [2- (4-chlorophenyl) -4-rnethylthia zol-5-yl]ethenyl]piperidine (1.16 g, 2.56 mmol) in 6mol/L hydrochloric acid (25 mL) was stirred for 1 hour while being refluxed. Subsequently, the reaction mixture was washed with ethyl acetate. A lOmol/L aqueous sodium hydroxide solution was then added to make the mixture basic and the mixture was extracted with ethyl acetate. The extract was washed with brine, followed by drying over magnesium sulfate and evaporation of the solvent. The residue was air-dried to give 749 mg (92%) of the desired compound as a yellow powder. FAB+(m/z): 319 (M+H).

[0840] Step 88d) Methyl (E)-3-[3-[2-[2-(4-chlorophenyl)-4-methylthiazol-5-yl]ethenyl]p iperidin-l-yl]benzoate

[0841] [Chemical formula 201] CI COOMe

[0842] Using 251 552501 3-[2-[2-(4-chlorophenyl)-4-methylthiazol-5-yl]ethenyl]piperidi ne (153 mg, 0.480 mmol) and 3-(methoxycarbonyl)phenylboric acid (173 mg, 0.960 mmol), the same procedure was followed as in Example 2 to give 77.7 mg (36%) of the desired compound as a yellow powder. 5 lH NMR (400 MHz, CDC13) 5 1.35-1.45 (IH, m), 1.70-1.81 (IH, m) , 1.83-1.90 (IH, m) , 1.95-2.01 (IH, m) , 2.46 (3H, s) , 2.52-2.62 (IH, m), 2.67-2.72 (IH, m), 2.80 (IH, td, J = 12.2, 3.1 Hz), 3.65-3.68 (IH, m), 3.70-3.74 (IH, m), 3.91 (3H, s), 5.94 (IH, dd, J =15.9, ^ 7.3 Hz), 6.57 (IH, dd, J = 15.9, 1.2 Hz), 7.14 (IH, dd, J = 7.9, 10 2.4 Hz), 7.31 (IH, t, J = 7.9 Hz), 7.39 (2H, d, J = 8.6 Hz), 7.49 (IH, d, J = 7.3 Hz), 7.62-7.63 (IH, m), 7.8 3 (2H, d, J = 8.6 Hz). FAB+(m/z): 453 (M+H).

[0843] <Example 8 9> 15 Methyl 3- [2-[[2-(4-chlorophenyl)-4-methylthiazol-5-yl]carbonylaminome | thyl]morpholine-4-yl]benzoate

[0844] Step 89a) 20 N-[[4-(tert-Butoxycarbonyl)morpholin-2-yl]methyl]-2-(4-chlorop henyl)-4-methylthiazole-5-carboxamide

[0845] [Chemical formula 202] 252 552501

[0846] Using 2-(4-chlorophenyl)-4-methylthiazole-5-carboxylic acid (307mg, 1.21mmol) and 4-(tert-butoxycarbonyl)morpholine-2-yl methylamine (262 mg, 1.21 mmol), the same procedure was followed as in Step la of Example 1 to give 483 mg (88%) of the desired compound as a colorless powder. 1HMR (400 MHz, CDCl3) 5 1.47 (9H, s), 2.66-2.7 6 (4H, m) , 2.93 (IH, m) , 3.25-3.36 (IH, m) , 3.53-3.62 (2H, m) , 3.74-3.79 (IH, m) , 3.83-4.04 (3H, m), 6.20 (IH, m), 7.42 (2H, d, J = 8.6 Hz), 7.87 (2H, d, J = 8.6 Hz).

[0847] Step 89b) N-(Morpholin-2-yl methyl)-2-(4-chlorophenyl)-4-methylthiazole-5-carboxamide

[0848] [Chemical formula 203] N-[[4-(tert-butoxycarbonyl)morpholin-2-yl]methyl]-2-(4-chlorop henyl)-4-methylthiazole-5-carboxamide (483mg, 1.07mmol), the same procedure was followed as in Step 76b of Example 76 to give 366 O Using 253 552501 10 •s mg (97%) of the desired compound as a colorless powder. NMR (400 MHz, DMSO-d6) 5 2.36 (IH, dd, J = 12.2, 9.8 Hz) , 2.58-2. 67 (5H, m), 2.80 (IH, dd, J = 12.2, 1.8 Hz), 3.23 (2H, td, J = 5.5, 1.8Hz), 3.42 (IH, td, J = 11.0, 3.7 Hz) , 3.4 6-3.52 (IH, m) , 3.72-3.7 4 (IH, m), 7.58 (2H, d, J = 8.6 Hz), 7.95 (2H, d, J = 8.6 Hz), 8.33 (IH, t, J = 5.5 Hz).

[0849] Step 8 9c) Methyl 3-[2- [ [2- (4-chlorophenyl)-4-methylthiazol-5-yl]carbonylaminome thyl]morpholin-4-yl]benzoate

[0850] [Chemical formula 204] Using N-(morpholin-2-yl methyl)-2-(4-chlorophenyl)-4-methylthiazole-5-carboxamide (120 mg, 0.341 mmol) and 3-(methoxycarbonyl)phenylboric acid (123 mg, 0.682 mmol), the same procedure was followed as in Example 2 to give 102 mg (62%) of the desired compound as a colorless powder. 1H NMR (400 MHz, CDC13) 5 2.64-2.69 (IH, m) , 2.75 (3H, s) , 2.90 (IH, td, J = 11.6, 3.1Hz), 3.42-3.51 (2H, m) , 3.58-3.62 (IH, m) , 3.8 0-3.92 (6H, m) , 4.07-4.11 (IH, m), 6.26 (IH, t, J = 5.5 Hz), 7.11 (IH, 254 552501 dd, J = 7.9, 2.4 Hz), 7.35 (IH, d, J = 7.9 Hz), 7.42 (2H, d, J = 8.6 Hz), 7.55-7.59 (2H, m) , 7.88 (2H, d, J = 8.6 Hz).

[0852] <Example 90> Methyl 3-[2-[N-[[2-(4-chlorophenyl)-4-methylthiazol-5-yl]methyl]carba moyl]morpholin-4-yl]benzoate

[0853] Step 90a) N-[[2-(4-Chlorophenyl)-4-methylthiazol-5-yl]methyl]-4-(tert-bu toxycarbonyl)morpholine-2-carboxamide

[0854] [Chemical formula 205] Using 2-(4-chlorophenyl)-4-methylthiazol-5-yl methylamine (39.4 mg, 0.165 mmol) and 4-(tert-butoxycarbonyl)morpholine-2-carboxylic acid (38.3 mg, 0 .165 mmol) , the same procedure was followed as in Step 3a of Example 3 to give 4 9 . 5 mg (67%) of the desired compound as a colorless amorphous product. XH NMR (400 MHz, CDC13) 5 1.47 (9H, s), 2.46 (3H, s), 2.76 (IH, t, J = 12.2 Hz), 2.88 (IH, t, J = 12.2 Hz), 3.57 (IH, td, J = 11.6,

[0855] 255 552501 3.1 Hz), 3.92-3.96 (3H, m), 4.32-4.43 (IH, m), 4.60 (2H, d, J = 6.1 Hz), 6.90 (IH, m), 7.39 (2H, d, J = 8.6 Hz), 7.82 (2H, d, J = 8.6 Hz) .

[0856] 5 Step 90b) N-[[2- ( 4-Chlorophenyl)-4-methylthiazol-5-yl]methyl]morpholine-2-carboxamide

[0857] [Chemical formula 206] Using N-[[2-(4-chlorophenyl)-4-methylthiazol-5-yl]methyl]-4-(tert-bu toxycarbonyl)morpholine-2-carboxamide (49.5 mg, 0.110 mmol), the ^^5 same procedure was followed as in Step 7 6b of Example 7 6 to give 29.5 mg (76%) of the desired compound as a colorless powder. NMR (400 MHz, DMS0-d6) 5 2.39 (3H, s) , 2.46 (IH, dd, J = 12.2 10.4 Hz), 2.58-2.70 (3H, m), 3.00 (IH, dd, J = 12.2 3.1 Hz), 3.49 (IH, td, J = 11.0 3.1 Hz), 3.77-3.83 (2H, m), 4.39 (2H, d, J = 6.1 20 Hz), 7.52 (2H, d, J = 8.6 Hz), 7.87 (2H, d, J = 8.6 Hz), 8.43 (IH, t, J = 6.1 Hz) . o 10

[0858]

[0859] 256 552501 Step 90c) Methyl 3-[2-[N-[[2-(4-chlorophenyl)-4-methylthiazol-5-yl]methyl]carba moyl]morpholin-4-yl]benzoate [Chemical formula 207] N-[[2-(4-chlorophenyl)-4-methylthiazol-5-yl]methyl]morpholine-2-carboxamide (29.5 mg, 0.0838 mmol) and 10 3-(methoxycarbonyl) phenylboric acid (30.2 mg, 0.168 mmol), the same procedure was followed as in Example 2 to give 28.9 mg (71%) of the desired compound as a colorless oil. NMR (4 00 MHz, CDC13) 5 2.4 7 (3H, s) , 2.71 (IH, dd, J = 12.2, 11.0 Hz), 2.89 (IH, td, J = 12.2 3.1 Hz), 3.47-3.50 (IH, m), 3.83 (IH, dd, J = 8.6, 2.4 Hz), 3.91 (3H, s) , 4.04-4.11 (2H, m) , 4.22 (IH, dd, J = 11.4 Hz, J = 3.1 Hz), 4.63 (2H, d, J = 6.1 Hz), 6.96 (IH, t, J = 5.5 Hz), 7.15 (IH, dd, J = 7.9, 2.4 Hz), 7.35 (IH, t, J = 7.9Hz), 7.38 (2H, d, J=8.6Hz), 7.58 (IH, d, J = 7.3Hz), 7.60-7.61 (IH, m), 7.82 (2H, d, J = 8.6 Hz). 20 [0861] <Example 91> 5

[0860] Using 257 552501 Methyl 2-[2-[N-[[2-(4-chlorophenyl)-4-methylthiazol-5-yl]methyl]carba raoyl j morpholin-4-yl] benzoate

[0862] 5 [Chemical formula 208] N-[[2-(4-chlorophenyl)-4-methylthiazol-5-yl]methyl]morpholine-10 2-carboxamide (54.4 mg, 0.15.5 mmol) and methyl 2-iodobenzoate (40.6 mg, 0.155 mmol), the same procedure was followed as in Example 58 to give 64.5 mg (86%) of the desired compound as a colorless powder. 1H NMR (4 00 MHz, CDC13) 5 2.47 (3H, s) , 2.76 (IH, dd, J = 11. 6, 10.4 Hz), 2.89 (IH, td, J = 11.0 Hz, J = 3.1 Hz), 3.15-3.20 (IH, m), ^5 3. 69 (IH, dt, J = 12.2 Hz, J = 2.4 Hz) , 3.87-3.93 (4H, m) , 3.99-4.03 (IH, m), 4.28 (IH, dd, J = 10.4, 2.4 Hz), 4.55-4.66 (2H, m), 6.97 (IH, t, J = 6.1 Hz), 7.03-7.08 (2H, m), 7.39 (2H, d, J = 8.6 Hz), 7.43 (IH, td, J = 7.9, 1.8 Hz), 7.79 (IH, dd, J = 7.9, 1.8 Hz), 7.83 (2H, d, J = 8.6 Hz) . 20 [0864] <Example 92>

[0863] Using 258 552501 Methyl 3-[2-[[2-(4-chlorophenyl)-4-methylthiazol-5-yl]methoxymethyl]m orpholin-4-yl]benzoate

[0865] Step 92a) 4-(tert-Butoxycarbonyl)-2-[[2-(4-chlorophenyl)-4-methylthiazol -5-yl]methoxymethyl]morpholine

[0866] [Chemical formula 209] 10

[0867] Using 4- (tert-butoxycarbonyl)morpholin-2-ylmethanol (217 mg, 1.00 mmol) and 5-chloromethyl-2-(4-chlorophenyl)-4-methylthiazole (258 mg, 1.00 mmol), the same procedure was followed as in Step ^5 5a of Example 5 to give 303 mg (69%) of the desired compound as a yellow oil. XH NMR (400 MHz, CDC13) 5 1.46 (9H, s), 2.45 (3H, s), 2.74 (IH, t, J = 11.6 Hz), 2.88-3.00 (IH, m), 3.4 9-3.63 (4H, m), 3.7 8-4.00 (3H, m), 4.71 (2H, s), 7.39 (2H, d, J = 8.6 Hz), 7.83 (2H, d, J = 8.6 20 Hz) .

[0868] 259 552501 Step 92b) 2- [ [2-(4-Chlorophenyl)-4-methylthiazol-5-yl]methoxymethyl]morp holine

[0869] [Chemical formula 210] Using 4-tert-butoxycarbonyl-2-[[2-(4-chlorophenyl)-4-methylthiazol-5 -yl]methoxymethylJmorpholine (303 mg, 0.690 mmol), the same procedure was followed as in Step 76b of Example 76 to give 220 mg (94%) of the desired compound as a yellow oil. NMR (400 MHz, DMS0-d6) 5 2.33-2.42 (4H, m) , 2.57-2.68 (2H, m) , 2.76 (IH, dd, J = 12.2, J = 2.4 Hz), 3.36-3.45 (4H, m) , 3.48-3.53 (IH, m), 3.68-3.72 (IH, m),4.67 (2H, s), 7.54 (2H, d, J = 8.6 Hz), 7.91 (2H, d, J = 8.6 Hz).

[0871] Step 92c) Methyl 3-[2-[[2-(4-chlorophenyl)-4-methylthiazol-5-yl]methoxymethyl]m orpholin-4-yl]benzoate

[0872] [Chemical formula 211] CI O'^V^NH

[0870] 260 552501 r°x? COOMe

[0873] Using 2-[2-(4-chlorophenyl)-4-methylthiazol-5-yl]methoxymethyl]morph oline (49.0mg, 0.145mmol) and 3-(methoxycarbonyl) phenylboric acid (52.2 mg, 0.290 mmol) , the same procedure was followed as in Example 2 to give 50.5 mg (74%) of the desired compound as a pale yellow oil. 1H NMR (400 MHz, CDCI3) 5 2.47 (3H, s) , 2.68 (IH, dd, J = 11.6, 10.4 Hz), 2.90 (IH, dd, J - 11.6, 3.1 Hz), 3.47 (IH, d, J = 12.2 Hz), 3.5 6-3. 66 (3H, m) , 3.82 (IH, td, J = 11.6 Hz, J = 2.4 Hz) , 3.8 9-3.90 (4H, m), 4.06-4.10 (IH, m), 4.75 (2H, s), 7.10 (IH, dd, J =7.9, 2.4 Hz), 7.33 (IH, t, J = 7.9 Hz), 7.39 (2H, d, J= 8.6 Hz), 7.54 (IH, dt, J = 7.3, 1.2 Hz) , 7.58-7.5 9 (IH, m) , 7.8 5 (2H, d, J = 8.6 Hz) .

[0874] <Example 93> Methyl 2-[2-[[2-(4-chlorophenyl)-4-methylthiazol-5-yl]methoxymethyl]m orpholin-4-yl]benzoate

[0875] [Chemical formula 212] 261 552501 o^rv , O^J COOMe

[0876] Using 2-[2-(4-chlorophenyl)-4-methylthiazol-5-yl]methoxymethyl]morph 5 oline (110 mg, 0.325 mmol) and a solution of methyl 2-iodobenzoate (85.2 mg, 0.325 mmol) in toluene (1 mL), the same procedure was ^ followed as in Example 58 to give 81. 4 mg (53%) of the desired compound as a pale yellow oil. lH NMR (400 MHz, CDC13) 5 2.45 (3H, s) , 2.73 (IH, dd, J = 11.6, 10.4 10 Hz) , 2.94 (IH, td, J = 11. 5, 3.1 Hz) , 3.11-3.15 (IH, m) , 3.23 (IH, dt, J = 11.6, 1.8 Hz), 3.5 3-3.63 (2H, m) , 3. 8 6-3. 91 (4H, m) , 3.93-3.97 (IH, m), 4.00 (IH, dt, J= 12.2, 2.4 Hz), 4.72 (2H, s), 7.01-7.05 (2H, m) , 7.3 8-7.4 4 (3H, m) , 7.7 5 (IH, dd, J = 7.9 Hz, J = 1.2 Hz) , 7.83 (2H, d, J = 8.6 Hz).

[0877] <Example 94> Methyl 5-[3-[[2-(4-chlorophenyl)-4-methylthiazoI-5-yl]carbonylamino]p iperidin-l-yl]-2-methoxybenzoate 20 [0878] Step 94a) 5-[3-[[2-(4-Chlorophenyl)-4-methylthiazol-5-yl]carbonylamino]p iperidin-l-yl]-2-methoxybenzaldehyde 2 62 552501

[0879] [Chemical formula 213] a^rytY h j3c0Me

[0880] Using N-(piperidin-3-yl)-2- (4-chlorophenyl)-4-methylthiazole-5-carbo xamide (254 rag, 0.756 mmol) and 3-formyl-4-methoxyphenylboric acid (273 mg, 1.52 mmol) , the same procedure was followed as in Example 2 to give 49.8 mg (14%) of the desired compound as a yellow powder. XH NMR (400 MHz, CDC13) 5 1. 7 3-1.94 (4H, m) , 2.7 4 (3H, s) , 2.92-2. 98 (IH, m), 3.13-3.30 (3H, m) , 3.90 (3H, s), 4.37-4.44 (IH, m), 6.39 (IH, d7 J = 7.9 Hz), 6.95 (IH, d, J = 9.1 Hz), 7.20-7.25 (IH, m), 7.39-7.44 (3H, m), 7.87 (2H, d, J = 8.6 Hz), 10.45 (IH, s). FAB+ (m/z): 470 (M+H).

[0881] Step 94b) Methyl 5-[3-[[2-(4-chlorophenyl)-4-methylthiazol-5-yl]carbonylamino]p iperidin-l-yl]-2-methoxybenzoate

[0882] [Chemical formula 214] 263 552501

[0883] Using 5- [3- [ [2-(4-chlorophenyl)-4-methylthiazol-5-yl]carbonylamino]p iperidin-l-yl]-2-methoxybenzaldehyde (45.2 mg, 0.0962 mmol), the 5 same procedure was followed as in Step 5d of Example 5 to give 31.8 mg (66%) of the desired compound as a cream-colored powder. lH NMR (4 00 MHz, CDC13) 5 1.72-1. 93 (4H, m) , 2.7 4 (3H, s) , 2.8 8-2.98 (IH, m), 3.18 (2H, d, J = 3.4 Hz), 3.24-3.30 (IH, m), 3.87 (3H, ^ s) , 3.90 (3H, s) , 4. 37-4.44 (IH, m) , 6.4 5 (IH, d, J = 8.6 Hz) , 6.93 10 (IH, d, J = 8.6 Hz), 7.12 (IH, dd, J= 8.6, 5.4 Hz) , 7.4 0-7.45 (3H, m) , 7.88 (2H, d, J = 8.6 Hz). FAB+(m/z) : 500 (M+H).

[0884] <Example 95> 15 Methyl 5-[3-[[2-(4-chlorophenyl)-4-methylthiazol-5-yl]carbonylamino]p iperidin-l-yl]-2-fluorobenzoate

[0885] Step 95a) 20 5—[3—[[2—(4-Chlorophenyl)-4-methylthiazol-5-yl]carbonylamino]p iperidin-l-yl]-2-fluorobenzaldehyde

[0886] [Chemical formula 215] 264 552501 c\~f\^X H J0CF

[0887] Using N-(piperidin-3-yl)-2-(4-chlorophenyl)-4-methylthiazole-5-carbo xamide (238 mg, 0.7 09 mmol) and 3-formyl-4-fluorophenylboric acid (238 mg, 1.42 mmol), the same procedure was followed as in Example 2 to give 55.0 mg (17%) of the desired compound as a pale yellow powder. XH NMR (400 MHz, CDC13) 5 1.76-1.93 (4H, m) , 2.73 (3H, s) , 3.02-3.09 (IH, m), 3.16 (IH, dd, J = 11.6, 5.5 Hz), 3.22-3.30 (IH, m), 3.34 (IH, dd, J = 11.6, 3.0 Hz), 4.36-4.43 (IH, m) , 6.24 (IH, d, J = 7.9 Hz), 7.10 (IH, t, J = 9.1 Hz), 7.20-7.25 (IH, m), 7.38 (IH, dd, J = 5.5, 3.0 Hz), 7.42 (2H, d, J = 8.6 Hz), 7.87 (2H, d, J = 8.6 Hz), 10.34 (IH, s) . FAB+(m/z): 458(M+H).

[0888] Step 95b) Methyl 5-[3-[[2-(4-chlorophenyl)-4-methylthiazol-5-yl]carbonylamino]p iperidin-l-yl]-2-fluorobenzoate

[0889] [Chemical formula 216] 265 552501 chtwy h ^ ntF \==/

[0890] Using 5-[3-[ [2-(4-chlorophenyl)-4-methylthiazol-5-yl]carbonylamino]p 5 iperidin-l-yl]-2-fluorobenzaldehyde (52.7mg, 0.115mmol), the same procedure was followed as in Step 5d of Example 5 to give 30.7 mg ^ (55%) of the desired compound as a colorless powder. lti NMR (400 MHz, CDC13) 5 1.76-1.94 (4H, m) , 2.74 (3H, s) , 2.97-3.05 (IH, m) , 3.16-3.22 (IH, m) , 3.2 5-3.33 (2H, m) , 3.93 (3H, s) , 4.37-4.44 10 (IH, m), 6.31 (IH, d, J = 7.9 Hz), 7.04-7.08 (IH, m) , 7.09-7.15 (IH, m) , 7.42 (2H, d, J = 8.6 Hz), 7.4 8 (IH, dd, J = 5.5, 3.1 Hz), 7.87 (2H, d, J = 8.6 Hz). EI+(m/z): 487(M+).

[0891] ^ <Example 96> Methyl 3-benzyloxy-5-[3-[[2-(4-chlorophenyl)-4-methylthiazol-5-yl]car bonylamino]piperidin-l-yl]benzoate

[0892] 20 Step 96a) Methyl 3-benzyloxy-5-[3-(tert-butoxycarbonylamino)piperidin-l-yl]benz oate

[0893] 266 552501 [Chemical formula 217] OBn ^ o ^ C02Me

[0894] Using 3-(tert-butoxycarbonylamino)piperidine (301 mg, 1.50 mmol) and methyl 3-benzyloxy-5-(trifluoromethanesulfonyloxy)benzoate (595 mg, 1.52 mmol), the same procedure was followed as in Example 58 to give 39.7 mg (6.0%) of the desired compound as a brown oil. XH NMR (400 MHz, CDCI3) 5 1.38-1.54 (10H, m), 1.63-1.73 (IH, m) , 1.75-1. 87 (2H, m) , 2.97-3.05 (IH, m) , 3.10-3.18 (2H, m) , 3.32-3.38 (IH, nt) , 3. 80-3.93 (4H, m) , 4.81-4.89 (IH, m) , 5.08 (2H, s), 6.74 (IH, s), 7.13-7.17 (IH, m), 7.23-7.27 (IH, m), 7.30-7.47 (5H, m). FAB+ (m/z): 441 (M+H).

[0895] Step 96b) Methyl 3-benzyloxy-5-[3-[[2-(4-chlorophenyl)-4-methylthiazol~5-yl]car bony1amino]piperidin-l-yl]benzoate

[0896] [Chemical formula 218] OBn

[0897] 267 552501 Methyl 3-benzyloxy-5-(3-tert-butoxycarbonylaminopiperidin-l-yl)benzoa te (23.0 mg, 0 . 0522 mmol) was dissolved in anhydrous dichloromethane (0.5 mL) . While this solution is chilled in an ice bath and stirred, 5 trifluoroacetic acid (80 |jL, 6.82 mmol) was added and the reaction mixture was stirred for 2 hours. Subsequently, the mixture was concentrated and a 10% hydrochloric acid/methanol solution (1.5 mL) was added to the residue. The mixture was then stirred at room ^ temperature for 1 hour and was concentrated. The same process was 10 repeated 3 times and the resulting solid were washed with ethyl acetate. This gave 20.9 mg of a blown powder. This product (19.8 mg) was dissolved in N,N-dimethylformamide (1 mL) . While the solution was chilled to 0°C and stirred, 2-(4-chlorophenyl)-4-methylthiazole-5-carboxylic acid (15.5 mg, 15 0.0611 mmol), 1-hydroxybenzotriazole monohydrate (8.8 mg, 0.0575 mmol), N-methylmorpholine (17 |jL, 0.155 mmol) and ^ 3-(3-dimethylaminopropyl)-1-ethylcarbodiimide hydrochloride (11.7 mg, 0.0610 mmol) were added and the mixture was stirred for 20 min. The reaction mixture was further stirred at room temperature 20 for the subsequent 6 hours. Subsequently, the mixture was diluted with ethyl acetate and the organic layer was washed sequentially with 5% aqueous citric acid, a saturated aqueous sodium bicarbonate solution, water and brine. The washed product was then dried over anhydrous sodium sulfate and was concentrated. Purification of the 25 resulting residue by silica gel column chromatography (hexane : 268 552501 ethyl acetate = 4:1) gave 22.8 mg (75%) of the desired compound as a colorless powder. 1H NMR (4 00 MHz, CDC13) 5 1.74-1. 92 (4H, m) , 2.71 (3H, s) , 3.01-3.08 (IH, m), 3.32 (2H, d, J = 3.6 Hz), 3.35-3.43 (IH, m), 3.90 (3H, s) , 4.36-4.42 (IH, m) , 5.08 (2H, s) , 6.27 (IH, d, J =7. 9 Hz) , 6.7 5-6.79 (IH, m) , 7.19 (IH, s) , 7.28-7. 43 (8H, m) , 7.86 (2H, d, J = 8.6 Hz) . FAB+ (m/z) : 576 (M+H)

[0898] <Example 97> Methyl 5~[3-[[2-(4-chlorophenyl)-4-methylthiazole-5-carbonyl]amino]pi peridin-l-yl]-2-nitrobenzoate

[0899] [Chemical formula 219] Potassium carbonate (5.08 g, 36.0mmol) was added to a solution N- (piperidin-3-yl)-2-(4-chlorophenyl)-4-methylthiazole-5-carbo xamide (10.1 g, 30.0mmol) andmethyl 5-fluoro-2-nitrobenzoate (5.97 g, 30.0mmol) in N, N-dimethylformamide (60mL) . The reactionmixture was stirred at room temperature for 2 hours. Subsequently, the solvent was evaporated and water was added to the residue. The COOMe

[0900] of 269 552501 precipitates were collected by filtration and were washed sequentially with O.lmol/L hydrochloric acid, a saturated aqueous sodium bicarbonate solution, water and ethanol to give 14.6 g (95%) of the desired compound as a yellow powder. 1R NMR (400 MHz, DMS0-d6) 5 1.51-1.61 (IH, m) , 1.67-1.76 (IH, m) , 1.80-1.87 (IH, m) , 1.95-1.99 (IH, m) , 2.57 (3H, s) , 3.16-3.24 (2H, m), 3.82 (3H, s), 3.85-3.92 (2H, m), 3.98-4.02 (IH, m), 7.07-7.11 (2H, m), 7.58 (2H, d, J = 8.6 Hz), 7.95 (2H, d, J = 8.6 Hz), 8.01 (IH, d, J = 9.1 Hz), 8.33 (IH, d, J = 6.7 Hz).

[0901] <Example 98> Methyl 2~amino-5-[3-[[2-(4-chlorophenyl)-4-methylthiazole-5-carbonyl] amino]piperidin-l-yl]benzoate

[0902] [Chemical formula 220] 5-[3- [ [2-(4-chlorophenyl)-4-methylthiazole-5-carbonyl]amino]pi peridin-l-yl]-2-nitrobenzoate (14.6 g, 28.4 mmol) was suspended in acetic acid (140 mL) . To this suspension, reduced iron (9.49 g, 170 mmol) was added and the mixture was stirred at 80°C for 3

[0903] Methyl 270 552501 hours . The mixture was then allowed to cool and was filtered through Celite. The solvent was removed and a saturated aqueous sodium bicarbonate solution was added to the residue to make it basic. The crystallized powdery product was collected by filtration and 5 washed with water. The resulting powder was dissolved in ethyl acetate and was filtered through Celite . The solvent was then removed to give 12.7 g (26.2 mmol, 92%) of the desired compound as a pale yellow powder. ^ 1R NMR (400 MHz, DMS0-d6) 5 1.46 (IH, qd, J= 11.0, 3.7 Hz) , 1.60-1.69 10 (IH, m), 1.79-1.84 (IH, m) , 1.86-1.91 (IH, m) , 2.52-2.57 (2H, m) , 2.61 (3H, s), 3.19-3.24 (IH, m), 3.29-3.41 (IH, m), 3.78 (3H, s), 3.95-4.04 (IH, m), 6.29 (2H, s), 6.73 (IH, d, J = 8.6 Hz), 7.10 (IH, dd, J = 8.6, 3.1 Hz), 7.22 (IH, d, J = 3.1 Hz), 7.58 (2H, d, J = 8.6 Hz), 7.96 (2H, d, J = 8.6 Hz), 8.21 {IH, d, J = 7.3 Hz). 15 [0904] <Example 99> ^ Methyl (R)-3-[3-[[2-(4-chlorophenyl)-4-methylthiazol-5-yl]methoxy]pip eridin-l-yl]benzoate 20 [0905] Step 99a) (R)-1-(tert-Butoxycarbonyl)-3-[[2-(4-chlorophenyl) -4-methylthi azol-5-yl]methoxy]piperidine

[0906] 25 [Chemical formula 221] 271 552501 CI Mg

[0907] In an argon atmosphere, (R)-1-(tert-butoxycarbonyl)-3-hydroxypiperidine (604 mg, 3.00 mmol) and 5-chloromethyl-2-(4-chlorophenyl)-4-methylthiazole (775 mg, 3.00 mmol) were reacted in the same manner as in Step 6a of Example 6 to give 996 mg (78%) of the desired compound as a yellow oil. XH NMR (400 MHz, CDC13) 5 1.42-1.50 {10H, m), 1.53-1.62 (IH, m) , 1.73-1.81 (IH, m) , 1.90-1.96 (IH, m) , 2.44 (3H, s) , 3.12-3.22 (2H, m) , 3.42-3.4 9 (IH, m) , 3.52-3.58 (IH, m) , 3.67-3.89 (IH, m) , 4.64-4.67 (IH, m) , 4.73-4.80 (IH, m), 7.38 (2H, d, J = 8.6 Hz), 7.83 (2H, d, J = 8.6 Hz).

[0908] Step 99b) (R)-3-[ [2-(4-Chlorophenyl)-4-methylthiazol-5-yl]methoxy]piperi dine

[0909] [Chemical formula 222]

[0910] 272 552501 Using (R)-1-(tert-butoxycarbonyl)-3-[[2-(4-chlorophenyl)-4-methylthi azol-5-yl] methoxy] piperidine (946mg, 2.24mmol), the same procedure was followed as in Step 76b of Example 76 to give 608 mg (84%) of the desired compound as a pale yellow oil. 1H NMR (400 MHz, DMS0-d5) 5 1.26-1.37 (2H, m), 1. 56-1.64 (IH, m) , 1.92-2.00 (IH, m), 2.31-2.41 (5H, m), 2.71 (IH, td, J = 11.6, J = 3.7 Hz), 3.03 (IH, dd, J = 11.6 Hz, J = 2.4 Hz), 3.30-3.36 (IH, m) , 4.69 (2H, s), 7.54 (2H, d, J = 8.6 Hz), 7.90 (2H, d, J = 8.6 Hz) .

[0911] Step 99b) Methyl (R)-3-[3-[[2-(4-chlorophenyl)-4-methylthiazol-5-yl]methoxy]pip eridin-l-yl]benzoate

[0912] [Chemical formula 223] (R)-3-[[2-(4-chlorophenyl)- 4-methyIthiazol-5-yl]methoxy]piperi dine (294 mg, 0.911 mmol) and 3-(methoxycarbonyl)phenylboric acid (328 mg, 1.82 mmol), the same procedure was followed as in Example 2 to give 167 mg (40%) of the desired compound as a colorless oil. Me

[0913] Using 273 552501 1R NMR (400 MHz, CDCl3) 5 1.48-1.57 (IH, m), 1.62-1.73 (IH, m) , 1.88-1.96 (IH, m) , 2.06-2.12 (IH, m) , 2.46 (3H, s) , 2.85-2.93 (2H, m) , 3.47 (IH, td, J= 12.2, 4.3 Hz), 3.63-3.72 (2H, m), 3.90 (3H, s), 4.74 (IH, d, J = 12.8 Hz), 4.7 7 (IH, d, J = 12.8 Hz), 7.11 (IH, dd, J = 7.9, 2.4 Hz), 7.29 (IH, t, J = 7.9 Hz), 7.39(2H, d, J = 8.6 Hz), 7.49 (IH, d, J = 7.3 Hz), 7.60-7.61 (IH, m), 7.84 (2H, d, J = 8.6 Hz).

[0914] <Example 100> tert-Butyl 2-[2- [ [2- (4-chlorophenyl)-4-methylthiazole-5-carbonyl]aminomet hyl]morpholin-4-y1]benzoate

[0915] [Chemical formula 224] Using N-(morpholin-2-yl methyl)-2 - (4-chlorophenyl)-4-methylthiazole-5-carboxamide (12 0 mg, 0.341 mmol) and tert-butyl 2-iodobenzoate (104 mg, 0.341 mmol), the same procedure was followed as in Example 58 to give 113 mg (63%) of the desired compound as a pale yellow amorphous product. XH NMR (400 MHz, CDCI3) 5 1.59 (9H, s) , 2.7 0-2.78 (4H, m) , 2 . 94 (IH, td, J = 11.6, 3.1 Hz), 3.15-3.19 (IH, m), 3.24 (IH, dt, J = 11.6,

[0916] 274 552501 1.8 Hz), 3.40-3.47 (IH, m), 3.71-3.77 (IH, m), 3.87-3.96 (2H, m), 4.00 (IH, dt, J = 10.4, 2.4 Hz) , 6.2 9 (IH, t, J = 5.5 Hz) , 7.01-7.05 (2H, m), 7.38 (IH, td, J = 7.9, 1.8 Hz), 7.42 (2H, d, J = 8.6 Hz) , 7.60 (IH, dd, J = 7.9, 1.8 Hz), 7.87 (2H, d, J = 8.6 Hz). 5 [0917] <Examples 101 through 163> The procedures were performed in the same manner as in Example 18 to make compounds given in Table 9 below. 10 15 20 25 275 552501 [Table 9-1] (*>Yv^ OOH Absolute configuration Ar X cart Example 101 S ci "4 )—? jf N Exarrple 102 S CI—^ Example 103 S ci // Example 104 S Example 105 S Me // Example 106 S MeO~\ // Example 107 S FC"\\ // 3 y s- Example 108 S Example 109 S CI-\ // p U. O Example 110 S Example 111 S CI" Example 112 Racemic CI" mixture Example 113 Racemic Fx\<x mixture Example 114 Racemic mixture Example 115 S q? H H H H H H H H H H H H H H CONH CONH CONH CONH CONH CONH CONH CONH CONH CONH CONH CONH CONH CONH CH, C4 C4 CH Ch| CH C4 H CONH CH, CH, CH CH CH CH CH CH Position 3 Position 3 Position 3 Position 3 Position 3 Position 3 Position 3 Position 3 Position 3 Position 3 Position 3 Position2 Positbn2 Position2 Position3

[0919] 27 < 552501 [Table 9-2] Absolute configuration Ar X Y _ Binding position pi Z caiTOwfcaci Example 116 S Example 117 S Example 118 S Example 119 S Example 120 Example121 Example122 Example 123 Example 124 Example 125 Example 126 Example 127 Example 128 Example 129 Example 130 Exampie131 Example 132 Racemic mixture Racemb mixture Racemic mixture Racemc mixture Rajemb mixfure Rassnfc mixtuie Racemb mixSuie Racemc rrMure Racemic mixture Racemb mixture Racemic mixture Racemb mixture mMire ci-O^X, o o a-O-O- f-a0rr A c\~€y~\ r :o0xx :x>0xr rv :xx H CONH CH H CONH CH H CONH CH H CONH CH H CONHCH CH H CONHCjH CH H CONHCy CH H CONHCH CH H CONHCy CH H CONHCy Cb\ H CHNHCO CH H CHNHCO CH H CHNHCO CH CI-OO" H CHNHCO CH H CHNHCO CH H CHNHCO CH H NHCO CH Posion3 Position 3 Positions Position 3 Position 2 Posittan 2 Position 2 Position 3 Position 3 Position 3 Position 2 Posion 2 Position 2 Position 3 Position 3 Position 3 Position 3 [0920; 277 552501 [Table 9-3] Absolute configuration Ar Y Example 133 Racemic mixture Example 134 Racemic Ci-<Q^O-mixture Example 135 Racemic mixture Example 136 Racemic CI V_^ (Tj) mixture FY^i fY' Example 137 Racemic mixture Example 138 Racemic "C0Cr mixture Example139 Racemb CI '\Jj> mixture Example140 Racemic Ci~~^3 mixture Example 141 Racemic mixture Example142 Rasmb Cl~^3 mixture Exampie143 Racemb oi^T^ mixture Example144 Racemb mixture Example 145 Racemic C! ^ mixture Exampfe146 Racemb Cl~^3 mixture Example 147 Racemic mixture Example 148 Racemc a-O-gJ? mixture Example 149 C!"~^ H H H 0C4 CH cho CH OC4 CH, H CH.OC4 CH H Chip Ch| H CHOCH CH 4-MeO CONH CH H CHCONH CH, H CI^NH CH, H CHNH CH H NHCO CH H H H NHCO CH ^x. h ch CH H CH,CH,CONH CH H CHCI^CONH CH H CHOCONH CH Position 3 Position 3 Position 3 Position 3 Position 3 Position 3 Position 3 Position 2 Position 3 Position 2 Positbn3 Position 2 Position 3 Position 2 Position 3 Position 2 Position 3 '0921' 27 8 552501 [Table 9-4] Absolute configuration Ar _ Binding position of ^ carboxylic acid Example 150 Example 151 Example 15Z Example 153 Example 154 Example 155 Example 156 Example 157 Example 158 Example 159 Example 160 Example 16] Example 162 Example 163 Example 164 Example 165 Racemic r. // \__/J mixture 01 \__/v, KHxT Racemic p. mixture .Me s. .Me Racemic mixture Me Racemic p.. mixture Racemic (/ V_/J mixture ° \—/\ .N^Me Racemic fj \> mixture \ f N* Racemic <%< mixture K3H Racemic p. mixture Racemic mixture Racemic mixture Racemic £. mixture Racemic mixture Racemic qj—ft y mixture \=J "g- Me • »-0-gC ? o-o-cc Racemic mixture Racemic mixture H CH2OCONH CH2 Position 2 H NHCONH GHs Position 3 H NHCONH CHg Position 2 H COCH2 CH2 Position 3 H CHa Position 3 H SCH2 CH2 Position 3 H CONHCH2 O Position 3 H CH2NHCO 0 Position 3 H CH2NHCO O Position 2 H CH2OCH2 0 Position 3 H CHaOCH2 O Position 2 4-N02 CONH CHZ Position 3 4-NHa CONH CH2 Position 3 H CHzO CH2 Position 3 4-F CONH CH2 Position 3 5-BnO CONH CH2 Position 3

[0922] 279 552501 CCompound of Example 101> Colorless powder NMR (400 MHz, DMSO-d6) 5 1.62-1. 72 (2H, m), 1.75-1.85 (IH, m) , 1.88-1.96 (IH, m), 2.80 (3H, s), 2.88-2.94 (2H, m) , 3.60 (IH, d, 5 J = 12.8 Hz) , 3.69 (IH, d, J = 8.9 Hz), 3.98-4.06 (IH, m) , 7.21-7.25 (IH, m), 7.31-7.36 (2H, m), 7.48 (IH, s), 7.57 (2H, dd, J = 6.7, 1.8 Hz), 8.00 (2H, dd, J = 6.7, 2.4 Hz), 8.28 (IH, d, J = 7.9 Hz), 12.85 (IH, brs). ® HR-FAB+ (m/z) : 456.1180 (+3.1 mmu). 10 Elemental analysis calcd (%) for C23H22ClN303S*2/10H20: C 60.11, H 4.8 7 r N 9.14; found: C 60.15, H 4.72, N 9.10. [a]28-3Vl31° (C = 1.0, DMF)

[0923] CCompound of Example 102> 15 Colorless powder lH NMR (400 MHz, DMSO-dg) 6 1.55-1.73 (2H, m), 1.80-1.90 (IH, m) , £ 1.93-2.02 (IH, m), 2.45 (3H, s), 2.75 (2H, t, J= 11.7 Hz), 3.72 (IH, d, J = 11.7 Hz), 3.80 (IH, d, J = 11.7 Hz), 3.95-4.05 (IH, m) , 7 .22-7.2 7 (IH, m) , 7.30-7.37 (2H, m) , 7.4 7 (IH, d, J = 1.8 Hz), 20 7.67 (2H, dd, J = 6.7, 1.8 Hz), 8.19 (2H, dd, J = 6,7, 1.8 Hz), 8.43 (IH, d, J = 7.3 Hz), 12.85 (IH, brs). HR-FAB+(m/z) : 440.1388 ( + 1.1 mmu). Elemental analysis calcd (%) for C23H22CIN3O4* 3/10H20: C62.04, H5.05, N 9.44; found: C 62.03, H 4.90, N 9.40. 25 [a] 27'2°D+1780 (C = 1.1, DMF) 280 552501

[0924] CCompound of Example 103> Colorless powder 1H NMR (400 MHz, DMSO-d6) 5 1.60-1.75 (2H, m) , 1.76-1.93 (2H, m), 5 2.67 (3H, s), 2.80-2.93 (2H, m) , 3.56-3.68 (2H, m) , 3. 96-4.08 (IH, m) , 7.23-7.26 (IH, m) , 7.30-7.36 (2H, m), 7.47 (IH, m), 7.63 (2H, dd, J = 6.7, 1.8 Hz), 7.99 (2H, dd, J = 6.7, 2.4 Hz), 8.04 (IH, s), 12.84 (IH, brs) . ® HR-FAB+(m/z) : 440.1384 ( + 0.7 mmu). 10 Elemental analysis calcd (%) for C23H22CIN3O4 • 3/IOH2O: C62.03, H5.05, N 9.44; found: C 62.02, H 4.90, N 9.43. [a] 27"°°d+110 0 (C = 1.0, DMF)

[0925] CCompound of Example 104> 15 Colorless powder NMR (400 MHz, DMSO-d6) 5 1.50-1.70 (2H, m), 1.79-1.85 (IH, m), ^ 1.90-1.95 (IH, m), 2.60 (3H, s), 2.75-2.85 (2H, m), 3.60 (IH, d, J = 12.2 Hz) , 3.7 3 (IH, d, J = 12.2 Hz) , 3. 90-3. 99 (IH, m) , 7.20-7 .24 (IH, m) , 7.31-7.35 (2H, m) , 7.47 (IH, s) , 7.51-7.54 (3H, m) , 7.93-7.97 20 (2H, m), 8.25 (IH, d, J = 7.3 Hz), 12.85 (IH, brs). HR-FAB+ (m/z) : 422.1545 ( + 0.7 mmu). Elemental analysis calcd (%) f or C23H23N303S* I/IOH2O: C 65.26, H5.50, N 9.93; found: C 65.20, H 5.45, N 9.81. [a] 27"9°d+117 0 (C = 1.1, DMF) 25 [0926] 281 552501 <Compound of Example 105> Colorless powder lH NMR (400 MHz, DMSO-d6) 5 1.51-1.69 (2H, m) , 1.78-1.85 (IH, m) , 1.88-1.95 (IH, m), 2.36 (3H, s), 2.59 (3H, s) , 2.78-2.84 (2H, m), 5 3.57-3.65 (IH, m) , 3.73-3.77 (IH, m) , 3.90-4.01 (IH, m) , 7.19-7.25 (IH, m) , 7.30-7.36 (4H, m) , 7.4 7 (IH, s) , 7.83 (2H, d, J = 8.6 Hz), 8.21 (IH, d, J = 7.3 Hz), 12.83 (IH, brs). HR-FAB* (m/z) : 436.1715 (+2.0 mmu). ^ Elemental analysis calcd (%) for C24H25N3O3S: C 66.18, H 5.79, N 9.65; 10 found: C 66.08, H 5.78, N 9.48. [a] 27"6°D+1200 (C - 1.1, DMF)

[0927] CCompound of Example 106> Colorless powder 15 1H NMR (400 MHz, DMSO-d6) 5 1.53-1.69 (2H, m), 1.78-1.87 (IH, m), 1.91-1.97 (IH, m), 2.59 (3H, s), 2.75-2.83 (2H, m), 3.61 (IH, d, £ J = 12 . 7 Hz) , 3.73 (IH, dd, J=11.3, 3.0Hz), 3.83 (3H, s), 3.90-4.02 (IH, m) , 7.0 6 (2H, dd, J= 6.7, 1.8 Hz) , 7.19-7.2 6 (IH, m) , 7.30-7.35 (2H, m), 7.45-7.48 (IH, m), 7.88 (2H, dd, J = 6.7, 2.5 Hz), 8.17 20 (IH, d, J = 7.3 Hz), 12.83 (IH, brs). HR-FAB+(m/z) : 452.1613 (-3.1 mmu). [a]26'5°D+1400 (C = 1.1, DMF)

[0928] CCompound of Example 107> 25 Pale reddish brown powder 282 552501 1H NMR {400 MHz, DMSO-d6) 5 1.53-1.71 (2H, m) , 1. 82-1.87 (IH, m) , 1.90-1.98 (IH, m), 2.63 (3H, s) , 2.76-2.86 (2H, m), 3.62 (IH, d, J = 11.6 Hz), 3.71-3.7 6 (IH, m), 3.91-4.02 (IH, m), 7.24 (IH, s), 7.31-7.36 (2H, m), 7.47 (IH, s), 7.89 (2H, d, J = 8.6 Hz), 8.16 5 (2H, d, J = 7.9 Hz), 8.34 (IH, d, J = 7.3 Hz), 12.83 (IH, brs). HR-FAB"1'(m/z) : 490.1456 ( + 4.4 mmu). Elemental analysis calcd (%) for C24H22F3N3O3S: C 58.89, H 4.53, N 8.58; found: C 58.96, H 4.48, N 8.30. ^ [a] 28"4°D +101° (C = 1.1, DMF) 10 [0929] CCompound of Example 108> Yellow powder XH NMR (400 MHz, DMSO-de) 5 1.49-1.68 (2H, m), 1.78-1.86 (IH, m), 1.88-1.96 (IH, m), 2.59 (3H, s), 2.74-2.85 (2H, m), 3.58 (IH, d, 15 J = 12.2 Hz) , 3.71 (IH, dd, J = 12.2, 3.6 Hz) , 3.90-4.05 (IH, m), 7.18-7.24 (2H, m), 7.29-7.34 (2H, m), 7.44 (2H, m), 7.64 (2H, dd, 4) J = 7.9, 1.8 Hz), 8.34 (IH, d, J = 7.3 Hz), 12.85 (IH, brs). HR-FAB+(m/z) : 458.1371 (+2.2 mmu). Elemental analysis calcd (%) for C23H21F2N3O3S: C 60.38, H 4.63, N 20 9.18; found: C 60.15, H 4.55, N 8.91. [a] 26'7°d +105° (C = 1.1, DMF)

[0930] CCompound of Example 109> Colorless powder 283 552501 XH NMR (400 MHz, DMSO-d6) 5 1.46-1. 54 (IH, m) , 1.56-1.69 (IH, m) , 1.79-1.87 (IH, m) , 1.88-1.96 (IH, m) , 2.73-2.89 (2H, m) , 3.49-3.58 (IH, m), 3.66-3.72 (IH, m), 3.91-4.00 (IH, m) , 7.18-7.24 (IH, m) , 7.36 (2H, d, J = 6.7 Hz), 7.46-7.48 (3H, m), 7.69 (IH, s) , 8.56 5 (IH, d, J = 7.3 Hz), 12.79 (IH, brs). HR-FAB+(m/z) : 393.0811 ( + 3.8 mmu). Elemental analysis calcd (%) for CigHigCl2N203* 1/10H20: C 57.76, H 4.62, N 7.09; found: C 57.58, H 4.48, N 7.08. ^ [a] 2e'6°D +75.9° (C = 1.0, DMF) 10 [0931] <Compound of Example 110> Colorless powder *H NMR (400 MHz, DMSO-d6) 5 1.51-1.70 (2H, m) , 1.79-1.86 (IH, m) , 1.89-1.97 (IH, m), 2.64-2.78 (2H, m), 3.67 (IH, d, J = 11.8 Hz), 15 3.76 (IH, d, J = 11.8 Hz), 3.92-4.03 (IH, m), 7.01 (2H, dd, J = 6.7, 1.8 Hz), 7.12-7.16 (2H, m), 7.18-7.35 (5H, m), 7.46 (IH, s), ^ 7.89 (2H, dd, J = 6.7, 1.8 Hz), 8.29 (IH, d, J = 8.0 Hz), 12.75 (IH, brs). HR-FAB+(m/z) : 435.1718 (-0.2 mmu). 20 Elemental analysis calcd (%) for C25H23FN204* 3/IOH2O: C 68.26, H 5.34, N 6.37; found: C 68.17, H 5.25, N 6.38. [a] 28'5°D+81. 7 0 (C = 1.1, DMF)

[0932] CCompound of Example 111> 25 Pale reddish brown powder 284 552501 1H NMR (400 MHz, DMSO-d6) 5 1.55-1.1.69 (2H, m) , 1.80-1.87 (IH, m) , 1.92-1.98 (IH, m), 2.69-2.79 (2H, m), 3.68 (IH, d, J = 12.2 Hz), 3.81 (IH, d, J = 12.2 Hz), 3.97-4.07 (IH, rti) , 7.20-7.25 (IH, m) , 7.30-7.36 (2H, m), 7.46-7.48 (IH, m), 7.55 (2H, dd, J= 6.8, 2.4 5 Hz), 7.72-7.79 (4H, m), 7.97 (2H, d, J = 8.5 Hz), 8.42 (IH, d, J =7.3 Hz), 12.90 (IH, brs). HR-FAB'1" (m/z) : 435. 1466 (-1. 0 mmu). [a]27-8°D +95.9° (C = 1.0, DMF) 10 CCompound of Example 112> Colorless powder XH NMR (400 MHz, DMSO-d6) 5 1.65-1.80 (2H, m), 1.90-2.06 (2H, m), 2.93-3.13 (3H, m) , 3.2 4 (IH, dd, J = 11.0, 3.0 Hz), 4.0 9-4.2 5 (IH, m) , 7.40 (IH, t, J = 7.3 Hz), 7.55 (2H, d, J = 8.6 Hz), 7.60-7.70 15 (2H, m), 7.74-7.88 (4H, m), 7.96 (2H, d, J = 8.6 Hz), 8.00 (IH, d, J = 7.3 Hz), 8.49 (IH, d, J = 7.3 Hz), 16.94 (IH, brs). HR-FAB+ (m/z): 435.1483 (+0.7 mmu). Elemental analysis calcd (%) for C25H23CIN2O3* 1 /5H2O: C 68.47, H5.38, N 6.39; found: C 68.23, H 5.33, N 6.29. 20 [0934] CCompound of Example 113> Colorless powder XH NMR (400 MHz, DMSO-dg) 5 1.65-1.77 (2H, m) , 1.87-2.03 (2H, m) , 2.92-3.10 (2H, m) , 3.14-3.27 (2H, m) , 4.01-4.15 (IH, m) , 7.01 (2H, 25 d, J = 8.6 Hz), 7.08-7.17 (2H, m) , 7.23-7.30 (2H, m), 7.38 (IH, 285 552501 t, J = 7.9 Hz), 7.55-7.68 (2H, m), 7.89 (2H, d, J = 8.6 Hz), 7.98 (IH, d, J = 7.9 Hz), 8.41 (IH, brs). HR-FAB* (m/z): 435.1750 (+2.9 mmu). Elemental analysis calcd (%) for C25H23FN2CV 3/10H20: C 68.26, H5.41, 5 N 6.37; found: C 68.23, H 5.30, N 6.33.

[0935] CCompound of Example 114> Pale yellow powder ^ XH NMR (400 MHz, DMS0-d6) 5 1.65-1.85 (2H, m), 1.88-2.02 (2H, m), 10 2.93 (IH, t, J = 9.2 Hz) , 3.03-3.12 (2H, m) , 3.2 0 (IH, dd, J = 11.0, 3.7 Hz), 4.10-4.20 (IH, m), 7.34 (IH, t, J = 7.9 Hz), 7.53-7.68 (4H, m), 7.95 (IH, dd, J = 7.9, 1.8 Hz),8.14 (IH, d, J = 7.9 Hz), 8.22 (IH, d, J - 7.9 Hz) , 9.2 0 (IH, d, J = 7.9 Hz) , 16.30 (IH, brs) . HR-FAB+ (m/z): 382.1197 (-2.8 mmu). 15 [0936] CCompound of Example 115> ^ Cream-colored powder LH NMR (400 MHz, DMSO-d6) 5 1.58-1. 85 (3H, m), 1 . 88-1.95 (IH, m) , 2.78 (IH, t, J = 11.6 Hz), 2.88 (IH, t, J = 11.6 Hz), 3.64 (IH, 20 d, J = 11. 6 Hz) , 3.7 5 (IH, d, J = 11. 6 Hz) , 3. 97-4.08 (IH, m) , 7 .20-7.2 6 (IH, m), 7.28-7.35 (2H, m), 7.47 (IH, s), 7.55-7.65 <2H, m), 8.14 (IH, d, J = 7.9 Hz), 8.23 (IH, d, J = 7.9 Hz), 9.09 (IH, d, J = 7.9 Hz), 12.81 (IH, brs). HR-FAB+ (m/z): 382.1191 (-3.4 mmu). 286 552501 Elemental analysis calcd (%) for C2oHi9N303S*3/10H20: C 62.09, H5.ll, N 10.86; found: C 62.39, H 5.15, N 10.58. [a] 27-O°D+108 0 (C = 1.1, DMF)

[0937] 5 CCompound of Example 116> Cream-colored powder lH NMR (400 MHz, DMSO-d6) 5 1.54-1.70 (2H, m), 1. 78-1.88 (IH, m) , 1.93-2.01 (IH, m) , 2.63-2.81 (2H, m), 3.68 (IH, d, J = 12.2 Hz), ^ 3.82 (IH, d, J = 12.2 Hz), 3.97-4.07 (IH, m) , 7.18-7.26 (IH, m), 10 7.28-7.35 (2H, m), 7.47 (IH, s), 7.52-7.68 (3H, m), 7.76 (2H, d, J = 8.6 Hz), 7.8 0-7.90 (2H, m), 8.11 (IH, s), 8.4 7 (IH, d, J = 7.3 Hz) , 12.81 (IH, brs) . HR-FAB+ (m/z): 435.1512 (+3.6 mmu). Elemental analysis calcd (%) f or C25H23C1N203*2/5H20: C 67 . 92, H 5 . 43, 15 N 6.34; found: C 67.76, H 5.23, N 6.38. [oc] 28'7°d +73.2° (C = 1.1, DMF) 0 [0938] CCompound of Example 117> Colorless powder 20 2H NMR (400 MHz, DMSO-d5) 5 1.55-1.70 (2H, m) , 1.75-1.85 (IH, m) , 1.86-1.95 (IH, m) , 2.73-2.83 (2H, m) , 3.63 (IH, d, J = 12.2 Hz), 3.74 (IH, d, J = 12.2 Hz), 3.95-4.06 (IH, m), 7.18-7.25 (IH, m), 7.28-7.36 (2H, m), 7.44 (IH, s), 7.46 (IH, s), 7.63 (2H, d, J= 8.6 Hz) , 7.95 (2H, d, J = 8.6 Hz) , 8.80 (IH, d, J = 7.3 Hz) , 12.80 25 (IH, brs). 287 552501 HR-FAB+ (m/z): 426.1242 (+2.2 mmu). Elemental analysis calcd (%) for C22H20CIN3O4: C 62.05, H 4.73, N 9.87; found: C 61.73, H 4.69, N 9.75. [a] 28,7'd +40.6° (C = 1.1, DMF) 5 [0939] CCompound of Example 118> Cream-colored powder XH NMR (400MHz, DMS0-d6) 5 1.50-1.72 (2H, m), 1.79-1.88 (IH, m) , ^ 1.92-2.02 (IH, m) , 2.65-2.80 (2H, m), 3.66 (IH, d, J = 12.2 Hz), 10 3.79 (IH, d, J = 12.2 Hz), 3.90-4.02 (IH, m) , 7.19 (IH, d, J = 7.9 Hz), 7.26-7.35 (2H, m), 7.47 (IH, s) , 7.59 (2H, d, J = 8.6 Hz), 8.00 (2H, d, J = 8.6 Hz), 8.51 (IH, s), 8.66 (IH, d, J =7.9 Hz), 12.83 (IH, brs). HR-FAB+ (m/z): 442.1001 (+0.9 mmu). 15 [a] 28"7°d +53.1° (C = 0.5, DMF)

[0940] ^ CCompound of Example 119> Orange powder XH NMR (400MHz, DMS0-ds) 5 1.50-1.70 (2H, m), 1.75-1.86 (IH, m), 20 1.87-1.96 (IH, m), 2.41 (3H, s), 2.81 (2H, t, J = 10.4 Hz), 3.58 (IH, d, J = 12.2 Hz), 3.71 (IH, d, J = 12.2 Hz), 3.90-4.03 (IH, m) , 7 .24 (IH, d, J = 7.3 Hz) , 7 . 30-7. 37 (2H, m) , 7.41 (IH, s) , 7. 4 4-7.74 (3H, m), 7.68 (2H, d, J = 8.6 Hz), 7.94 (IH, d, J =7.3 Hz), 12.83 (IH, brs) . 2 5 HR-FAB+ (m/z): 455.1160 (-3.6 mmu). 288 552501 [a] 28-8°d +118° (C = 1.0, DMF)

[0941] CCompound of Example 120> Colorless powder 5 1H NMR (400 MHz, DMSO-d6) 5 1.20-1.33 (IH, m) , 1.56-1.72 (IH, m), 1.8 9 (2H, t, J = 14.0 Hz) , 2.00-2.10 (IH, m) , 2.8 6 (IH, t, J = 11.0 Hz), 2.96-3.06 (2H, m), 3.10 (IH, d, J = 7.9 Hz), 3.18-3.30 (2H, m) , 7.42 (IH, t, J = 7.9 Hz), 7.53 (2H, d, J = 8.6 Hz), 7.66 (IH, w t, J = 7.9 Hz), 7.7 0-7.7 8 (5H, m), 7.91 (2H, d, J - 8.6 Hz) , 8.02 10 (IH, d, J =7.9 Hz), 8.54-8.62 (IH, m), 17.99 (IH, brs). HR-FAB4" (m/z): 449.1657 (+2.5 mmu). Elemental analysis calcd (%) for C26H25CIN2O3: C 69.56, H 5.61, N 6.24; found: C 69.46, H 5.60, N 6.14.

[0942] 15 CCompound of Example 121> Colorless powder £ XH NMR (400 MHz, DMSO-d5) 5 1.18-1.32 (IH, m) , 1.55-1.72 (IH, m) , 1.7 4 -2.08 (2H, m), 2.8 4 (IH, t, J = 11.0 Hz) , 2.95-3.10 (2H, m), 3.15-3.35 (2H, m), 6.98 (2H, d, J = 8.6 Hz), 7.07-7.15 (2H, m), 20 7.20-7.28 (2H, m) , 7.42 (IH, t, J = 7.9 Hz) , 7.66 (IH, td, J = 7. 9, 1.2 Hz), 7.72 (IH, d, J = 7.9 Hz), 7.83 (2H, d, J = 8.6 Hz), 8.02 (IH, d, J = 6.1 Hz), 8.40-8.48 (IH, m), 17.99 (IH, brs). HR-FAB+ (m/z): 449.1883 (+0.6 mmu). Elemental analysis calcd (%) for C26H25FN204* 3/10H20: C 68. 80, H5.68, 25 N 6.17; found: C 68.83, H 5.76, N 5.87. 289 552501

[0943] <Compound of Example 122> Colorless powder 1H NMR (400MHz, DMS0-d6) 5 1.20-1.35 (IH, m), 1.55-1.70 (IH, m), 5 1.78-1.98 (2H, m), 2.04-2.17 (IH, m), 2.86 (IH, t, J = 11.0 Hz), 3.02 (2H, d, J = 6.7 Hz), 3.10 (IH, d, J = 7.9 Hz), 7.41 (IH, t, J = 7.9 Hz) , 7.55 (IH, td, J = 7.9, 1.2 Hz) , 7.61 (IH, td, J = 7.9, 1.2 Hz), 7.66 (IH, td, J = 7.9, 1.2 Hz), 7.73 (IH, d, J= 7.9 Hz), ® 8.01 (IH, dd, J = 7.9, 1.2 Hz), 8.10 (IH, d, J = 7.9 Hz), 8.20 (IH, 10 dd, J = 7.9, 1.2 Hz), 9.31 (IH, t, J = 6.1 Hz), 17.92 (IH, brs) . HR-FAB+ (m/z): 396.1402 (+2.0 mmu).

[0944] CCompound of Example 123> Colorless powder 15 XH NMR (400 MHz, DMSO-d6) 5 1.10-1.24 (IH, m), 1.48-1.65 (IH, m) , 1.70-1.83 (2H, m) , 1. 83-2.00 (IH, m) , 2.70-2.80 (IH, m) , 3.59 (IH, 0 d, J = 12.2 Hz) , 3.67 (IH, d, J = 12.2 Hz) , 7.12-7.2 3 (IH, m) , 7.25-7.3 8 (2H, m), 7.47 (IH, s), 7.54 (2H, d, J = 8.6 Hz), 7.70-7.83 (4H, m) , 7.95 (2H, d, J = 8.6 Hz), 8.62 (IH, t, J = 5.5 Hz), 12.81 (IH, 20 brs). HR-FAB+ (m/z): 449.1657 (+2.5 mmu).

[0945] CCompound of Example 124> Colorless powder 290 552501 1H NMR (400 MHz, DMSO-d6) 5 1.10-1.25 (IH, m), 1.48-1.62 (IH, m), 1.70-1.82 (2H, m), 1.83-1.95 (IH, m), 2.72 (IH, t, J = 11.0 Hz), 3.15-3.30 (3H, m), 3.54-3.68 (2H, m), 7.01 (2H, d, J = 8.6 Hz), 7.08-7.20 (3H, m), 7.21-7.35 (4H, m), 7.45 (IH, s), 7.87 (2H, d, 5 J = 8.6 Hz), 8.49 (IH, t, J = 5.5 Hz), 12.79 (IH, brs). HR-FAB4" (m/z): 449.1913 (+3.7 mmu). Elemental analysis calcd (%) for C26H25FN2O4■ I/5H2O: C 69.07, H 5.66, N 6.20; found: C 68.83, H 5.56, N 6.07. 10 CCompound of Example 125> Colorless powder lti NMR (400 MHz, DMSO-d6) 5 1.10-1.23 (IH, m), 1.48-1.62 (IH, m), 1.70-1.83 (2H, m) , 1.92-2.05 (IH, m), 2.48-2.60 (IH, m), 2.72 (IH, t, J = 12.2 Hz), 3.57 (IH, d, J = 12.2 Hz), 3.64 (IH, d, J - 12.2 15 Hz), 7.15-7.20 (IH, m) , 7.25-7.34 (2H, m), 7.45 (IH, s), 7.57 (IH, td, J = 7.9, 1.2 Hz), 7.63 (IH, td, J = 7.9, 1.2 Hz), 8.14 (IH, ^ d, J = 7.3 Hz), 8.22 (IH, d, J = 7.3 Hz), 9.36 (IH, t, J = 6.1 Hz), 12.76 (IH, brs). HR-FAB+ (m/z) : 396.1354 (-2.8 mmu). 20 Elemental analysis calcd (%) for C2iH2iN303S'l/10H20: C 63.49, H5.38, N 10.58; found: C 63.39, H 5.27, N 10.48.

[0947] CCompound of Example 126> Colorless powder 291 552501 XH NMR (400 MHz, DMSO-d6) 5 1.60-1.74 (2H, m), 1.85-2.00 (2H, m), 2.65-2.75 (IH, m), 2.95-3.07 (2H, m), 3.16 (2H, d, J = 7.9 Hz), 4.29 (2H, d, J = 5.5 Hz), 7.31 (2H, d, J = 7.9 Hz), 7.42 (IH, t, J = 7.9 Hz), 7.49 (2H, d, J = 8.6 Hz), 7.59 (2H, d, J = 8.6 Hz), 5 7.62-7.69 (3H, m) , 7.75 (IH, d, J = 7.9 Hz), 8.02 (IH, dd, J = 7.9, 1.2 Hz), 8.56 (IH, t, J = 5.5 Hz), 17.41 (IH, brs). HR-FAB* (m/z): 449.1596 (-3.6 mmu). Elemental analysis calcd (%) for C26H25CIN2O3*3/5H2O: C 67.92, H5.74, ^ N 6.09; found: C 67.75, H 5.51, N 6.02. 10 [0948] CCompound of Example 127> Colorless powder 1H NMR (400MHz, DMS0-d6) 5 1.57-1.72 (2H, m), 1.85-1.97 (2H, m), 2.55-2.73 (IH, m) , 2.95-3.05 (2H, m) , 3.08-3.18 (2H, m) , 4.23 (2H, 15 d, J = 6.1 Hz) , 6.91 (2H, d, J = 8.6 Hz) , 6.96-7.0 5 (2H, m) , 7.15-7.25 (4H, m), 7.41 (IH, t, J = 7.3 Hz), 7.65 (IH, t, J = 7.3 Hz), 7.72 (IH, d, J = 7.9 Hz), 8.01 (IH, dd, J = 7.9, 1.8 Hz), 8.50 (IH, t, J = 5.5 Hz), 17.51 (IH, brs) . HR-FAB+ (m/z): 449.1907 (+3.0 mmu). 20 Elemental analysis calcd (%) for C26H25FN204* 1/5H20: C 69.07, H 5.66, N 6.20; found: C 68.81, H 5.62, N 5.99.

[0949] CCompound of Example 128> Colorless powder 292 552501 1H NMR (400MHz, DMSO-d5) 5 1.60-1.75 (2H, m), 1.90-2.03 (2H, m), 2.68-2.80 (IH, m), 2.96-3.07 (2H, m), 3.17 (2H, d, J = 7.3 Hz), 4.60-4.72 (2H, m), 7.38 (IH, d, J = 7.9 Hz), 7.41 (IH, d, J = 7.9 Hz) , 7.48 (IH, d, J = 8.6 Hz) , 7.66 (IH, td, J = 7.9, 1.8 Hz) , 7.73 5 (IH, d, J = 7.9 Hz), 7.91 (IH, d, J = 7.9 Hz), 8.02 (2H, td, J = 7.9, 1.8 Hz), 9.07 (IH, t, J = 6.1 Hz), 17.32 (IH, brs). HR-FAB+ (m/z): 396.1402 (+2.0 mmu). Elemental analysis calcd (%) for C21H21N3O3S: C 63.78, H5.35, N 10.63; ^ found: C 63.51, H 5.29, N 10.33. 10 [0950] CCompound of Example 129> Colorless powder JH NMR (400MHz, DMSO-d6) 5 1.51-1.67 (2Hr m), 1.72-1.80 (IH, m), 1.84-1.95 (IH, m), 2.48-2.59 (IH, m), 2.73 (IH, t, J = 12.2 Hz), 15 2.87 (IH, t, J = 12.2 Hz), 3.66 (IH, d, J = 12.2 Hz), 3.76 (IH, d, J = 12.2 Hz), 4.30 (IH, dd, J = 15.3, 5.5 Hz), 4.37 (IH, dd, ^ J = 15.3, 5.5 Hz) , 7.18-7.24 (IH, m) , 7.28-7.38 (4H, m) , 7.47 (IH, s), 7.51 (2H, d, J = 8.6 Hz), 7.63 (2H, d, J = 7.9 Hz), 7.68 (2H, d, J = 8.6 Hz), 8.50 (IH, t, J = 6.1 Hz). 20 HR-FAB+ (m/z): 449.1648 (+1.6 mmu). Elemental analysis calcd (%) for C26H25CIN2O3: C 69.56, H 5.61, N 6.24; found: C 69.39, H 5.62, N 6.13.

[0951] CCompound of Example 130> 25 Colorless powder 293 552501 NMR (400 MHz, DMSO-d6) 5 1.50-1.63 (2H, m) , 1.70-1.77 (IH, m) , 1.83-1.90 (IH, m) , 2.45-2.55 (IH, m), 2.65-2.75 (IH, m), 2.83 (IH, t, J = 12.2 Hz), 3.64 (IH, d, J = 12.2 Hz), 3.73 (IH, d, J = 12.2 Hz), 4.22 (IH, dd, J = 15.3, 5.5 Hz), 4.29 (IH, dd, J = 15.3, 5.5 5 Hz), 6.93 (2H, d, J = 9.2 Hz), 6.98-7.05 (2H, m) , 7.15-7.35 (7H, m), 7.45 (IH, s), 8.42 (IH, t, J = 6.1 Hz), 12.78 (IH, brs). HR-FAB+ (m/z): 449.1869 (-0.7 mmu). Elemental analysis calcd (%) for C26H25FN2O4: C 69.63, H5.62, N 6.25; ^ found: C 69.58, H 5.61, N 6.11. 10 [0952] <Compound of Example 131> Colorless powder NMR (400 MHz, DMSO-d6) 5 1.56-1.67 (2H, m) , 1.73-1.82 (IH, m) , 1.87-1.97 (IH, m), 2.52-2.63 (IH, m), 2.73 (IH, t, J = 12.2 Hz), 15 2.87 (IH, t, J = 12.2 Hz), 3.66 (IH, d, J = 12.2 Hz), 3.80 (IH, d, J = 12.2 Hz), 4.65 (IH, dd, J = 16.5, 6.1 Hz), 4.71 (IH, dd, 0 J= 16.5, 6.1 Hz), 7.18-7.25 (IH, m), 7.28-7.35 (2H, m), 7.40 (IH, t, J = 7.9 Hz), 7.45-7.53 (2H, m), 7.93 (IH, d, J = 7.9 Hz), 8.05 (IH, d, J = 7.3 Hz), 8.98 (IH, t, J = 6.1 Hz), 12.83 (IH, brs). 20 HR-FAB+ (m/z): 396.1373 (-0.9 mmu). Elemental analysis calcd (%) f or C21H21N3O3S * I/5H2O: C 63.20, H 5.41, N 10.53; found: C 63.04, H 5.33, N 10.50.

[0953] CCompound of Example 132> 25 Colorless powder 294 552501 2H NMR (400 MHz, DMSO-d6) 5 1.53-1.68 (2H, m) , 1.74-1.83 (IH, m) , 1.90-2.00 (IH, m), 2.60-2.78 (2H, m), 2.87 (IH, t, J = 12.2 Hz), 3.70 (IH, d, J = 12.2 Hz), 3.84 (IH, d, J = 12.2 Hz), 6.92-7.02 (4H, m), 7.14-7.26 (3H, m), 7.28-7.36 (2H, m), 7.48 (IH, s) , 7.61 5 (2H, d, J = 8.6 Hz), 10.00 (IH, s), 12.81 (IH, brs). HR-FAB4" (m/z): 435.1703 (-1.8 mmu). Elemental analysis calcd (%) for C25H23FN2CV I/IOH2O: C 68.83, H5.36, N 6.42; found: C 68.77, H 5.31, N 6.34. 10 CCompound of Example 133> Colorless powder ^ NMR (400 MHz, DMS0-d6) 5 1.30-1.40 (IH, m) , 1.57-1.67 (IH, m) , 1.76-1.82 (IH, m) , 1.84-1.90 (IH, m) , 2.17-2.27 (IH, m) , 2.75 (IH, dd, J = 11.6, 10.4 Hz), 2.81 (IH, dd, J = 12.2, 3.1 Hz) , 3.58 (IH, 15 td, J = 12.2, 3.1 Hz), 3.71 (IH, dd, J = 12.2, 3.1 Hz), 4.54 (2H, d, J = 6.7 Hz) , 7.20 (IH, td, J = 8.6, 2.4 Hz) , 7.2 6-7.35 (3H, m) , ^ 7.40 (IH, td, J = 7.9, 1.2 Hz), 7.48 (IH, brs), 7.67 (IH, d, J = 7.3 Hz), 7.88 (IH, d, J = 7.3 Hz). HR-FAB4 (m/z) : 369.1258 (-1.5 mmu). 20 [0955] CCompound of Example 134> Colorless powder XH NMR (400 MHz, DMSO-d6) 5 1.42-1.59 (2H, m), 1.78-1.85 (IH, m) , 1.99-2.06 (IH, m) , 2.83-2.91 (2H, m), 3.45 (IH, td, J = 12.2, 3.6 25 Hz), 3.54-3.60 (IH, m) , 3.71 (IH, dd, J = 12.2, 3.6 Hz), 4.64 (2H, 295 552501 s), 7.20 (IH, td, J = 7.9, 2.4 Hz), 7.28-7.34 (2H, m) , 7.43-7.45 (3H, m), 7.51 (2H, d, J = 8.6 Hz), 7.64 (2H, d, J = 8.6 Hz), 7.69 (2H, d, J = 8.6 Hz), 12.82 (IH, brs). HR-FAB+ (m/z) : 422. 1514 (-0.9 mmu). 5 Elemental analysis calcd (%) for C25H24CINO3: C71.17, H5.73, N3.32; found: C 71.30, H 5.70, N 3.26.

[0956] CCompound of Example 135> ^ Colorless powder 10 XH NMR (400 MHz, DMSO-d6) 5 1.28-1.38 (IH, m) , 1.57-1.68 (IH, m) , 1.76-1.83 (IH, m) , 1.85-1.92 (IH, m) , 2.09-2.17 (IH, m) , 2.72 (IH, dd, J = 11.6, 10.4 Hz) , 2.80 (IH, td, J = 11.6, 2.4 Hz) , 3.61 (IH, td, J = 12.8, 3.1 Hz), 3.75 (IH, dd, J = 11.6, 3.1 Hz), 3.97-4.04 (2H, m) , 7.07 (2H, d, J - 8.6 Hz), 7.20 (IH, td, J = 7.3, 2.4 Hz), 15 7.29-7.36 (2H, m), 7.46-7.48 (3H, m) , 7.61 (2H, d, J = 8.6 Hz), 7.64 (2H, d, J = 8.6 Hz), 12.87 (IH, brs) . ^ HR-FAB+(m/z) : 422.1552 (+2.9 mmu).

[0957] CCompound of Example 136> 20 Colorless powder 1H NMR (400 MHz, DMSO-d6) 5 1.15-1.25 (IH, m) , 1.52-1.63 (IH, m) , 1.69-1.80 (2H, m) , 1.91-2.01 (IH, m) , 2.61 (IH, dd, J = 12.2, 10.4 Hz), 2.72-2.79 (IH, m), 3.41 (2H, d, J = 6.7 Hz), 3.56-3.62 (IH, m), 3.68-3.72 (IH, m) , 4.52 (IH, d, J =12.8 Hz), 4.55 (IH, d, J 25 =12.8 Hz) , 7.16 (IH, td, J = 7. 3, 2.4 Hz) , 7.2 9-7 . 34 (2H, m) , 7.4 3-7.4 6 296 552501 (3H, m) , 7.52 (2H, d, J = 8.6 Hz), 7.66 (2H, d, J = 8.6 Hz), 7.70 (2H, d, J = 8.6 Hz), 12.82 (IH, brs). HR-FAB+(m/z) : 436.1701 (+2.2 mmu). Elemental analysis calcd (%) for C26H26CINO3: C 71.63, H 6.01, N 3.21; 5 found: C 71.61, H 5.96, N 3.13.

[0958] CCompound of Example 137> Colorless powder ® 1H NMR (400 MHz, DMSO-ds) 5 1.37-1.56 (2H, m) , 1.74-1.81 (IH, m) , 10 1.95-2.01 (IH, m) , 2.77-2 . 87 (2H, m), 3.41 (IH, td, J = 12.2, 4.3 Hz), 3.49-3.54 (IH, m) , 3.64-3.68 (IH, m) , 4.54 (2H, s), 6.92 (2H, d, J = 8.6 Hz), 6.99-7.05 (2H, m), 7.15-7.22 (3H, m), 7.25-7.33 (4H, m), 7.41 (IH, brs), 12.78 (IH, brs). HR-FAB+(m/z) : 422.1748 (-1.9 mmu). 15 Elemental analysis calcd (%) for C25H24FNO4: C 71.24, H 5.74, N 3.32; found: C 71.05, H 5.79, N 3.19. ^ [0959] CCompound of Example 138> Colorless oil 20 XH NMR (400 MHz, DMS0-d6) 5 1.13-1.23 (IH, m), 1.51-1.62 (IH, m) , 1.69-1.77 (2H, m), 1.88-1.98 (IH, m), 2.58 (IH, dd, J= 12.2, 9.8 Hz), 2.71-2.78 (IH, m), 3.38 (2H, d, J = 6.7 Hz), 3.56-3.61 (IH, m) , 3. 65-3. 69 (IH, m) , 4.46 (2H, s) , 6. 97 (2H, d, J = 8 . 6 Hz) , 7.05 (2H, dd, J = 9.2, 4.3 Hz), 7.15 (IH, td, J = 7.3, 1.8 Hz), 7.22 297 552501 (2H, t, J = 8.6 Hz), 7.28-7.36 (4H, m) , 7.44 (IH, brs), 12.80 (IH, brs) . HR-FAB+(m/z) : 436.1947 (+2.3 mmu).

[0960] 5 CCompound of Example 139> Colorless powder XH NMR (400 MHz, DMS0-d6) 5 1.48-1.62 (IH, m) , 1.63-1.77 (IH, m) , 1.78-1.97 (2H, m), 2.61 (3H, s) , 2.66-2.88 (2H, m), 3.77 (3H, s), ^ 4.97-4.12 (IH, m), 7.07 (IH, d, J = 9.1 Hz), 7.20-7.43 (2H, m) , 10 7.59 (2H, d, J = 8.6 Hz), 7.96 (2H, d, J = 8.6 Hz). HR-FAB+(m/z) : 486.1274 (+2.0 mmu).

[0961] CCompound of Example 140> Colorless powder 15 NMR (400 MHz, DMSO-dg) 5 1. 48-1.57 (IH, m) , 1.63-1.73 (IH, m) , 1.85-1.99 (2H, m) , 2.33 (3H, s), 2.83-2.88 (IH, m) , 2.92-2.97 (IH, £ m) , 3.00-3.05 (IH, m) , 3.11-3.14 (IH, m) , 3.66 (IH, d, J = 6.5 Hz) , 3.70 (IH, d, J = 6.5 Hz), 3.81-3.89 (IH, m), 7.34-7.38 (IH, m) , 7.50 (2H, d, J = 8.6 Hz) , 7.59-7.64 (2Hr m), 7.84 (2H, d, J = 8.6 20 Hz) , 7.95 (IH, d, J = 7.3 Hz), 8.3 6-8.37 (IH, m), 16.78 (IH, brs) . HR-FAB+ (m/z) : 470.1315 ( + 1.0 mmu).

[0962] CCompound of Example 141> Pale yellow powder 298 552501 1H NMR (400 MHz, DMSO-d6) 5 1.20-1.30 (IH, m) , 1.49-1.58 (IH, m) , 1.72-1.80 (IH, m), 1.93-2.00 (IH, m), 2.36 (3H, s) , 2.54-2.59 (IH, m), 2.65-2.77 (2H, m), 3.52-3.55 (IH, m), 3.73-3.75 (IH, m) , 3.95 (IH, d, J- = 15.9 Hz), 3.97 (IH, d, J = 15.9 Hz), 7.17 (IH, td, J 5 = 7.3, 2.4 Hz), 7.27-7.32 (2H, m) , 7.45 (IH, brs), 7.52 (2H, d, J = 8.6 Hz), 7.88 (2H, d, J = 8.6 Hz). HR-FAB+(m/z) : 442.1395 (+3.9 mmu).

[0963] ^ CCompound of Example 142> 10 Pale yellow powder XH NMR (400 MHz, DMSO-d6) 5 1.45-1.57 (IH, m) , 1.60-1.70 (IH, m), 1.93-1.99 (IH, m), 2.05-2.15 (IH, m), 2.39 (3H, s) , 2.89-2.95 (2H, m) , 3.05-3.08 (IH, m), 3.09-4.00 (2H, m), 4.08-4.40 (2H, m), 7.37 (IH, t, J = 7.3 Hz), 7.51-7.60 (3H, m), 7.66 (IH, t, J = 7.3 Hz), 15 7.90 (2H, d, J = 8.6 Hz), 7.97 (IH, d, J = 7.3 Hz). HR-FAB+(m/z) : 442.1399 ( + 4.3 mmu). ^ [0964] CCompound of Example 143> Pale yellow powder 20 XH NMR (400 MHz, DMS0-d6) 5 1.57-1.70 (2H, m) , 1.76-1.85 (IH, m) , 1.93-2.02 (IH, m) , 2.43 (3H, s) , 2.75-2.80 (IH, m) , 2.88-2 . 95 (2H, m), 3.70-3.73 (IH, m), 3.85-3.92 (IH, m), 7.25 (IH, td, J = 7.3, 1.8 Hz), 7.31-7.37 (2H, m), 7.49-7.53 (3H, m), 7.85 (2H, d, J = 8.6 Hz), 10.67 (IH, s), 12.83 (IH, brs). 25 HR-FAB+(m/z) : 456.1153 ( + 0.5 mmu). 299 552501

[0965] CCompound of Example 144> Colorless powder 1H NMR (400 MHz, DMSO-d6) 5 1.64-1.75 (2H, m) , 1.93-2.04 (2H, m) , 5 2.38 (3H, s), 2.97-3.09 (3H, m), 3.17-3.26 (2H, m), 7.39 (IH, td, J = 7.3, 1.2 Hz) , 7.47 (2H, d, J = 8.6 Hz), 7.64 (IH, td, J = 7.3, 1.2 Hz), 7.72 (IH, d, J = 7.9 Hz), 7.82 (2H, d, J = 8.6 Hz), 7.9 9 (IH, dd, J = 7.3, 1.2 Hz), 10.71 (IH, brs), 17.26 (IH, brs). HR-FAB4" (m/z) : 456.1151 (+0.2 mmu). 10 [0966] CCompound of Example 145> Colorless powder XH NMR (400 MHz, DMSO-d6) 5 1.43-1.52 (IH, m) , 1 . 58-1.68 (IH, m) , 1.78-1.92 (2H, m), 2.51 (3H, s), 2.73 (IH, dd, J = 11.6, 8.6 Hz), 15 2.87-2.93 (IH, m), 3.51 (IH, td, J = 12.2, 3.7 Hz), 3.66 (IH, dd, J = 12.2, 3.7 Hz), 3.86-3.95 (IH, m), 6.42 (IH, d, J = 15.3 Hz), 0 7.20 (IH, td, J = 7.3, 2.4 Hz), 7.30-7.35 (2H, m), 7.4 5 (IH, brs), 7.59 (2H, d, J = 8.6 Hz), 7.60 (IH, d, J = 15.3 Hz), 7.96 (2H, d, J =8.6 Hz), 8.27 (IH, d, J = 7.3 Hz), 12.81 (IH, brs). 20 HR-FAB4 (m/z) : 482.1319 ( + 1.4 mmu). Elemental analysis calcd (%) for C25H24CIN3O3S-I/IOH2O: C 62.06, H 5.04, N 8.69; found: C 61.98, H 5.01, N 8.46.

[0967] CCompound of Example 146> 25 Colorless powder 300 552501 1H NMR {400 MHz, DMSO-d6) 5 1.50-1.60 (IH, m) , 1.67-1.77 (IH, m) , 1.90-2.02 (2H, m) , 2.47 (3H, s) , 2.87-2.92 (IH, m) , 2.94-2.99 (IH, m) , 3.03-3.08 (IH, m), 3.20-3.23 (IH, m), 3.95-4.03 (IH, m), 6.39 (IH, d, J = 15.3 Hz), 7.36-7.40 (IH, m) ,7.56 (IH, d, J = 15.3 Hz), 5 7.58 (2H, d, J = 8.6 Hz), 7.63-7 . 68 (2H, m) , 7.94-7.99 (3H, m) , 8.33 (IH, d, J = 6.7 Hz), 16.75 (IH, brs). HR-FAB+(rn/z) : 482. 1344 ( + 3.9 mmu). Elemental analysis calcd (%) for C25H24C1N303S*3/5H20: C 60 . 93, H 5 .15, ^ N 8.53; found: C 60.64, H 4.85, N 8.38. 10 [0968] <Compound of Example 147> Colorless powder XH NMR (400 MHz, DMSO-d6) 5 1.31-1.40 (IH, m) , 1.52-1.62 (IH, m) , 1.74-1.81 (2H, m) , 2.35 (3H, s) , 2.42 (2H, t, J = 7.3 Hz) , 2.52-2.57 15 (IH, m) , 2.74-2.80 (IH, m), 3.03 (2H, t, J = 7.3 Hz), 3.47-3.52 (IH, m), 3.58 (IH, dd, J = 11.6, 2.4 Hz), 3.73-3.82 (IH, m), 7.12 ^ (IH, d, J = 7.9 Hz), 7.28 (IH, t, J = 7.9 Hz), 7.33 (IH, d, J = 7.3 Hz), 7.44 (IH, brs), 7.49 (2H, d, J = 8.6 Hz), 7.83 (2H, d, J = 8.6 Hz), 7.95 (IH, d, J = 7.3 Hz), 12.8 9 (IH, brs) . 20 HR-FAB4" (m/z) : 484.1488 ( + 2.6 mmu). Elemental analysis calcd (%) f or C25H26CIN3O3S • I/4H2O: C 61.47, H5.47, N 8.60; found: C 61.33, H 5.29, N 8.41.

[0969] CCompound of Example 148> 25 Colorless powder 301 552501 1H NMR (400 MHz, DMSO-d6) 5 1.41-1.48 (IH, m), 1.61-1.68 (IH, m) , 1.81-1.93 (2H, rrt) , 2.31 (3H, s) , 2.41 (2H, t, J = 7.3 Hz) , 2.74-2.79 (IH, m) , 2.87-2.92 (IH, m) , 2.97-3.01 (3H, m) , 3.05-3.08 (IH, ru) , 3.85 (IH, m), 7.36 (IH, t, J = 7.3 Hz), 7.48 (2H, d, J = 8.6 Hz), 5 7.54-7.61 (2H, ra), 7.77 (2H, d, J = 8.6 Hz), 7.95 (IH, d, J = 7.3 Hz), 8.03 (IH, d, J = 6.1 Hz), 16.83 (IH, brs). HR-FAB+(m/z) : 484.1485 (+2.3 mmu). Elemental analysis calcd (%) for C25H26CIN3O3S • 3/10H20: C 61.35, H ® 5.48, N 8.59; found: C 61.28, H 5.34, N 8.42. 10 [0970] <Compound of Example 149> Colorless powder NMR (400 MHz, DMSO-ds) 5 1.32-1.42 (IH, m), 1.51-1.61 (IH, m) , 1.74-1.79 (IH, m) , 1.82-1.87 (IH, m) , 2.43 (3H, s), 2.58-2.63 (IH, 15 m), 2.69-2.75 (IH, m), 3.49-3.56 (2H, m), 3.64-3.67 (IH, m), 5.21 (IH, d, J = 13.4 Hz), 5.26 (IH, d, J = 13.4 Hz), 7.16 (IH, d, J £ =7.9 Hz), 7.28-7 .34 (2H, m) , 7.4 4 (IH, brs) , 7.46 (IH, d, J=7.3 Hz), 7.54 (2H, d, J = 8.6 Hz), 7.91 (2H, d, J = 8.6 Hz), 12.80 (IH, brs) . 20 HR-FAB+ (m/z) : 486.1230 (-2.5 mmu).

[0971] CCompound of Example 150> Colorless amorphous 1H NMR (400 MHz, DMSO-d6) 5 1.42-1.52 (IH, m) , 1.60-1.70 (IH, m), 25 1.85-1.95 (2H, m) , 2.42 (3H, 3), 2.78-2.83 (IH, m) , 2.86-2.91 (IH, 302 552501 m) , 2.99-3.02 (IH, m) , 3.13 (IH, dd, J= 11.0, 3.1 Hz), 3.58-3.67 (IH, m), 5.21 (2H, s), 7.36 (IH, t, J = 7.3 Hz), 7.54 (2H, d, J = 8.6 Hz), 7.57-7.65 (3H, m), 7.89 (2H, d, J = 8.6 Hz), 7.97 (IH, dd, J = 7.9, 1.2 Hz), 16.65 (IH, brs). 5 HR-FAB+ (m/z) : 486.1281 (+2.7 mmu).

[0972] CCompound of Example 151> Colorless powder ^ NMR (400 MHz, DMSO-d6) 5 1.52-1.58 (IH, m), 1.62-1.70 (IH, m) , 10 1.75-1.84 (2H, m), 2.30 (3H, s), 3.00 (IH, dd, J = 11.6, 7.3 Hz), 3.11-3.16 (IH, m), 3.20-3.26 (IH, m), 3.44 (IH, dd, J= 11.6, 2.4 Hz), 3.79-3.87 (IH, m), 6.77 (IH, d, J = 7.9 Hz), 7.22 (IH, td, J = 7.9, 1.8 Hz), 7.32-7.38 (2H, m), 7.46-7.50 (3H, m), 7.81 (2H, d, J = 8.6 Hz), 9.09 (IH, s), 12.80 (IH, brs). 15 HR-FAB+ (m/z) : 471.1260 ( + 0.2 mmu).

[0973] ^ CCompound of Example 152> Colorless powder XH NMR (400 MHz, DMSO-dg) 5 1.49-1.58 (IH, m), 1.68-1.79 (IH, m), 20 1.89-1.98 (2H, m), 2.32 (3H, s), 2.92 (IH, dd, J = 11.0, 8.6 Hz), 2.98-3.06 (2H, m), 3.22 (IH, dd, J = 11.0, 3.1 Hz), 3.80-3.88 (IH, m) , 6.82 (IH, d, J = 6.1 Hz), 7.35 (IH, t, J = 7.3 Hz), 7.47 <2H, d, J = 8.6 Hz), 7.57-7.65 (2H, m), 7.79 (2H, d, J = 8.6 Hz), 7.94 (IH, d, J = 7.9 Hz), 9.18 (IH, s), 16.72 (IH, brs). 2 5 HR-FAB+(m/z) : 471.1273 ( + 1.5 mmu). 303 552501

[0974] <Compound of Example 153> Pale yellow powder lH NMR (400 MHz, DMSO-d6) 5 1.20-1.30 (IH, m), 1.54-1.64 (IH, m), 5 1.70-1.75 (IH, m) , 1.79-1.86 (IH, m) , 2.19-2.27 (IH, m) , 2.58-2.67 (IH, m), 2.7 3 (3H, s), 2.7 9 (IH, td, J = 12.2, 3.1 Hz), 2.8 9 (IH, dd, J = 17.1, 6.1 Hz), 3.02 (IH, dd, J =17.1, 6.7 Hz), 3.61 (IH, td, J = 12.2, 3.7 Hz), 3.68 (IH, dd, J = 12.2, 1.8 Hz), 7.17-7.21 ® (IH, m) , 7 . 31-7.32 (2H, m) , 7.45 (IH, m) , 7 . 60 (2H, d, J = 8 . 6 Hz) , 10 8.02 (2H, d, J = 8.6 Hz), 12.77 (IH, brs). HR-FAB+(m/z) : 455. 1192 (-0. 4 mmu). Elemental analysis calcd (%) for C24H23C1N203S* 1/4H20: C 62.74, H5.16, N 6.10; found: C 62.71, H 4.96, N 5.87.

[0975] 15 CCompound of Example 154> Colorless powder £ 1H NMR (400MHz, DMSO-dg) 5 1.36-1.46 (IH, m), 1.57-1.68 (IH, m), 1.76-1.81 (IH, m) , 1.89-1.93 (IH, m) , 2.42 (3H, s), 2.46-2.55 (IH, m), 2.69 (IH, dd, J = 12.2, 10.4 Hz), 2.76 (IH, td, J = 12.2, 2.4 20 Hz), 3.65 (IH, td, J = 12.2, 4.3 Hz), 3.73 (IH, dd, J = 11.6, 3.1 Hz), 6.03 (IH, dd, J = 15.9, 7.3 Hz), 6.75 (IH, dd, J = 15.9, 1.2 Hz), 7.23 (IH, td, J = 7.3, 2.4 Hz), 7.30-7.35 (2H, m), 7.48 (IH, m) , 7.55 (2H, d, J = 8 . 6 Hz) , 7.89 (2H, d, J = 8.6 Hz), 12.8 0 (IH, brs) . 25 HR-FAB+(m/z) : 439.1255 ( + 0.8 mmu). 304 552501 Elemental analysis calcd (%) for C24H23CIN2O2S: C 65.67, H 5.28, N 6.38; found: C 65.62, H 5.32, N 6.15.

[0976] <Compound of Example 155> 5 Colorless powder XH NMR (400 MHz, DMS0-d6) 5 1.26-1.36 (IH, m), 1.50-1.61 (IH, m), I.73-1.80 (IH, m) , 1.91-1.98 (IH, m) , 1.99-2.10 (IH, m) , 2.68 (IH, dd, J = 12.2, 10.4 Hz) , 2.78 (IH, td, J = 11.6, 2.4 Hz) , 3.27-3.40 ^ (2H, m), 3.59 (IH, td, J= 12.8, 4.3 Hz), 3.76-3.80 (IH, m), 7.17 10 (IH, ddd, J = 7.9, 2.4, 1.2 Hz), 7.28 (IH, t, J = 7.3 Hz), 7.31-7.36 (2H, m), 7.42-7.44 (2H, m), 7.46-7.47 (IH, m), 7.92-7.94 (2H, m), 8.03 (IH, s), 12.82 (IH, brs). HR-FAB+(m/z) : 411.1177 (-2.4 mmu). Elemental analysis calcd (%) f or C22H22N2O2S: C 64.36, H5.40, N6.82; 15 found: C 64.46, H 5.35, N 6.58.

[0977] ^ CCompound of Example 156> Colorless powder XH NMR (400 MHz, DMS0-d6) 5 2.49-2.55 (IH, m), 2.63 (3H, s), 2.75 20 (IH, td, J = 11.6, 3.1 Hz), 3.39-3.50 (2H, m), 3.55 (IH, d, J = 12.2 Hz), 3.64-3.69 . (2H, m), 3.72-3.78 (IH, m), 4.00 (IH, d, J = II.6 Hz), 7.22-7.24 (IH, m) , 7.34-7.41 (2H, m) , 7.49 (IH, m) , 7.59 (2H, d, J = 8.6 Hz), 7.97 (2H, d, J - 8.6 Hz), 8.47 (IH, t, J = 5.5 Hz), 12.88 (IH, brs). 25 HR-FAB+(m/z) : 472.1117 ( + 1. 9 mmu). 305 552501 Elemental analysis calcd (%) for C23H22C1N304S*1/5H20: C 58 . 09, H 4 . 75, N 8.84; found: C 57.95, H 4.66, N 8.72.

[0978] <Compound of Example 157> 5 Colorless powder JH NMR (400 MHz, DMSO-d6) 5 2.41 (3H, s), 2.73 (IH, dd, J = 12.2, 9.8 Hz), 2.83 (IH, td, J = 12.2, 3.1 Hz), 3.52 (IH, d, J = 11.6 Hz) , 3.72-3.7 8 (2H, m), 4.04 (IH, dt, J = 11.0, 2.4 Hz), 4.16 (IH, ^ dd, J = 9.8, 3.1 Hz), 4.45 (2H, d, J = 6.1 Hz) , 7.22-7.2 5 (IH, m) , 10 7.36 (IH, t, J = 7.3 Hz), 7.41-7.42 (IH, d, J = 7.3 Hz), 7.47 (IH, m) , 7.52 (2H, d, J = 8.6 Hz), 7.87 (2H, d, J = 8.6 Hz), 8.70 (IH, t, J = 5.5 Hz), 12.90 (IH, brs). HR-FAB+(m/z) : 472. 1118 (+2.1 mmu). Elemental analysis calcd (%) for C23H22C1N304S*2/5H20: C 57 . 65, H 4 . 80, 15 N 8.77; found: C 57.73, H 4.69, N 8.48.

[0979] ^ CCompound of Example 158> Colorless powder 1H NMR (400 MHz, DMSO-d6) 5 2.40 (3H, s), 2.91 (IH, dd, J = 11.6, 20 10.4 Hz), 2. 99-3.08 (2H, m) , 3.27-3.43 (IH, m), 3.74-3.80 (IH, m) , 4.07 (IH, dt, J = 11.6, 2.4 Hz), 4.19 (IH, dd, J = 10.4, 2.4 Hz), 4.38-4.48 (2H, m), 7.29 (IH, t, J = 7.9 Hz), 7.49-7.54 (3H, m) , 7.58 (IH, dd, J = 7.3, 1.8 Hz), 7.86-7.89 (3H, m) , 8.70 (IH, t, J = 6.1 Hz), 14.91 (IH, brs). 25 HR-FAB+(m/z) : 472.1118 (+2.1 mmu). 306 552501 Elemental analysis calcd (%) for Cas^ClNaCuS11/4H20: C 57.98, H4.76, N 8.82; found: C 57.97, H 4.61, N 8.53.

[0980] CCompound of Example 159> 5 Colorless powder XH NMR (400 MHz, DMSO-ds) 5 2.40 (3H, s), 2.49-2.55 (IH, m) , 2.71 (IH, td, J = 11.6, 3.1 Hz), 3.54 (IH, d, J = 12.2 Hz), 3.59-3.68 (4H, m), 3.74-3.79 (IH, m), 3.97 (IH, dd, J = 11.6, 1.8 Hz) , 4.74 ^ (2H, s), 7.20 (IH, dd, J = 7.9, 1.2 Hz), 7.34 (IH, t, J = 7.9 Hz), 10 7.3 9 (IH, d, J = 7.9 Hz), 7.4 6-7.4 8 (IH, m), 7.54 (2H, d, J = 8.6 Hz), 7.91 (2H, d, J = 8.6 Hz), 12.87 (IH, brs). HR-FAB+(m/z) : 459.1186 ( + 4.1 mmu). Elemental analysis calcd (%) for C23H23C1N204S*2/5H20: C 59.26, H5.15, N 6.01; found: C 59.29, H 4.99, N 5.86. 15 [0981] CCompound of Example 160> ^ Colorless powder 1H NMR (4 00 MHz, DMSO-d6) 5 2 . 38 (3H, s) , 2.86-2. 91 (IH, m) , 3.0 0-3.10 (3H, m) , 3.52-3.61 (2H, m) , 3.70 (IH, td, J = 11.0, 3.1 Hz) , 3.80-3.85 20 (IH, m), 4.00-4.03 (IH, m), 4.72 (2H, s), 7.35 (IH, td, J = 7.9, 1.2 Hz), 7.54 (2H, d, J = 8.6 Hz), 7.57-7.65 (2H, m) , 7.90 (2H, d, J = 8.6 Hz), 7.95 (IH, dd, J = 7.9, 1.2 Hz), 15.97 (IH, brs). HR-FAB+(m/z) : 459.1193 ( + 4.8 mmu).

[0982] 25 CCompound of Example 161> 307 552501 Yellow powder XH NMR (400 MHz, DMSO-d6) 5 1.50-1.62 (IH, in), 1.66-1.75 (IH, m) , 1.78-1.88 (IH, m), 1.92-2.01 (IH, m), 2.58 (3H, s), 3.11-3.21 (2H, m) , 3.84-3. 95 (2H, m), 4.01 (IH, dd, J = 12.8, 2.4 Hz), 7.01 (IH, d, J = 2.4 Hz), 7.06 (IH, dd, J =9.2, 2.4 Hz), 7.58 (2H, d, J = 8.6 Hz), 7.92-8.01 (3H, m) , 8.32 (IH, d, J = 7.3 Hz), 13.44 (IH, brs) . HR-FAB+(m/z) : 501.1036 (+3.7 mmu).

[0983] CCompound of Example 162> Colorless powder XH NMR (400MHz, DMSO-dg) 5 1.41-1.54 (IH, m), 1.59-1.73 (IH, m), 1.77-1.85 (IH, m) , 1.86-1.94 (IH, m) , 2.53-2 . 64 (5H, m) , 3.22-3.37 (2H, m) , 3.94-4.07 (IH, m) , 6.71 (lHr d, J = 9.2 Hz), 7.09 (IH, d, J = 7.3 Hz), 7.27 (IH, brs), 7.58 (2H, d, J = 8.6 Hz), 7.9 6 (2H, d, J = 8.6 Hz), 8.14-8.59 (3H, m) . HR-FAB+(m/z) : 471.1272 ( + 1.4 mmu).

[0984] CCompound of Example 163> Pale yellow powder XH NMR (400 MHz, DMS0-d6) 5 1.41-1.60 (2H, m) , 1.77-1.84 (IH, m) , 1.97-2.04 (IH, m), 2.38 (3H, s), 2.83-2.92 (2Hr m), 3.43 (IH, td, J = 12.2, 3.7 Hz), 3.58-3.64 (IH, m), 3.70 (IH, dd, J = 12.2, 3.7 Hz), 4.79 (2H, s), 7.21 (IH, td, J= 7.3, 1.8 Hz), 7.28-7.34 (2H, 308 552501 m) , 7.46 (IH, m), 7.54 (2H, d, J = 8.6 Hz), 7.90 (2H, d, J = 8.6 Hz), 12.82 (IH, brs). HR-FAB+(m/z) : 443.1204 ( + 0.8 mmu). Elemental analysis calcd (%) for C23H23CIN2O3S: C 62.36, H 5.23, N 5 6.32; found: C 62.06, H 5.31, N 6.06. [a] 28-8°d-14 . 10 (C = 1.0, DMF) HPLC (CHIRALCEL OJ (Daicel Chemical Industries, Co,. Ltd.) ((> 0.46 x 25 cm, mobile phase: hexane/ethanol = 85/15 (0.1% TFA) , flow rate : ^ 1 mL/min, Temp.:40°C): Rt 27.5 min (> 99% ee) 10 [0985] <Compound of Example 164> Colorless crystals XH NMR(400 MHz, DMSO-d6) 5 1. 46-1.67 (2H, m) , 1.75-1.93 (2H, m), 2.58 (3H, s), 2.67-2.78 (2H, m), 3.47 (IH, d, J = 12.2 Hz), 3.60 15 (IH, d, J = 12.2 Hz) , 3.88-4.02 (IH, m) , 7.13 (IH, d, J = 9.1 Hz) , 7.17-7.24 (IH, m) , 7 .28-7.33 (IH, m), 7.56 (2H, d, J = 8.6 Hz), ) 7.93 (2H, d, J= 8.6 Hz), 8.24 (IH, d, J = 7. 9 Hz) , 13. 14 (IH, brs) . HR-FAB+ (m/z) : 474.1072 ( + 1.8 mmu). Elemental analysis calcd (%) for C23H2iClFN303S,H20: C 56.15, H4.71, 2 0 N 8.54; found: C 56.05, H 4.45, N 8.28.

[0986] CCompound of Example 165> Colorless crystals XH NMR (400 MHz, DMSO-d5) 5 1.52-1.62 (2H, m), 1.74-1.83 (IH, m), 25 1.86-1.93 (IH, m), 2.57 (3H, s), 2.66-2.79 (2H, m), 3.58 (IH, d, 309 552501 J = 12.2 Hz), 3.70 (IH, d, J= 12.2 Hz), 3.86-3.97 (IH, m), 5.10 (2H, s), 6.78-6.83 (IH, m), 6.93 (IH, s) , 7.09 (IH, s) , 7.23-7.32 (IH, m), 7.36 <2H, t, J = 7.3 Hz), 7.43 (2H, d, J = 7.3 Hz), 7.56 (2H, d, J = 8.6 Hz), 7.93 (2H, d, J = 8.6 Hz), 8.23 (IH, d, J = 7.3 Hz), 12.85 (IH, brs). HR-FAB+(m/z) : 562.1542 (-2.5 mmu). Elemental analysis calcd (%) for C30H28CIN3O4S• 3/10H20: C 63.50, H 5.08, N 7.40/ found: C 63.35, H 5.05, N 7.40.

[0987] <Example 166> 2-[2-[[2-(4-Chlorophenyl)-4-methylthiazole-5-carbonyl]aminomet hyl]morpholin-4-yl]benzoic acid

[0988] [Chemical formula 225] Trifluoroacetic acid (1 mL) was added to tert-butyl 2-[2-[[2-(4-chlorophenyl)-4-methylthiazole-5-carbonyl]aminomet hyl]morpholin-4-yl]benzoate (113mg, 0.214mmol) in dichloromethane (1 mL) . The mixture was stirred at room temperature for 2 hours. Subsequently, the solvent was removed and a lmol/L aqueous potassium hydroxide solution was added to the residue to make it basic. The mixture was then made acidic by the addition of 2mol/L hydrochloric

[0989] 310 552501 acid. The crystallized powdery product was collected by filtration and washed with water to give 7 8.2 mg (78%) of the desired compound as a colorless powder. 1H NMR (400 MHz, DMS0-d6) 5 2.61 (3H, s) , 2.86 (IH, t, J = 11.6 Hz) , 3.01-3.16 (3H, m), 3.39-3.46 (2H, m), 3.70 (IH, td, J = 11.6, 1.8 Hz), 3.79-3.84 (IH, m) , 4.05 (IH, d, J = 11.6 Hz), 7.36 (IH, t, J = 7.3 Hz), 7.57-7.67 (4H, m), 7.94-7.96 (3H, m), 8.40 (IH, t, J = 5.5 Hz), 15.96 (IH, brs). HR-FAB+ (m/z) : 472.1143 (+4.5 mmu). Elemental analysis calcd (%) for C23H22C1N304S*3/10H20: C 57.87, H 4.77, N 8.80; found: C 57.71, H 4.60, N 8.50.

[0990] <Example 167> 2 — L3—[(Benzothiazol-2-yl)oxymethyl]piperidin-l-yl]benzoic acid

[0991] Step 167a) 2-[3-[ (Benzothiazol-2-yl)oxymethyl]piperidin-l-yl]benzaldehyde

[0992] [Chemical formula 226] Using 3-[(benzothiazol-2-yl)oxymethyl]piperidine (58.0 mg, 0.234 mmol) and 2-fluorobenzaldehyde (0.0381 mL, 0.351 mmol), the CHO

[0993] 311 552501 same procedure was followed as in Step lc of Example 1 to give 10.1 mg (12%) of the desired compound as a colorless oil. lH NMR (400 MHz, CDC13) 5 1.58-1.62 (IH, m), 1.71-1.82 (IH, m) , 1.86-1.93 (1H, m) , 2.00-2.06 (IH, m) , 2.28-2.38 (IH, m) , 3.22 (IH, dd, J =12.8, 10.4Hz), 3.2 6-3.33 (1H, m) , 4.02-4.0 9 (3H, m) , 4.22-4.2 6 (IH, m) , 6.97 (IH, d, J = 8.6 Hz), 7.04-7.09 (2H, m), 7.29 (IH, td, J = 7.3, 1.2 Hz), 7.52-7.57 (2H, m), 7.60 (IH, dd, J = 7.9, 1.2 Hz), 7.86 (IH, dd, J = 7.9, 1.2 Hz), 10.59 (IH, s). FAB+ (m/z) : 353(M+H) .

[0994] Step 167b) 2-[3-[(Benzothiazol-2-yl)oxymethyl]piperidin-l-yl]benzoic acid

[0995] [Chemical formula 227] An aqueous solution (1 mL) of sodium chlorite (7.46 mg, 0.0660 mmol) and sodium dihydrogen phosphate (6.89 mg, 0.0574 mmol) was added to a solution of 2 —[3 —[(benzothiazol-2-yl)oxymethyl]piperidin-l-yl]benzaldehyde (10.1 mg, 0.0287 mmol) and 2-methyl-2-butene (0.00912 mL, 0.0861 mmol) in tert-butanol (3 mL). The mixture was stirred at room temperature for 5 hours. Subsequently, 2mol/L hydrochloric acid COOH

[0996] 312 552501 was added to make the mixture acidic. The mixture was then extracted with ethyl acetate and was washed with brine. The washed product was dried over magnesium sulfate and the solvent was evaporated. The resulting residue was air-dried to give 7.50 mg (71%) of the 5 desired compound as a colorless powder. lH NMR (400 MHz, DMSO-d6) 5 1.38-1.48 (IH, m) , 1.51-1.62 (1H, m) , 1.74-1.81 (IH, m) , 1.85-1.92 (IH, m) , 2.05-2.13 (1H, m) , 3.10-3.16 (2H, m), 3.91 (IH, dd, J =9.8, 7.3 Hz), 3.99-4.05 (2H, m), 4.10 ^ (IH, dd, J = 12.8, 3.6 Hz), 6.97 (lH, t, J = 7.3 Hz), 7.02 (IH, 10 td, J = 7.9, 1.2 Hz), 7.10 (IH, d, J = 8.6 Hz), 7.23 (IH, td, J = 7.9, 1.2 Hz), 7.40 (IH, d, J = 7.3 Hz), 7.46 (IH, td, J = 7.3, 1.8 Hz), 7.63 (IH, dd, J = 7.3, 1.8 Hz), 7.68 (IH, dd, J = 7.9, 1.2 Hz). HR-FAB+ (m/z) : 369.1250(-2.3 mmu). 15 [0997] <Example 168> ^ 2-[3-[(4'-Chlorobiphenyl-4-yl)methoxy]piperidin-l-yl]benzoic acid

[0998] 20 Step 168a) 3-[3-[(4'-Chlorobiphenyl-4-yl)methoxy]piperidin-l-yl]benzaldeh yde

[0999] [Chemical formula 228] 313 552501 CHO

[1000] Tetrabutylammonium iodide (26.9mg, 0.0729mmol) and potassium carbonate (206 mg, 1.46 mmol) were added to a solution of 5 3-[(4'-chlorobiphenyl-4-yl)methoxy]piperidine (220 mg, 0.729 ^ mmol) and 2-fluorobenzaldehyde (0.159 mL, 1.46 mmol) in N,N-dimethylformamide (5 mL) . The mixture was stirred at 100 °C for 8 hours . Subsequently, water was added and the mixture was extracted with ethyl acetate and was washed with brine. The washed product 10 was dried over magnesium sulfate and the solvent was evaporated. Purification of the resulting residue by silica gel column chromatography (hexane : ethyl acetate = 40:1 -> 10:1) gave 156 mg (53%) of the desired compound as a pale yellow powder. ^ XH NMR (400 MHz, CDC13) 5 1.48-1.57 (IH, m) , 1.71-1.82 (IH, m) , 15 1.89-1.96 (IH, m) , 2.12-2.19 (IH, m) , 2.85-2.92 (2H, m) , 3.17 (IH, td, J = 7.3, 3.6 Hz), 3.46-3.50 (IH, m), 3.70-3.77 (IH, m), 4.62 (1H, d, J = 12.2 Hz), 4.65 (IH, d, J = 12.2 Hz), 7.09-7.12 (2H, m), 7.39-7.43 (4H, m), 7.49-7.55 (5H, m), 7.80 (IH, dd, J = 7.9, 1.2 Hz), 10.31 (IH, s). 20 FAB+(m/z): 406(M+H).

[1001] 314 552501 Step 168b) 2-[3-[(4' -Chlorobiphenyl-4-yl)methoxy]piperidin-l-yl]benzoic acid

[1002] 5 [Chemical formula 229] Using 3-[3-[(4'-chlorobiphenyl-4-yl)methoxy]piperidin-l-yl]benzaldeh 10 yde (156 mg, 0.384 mmol), the same procedure was followed as in Step 167b of Example 167 to give 95.7 mg (59%) of the desired compound as a colorless powder. 1H NMR (400 MHz, DMS0-ds) 5 1.61-1.69 (IH, m), 1.76-1.88 (2H, m), £ 1.94-2.03 (IH, m), 2.93-3.06 (2H, m), 3.11 (IH, dd, J =11.6, 5.5 15 Hz), 3. 30-3.37 (1H, m) , 3.76-3.81 (IH, m), 4.56 (IH, d, J = 12.2 Hz), 4.64 (IH, d, J = 12.2 Hz), 7.43 (IH, td, J = 7.3, 1.2 Hz), 7.47 (2H, d, J = 8.6 Hz), 7.51 (2H, d, J = 8.6 Hz), 7.65 (2H, d, J = 8.6 Hz), 7.68-7.75 (4H, m), 8.04 (IH, dd, J = 7.9, 1.2 Hz), 17.39 (IH, brs). 20 HR-FAB+ (m/z) : 422.1562 ( + 3.9 mmu). Elemental analysis calcd (% ) for C25H24C1N03* 1/10H20: C70.86, H5.76, N 3.28; found: C 70.57, H 5.77, N 3.19. COOH

[1003] 315 552501

[1004] <Examples 169 through 179> The procedures were performed in the same manner as in Example 168 to make compounds given in Table 10 below.

[1005] [Table 10] COOH Ar Absolute configuration Example 169 Racemic CI \_/ % ff~ mixture Example 170 Racemc c! \__/ mixture Example 171 Racemic mixture Example 172 Raoemic mixture 'a 'XX Example 173 Racemic CI mixture Example 174 Racemic CI mixture Example 175 Racemic mixture Example 176 R CI O r\~p -ch£ Example 177 S Example 178 S CI Example 179 R Gl~~\= och. ch2och, ch2o ch2ochz coch, sch„ CONHCH, CONHCH, ch2och2 ch2och? 316 552501

[1006] CCompound of Example 169> Colorless powder XH NMR (400 MHz, DMSO-ds) 5 1.37-1.45 (IH, m), 1. 68-1.77 (IH, m) , 5 1.91-1.98 {2H, m) , 2.20-2.30 (IH, m) , 2.95-3.11 (3H, m) , 3.25 (1H, dd, J = 11.6, 3.7 Hz}, 3.94 (1H, dd, J = 9.8, 7.3 Hz), 4.04 (IH, dd, J = 9.8, 5.5 Hz) , 7.04 (2H, d, J = 8.6 Hz) , 7.42-7.48 (3H, m) , 7.59 (2H, d, J = 8.6 Hz), 7.64 (2H, d, J = 8.6 Hz), 7.68 (IH, td, ^ J = 7.3, 1.8 Hz), 7.72 (IH, dd, J = 8.6, 1.2 Hz), 8.04 (IH, dd, 10 J = 7.3, 1.2 Hz), 17.76 (IH, brs). HR-FAB+(m/z) : 422.1510 (-1.3 mmu). Elemental analysis calcd (%) f or C25H24C1NC>3* I/IOH2O: C 70.86, H5.76, N 3.28; found: C 70.58, H 5.67, N 3.21.

[1007] 15 CCompound of Example 17 0> Colorless amorphous ^ 1H NMR (400 MHz, DMSO-d6) 5 1.22-1.32 (IH, m), 1.60-1.71 (IH, m) , 1.79-1.89 (2H, m) , 2.00-2.10 (IH, m) , 2.82-2. 88 (IH, m) , 2.94-3.04 (2H, m), 3.10 (IH, dd, J = 11.6, 3.7 Hz), 3.35 (IH, dd, J = 9.8, 20 7.3 Hz), 3.42 (IH, dd, J = 9.8, 5.5 Hz), 4.47 (2H, s), 7.36 (2H, d, J = 8.6 Hz), 7.40 (IH, td, J = 7.3, 1.2 Hz), 7.48 (2H, d, J = 8.6 Hz), 7.60 (2H, d, J = 8.6 Hz), 7.63-7.70 (4H, m), 8.01 (IH, dd, J =7.9, 1.8 Hz), 17.89 (IH, brs). HR-FAB+(m/z) : 436. 1694 ( + 1.5 mmu). 25 [1008] 317 552501 <Compound of Example 171> Colorless oil 1H NMR (400 MHz, DMSO-d6) 5 1.59-1.67 (IH, m) , 1.71-1.79 (1H, m) , 1.80-1.88 (IH, m) , 1.91-2.01 (IH, m) , 2.92-2.97 (IH, m) , 2.99-3.02 5 (IH, m), 3.04-3.10 (IH, m), 3.28-3.31 (IH, m) , 3.73-3.77 (IH, m), 4.48 (IH, d, J = 11.6 Hz), 4.56 (IH, d, J = 11.6 Hz), 6.96 (2H, d, J = 8.6 Hz), 7.05 (2H, dd, J = 9.2, 4.9 Hz), 7.22 (2H, t, J = 8.6 Hz), 7.38 (2H, d, J = 8.6 Hz), 7.4 3 (IH, td, J = 7.3, 1.2 Hz) , ^ 7 . 66-7 . 74 (2H, rti) , 8.04 (IH, dd, J = 7 . 9, 1.8 Hz), 17.40 (IH, brs) . 10 HR-FAB+(m/z): 422.1786 ( + 1. 9 mmu).

[1009] CCompound of Example 172> Colorless oil XH NMR (400 MHz, DMSO-d6) 5 1.23-1.33 (IH, m), 1.61-1.72 (IH, m) , 15 1.79-1. 85 (IH, m), 1.86-1.91 (IH, m) , 2.01-2.09 (IH, m) , 2.83-2.88 (IH, m), 2.96-3.06 (2H, m), 3.10-3.13 (IH, m), 3.29-3.37 (IH, m), 0 3.42 (IH, dd, J = 9.8, 5.5 Hz), 4.42 (2H, s), 6.94 (2H, d, J = 8.6 Hz) , 7.05 (2H, dd, J = 9.2, 4.9 Hz), 7.22 (2H, t, J = 8.6 Hz) , 7.3 0 (2H, d, J = 8.6 Hz), 7.4 3 (IH, td, J = 7.3, 1.2 Hz) , 7.66 (IH, td, 20 J = 7.9, 1.8 Hz), 7.71 (IH, dd, J = 7.9, 1.2 Hz), 8.03 (IH, dd, J = 7.9, 1.8 Hz), 17.76 (IH, brs). HR-FAB+ (m/z} : 436. 1937 ( + 1.3 mmu).

[1010] CCompound of Example 173> 25 Colorless amorphous 318 552501 2H NMR (400 MHz, DMSO-d6) 5 1.28-1.36 (1H, m), 1.65-1.75 (1H, m), 1.86-1.93 (2H, m), 2.32-2.41 (1H, m) , 2.71 (3Hf s), 2.88 (IH, t, J = 9.4 Hz), 2.98-3.08 (4H, m), 3.13 (IH, dd, J = 11.0, 3.7 Hz), 7.40-7.44 (IH, m) , 7.60 (2H, d, J = 8.6 Hz), 7.64-7.69 (2H, m) , 5 8.01-8.04 (3H, m), 17.78 (IH, brs). HR-FAB"1" (m/z) : 455.1192 (-0.4 mmu).

[1011] <Compound of Example 174> Colorless amorphous 10 1H NMR (400MHz, DMSO-d6) 5 1.44-1.55 (IH, m), 1.67-1.79 (IH, m), 1.91-2.01 (2H, m) , 2.41 (3Hf s) , 2.63-2.72 (IH, m) , 2.97-3. 09 (3H, m), 3.19 (IH, dd, J = 11.6, 4.3 Hz), 5.97 (IH, dd, J = 15.9, 6.7 Hz), 6.77 (IH, dd, J = 15.9, 1.2 Hz), 7.43 (IH, td, J = 7.9, 1.2 Hz), 7.55 (2H, d, J = 8.6 Hz), 7.66-7.74 (2H, m), 7.89 (2H, d, J 15 = 8.6 Hz), 8.04 (1H, dd, J = 7.9, 1.2 Hz), 17.64 (IH, brs). HR-FAB+(m/z) : 439.1272 (+2.5 mmu). £ [1012] <Compound of Example 175> Colorless powder 20 !H NMR (400 MHz, DMSO-d6) 5 1.33-1.43 (IH, m) , 1.61-1.72 (lH, m) , 1.90-1.95 (IH, m) , 2. 00-2.04 (IH, m) , 2.16-2.27 (lH, m) , 2.91-2.97 (IH, m) , 2.98-3.0 8 (2H, m) , 3.2 4 (IH, dd, J = 11.6, 3.1 Hz) , 3.28-3.35 (2H, m) , 7.35 (IH, td, J = 7.3, 1.8 Hz) , 7.4 0-7 . 4 6 (3H, m) , 7.64-7.7 0 (2H, m) , 7.90-7.93 (2H, m), 8. 02-8.04 (2H, m), 17.47 (IH, brs). 25 HR-FAB+(m/z) : 411.1174 (-2.7 mmu). 319 552501

[1013] <Compound of Example 176> Colorless amorphous XH NMR (400 MHz, DMSO-dg) 5 1.2 6 (IH, qd, J = 11.6, 3.1 Hz) , 1.60-1.73 5 (IH, m), 1.83-1.97 (2H, m), 1.98-2.08 (IH, m), 2.58 (3H, s), 2.85 (IH, t, J = 11.0 Hz), 2.99-3.06 (2H, m), 3.10 (IH, dd, J = 11.6, 3.7 Hz), 3.16-3.22 (1H, m), 3.25-3.30 (IH, m), 7.44 (IH, td, J = 8.6, 1.2 Hz), 7.57 (2H, d, J = 8.6 Hz), 7.68 (IH, td, J = 7.9, 1.8 ® Hz) , 7.73 (IH, dd, J = 7 . 9, 1.2 Hz) , 7 . 94 (2H, d, J = 8.6 Hz), 8.03 10 (IH, dd, J = 7.9 Hz, J = 1.2 Hz), 8.37 (lH, t, J = 5.5 Hz), 17.90 (IH, brs) . HR-FAB+(m/z) : 470.1336 ( + 3.1 mmu). [CC] 28' 6°d_44 . 3 ° (C = 1.1, DMF) HPLC (CHIRALCEL OJ (Daicel Chemical Industries, Co,. Ltd.) i|) 0.46 15 x 25 cm, mobile phase: hexane/ethanol = 60/40 (0.1% TFA), flow rate : 1 mL/min, Temp.: 40°C): Rt 12.8 min {> 99% ee) O [1014] CCompound of Example 177> Colorless amorphous 20 1H NMR (4 00 MHz, DMSO-d6) 5 1.2 6 (1H, qd, J = 11.6, 3.1 Hz) , 1.60-1.72 (IH, m), 1.83-1.97 (2H, m), 1.98-2.09 (IH, m), 2.59 (3H, s), 2.85 (IH, t, J = 11.0 Hz), 2.99-3.07 (2H, m), 3.10 (IH, dd, J = 11.6, 3.7 Hz), 3.16-3.23 (lH, m), 3.25-3.28 (IH, m), 7.44 (IH, td, J = 8.6, 1.2 Hz) , 7.57 (2H, d, J = 8.6 Hz), 7.68 (IH, td, J = 7.9, 1.8 25 Hz) , 7.73 (IH, dd, J = 7. 9, 1.2 Hz) , 7.94 (2H, d, J = 8.6 Hz), 8.03 320 552501 (1H, dd, J = 7.9 Hz, J = 1.2 Hz), 8.37 (1H, t, J = 5.5 Hz), 17.89 (IH, brs) . HR-FAB+(m/z) : 470.1313 ( + 0.7 mmu). [a] 28'8°d+41 . 4 0 (C = 1.1, DMF) 5 HPLC (CHIRALCEL OJ (Daicel Chemical Industries, Co,. Ltd.) <|> 0.46 x 25 cm, mobile phase: hexane/ethanol = 60/40 (0.1% TFA) , flow rate : 1 mL/min, Temp.: 40°C): Rt 7.4 min (93% ee)

[1015] ^ CCompound of Example 178> 10 Colorless powder NMR (4 00 MHz, DMS0-ds) 5 1.27 (IH, qd, J = 11.6, 3.1 Hz) , 1. 61-1.72 (IH, m), 1.77-1.93 (2H, m), 1.99-2.10 (IH, m), 2.36 (3H, s), 2.85 (IH, t, J = 11.0 Hz), 2.96-3.06 (2H, m), 3.09 (IH, dd, J = 11.6, 3.1 Hz), 3.39 (IH, dd, J = 9.2, 7.3 Hz), 3.47 (IH, dd, J = 9.2, 15 5.5 Hz), 4.66 (2H, s) , 7.41-7.45 (lH, m) , 7.53 (2H, d, J = 8.6 Hz) , 7.66 (IH, td, J = 7.9, 1.2 Hz), 7.70 (IH, dd, J = 7.9, 1.2 Hz), 7.89 (2H, d, J = 8.6 Hz), 8.03 (IH, dd, J = 7.9, 1.8 Hz), 17.83 (IH, s). HR-FAB4(m/z): 457.1327 (-2.6 mmu). 20 Elemental analysis calcd (%) for C24H25C1N203S*1/10H20: C 62.83, H 5.54, N 6.11; found: C 62.66, H 5.47, N 5.95. [a] 28" 5°d+17 . 2 0 (C = 1.1, CHC13) HPLC (CHIRALCEL OJ (Daicel Chemical Industries, Co, . Ltd.) <J) 0.46 x 25 cm, mobile phase : hexane/ethanol = 90/10 (0.1% TFA), flow 25 rate : 1 mL/min, Temp.: 40°C): Rt 65.3 min (> 99% ee) 321 552501

[1016] CCompound of Example 179> Colorless powder XH NMR (4 00 MHz, DMS0-d6) 5 1.33 (IH, qd, J = 11. 6, 3.1 Hz) , 1. 67-1. 78 5 (IH, m), 1.83-1.98 (2H, m), 2.04-2.16 (IH, m), 2.42 (3H, s), 2.90 (IH, t, J = 11.0 Hz), 3.01-3.12 (2H, m), 3.15 (IH, dd, J = 11.6, 3.1 Hz), 3.45 (IH, dd, J = 9.2, 7.3 Hz), 3.52 (IH, dd, J = 9.2, 5.5 Hz), 4.72 (2H, s), 7. 46-7.50 (IH, m) , 7.59 (2H, d, J = 8.6 Hz), ^ 7.71 (1H, dt, J = 7.9, 1.2 Hz), 7.76 (IH, dd, J = 7.9, 1.2 Hz), 10 7.94 (2H, d, J = 8.6 Hz), 8.09 (IH, dd, J = 7.9, 1.8 Hz), 17.90 (IH, s) . HR-FAB+(m/z) : 457. 1340 (-1.3 mmu). Elemental analysis calcd (%) for C24H25CIN2O3S• 3/IOH2O: C 62.34, H 5.58, N 6.06; found: C 62.33, H 5.50, N 5.87. 15 [a] 28'7°d-16 . 0 0 (C = 0.9, CHCI3) HPLC (CHIRALCEL OJ (Daicel Chemical Industries, Co, . Ltd.) <j)0. 46x25 ^ cm, mobile phase: hexane/ethanol = 90/10 (0.1% TFA), flow rate: 1 mL/min, Temp.: 40°C): Rt 57.7 min (> 99% ee)

[1017] 20 CExample 180> 3— [3 — [2—[2—(4-Chlorophenyl)-4-methylthiazol-5-yl]ethyl]piperid in-l-yl]benzoic acid

[1018] [Chemical formula 230] 322 552501 N .Me

[1019] 10% Palladium on activated carbon (5 mg) was added to 3-[3-[2-[2-(4-chlorophenyl)-4-methylthiazol-5-yl]ethenyl]piper 5 idin-l-yl]benzoic acid (35.0 mg, 0.0797 mmol) in tetrahydrofuran (5 mL) . The reaction mixture was stirred at room temperature for m 5 hours in a hydrogen atmosphere. Subsequently, the mixture was filtered through Celite and the solvent was evaporated to give 35.1 mg (quant.) of the desired compound as a colorless powder. 10 XH NMR (400 MHz, DMSO-d6) 5 1.08-1.18 (IH, m) , 1.49-1.58 (2H, m) , 1. 59-1.67 (2H, m) , 1.71-1.76 (IH, m) , 1.85-1.89 (IH, m) , 2.35 (3H, s), 2.46-2.53 (1H, m), 2.71 (IH, dd, J = 11.6, 2.4 Hz), 2.88 (2H, t, J = 7.3 Hz), 3.60-3.63 (IH, m) , 3.67-3.70 (IH, m), 7.19 (IH, td, J= 7.3, 1.8 Hz), 7.27-7.33 (2H, m), 7.45-7.47 (IH, m), 7.52 O (2H, d, J = 8.6 Hz), 7.86 (2H, d, J = 8.6 Hz), 12.78 (IH, brs). HR-FAB+(m/z) : 441.1441 ( + 3.7 mmu).

[1020] <Example 181> 2-[3-[2-[2-(4-Chlorophenyl) -4-methylthiazol-5-yl]ethyl]piperid 2 0 in-l-yl]benzoic acid

[1021] [Chemical formula 231] 323 552501 COOH

[1022] Using 2- [3- [2-[2-(4-chlorophenyl)-4-methylthiazol-5-yl]ethenyl]piper 5 idin-l-yl]benzoic acid (10.0 mg, 0.0228 mmol), the same procedure was followed as in Example 180 to give 8.00 mg (79%) of the desired ^ compound as a colorless oil. XH NMR (400 MHz, DMSO-d6) 5 1.21-1.30 (IH, m) , 1.54-1.71 (3H, m) , 1.74-1.83 (IH, m) , 1.86-1.95 (2H, m) , 2.32 (3H, s), 2.79-2.86 (3H, 10 m), 2.98-3.08 (2H, m) , 3.16 (IH, dd, J = 11.0, 3.1 Hz) , 7.4 4 (IH, td, J = 7.3, 1.2 Hz), 7.52 (2H, d, J = 8.6 Hz), 7.67 (IH, td, J = 7.9, 1.8 Hz) , 7.73 (IH, d, J = 7.3 Hz), 7.86 (2H, d, J= 8.6 Hz), 8.04 (IH, dd, J = 7.9, 1.2 Hz), 18.07 (IH, brs). HR-FAB4 (m/z) : 441.1374 (-3.0 mmu). £ [1023] <Example 181> Methyl (S)-3-[3-[[2-(4-chlorophenyl)-4-methylthiazole-5-carbonyl]meth ylamino]piperidin-l-yl]benzoate 20 [1024] [Chemical formula 232] 324 552501 O^ij' XX Cl \ss/ ^ "COOMe

[1025] Methyl iodide (0.0530 mL, 0.852 mmol) and silver oxide (197 mg, 0.852 mmol) were added to 5 methyl (S)-3-[3-[[2-(4-chlorophenyl) -4-methylthiazole-5-carbony 1]amino]piperidin-l-yl]benzoate (100 mg, 0.213 mmol) in ^ N, N-dimethylformamide (2 mL) . The reaction mixture was stirred at 80 °C for 3 hours. Subsequently, the mixture was filtered through Celite and ethyl acetate was added to the filtrate. The mixture 10 was then washed sequentially with water and brine, followed by drying over magnesium sulfate and evaporation of the solvent. Purification of the resulting residue by silica gel column chromatography (hexane : ethyl acetate = 10 :1-> 2 :1) gave 59. 4 mg (58%) of the desired compound as a colorless oil. £i XH NMR (400 MHz, CDC13) 5 1.52-1.60 (IH, m) , 1.74-1.84 (2H, m) , 1.88-1.99 (2H, m), 2.51 (3H, s), 2.65-2.71 (IH, m), 2.92 (IH, t, J - 11.0 Hz), 3.06 (3H, s), 3.64-3.76 (2H, m), 3.91 (3H, s), 7.12 (IH, m), 7.30 (IH, t, J = 7.9 Hz) , 7.41 (2H, d, J = 8.6 Hz), 7.51 (IH, d, J = 7.3 Hz), 7.59 (IH, brs), 7.85 (2H, d, J = 8.6 Hz). 20 [1026] <Example 182> (S)-3- [3- [ [2-(4-Chlorophenyl)-4-methylthiazole-5-carbonyl]meth ylamino]piperidin-l-yl]benzoic acid 325 552501

[1027] [Chemical formula 233] CI COOH

[1028] 5 A lmol/L aqueous potassium hydroxide solution (lmL) was added to methyl(S)-3-[3-[[2-(4-chlorophenyl)-4-methylthiazole-5-carbony 1]methylamino]piperidin-l-yl]benzoate (59.4 mg, 0.123 mmol) in methanol (5 mL) . The mixture was stirred for 1 hour while being 10 refluxed. The solvent was then evaporated and the residue was dissolved in water. The mixture was made acidic by the addition of 2mol/L hydrochloric acid. The crystallized powdery product was collected by filtration. Washing this product with water gave 56.4 mg (98%) of the desired product as a colorless amorphous product. Qb 1H NMR (400 MHz, DMSO-d6) 5 1.53-1.69 (1H, m) , 1.76-1.90 (3H, m) , 2.40 (3H, s) , 2.7 0 (IH, t, J = 12.2 Hz) , 2.9 4-3.03 (4H, m) , 3.2 6-3.42 (IH, m), 3.64-3.76 (2H, m) , 7.14-7.23 (lH, m), 7.25-7.35 (2H, m), 7.46 (IH, brs) , 7 . 57 (2H, d, J = 8.6 Hz), 7 . 93 (2H, d, J = 8 . 6 Hz) , 12.83 (IH, brs). 20 HR-FAB+(m/z) 470.1286 (-1.9 mmu). [a] 28'8°d-58 . 0 0 (C = 1.0, DMF)

[1029] CTest Example 1> 326 552501 Activation of transcription of human peroxisome proliferator-activated receptor (PPAR) « CHO-K1 cells cultured in Ham's F12 medium supplemented with 10% fetal calf serum were cotransfected with the following plasmids : 5 A receptor plasmid encoding a fusion protein consisting of the DNA-binding domain of yeast transcription factor Gal4 fused to the ligand-binding domain of human PPARa (Biochemistry, 1993, 32, 5598), a reporter plasmid (STRATAGENE, firefly luciferase reporter plasmid) , and a renilla luciferase plasmid for internal standard (Promega). 10 The cotransfection was performed over a 2-hour period by using Lipofectamine (INVITROGEN) in the absence of serum. Subsequently, a test compound was added in Ham's F12 medium supplemented with 10% defatted bovine serum. The cells were then incubated at 37 °C for 20 hours. The activity of each luciferase was then determined 15 and corrected for internal standard. The results are shown in Table 11 below. 0 [1030] [Table 11] Ex. No. E C 5 o (u mol/L) 18 0. 065 19 0. 97 20 1. 36 22 0. 16 24 1. 54 25 0. 56 32 0.02

[1031] 25 These results indicate that the cyclic amino benzoic acid 327 </div>

Claims

<div class="application article clearfix printTableText" id="claims"> 552501 derivatives of the present invention are a group of novel compounds that can effectively activate transcription of human PPARa. INDUSTRIAL APPLICABILITY [1032] 5 The cyclic amino benzoic acid derivatives of the present invention are a group of novel compounds that can effectively activate transcription of human PPARa. [1033] Agonists of the human PPARa, the compounds of the present 10 invention can serve not only as hypolipidemic drugs that are particularly effective in liver, but also as potent suppressants of arteriosclerosis. The compounds of the present invention therefore are of significant pharmaceutical importance. 328 552501 CLAIMS

1. A cyclic amino benzoic acid derivative represented by the general formula (1) [Chemical formula 1] [wherein a ring Ar represents an aryl group which may have substituent , 5-membered or 6-membered aromatic heterocyclic group which may have substituent or condensed ring group thereof, Y represents a C1-C4alkylene, C2-C4alkenylene, C2-C4alkynylene or the general formula (2) [Chemical formula 2] (wherein T represents a single bond, C1-C4 alkylene, C2-C4 alkenylene or C2-C4 alkynylene, U represents a single bond, C1-C4 alkylene or C2-C4 alkenylene, A represents a carbonyl group, oxygen atom, sulfur atom, -NR1- substituted with a halogen atom, aralkyl group which may have substituent, aryl group which may have substituent or 5-membered (1) — T —A — U — (2) (R1 represents a hydrogen atom, lower alkyl group which may be 329 RECEIVED at IPONZ on 30 November 2009 552501 or 6-membered aromatic heterocyclic group which may have substituent or condensed ring group thereof), the general formula (3) [Chemical formula 3] (3) I R1 (wherein L1 represents a single bond or -NR1-, and R1 is as defined above) or the general formula (4) [Chemical formula 4] 0 <4> R1 (wherein L2 represents a single bond or oxygen atom, and R1 is as defined above)), Z represents an oxygen atom, sulfur atom or -(CH2)n~ (n represents 0,1 or 2), X represents a hydrogen atom, halogen atom, lower alkyl group which may be substituted with a halogen atom, lower alkoxy group which may be substituted with a halogen atom, hydroxyl group, nitro group, cyano group, optionally substituted amino group, aryl group which may have substituent, 5-membered or 6-membered aromatic heterocyclic group which may have substituent or condensed ring group thereof, aralkyl group which may have substituent, aryloxy group which may have substituent or aralkyloxy group which may have substituent, 330 RECEIVED at IPONZ on 30 November 2009 552501 R represents a hydrogen atom or lower alkyl group, and -COOR is substituted at ortho position or metha position of binding position of the ring W], or a pharmaceutically acceptable salt thereof,

2. A cyclic amino benzoic acid derivative according to claim 1, wherein in the general formula (1), Y is represented by the general formula (2a) [Chemical formula 5] — T1—A1—U1— (2a) (whereinT1 represents a singlebond, C1-C4 alkylene or C2-C4 alkenylene, U1 represents a single bond or C1-c4 alkylene, and A1 represents an oxygen atom, sulfur atom, the general formula (3) [Chemical formula 6] A R1 (wherein L1 represents a single bond or -NR1-, and R1 is as defined above) or the general formula (4) [Chemical formula 7] R1 (wherein L2 represents a single bond or oxygen atom, and R1 is as defined above)), or a pharmaceutically acceptable salt thereof. 331 552501

3. A cyclic amino benzoic acid derivative according to claim 1, wherein in the general formula (1) , Y is represented by the general formula (2b) [Chemical formula 8] — T1 — A2— U1— (2b) (wherein T1 represents a single bond, C1-C4 alkylene or C2-C4 alkenylene, CJ1 represents a single bond or C1-C4 alkylene, A2 represents an oxygen atom, sulfur atom, the general formula (3a) [Chemical formula 9] o (3a) i R1a (wherein Rla represents a hydrogen atom, alkyl group which may be substituted with a halogen atom or aralkyl group which may have substituent), or represented by the general formula (4a) [Chemical formula 10] o (4a) R1a (wherein Rla is as defined above) ) , or a pharmaceutically acceptable salt thereof. 332 552501

4. A cyclic amino benzoic acid derivative according to claim 1, wherein in the general formula (1) , Y is represented by the general formula (2c) [Chemical formula 11] — T1 —A3—U2— (2c) (wherein T1 represents a single bond, C1-C4 alkylene or C2-C4 alkenylene, U2 represents a single bond or methylene, A3 represents the general formula (3a) [Chemical formula 12] o N'^ I R1a (wherein Rla represents a hydrogen atom, alkyl group which may be substituted with halogen atom or aralkyl group which may have substituent) or the general formula (4a) [Chemical formula 13] o R1a (wherein Rla is as defined above) ) , or a pharmaceutically acceptable salt thereof.

5. A cyclic amino benzoic acid derivative according to any one of claims 1 to 4, wherein in the general formula (1) , Z represents an oxygen atom, sulfur atom or methylene, 333 552501 or a pharmaceutically acceptable salt thereof.

6. A cyclic amino benzoic acid derivative according to any one of claims 1 to 5, wherein in the general formula (1) , Z represents methylene, or a pharmaceutically acceptable salt thereof.

7. A cyclic amino benzoic acid derivative according to any one of claims 1 to 6, wherein in the general formula (1) , X represents a hydrogen atom, halogen atom, lower alkyl group which may be substituted with a halogen atom, lower alkoxy group which may be substituted with a halogen atom, hydroxyl group or optionally substituted amino group, or a pharmaceutically acceptable salt thereof.

8. A cyclic amino benzoic acid derivative according to any one of claims 1 to 7, wherein in the general formula (1), ring Ar represents 5-membered or 6-membered aromatic heterocyclic group which may have substituent, or a pharmaceutically acceptable salt thereof.

9. A cyclic amino benzoic acid derivative according to any one of claims 1 to 8, wherein in the general formula (1), ring Ar represents the general formula (5) [Chemical formula 14] 334 552501 (wherein R2 represents a lower alkyl group which may be substituted with a halogen atom, cyclic alkyl group, lower alkoxy group which may be substituted with a halogen atom, optionally substituted amino group, 5-membered or 6-membered cyclic amino group, aryl group which may have substituent or 5-membered or 6-membered aromatic heterocyclic group which may have substituent, R3 represents a hydrogen atom, lower alkyl group which may be substituted with a halogen atom or cycloalkyl group, and G represents an oxygen atom or sulfur atom), or a pharmaceutically acceptable salt thereof.

10 . A cyclic amino benzoic acid derivative according to claim 1, wherein the compound represented by the general formula (1) is 2-[3-[[2-(4-chlorophenyl)-4-methylthiazol-5-yl]methoxymet hyl]piperidin-l-yl] benzoic acid, 3~ [3-[ [2-(4-chlorophenyl)-4-methylthiazol-5-yl]methoxymet hyl]piperidin-l-yl] benzoic acid, 3-[3-[[2-(4-chlorophenyl)-4-methylthiazol-5-yl]methoxy]pi peridin-l-yl] benzoic acid, 2- [3-[ [2-(4-chlorophenyl)-4-methylthiazol-5-yl]carbonylam inomethyl]piperidin-l-yl] benzoic acid, 3- [3-[[2-(4-chlorophenyl)-4-methylthiazol-5-yl]carbonylam inomethyl]piperidin-l-yl] benzoic acid, 3_ [3-[[2-(4-chlorophenyl)-4-methylthiazol-5-yl]carbonylam ino]piperidin-l-yl] benzoic acid, 335 552501 2-[3-[N-[[2-(4-chlorophenyl)-4-methylthiazol-5-yl]methyl] carbamoyl]piperidin-l-yl] benzoic acid, (S)—2—[3—[[2-(4-chlorophenyl)-4-methylthiazol-5-yl]methox ymethyl]piperidin-l-yl] benzoic acid, (R)-2-[3-[[2-(4-chlorophenyl)-4-methylthiazol-5-yl]methox ymethyl]piperidin-l-yl] benzoic acid, (S)-3-[3-[[2-(4-chlorophenyl)-4-methylthiazol-5-yl]methox ymethyl]piperidin-l-yl] benzoic acid, (R)—3—[3—[[2-(4-chlorophenyl)-4-methylthiazol-5-yl]methox ymethyl]piperidin-l-yl] benzoic acid, (S)-3-[3-[[2-(4-chlorophenyl)-4-methylthiazol-5-yl]methox y]piperidin-l-yl] benzoic acid, (R)-3-[3-[[2—(4-chlorophenyl)-4-methylthiazol-5-yl]methox y]piperidin-l-yl] benzoic acid, (S)-2-[3-[[2-(4-chlorophenyl)-4-methylthiazol-5-yl]carbon ylaminomethyl]piperidin-l-yl] benzoic acid, (R)-2-[3-[[2-(4-chlorophenyl)-4-methylthiazol-5-yl]carbon ylaminomethyl]piperidin-l-yl] benzoic acid, (S)-3-[3-[[2-(4-chlorophenyl)-4-methylthiazol-5-yl]carbon ylaminomethyl]piperidin-l-yl] benzoic acid, (R)-3-[3-[[2-(4-chlorophenyl)-4-methylthiazol-5-yl]carbon ylaminomethyl]piperidin-l-yl] benzoic acid, (S)-3-[3-[[2-(4-chlorophenyl)-4-methylthiazol-5-yl]carbon ylamino]piperidin-l-yl] benzoic acid, 336 552501 (R)-3-[3-[[2-(4-chlorophenyl)-4-methylthiazol-5-yl]carbon ylamino]piperidin-l-yl] benzoic acid, (S) -2- [3- [N- [ [2- (4-chlorophenyl) -4-raethylthiazol-5-yl]met hyl]carbamoyl]piperidin-l-yl] benzoic acid, or (R)-2-[3-[N-[[2-(4-chlorophenyl)-4-methylthiazol-5-yl]met hyl]carbamoyl]piperidin-l-yl] benzoic acid, or a pharmaceutically acceptable salt thereof.

11. A pharmaceutical comprising at least one of the cyclic amino benzoic acid derivative or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 10 as an active ingredient.

12. A PPARa agonist comprising at least one of the cyclic amino benzoic acid derivative or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 10 as an active ingredient.

13. A PPAR a, y dual agonist comprising at least one of the cyclic amino benzoic acid derivative or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 10 as an active ingredient.

14. A PPAR a, 5 dual agonist comprising at least one of the cyclic amino benzoic acid derivative or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 10 as an active ingredient.

15. A PPAR a, Y/ <5 triple agonist comprising at least one of the cyclic amino benzoic acid derivative or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 10 as an active ingredient. 337

16. A PPAR modulator comprislrfFSf'YIM2009 552501 amino benzoic acid derivative or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 10 as an active ingredient.

17. A lipid lowering agent comprising at least one of the cyclic amino benzoic acid derivative or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 10 as an active ingredient.

18 . A prophylactic or therapeutic agent for arteriosclerosis, comprising at least one of the cyclic amino benzoic acid derivative or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 10 as an active ingredient.

19. A prophylactic or therapeutic agent for diabetes, comprising at least one of the cyclic amino benzoic acid derivative or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 10 as an active ingredient.

20. A prophylactic or therapeutic agent for obesity, comprising at least one of the cyclic amino benzoic acid derivative or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 10 as an active ingredient.

21. Use of at least one cyclic amino benzoic acid derivative or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 10 in the manufacture of a medicament for treating abnormal lipid metabolism in a subject in need thereof.

22. Use of at least one cyclic amino benzoic acid derivative or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 10 in the manufacture of a medicament for treating or preventing arteriosclerosis. 338 552501 RECEIVED at IPONZ on 30 November 2009

23. Use of at least one cyclic amino benzoic acid derivative or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 10 in the manufacture of a medicament for treating or preventing diabetes.

24. Use of at least one cyclic amino benzoic acid derivative or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 10 in the manufacture of a medicament for treating or preventing obesity.

25. A cyclic amino benzoic acid derivative of formula (I) as defined in claim 1 substantially as herein described with reference to any example thereof.

26. A pharmaceutical as claimed in claim 11 substantially as herein described with reference to any example thereof.

27. A PPARa agonist as claimed in claim 12 substantially as herein described with reference to any example thereof.

28. A PPARa, y dual agonist as claimed in claim 13 substantially as herein described with reference to any example thereof.

29. A PPARa, 5 dual agonist as claimed in claim 14 substantially as herein described with reference to any example thereof.

30. A PPARa, y, 5 triple agonist as claimed in claim 15 substantially as herein described with reference to any example thereof.

31. A PPAR modulator as claimed in claim 16 substantially as herein described with reference to any example thereof.

32. A lipid lowering agent as claimed in claim 17 substantially as herein described with reference to any example thereof. 339 RECEIVED at IPONZ on 25 February 2010 552501 r

33. A prophylactic or therapeutic agent as claimed in claim 18, 19 or 20 substantially as herein described with reference to any example thereof.

34. A use as claimed in any one of claims 21 to 24, substantially as herein described with reference to any example thereof. 340 </div>